FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Vasconcellos, AG
   Clarencio, J
   Andrade, D
   Araujo-Neto, CA
   Barral, A
   Nascimento-Carvalho, CM
AF Vasconcellos, Angela G.
   Clarencio, Jorge
   Andrade, Daniela
   Araujo-Neto, Cesar A.
   Barral, Aldina
   Nascimento-Carvalho, Cristiana M.
TI Systemic cytokines/chemokines associated to radiographic abnormalities
   in pneumonia in children
SO CYTOKINE
LA English
DT Article
DE Respiratory tract infections; Lung diseases; Pulmonary inflammation;
   Bronchopneumonia; Chest x-ray; Lung inflammation; Immunity
ID DIAGNOSIS; INFECTIONS; CYTOKINES; ETIOLOGY; ASSAYS
AB Community-acquired pneumonia (CAP) diagnosis remains a challenge in paediatrics. Chest radiography is considered gold standard for definition of pneumonia, however no previous study assessed the relationship between immune response and radiographic-confirmed-pneumonia. We assessed association between cytokines/chemokines levels and radiographic abnormalities in children with CAP.
   Children < 5-years-old hospitalized with CAP were investigated in a prospective study at the Federal University of Bahia Hospital, Brazil. On admission, clinical data and biological samples were collected to investigate 20 aetiological agents and determine serum cytokines/chemokines levels; chest radiographs were performed.
   Among 158 patients, radiographic diagnosis of pneumonia was confirmed in 126(79.7%) and 17(10.8%) had pleural effusion. Viral, bacterial and pneumococcal infection were detected in 80(50.6%), 78(49.4%) and 37(23.4%) cases. By comparing the median concentrations of serum cytokines/chemokines between children with or without pleural effusion, interleukin(IL)-6 was higher (26.6[18.6-103.7] vs 3.0[0.0-19.8]; p < 0.001) among those with pleural effusion; and between children with or without radiographic-confirmed-pneumonia, IL-6 was higher in the first subgroup (4.5[0.0-23.4] vs 0.0[0.0-3.6]; p = 0.02) after having excluded cases with pleural effusion. Stratified analyses according to aetiology showed IL-6 increase in the radiographic-confirmed-pneumonia subgroup inside the pneumococcal infection (28.2[5.9-64.1] vs 0.0[0.0-0.0]; p = 0.03) subgroup. By multivariable analysis, with IL-6 as dependent variable, pneumococcal infection and pleural effusion showed independent association with IL-6 elevation [respective OR: 5.071 (95%CI = 2.226-11.548; p < 0.001) and 13.604 (95%CI = 3.463-53.449; p = 0.0001)]. Considering the cases without pleural effusion, the area under the curve of IL-6 to predict pneumococcal infection was 0.76 (95%CI = 0.66-0.86; p < 0.001).
   IL-6 increase is a potential biomarker of pneumococcal infection among children with CAP without pleural effusion upon admission.
C1 [Vasconcellos, Angela G.; Barral, Aldina; Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Postgrad Program Hlth Sci, Sch Med, Salvador, BA, Brazil.
   [Vasconcellos, Angela G.] Univ Fed Reconcavo Bahia, Hlth Sci Ctr, Santo Antonio De Jesus, Brazil.
   [Clarencio, Jorge; Andrade, Daniela; Barral, Aldina] Fundacao Oswaldo Cruz, Ctr Pesquisa Goncalo Muniz, Salvador, BA, Brazil.
   [Araujo-Neto, Cesar A.] Univ Fed Bahia, Dept Image Diag, Sch Med, Salvador, BA, Brazil.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Dept Paediat, Sch Med, Salvador, BA, Brazil.
RP Vasconcellos, AG (corresponding author), Av Cardeal Silva 1132, BR-40231250 Salvador, BA, Brazil.
EM angelavasc@yahoo.com.br
FU Bahia State Agency for Research Funding (FAPESB) [PNX 0019/2009]
FX Supported by a grant (No PNX 0019/2009) from the Bahia State Agency for
   Research Funding (FAPESB). FAPESB had no role in study design, in the
   collection, analysis and interpretation of data, in the writing of the
   report, and in the decision to submit the article for publication.
CR Atkinson TP, 2014, PEDIATR INFECT DIS J, V33, P92, DOI 10.1097/INF.0000000000000171
   Bordon J, 2013, INT J INFECT DIS, V17, pE76, DOI 10.1016/j.ijid.2012.06.006
   Calbo E, 2010, INT J ANTIMICROB AG, V35, P107, DOI 10.1016/j.ijantimicag.2009.10.002
   Cherian T, 2005, B WORLD HEALTH ORGAN, V83, P353
   Chiu CY, 2008, PEDIATR INFECT DIS J, V27, P699, DOI 10.1097/INF.0b013e318170b678
   El-Rashdi AS, 2006, ARCH DIS CHILD, V91, P351, DOI 10.1136/adc.2005.088831
   Hyypia T, 1998, J CLIN MICROBIOL, V36, P2081
   Korppi M, 2010, PEDIATR INFECT DIS J, V29, P387, DOI 10.1097/INF.0b013e3181ce8e81
   Liu L, 2015, LANCET, V385, P430, DOI 10.1016/S0140-6736(14)61698-6
   Makela MJ, 1998, J CLIN MICROBIOL, V36, P539
   McIntosh K, 2002, NEW ENGL J MED, V346, P429, DOI 10.1056/NEJMra011994
   Medzhitov R, 2011, NAT REV IMMUNOL, V11, P693, DOI 10.1038/nri3063
   Moldoveanu B, 2009, J INFLAMM RES, V2, P1
   Morre SA, 2002, J CLIN MICROBIOL, V40, P584, DOI 10.1128/JCM.40.2.584-587.2002
   Nair H, 2013, LANCET, V381, P1380, DOI 10.1016/S0140-6736(12)61901-1
   Nascimento-Carvalho CM, 2008, PEDIATR INFECT DIS J, V27, P939, DOI 10.1097/INF.0b013e3181723751
   Nascimento-Carvalho CM, 2015, PEDIATR INFECT DIS J, V34, P490, DOI 10.1097/INF.0000000000000622
   Nascimento-Carvalho CM, 2012, J MED VIROL, V84, P253, DOI 10.1002/jmv.22268
   Nascimento-Carvalho CM, 2011, INFLUENZA OTHER RESP, V5, P285, DOI 10.1111/j.1750-2659.2011.00206.x
   Nascimento-Carvalho CM, 2009, J INFECTION, V58, P250, DOI 10.1016/j.jinf.2009.01.008
   NOHYNEK H, 1995, PEDIATR INFECT DIS J, V14, P478, DOI 10.1097/00006454-199506000-00003
   Saukkoriipi A, 2002, MOL CELL PROBE, V16, P385, DOI 10.1006/mcpr.2002.0443
   Scott JAG, 2012, CLIN INFECT DIS, V54, pS109, DOI 10.1093/cid/cir1065
   Utine GE, 2005, CHEST, V128, P1436, DOI 10.1378/chest.128.3.1436
   van der Poll T, 2009, LANCET, V374, P1543, DOI 10.1016/S0140-6736(09)61114-4
   Vasconcellos AG, 2018, CYTOKINE, V107, P1, DOI 10.1016/j.cyto.2017.11.005
   Wang SP, 2000, J INFECT DIS, V181, pS421, DOI 10.1086/315622
   World Health Organization (WHO), INT MAN CHILDH ILLN
   Yamaguchi T, 2005, FEMS IMMUNOL MED MIC, V43, P21, DOI 10.1016/j.femsim.2004.06.023
   Zhao JL, 2016, THER CLIN RISK MANAG, V12, P1683, DOI 10.2147/TCRM.S121928
NR 30
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-4666
EI 1096-0023
J9 CYTOKINE
JI Cytokine
PD NOV
PY 2020
VL 135
AR 155191
DI 10.1016/j.cyto.2020.155191
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA NT3HB
UT WOS:000572835200004
PM 32712459
DA 2020-12-17
ER

PT J
AU Camargos, P
   Zhang, LJ
   Nascimento-Carvalho, CM
AF Camargos, Paulo
   Zhang, Linjie
   Nascimento-Carvalho, Cristiana M.
TI Effect of pneumococcal conjugate vaccines on mortality from lower
   respiratory infections and pneumonia among under-fives
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Article; Early Access
DE Pneumococcal conjugate vaccines; pneumonial; lower respiratory
   infections; mortality; children
ID CHILDREN
AB There is a well-known inverse association between mortality rate from infectious diseases and improvements in socioeconomic status, even though longer time-series are required to demonstrate this relationship. This general rule seems to apply to mortality from pneumonia in children in the pneumococcal conjugate vaccine (PCV) era. Two recent published secular trend studies spanning from about 30 years among Brazilians under the age of five show either no effect of PCV - not even death rate decline from pneumococcal meningitis - or a modest one (8% reduction). Time-series mortality studies from pneumonia are needed for both, developed and developing countries, those who have implemented PCV or not. Results from these studies would provide critical input and feedback to public health policy makers.
C1 [Camargos, Paulo] Univ Fed Minas Gerais, Univ Hosp, Sch Med, Dept Pediat, Belo Horizonte, MG, Brazil.
   [Camargos, Paulo] Univ Fed Minas Gerais, Univ Hosp, Pediat Pulmonol Unit, Belo Horizonte, MG, Brazil.
   [Zhang, Linjie] Fed Univ Rio Grande, Dept Pediat, Sch Med, Rio Grande, RS, Brazil.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Dept Pediat, Sch Med, Salvador, BA, Brazil.
RP Camargos, P (corresponding author), Univ Fed Minas Gerais, Dept Pediat, Sch Med, Pediat & Pediat Pulmonol, BR-30130100 Belo Horizonte, MG, Brazil.
EM paulo.camargos@pq.cnpq.br
OI Nascimento-Carvalho, Cristiana/0000-0002-3942-2492
CR CAMARGOS PAM, 1988, INT J EPIDEMIOL, V17, P193, DOI 10.1093/ije/17.1.193
   Camargos P, 2020, VACCINE, V38, P2559, DOI 10.1016/j.vaccine.2020.01.084
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   Di Pietrantonj C, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004407.pub4
   Diaz J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153141
   GBD 2016 lower respiratory infections collaborators, 2018, LANCET INFECT DIS, V18, DOI [10.1016/S1473-3099(18)30310-4, DOI 10.1016/S1473-3099(18)30310-4]
   KASS EH, 1971, J INFECT DIS, V123, P110, DOI 10.1093/infdis/123.1.110
   Koelman DLH, 2020, CLIN MICROBIOL INFEC, V26, P199, DOI 10.1016/j.cmi.2019.04.032
   Kupek E, 2016, CAD SAUDE PUBLICA, V32, DOI 10.1590/0102-311X00131414
   Naghavi M, 2017, LANCET, V390, P1151, DOI 10.1016/S0140-6736(17)32152-9
   Roth GA, 2018, LANCET, V392, P1736, DOI [10.1016/S0140-6736(18)32203-7, 10.1016/s0140-6736(18)32203-7]
   Schuck-Paim C, 2019, LANCET GLOB HEALTH, V7, pE249, DOI 10.1016/S2214-109X(18)30455-8
   Styblo K, 1969, B WHO, V41
   Suarez V, 2016, VACCINE, V34, P4738, DOI 10.1016/j.vaccine.2016.07.027
   Troeger CE, 2020, LANCET INFECT DIS, V20, P60, DOI 10.1016/S1473-3099(19)30410-4
   von Mollendorf C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179905
   Wagner KS, 2012, VACCINE, V30, P7111, DOI 10.1016/j.vaccine.2012.09.029
   Wang HD, 2017, LANCET, V390, P1084, DOI 10.1016/S0140-6736(17)31833-0
NR 18
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
DI 10.1080/21645515.2020.1787071
EA JUL 2020
PG 9
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA MT7KL
UT WOS:000555149300001
PM 32730135
DA 2020-12-17
ER

PT J
AU Pimentel, AM
   Vilas-Boas, CC
   Vilar, TS
   Nascimento-Carvalho, CM
AF Pimentel, Alexandre M.
   Vilas-Boas, Caroline C.
   Vilar, Ticiana S.
   Nascimento-Carvalho, Cristiana M.
TI The Negative Predictive Ability of Immature Neutrophils for Bacteremia
   in Children With Community-Acquired Infections
SO FRONTIERS IN PEDIATRICS
LA English
DT Article
DE bacteremia; children; community-acquired pneumonia; community-acquired
   infections; immature neutrophils; Streptococcus pneumoniae; white blood
   cell count
ID FEBRILE CHILDREN; CONJUGATE VACCINE; BLOOD; AGE; PROCALCITONIN;
   EPIDEMIOLOGY; INFANTS; MANAGEMENT; CULTURES
AB Background: Bacteremia is a serious condition. We aimed to assess the role of immature neutrophils in peripheral blood smears for prediction of bacteremia in children.
   Methods: In this cross-sectional study conducted in Salvador, Brazil, blood cultures collected from patients aged <= 18 years were identified. White Blood Cell count (WBC) was performed upon admission. Medical charts were reviewed and cases from the community were included.
   Results: Out of 833 potentially eligible patients, 263 (31.6%) were excluded. Therefore, the study group comprised 570 patients being blood collected for culture upon admission from all of them and WBC performed upon admission from 566. The median age was 2 years (IQR: 9.4 mo-5 y) and 300 (52.6%) were male. Acute respiratory infection was the most frequent diagnosis (n = 388; 68.1%), being 250 (43.9%) lower (LRTI) and 138 (24.2%) upper respiratory tract infections. Blood culture was positive in 9 (1.6%; 95% CI: 0.8-2.9%) cases, out of which 7 (2.8%) had LRTI. Streptococcus pneumoniae (n = 3), Haemophilus (n = 2), Neisseria meningitidis, viridans streptococci, Streptococcus agalactiae, and Acinetobacter baumanii (n = 1 each) were isolated. The total WBC/mm3 did not differ when children with positive or negative blood culture were compared (12,100 [IQR: 6,950-15,250] vs. 11,000 [IQR: 7,900-14,900]; P = 0.9). However, presence of any immature neutrophil was significantly more frequent among patients with bacteremia in comparison with patients without bacteremia (100% [9/9] vs. 40% [223/557]; P < 0.001). The absolute number of immature neutrophils was significantly lower among children without bacteremia (0 [IQR: 0-259] vs. 325 [IQR: 275-1,106]; P < 0.001). Overall, the area under the ROC curve of the number of immature neutrophils in regard to bacteremia was 0.82 (95% CI: 0.76-0.88; P = 0.001). Among 413 patients with absolute number of immature neutrophils <242/mm(3), none had bacteremia; among 153 patients with absolute number of immature neutrophils >= 242/mm(3), 9 (5.9%) had bacteremia. Absolute number of immature neutrophils >= 242/mm3 showed: sensitivity 100% (95% CI: 71.7-100%), specificity 74.1% (95% CI: 70.4-77.7%), negative predictive value 100% (95% CI: 99.3-100.0%), and positive predictive value 5.9% (95% CI: 2.9-10.5%). When only children with LRTI were analyzed, the results were similar.
   Conclusion: The absolute number of immature neutrophils in peripheral blood smear is a potential tool to rule out bacteremia among children with community-acquired infections.
C1 [Pimentel, Alexandre M.] Bahiana Fdn Sci Dev, Bahiana Sch Med, Salvador, BA, Brazil.
   [Vilas-Boas, Caroline C.; Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Postgrad Program Hlth Sci, Salvador, BA, Brazil.
   [Vilar, Ticiana S.; Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Dept Pediat, Sch Med, Salvador, BA, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia, Sch Med, Postgrad Program Hlth Sci, Salvador, BA, Brazil.; Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia, Dept Pediat, Sch Med, Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
FU Brazilian Council for Scientific and Technological Development (CNPq)
   research fellowshipNational Council for Scientific and Technological
   Development (CNPq) [445034/2014-9]; research Federal University of Bahia
   fellowship; CNPq, BrazilNational Council for Scientific and
   Technological Development (CNPq) [313466/2018-1]
FX AP was recipient of the Brazilian Council for Scientific and
   Technological Development (CNPq) research fellowship (445034/2014-9).
   CV-B and TV were recipients of the research Federal University of Bahia
   fellowship. CN-C is a senior investigator at CNPq, Brazil
   (313466/2018-1). Neither CNPq nor the Federal University of Bahia had
   any role in study design, data collection, data analysis, as well as in
   the decision to report our results.
CR BARAFF LJ, 1993, ANN EMERG MED, V22, P1198, DOI 10.1016/S0196-0644(05)80991-6
   Bonsu BK, 2003, ANN EMERG MED, V42, P216, DOI 10.1067/mem.2003.299
   Cruz AT, 2017, JAMA PEDIATR, V171, DOI 10.1001/jamapediatrics.2017.2927
   Dierig A, 2018, FRONT PEDIATR, V6, DOI 10.3389/fped.2018.00222
   Diez-Padrisa N, 2012, TROP MED INT HEALTH, V17, P1100, DOI 10.1111/j.1365-3156.2012.03035.x
   Esposito S, 2012, PEDIATR INFECT DIS J, V31, P705, DOI 10.1097/INF.0b013e31825384ae
   Grando IM, 2015, CAD SAUDE PUBLICA, V31, P276, DOI 10.1590/0102-311X00169913
   Herz AM, 2006, PEDIATR INFECT DIS J, V25, P293, DOI 10.1097/01.inf.0000207485.39112.bf
   Jamal W, 2006, MED PRIN PRACT, V15, P223, DOI 10.1159/000092186
   Kim H, 2015, INT J LAB HEMATOL, V37, P869, DOI 10.1111/ijlh.12421
   Laney W, 2019, SAMJ S AFR MED J, V109, P952, DOI [10.7196/SAMJ.2019.v109i12.13981, 10.7196/samj.2019.v109i12.13981]
   Lee GM, 2001, PEDIATRICS, V108, P835, DOI 10.1542/peds.108.4.835
   Mahajan P, 2014, ACAD EMERG MED, V21, P171, DOI 10.1111/acem.12316
   Maniaci V, 2008, PEDIATRICS, V122, P701, DOI 10.1542/peds.2007-3503
   Mekitarian E, 2015, J PEDIAT-BRAZIL, V91, pS61, DOI 10.1016/j.jped.2015.06.004
   Mistry RD, 2013, J EMERG MED, V45, P813, DOI 10.1016/j.jemermed.2013.04.029
   Myers AL, 2013, PEDIATR INFECT DIS J, V32, P736, DOI 10.1097/INF.0b013e318290bf63
   Pai S, 2015, EXPERT REV ANTI-INFE, V13, P1073, DOI 10.1586/14787210.2015.1063418
   Azevedo LCP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064524
   Ribitzky-Eisner H, 2016, PEDIATR NEONATOL, V57, P378, DOI 10.1016/j.pedneo.2015.10.004
   Sard B, 2006, PEDIATR EMERG CARE, V22, P295, DOI 10.1097/01.pec.0000215137.51909.16
   TEELE DW, 1975, J PEDIATR-US, V87, P227, DOI 10.1016/S0022-3476(75)80584-1
   Yilmaz HL, 2008, ANN ACAD MED SINGAP, V37, P192
NR 23
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-2360
J9 FRONT PEDIATR
JI Front. Pediatr.
PD MAY 6
PY 2020
VL 8
AR 208
DI 10.3389/fped.2020.00208
PG 8
WC Pediatrics
SC Pediatrics
GA LS8UA
UT WOS:000536654600001
PM 32435627
OA DOAJ Gold, Green Published
DA 2020-12-17
ER

PT J
AU Meireles-Neto, I
   Pimentel, AM
   Parreira, JN
   Fontoura, MSH
   Nascimento-Carvalho, CM
AF Meireles-Neto, Ilson
   Pimentel, Alexandre M.
   Parreira, Juliana N.
   Fontoura, Maria-Socorro H.
   Nascimento-Carvalho, Cristiana M.
TI Recurrent wheezing, allergic rhinitis, and maternal asthma as predictors
   of asthma in children
SO ALLERGY AND ASTHMA PROCEEDINGS
LA English
DT Article
ID EARLY-CHILDHOOD; FOLLOW-UP; HIGH-RISK; SENSITIZATION; DIAGNOSIS; AGE;
   PATTERNS; BIRTH; ATOPY; EOSINOPHILIA
AB Background: Early prediction of asthma is crucial for asthma prevention.
   Objective: We estimated the odds ratio (OR) of recurrent wheezing during the first 3 years of life, atopic rhinitis, and maternal asthma for asthma in school-age children (ages >= 6 years).
   Methods: This case-control study was conducted in Salvador, Brazil. Medical records of children diagnosed with asthma (cases) and of children screened for pulmonary illnesses and without asthma (controls) were reviewed. Information was retrieved and registered in standardized forms.
   Results: We included 125 subjects (cases) and 375 controls, whose median (percentile 25th-percentile 75th) age was 8.1 years (6.6-10.0 years) and 9.2 years (7.0-11.9 years), respectively. The subjects (cases) and the controls had at least three episodes of wheezing during the first 3 years of life (69.7% and 1.4%, respectively), a maternal history of asthma (36.0% and 4.0%, respectively), and atopic rhinitis (95.9% and 35.1%, respectively). The adjusted OR of three or more episodes of wheezing during the first 3 years of life was OR 132.5 (95% confidence interval [CI], 36.8-477.1), of a personal history of atopic rhinitis was OR 21.3 (95% CI, 5.3-85.0), and of maternal asthma was OR 10.2 (95% CI, 3.1-33.6) for asthma in a logistic regression (which also included age, gender, and maternal history of allergic rhinitis [OR insignificant for these factors]).
   Conclusion: Children with a history of three or more episodes of wheezing during the first 3 years of life were at least 37 times more likely to develop asthma than children without this history. A maternal history of asthma and a personal history of atopic rhinitis are also predictors of asthma in children.
C1 [Meireles-Neto, Ilson; Pimentel, Alexandre M.] Bahiana Fdn Sci Dev, Bahiana Sch Med, Dept Med & Publ Hlth, Rua Nilson Costa 374-102, Salvador 40270550, BA, Brazil.
   [Parreira, Juliana N.; Fontoura, Maria-Socorro H.; Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Dept Pediat, Sch Med, Salvador, BA, Brazil.
RP Meireles-Neto, I (corresponding author), Bahiana Fdn Sci Dev, Bahiana Sch Med, Dept Med & Publ Hlth, Rua Nilson Costa 374-102, Salvador 40270550, BA, Brazil.
EM ilson_meireles@hotmail.com
FU Brazilian Council for Scientific and Technological Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [119397/2017-0, 445034/2014-9]; CNPq, BrazilNational Council for
   Scientific and Technological Development (CNPq) [307574/2014-8]
FX I. Meireles-Neto and A.M. Pimentel were recipients of the Brazilian
   Council for Scientific and Technological Development (CNPq) fellowships
   (grants 119397/2017-0 and 445034/2014-9, respectively). C.M.
   Nascimento-Carvalho is a senior investigator at CNPq, Brazil (grant
   307574/2014-8)
CR Blanken MO, 2013, NEW ENGL J MED, V368, P1791, DOI 10.1056/NEJMoa1211917
   Bobrowska-Korzeniowska M, 2019, ALLERGY ASTHMA PROC, V40, P329, DOI 10.2500/aap.2019.40.4237
   Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111
   Castro-Rodriguez JA, 2011, CURR OPIN ALLERGY CL, V11, P157, DOI 10.1097/ACI.0b013e3283464c4a
   Castro-Rodriguez JA, 2010, J ALLERGY CLIN IMMUN, V126, P212, DOI 10.1016/j.jaci.2010.06.032
   Caudri D, 2009, J ALLERGY CLIN IMMUN, V124, P903, DOI 10.1016/j.jaci.2009.06.045
   Devulapalli CS, 2008, THORAX, V63, P8, DOI 10.1136/thx.2006.060616
   Dodge R, 1996, J ALLERGY CLIN IMMUN, V98, P48, DOI 10.1016/S0091-6749(96)70225-7
   Eigenmann PA, 2013, PEDIAT ALLERG IMM-UK, V24, P195, DOI 10.1111/pai.12066
   Eysink PED, 2005, BRIT J GEN PRACT, V55, P125
   Global Initiative for Asthma, 2019, GLOB STRAT ASTHM MAN
   Global Initiative for Asthma, 2014, GLOB STRAT ASTHM MAN
   Guilbert TW, 2004, J ALLERGY CLIN IMMUN, V114, P1282, DOI 10.1016/j.jaci.2004.09.020
   Illi S, 2001, J ALLERGY CLIN IMMUN, V108, P709, DOI 10.1067/mai.2001.118786
   Jackson DJ, 2016, J ALLERGY CLIN IMMUN, V137, P659, DOI 10.1016/j.jaci.2016.01.002
   Just J, 2008, CLIN EXP ALLERGY, V38, P767, DOI 10.1111/j.1365-2222.2008.02966.x
   Karakoc F, 2002, CLIN EXP ALLERGY, V32, P51, DOI 10.1046/j.0022-0477.2001.01273.x
   Kulig M, 1998, PEDIAT ALLERG IMM-UK, V9, P61, DOI 10.1111/j.1399-3038.1998.tb00305.x
   Kurukulaaratchy RJ, 2003, EUR RESPIR J, V22, P767, DOI 10.1183/09031936.03.00005903
   Kwong GNM, 2001, THORAX, V56, P312, DOI 10.1136/thorax.56.4.312
   Leonardi NA, 2011, J ALLERGY CLIN IMMUN, V127, P1466, DOI 10.1016/j.jaci.2011.03.001
   Ly NP, 2006, PEDIATRICS, V117, pE1132, DOI 10.1542/peds.2005-2271
   Mallol J, 2005, Allergol Immunopathol (Madr), V33, P257, DOI 10.1157/13080928
   Martinez FD, 1999, ALLERGY, V54, P24, DOI 10.1111/j.1398-9995.1999.tb04384.x
   MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301
   Matricardi PM, 2008, EUR RESPIR J, V32, P585, DOI 10.1183/09031936.00066307
   McCallister M, 2018, ALLERGY ASTHMA PROC, V39, P273, DOI 10.2500/aap.2018.39.4125
   Moussu L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097236
   Radhakrishnan DK, 2014, J ALLERGY CLIN IMMUN, V134, P1057, DOI 10.1016/j.jaci.2014.05.012
   Rhodes HL, 2002, AM J RESP CRIT CARE, V165, P176, DOI 10.1164/ajrccm.165.2.2104032
   Rochat MK, 2010, J ALLERGY CLIN IMMUN, V126, P1170, DOI 10.1016/j.jaci.2010.09.008
   Ruotsalainen M, 2010, ALLERGY, V65, P503, DOI 10.1111/j.1398-9995.2009.02212.x
   Savenije OEM, 2012, J ALLERGY CLIN IMMUN, V130, P325, DOI 10.1016/j.jaci.2012.05.007
   Schonberger Hubert, 2004, Eur J Gen Pract, V10, P138
   Sherriff A, 2001, INT J EPIDEMIOL, V30, P1473, DOI 10.1093/ije/30.6.1473
   Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC
   Togias A, 2019, J ALLERGY CLIN IMMUN, V143, P1003, DOI 10.1016/j.jaci.2018.07.041
   ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9
   Zinelli C, 2009, CLIN EXP DERMATOL, V34, P607, DOI 10.1111/j.1365-2230.2008.03142.x
NR 39
TC 1
Z9 1
U1 1
U2 1
PU OCEAN SIDE PUBLICATIONS INC
PI PROVIDENCE
PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA
SN 1088-5412
EI 1539-6304
J9 ALLERGY ASTHMA PROC
JI Allergy Asthma Proc.
PD MAY 1
PY 2020
VL 41
IS 3
BP 204
EP 209
DI 10.2500/aap.2020.41.200023
PG 6
WC Allergy
SC Allergy
GA LK8GE
UT WOS:000531097500011
PM 32375965
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, GC
   Nascimento-Carvalho, EC
   VanDuijn, MM
   Ramos, CL
   Vilas-Boas, AL
   Moreno-Carvalho, OA
   Zeneyedpour, L
   Ferwerda, G
   de Groot, R
   Luider, TM
   Nascimento-Carvalho, CM
AF Nascimento-Carvalho, Gustavo C.
   Nascimento-Carvalho, Eduardo C.
   VanDuijn, Martijn M.
   Ramos, Clara L.
   Vilas-Boas, Ana-Luisa
   Moreno-Carvalho, Otavio A.
   Zeneyedpour, Lona
   Ferwerda, Gerben
   de Groot, Ronald
   Luider, Theo M.
   Nascimento-Carvalho, Cristiana M.
TI Cerebrospinal fluid immunoglobulins are increased in neonates exposed to
   Zika virus during foetal life
SO JOURNAL OF INFECTION
LA English
DT Article
DE Cerebrospinal fluid; Congenital Zika virus infection; Immunoglobulins;
   Mass spectrometry; Microcephaly
ID IGM
AB Objective: To compare immunoglobulin levels in cerebrospinal fluid (CSF) of neonates exposed to Zika virus (ZIKV) during foetal life (cases) with levels in CSF of control neonates.
   Methods: We identified 16 neonates who underwent lumbar puncture (LP), during the ZIKV epidemic (December/2015 to March/2016) whose mothers reported ZIKV clinical symptoms during gestation (cases). Congenital microcephaly was defined as head circumference <= 31.9cm (boys) and <= 31.5 cm (girls) for term neonates, or <= 2 standard deviations below the mean for premature (<37 weeks) neonates. Subsequently, we identified neonates who underwent LP in the same lab and fulfilled criteria to be controls: age <= 4 days, CSF white blood cell count <= 8/mm(3), CSF protein <= 132mg/dL, CSF red blood cell count <= 1,000/mm(3), neither central nervous system illness, nor congenital infection, nor microcephaly. CSF immunoglobulin concentrations were measured by mass spectrometry.
   Results: 13 controls were included. IgM, IgA, IgG, IgK, and IgL were significantly higher among cases (p < 0.001). Eight (50%) ZIKV exposed infants had congenital microcephaly. These showed the strongest immunoglobulin elevation of the IgM and IgA classes.
   Conclusion: Neonates exposed to ZIKV infection during gestation present with elevated distinct immunoglobulins in CSF, both in cases that developed microcephaly and in cases that did not. (C) 2020 Published by Elsevier Ltd on behalf of The British Infection Association.
C1 [Nascimento-Carvalho, Gustavo C.; Nascimento-Carvalho, Eduardo C.; Ramos, Clara L.; Vilas-Boas, Ana-Luisa] Bahiana Fdn Sci Dev, Bahiana Sch Med, BR-40290000 Salvador, BA, Brazil.
   [VanDuijn, Martijn M.; Zeneyedpour, Lona; Luider, Theo M.] Erasmus MC, Dept Neurol, NL-3000 CA Rotterdam, Netherlands.
   [Moreno-Carvalho, Otavio A.] Jose Silveira Fdn, Cerebrospinal Fluid Lab, BR-40170100 Salvador, BA, Brazil.
   [Ferwerda, Gerben; de Groot, Ronald] Radboudumc, Sect Paediat Infect Dis, Lab Med Immunol, Radboud Inst Mol Life Sci, NL-6525 GA Nijmegen, Netherlands.
   [Ferwerda, Gerben; de Groot, Ronald] Radboudumc, Radboud Ctr Infect Dis, NL-6525 GA Nijmegen, Netherlands.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Paediat, Sch Med, Rua Prof Aristides Novis 105, BR-40210630 Salvador, BA, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia, Paediat, Sch Med, Rua Prof Aristides Novis 105, BR-40210630 Salvador, BA, Brazil.
EM gcn.carvalho@hotmail.com; educn.carvalho@hotmail.com;
   m.m.vanduijn@erasmusmc.nl; ccclr1@gmail.com; anapediatria@ig.com.br;
   otavioliquor@hotmail.com; l.zeneyedpour@erasmusmc.nl;
   Gerben.ferwerda@radboudumc.nl; Ronald.deGroot@radboudumc.nl;
   t.luider@erasmusmc.nl; nascimentocarvalho@hotmail.com
OI van Duijn, Martijn/0000-0002-6654-994X
FU Brazilian Council for Scientific and Technological Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [313466/2018-1]
FX This work was supported by the Brazilian Council for Scientific and
   Technological Development (CNPq) [grant number 313466/2018-1]. CNPq did
   not have any role in study design, data collection, analysis and
   interpretation, in the writing of this article, nor in the decision to
   submit this article for publication.
CR Ben-Hur H, 2005, INT J MOL MED, V16, P401
   Carvalho AL, 2019, CLIN MICROBIOL INFEC, V25, P524, DOI 10.1016/j.cmi.2018.12.021
   Castanha PMS, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007246
   Chan JFW, 2016, J INFECTION, V72, P507, DOI 10.1016/j.jinf.2016.02.011
   Chimelli L, 2018, CHILD NERV SYST, V34, P95, DOI 10.1007/s00381-017-3651-3
   Chong J, 2019, METABOLITES, V9, DOI 10.3390/metabo9030057
   Cordeiro MT, 2016, LANCET, V387, P1811, DOI 10.1016/S0140-6736(16)30253-7
   Dirlikov E, 2018, JAMA NEUROL, V75, P1089, DOI 10.1001/jamaneurol.2018.1058
   Gulland A, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i595
   Gurung S, 2018, J VIROL, V92, DOI 10.1128/JVI.00186-18
   Kadkhoda K, 2017, DIAGN MICR INFEC DIS, V88, P233, DOI 10.1016/j.diagmicrobio.2017.04.002
   Lucey DR, 2016, JAMA-J AM MED ASSOC, V315, P865, DOI 10.1001/jama.2016.0904
   MacLean B, 2010, BIOINFORMATICS, V26, P966, DOI 10.1093/bioinformatics/btq054
   Marques VD, 2019, PEDIATR NEUROL, V91, P3, DOI 10.1016/j.pediatrneurol.2018.11.003
   Munjal A, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01469
   Pomar L, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4431
   Ramos CL, 2018, J INFECTION, V76, P565, DOI 10.1016/j.jinf.2018.02.004
   Reiber H, 1998, MULT SCLER, V4, P99, DOI 10.1191/135245898678909439
NR 18
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0163-4453
EI 1532-2742
J9 J INFECTION
JI J. Infect.
PD APR
PY 2020
VL 80
IS 4
BP 419
EP 425
DI 10.1016/j.jinf.2020.01.006
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA KW5XS
UT WOS:000521239700007
PM 31981639
DA 2020-12-17
ER

PT J
AU Camargos, P
   Nascimento-Carvalho, CM
   Teixeira, R
   Franca, E
AF Camargos, Paulo
   Nascimento-Carvalho, Cristiana M.
   Teixeira, Renato
   Franca, Elisabeth
TI Lower respiratory infections mortality among Brazilians under-five
   before and after national pneumococcal conjugate vaccine implementation
SO VACCINE
LA English
DT Article
DE Pneumococcal conjugate vaccine; PCV 10; Vaccine effectiveness;
   Mortality; Pneumonia
ID CHILDREN; DISEASE; MENINGITIS; PNEUMONIA; BURDEN; IMPACT; AGE
AB Background: Studies on the impact of pneumococcal conjugate vaccines (PCV) on mortality, especially among preschoolers are scarce. We aimed to assess time trend mortality from lower respiratory infections (LRI), taken as a proxy of pneumonia, from 1990 to 2017.
   Methods: This ecological study assessed the mortality rate among Brazilians under-five before and after the national PCV-10 implementation in 2010. Pneumococcal meningitis (PM) and diarrhea] diseases (DD) were included as a "positive and negative controls", respectively. Trend analysis was performed through Global Burden of Disease estimates. Joinpoint regression modeling was used to describe trends in mortality and to identify time points of its statistically significant decreases throughout the study period.
   Results: There was a sustainable reduction in mortality rates for these three diseases, with no relevant changes in the secular trends for LRI and PM after the PCV-10 implementation. For LRI, PM, and DD the higher and statistically significant (p < 0.05) annual percent change reduction occurred between 2000 and 2003, (-8.3%), 1997-2000 (-11.9%), and 1990-1994.
   (-13.8%), respectively, i.e., several years before the nationwide implementation of PCV-10. Moreover, for LRI the annual percent change (from -5.9 to -8.8) verified from 1990 to 2009, i.e., 20 years before countrywide vaccination, was comparable to that observed during the PCV era, that is, from minus 5.8 to minus 7.8, between 2010 and 2017.
   Conclusion: Mortality from LRI, PM, and DD decreased over time, irrespective of national PCV-10 implementation in Brazil. Other factors such as healthcare delivery, socioeconomic status improvement, and health interventions may have impacted this secular trend. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Camargos, Paulo; Teixeira, Renato; Franca, Elisabeth] Univ Fed Minas Gerais, Sch Med, Belo Horizonte, MG, Brazil.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Salvador, BA, Brazil.
RP Camargos, P (corresponding author), Univ Fed Minas Gerais, Med Sch, Dept Paediat, Ave Alfredo Balena 190,Room 267, BR-30130100 Belo Horizonte, MG, Brazil.
EM pcamargs@medicina.ufmg.br
OI Nascimento-Carvalho, Cristiana/0000-0002-3942-2492
FU Brazilian Ministry of Health (GBD 2017 Brasilia, Brazil, through the
   National Health Fund) [17217.9850001/17-018]
FX Brazilian Ministry of Health (GBD 2017 Brasilia, Brazil, through the
   National Health Fund, Grant number 17217.9850001/17-018). The Brazilian
   Ministry of Health had no influence in the design and conduct of the
   study; in the collection, management, analysis, and data interpretation;
   in the writing, review, or approval of the manuscript, and in the
   decision to submit the paper for publication.
CR [Anonymous], 2017, JOINP REGR VERS 4 5
   [Anonymous], 1989, REV SAUDE PUBLICA, V23, P388, DOI 10.1590/S0034- 89101989000500005
   Bahwere P, 2004, PEDIATR INFECT DIS J, V23, P739, DOI 10.1097/01.inf.0000135663.17018.51
   Brandileone MCC, 2018, VACCINE, V36, P2559, DOI 10.1016/j.vaccine.2018.04.010
   Brazilian Ministry of Health, NAT IMM PROGR INF SY
   Caierao J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111129
   de Oliveira LH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166736
   Diaz J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153141
   Domingues CMAS, 2014, LANCET RESP MED, V2, P464, DOI 10.1016/S2213-2600(14)70060-8
   Dowell SF, 2000, NEW ENGL J MED, V342, P1399, DOI 10.1056/NEJM200005113421904
   Grando IM, 2015, CAD SAUDE PUBLICA, V31, P276, DOI 10.1590/0102-311X00169913
   Hirose TE, 2015, J PEDIAT-BRAZIL, V91, P130, DOI 10.1016/j.jped.2014.07.002
   Kupek E, 2016, CAD SAUDE PUBLICA, V32, DOI 10.1590/0102-311X00131414
   Madhi SA, 2013, PEDIATR INFECT DIS J, V32, pE119, DOI 10.1097/INF.0b013e3182784b26
   Minamisava R, 2014, PNEUMONIA, V3, P248
   Morais Rinaldo Macedo de, 2017, Saúde debate, V41, P101, DOI 10.1590/0103-11042017s09
   Naghavi M, 2017, LANCET, V390, P1151, DOI 10.1016/S0140-6736(17)32152-9
   Nascimento-Carvalho CM, 2008, PEDIATR INFECT DIS J, V27, P939, DOI 10.1097/INF.0b013e3181723751
   O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6
   Roth GA, 2018, LANCET, V392, P1736, DOI [10.1016/S0140-6736(18)32203-7, 10.1016/s0140-6736(18)32203-7]
   Schuck-Paim C, 2019, LANCET GLOB HEALTH, V7, pE249, DOI 10.1016/S2214-109X(18)30455-8
   Suarez V, 2016, VACCINE, V34, P4738, DOI 10.1016/j.vaccine.2016.07.027
   Troeger C, 2018, LANCET INFECT DIS, V18, P1191, DOI 10.1016/S1473-3099(18)30310-4
   Troeger C, 2017, LANCET INFECT DIS, V17, P909, DOI 10.1016/S1473-3099(17)30276-1
   von Mollendorf C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179905
   Wang HD, 2017, LANCET, V390, P1084, DOI 10.1016/S0140-6736(17)31833-0
NR 26
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 4
PY 2020
VL 38
IS 11
BP 2559
EP 2565
DI 10.1016/j.vaccine.2020.01.084
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KX1PD
UT WOS:000521654200016
PM 32033849
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, CM
AF Nascimento-Carvalho, Cristiana M.
TI Community-acquired pneumonia among children: the latest evidence for an
   updated management
SO JORNAL DE PEDIATRIA
LA English
DT Review
DE Child; Community-acquired pneumonia; Diagnosis; Etiology; Treatment
ID STREPTOCOCCUS-PNEUMONIAE; HAEMOPHILUS-INFLUENZAE; ANTIBIOTIC-TREATMENT;
   PEDIATRIC PNEUMONIA; SYSTEMATIC ANALYSIS; CHEST RADIOGRAPHS; NATIONAL
   CAUSES; DOUBLE-BLIND; MORTALITY; AMOXICILLIN
AB Objective: To provide cutting-edge information for the management of community-acquired pneumonia in children under 5 years, based on the latest evidence published in the literature.
   Data source: A comprehensive search was conducted in PubMed, by using the expressions: "community-acquired pneumonia" AND "child" AND "etiology" OR "diagnosis" OR "severity" OR "antibiotic". All articles retrieved had the title and the abstract read, when the papers reporting the latest evidence on each subject were identified and downloaded for complete reading.
   Data synthesis: In the era of largely implemented bacterial conjugate vaccines and widespread use of amplification nucleic acid techniques, respiratory viruses have been identified as the most frequent causative agents of community-acquired pneumonia in patients under 5 years. Hypoxemia (oxygen saturation <= 96%) and increased work of breathing are signs most associated with community-acquired pneumonia. Wheezing detected on physical examination independently predicts viral infection and the negative predictive value (95% confidence interval) of normal chest X-ray and serum procalcitonin <0.25 ng/dL was 92% (77-98%) and 93% (90-99%), respectively. Inability to drink/feed, vomiting everything, convulsions, lower chest indrawing, central cyanosis, lethargy, nasal flaring, grunting, head nodding, and oxygen saturation <90% are predictors of death and can be used as indicators for hospitalization. Moderate/large pleural effusions and multilobar infiltrates are predictors of severe disease. Orally administered amoxicillin is the first line outpatient treatment, while ampicillin, aqueous penicillin G. or amoxicillin (initiated initially by intravenous route) are the first line options to treat inpatients.
   Conclusions: Distinct aspects of childhood community-acquired pneumonia have changed during the last three decades. (C) 2019 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda.
C1 [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia UFBA, Fac Med Bahia, Dept Pediat, Salvador, BA, Brazil.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia UFBA, Programa Posgrad Ciencias Saude, Salvador, BA, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia UFBA, Fac Med Bahia, Dept Pediat, Salvador, BA, Brazil.; Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia UFBA, Programa Posgrad Ciencias Saude, Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
OI Nascimento-Carvalho, Cristiana/0000-0002-3942-2492
CR Andes D, 2004, CLIN LAB MED, V24, P477, DOI 10.1016/j.cll.2004.03.009
   Andrade DC, 2018, J PEDIAT-BRAZIL, V94, P23, DOI 10.1016/j.jped.2017.03.004
   Benet T, 2017, AM J TROP MED HYG, V97, P68, DOI 10.4269/ajtmh.16-0733
   Benet T, 2017, CLIN INFECT DIS, V65, P604, DOI 10.1093/cid/cix378
   Berg AS, 2017, EUR J PEDIATR, V176, P629, DOI 10.1007/s00431-017-2887-y
   Bhuiyan MU, 2019, BMC PULM MED, V19, DOI 10.1186/s12890-019-0835-5
   Bhuiyan MU, 2019, THORAX, V74, P261, DOI 10.1136/thoraxjnl-2018-212096
   Borges IC, 2015, EUR J CLIN MICROBIOL, V34, P1551, DOI 10.1007/s10096-015-2385-y
   Bradley JS, 2011, CLIN INFECT DIS, V53, pE25, DOI 10.1093/cid/cir531
   Brandao A, 2014, ANTIMICROB AGENTS CH, V58, P1343, DOI 10.1128/AAC.01951-13
   Brazilian Ministry of Health, 2017, INF SAUD
   Cherian T, 2005, B WORLD HEALTH ORGAN, V83, P353
   Esposito S, 2012, PEDIATR INFECT DIS J, V31, pE78, DOI 10.1097/INF.0b013e318255dc5b
   Esposito S, 2011, RESP MED, V105, P1939, DOI 10.1016/j.rmed.2011.09.003
   Floyd J, 2015, NATURE, V528, pS53, DOI 10.1038/nature16043
   Fonseca TS, 2019, CLIN CHIM ACTA, V489, P212, DOI 10.1016/j.cca.2017.12.021
   Fonseca W, 2003, ANTIMICROB AGENTS CH, V47, P997, DOI 10.1128/AAC.47.3.997-1001.2003
   Gallagher KE, 2020, CLIN INFECT DIS, V70, P1050, DOI 10.1093/cid/ciz350
   Gessner BD, 2005, EPIDEMIOL INFECT, V133, P877, DOI 10.1017/S0950268805004449
   Greenberg D, 2014, PEDIATR INFECT DIS J, V33, P136, DOI 10.1097/INF.0000000000000023
   Haider BA, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005976.pub2
   Higdon MM, 2017, CLIN INFECT DIS, V64, pS378, DOI 10.1093/cid/cix150
   JADAVJI T, 1997, CMAJ, V156, pS70
   Katz SE, 2018, INFECT DIS CLIN N AM, V32, P47, DOI 10.1016/j.idc.2017.11.002
   Liu L, 2016, LANCET, V388, P3027, DOI 10.1016/S0140-6736(16)31593-8
   Liu L, 2012, LANCET, V379, P2151, DOI 10.1016/S0140-6736(12)60560-1
   Madhi SA, 2013, PEDIATR INFECT DIS J, V32, pE119, DOI 10.1097/INF.0b013e3182784b26
   McClain L, 2014, J HOSP MED, V9, P559, DOI 10.1002/jhm.2227
   McCollum ED, 2016, B WORLD HEALTH ORGAN, V94, P893, DOI 10.2471/BLT.16.173401
   McIntosh K, 2002, NEW ENGL J MED, V346, P429, DOI 10.1056/NEJMra011994
   Modi P, 2013, J EMERG MED, V45, P752, DOI 10.1016/j.jemermed.2013.04.041
   Nagy B, 2013, PEDIATR PULM, V48, P168, DOI 10.1002/ppul.22574
   Nair H, 2013, LANCET, V381, P1380, DOI 10.1016/S0140-6736(12)61901-1
   Nascimento-Carvalho AC, 2019, PEDIATR PULM, V54, P1022, DOI 10.1002/ppul.24339
   Nascimento-Carvalho AC, 2019, EXPERT OPIN PHARMACO, V20, P435, DOI 10.1080/14656566.2018.1552257
   Nascimento-Carvalho AC, 2018, J CLIN VIROL, V105, P77, DOI 10.1016/j.jcv.2018.06.003
   Nascimento-Carvalho AC, 2018, PEDIATR PULM, V53, P88, DOI 10.1002/ppul.23891
   Nascimento-Carvalho C M, 2001, Braz J Infect Dis, V5, P87
   Nascimento-Carvalho CM, 2008, PEDIATR INFECT DIS J, V27, P939, DOI 10.1097/INF.0b013e3181723751
   Nascimento-Carvalho CM, 2017, J ANTIMICROB CHEMOTH, V72, P2378, DOI 10.1093/jac/dkx126
   Nascimento-Carvalho CM, 2016, EXPERT OPIN PHARMACO, V17, P53, DOI 10.1517/14656566.2016.1109633
   Nascimento-Carvalho CM, 2015, PEDIATR INFECT DIS J, V34, P490, DOI 10.1097/INF.0000000000000622
   Nascimento-Carvalho CM, 2014, PEDIATR INFECT DIS J, V33, P229, DOI 10.1097/INF.0000000000000121
   Nascimento-Carvalho CM, 2013, PEDIATR INFECT DIS J, V32, P1281, DOI 10.1097/INF.0b013e3182a4dcfa
   Nascimento-Carvalho CM, 2012, J MED VIROL, V84, P253, DOI 10.1002/jmv.22268
   Nascimento-Carvalho CM, 2011, INFLUENZA OTHER RESP, V5, P285, DOI 10.1111/j.1750-2659.2011.00206.x
   Nascimento-Carvalho CM, 2009, J MED MICROBIOL, V58, P1390, DOI 10.1099/jmm.0.007765-0
   Nascimento-Carvalho Cristiana M.C., 2002, Braz J Infect Dis, V6, P22, DOI 10.1590/S1413-86702002000100004
   NASCIMENTOCARVALHO, 2004, PAN AM J PUBLIC HLTH, V15, P380
   Nolan VG, 2018, J INFECT DIS, V218, P179, DOI 10.1093/infdis/jix641
   Pneumonia Etiology Research for Child Health (PERCH) Study Group, 2019, LANCET, DOI [10.1016/50140-6736(19)30771-4, DOI 10.1016/50140-6736(19130771-4]
   Rajapakse NS, 2016, PAED CHILD HEALT-CAN, V21, P65, DOI 10.1093/pch/21.2.65
   Reese RE, 2000, HDB ANTIBIOTICS
   Rhedin S, 2015, THORAX, V70, P847, DOI 10.1136/thoraxjnl-2015-206933
   Ruuskanen O, 2011, LANCET, V377, P1264, DOI 10.1016/S0140-6736(10)61459-6
   Sazawal S, 2003, LANCET INFECT DIS, V3, P547, DOI 10.1016/S1473-3099(03)00737-0
   Shah D, 2008, INDIAN PEDIATR, V45, P577
   Shah SN, 2017, JAMA-J AM MED ASSOC, V318, P462, DOI 10.1001/jama.2017.9039
   SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017
   Simbalista R, 2011, CLINICS, V66, P95, DOI 10.1590/S1807-59322011000100017
   Srugo I, 2017, PEDIATRICS, V140
   Stern A, 2017, COCHRANE DB SYST REV, V12
   Tagarro A, 2017, J PEDIATR-US, V185, P117, DOI 10.1016/j.jpeds.2017.02.043
   van Houten CB, 2017, LANCET INFECT DIS, V17, P431, DOI 10.1016/S1473-3099(16)30519-9
   van Werkhoven CH, 2017, HUM VACC IMMUNOTHER, V13, P1177, DOI 10.1080/21645515.2016.1264548
   Vasconcellos AG, 2018, CYTOKINE, V107, P1, DOI 10.1016/j.cyto.2017.11.005
   Vilas-Boas AL, 2014, J ANTIMICROB CHEMOTH, V69, P1954, DOI 10.1093/jac/dku070
   Wahl B, 2018, LANCET GLOB HEALTH, V6, pE744, DOI 10.1016/S2214-109X(18)30247-X
   *WHO, 1994, AC RESP INF CHILDR C
   World Bank, UPP MIDDL INC
   World Health Organization, 2013, GUID MAN COMM CHILDH
   World Health Organization, 1990, AC RESP INF CHILDR C
NR 72
TC 1
Z9 2
U1 0
U2 1
PU SOC BRASIL PEDIATRIA
PI RIO DE JANEIRO, RJ
PA RUA SANTA CLARA 292, RIO DE JANEIRO, RJ, CEP 22401-01, BRAZIL
SN 0021-7557
EI 1678-4782
J9 J PEDIAT-BRAZIL
JI J. Pediatr.
PD MAR-APR
PY 2020
VL 96
SU 1
BP 29
EP 38
DI 10.1016/j.jped.2019.08.003
PG 10
WC Pediatrics
SC Pediatrics
GA LG5TX
UT WOS:000528163900005
PM 31518547
OA DOAJ Gold, Green Published
DA 2020-12-17
ER

PT J
AU Salgado, VR
   Fukutani, KF
   Fukutani, E
   Lima, JV
   Rossi, EA
   Barral, A
   de Oliveira, CI
   Nascimento-Carvalho, C
   Van Weyenbergh, J
   Queiroz, ATL
AF Salgado, Vanessa R.
   Fukutani, Kiyoshi F.
   Fukutani, Eduardo
   Lima, Joao V.
   Rossi, Erik A.
   Barral, Aldina
   de Oliveira, Camila I.
   Nascimento-Carvalho, Cristiana
   Van Weyenbergh, Johan
   Queiroz, Artur T. L.
TI Effects of 10-valent pneumococcal conjugate (PCV10) vaccination on the
   nasopharyngeal microbiome
SO VACCINE
LA English
DT Article
DE PCV10; Microbiome; Vaccine
ID HAEMOPHILUS-INFLUENZAE; GUT MICROBIOME; CARRIAGE; HEALTH
AB Pathogenic bacteria, such as Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae and Moraxella catarrhalis, are important vaccine targets. The 10-valent pneumococcal conjugate vaccine (PCV10) acts on 10 differents S. pneumoniae serovars. However, this vaccine could also act on other bacteria genera, leading to dysbiosis. Moreover, the vaccination has also been associated with imbalances in the ratio between commensal and potentially pathogenic bacteria. Despite the wealth of studies assessing the influence of the microbiome on vaccine effects, how vaccination can influence the microbiome remains poorly understood. Herein, we assessed the effects of PCV10 on infant nasopharyngeal microbiome composition. Nasopharyngeal aspirates were collected from children with acute respiratory infection (ARI) aged 6-23 months. Two groups were composed of 48 vaccinated and 36 unvaccinated subjects. 16S ribosomal RNA sequencing was performed to assess bacterial composition and results were analyzed with QIIME. Similar bacterial compositions were observed in the unvaccinated and vaccinated samples. Principal component analysis also indicated a similar bacterial composition between the groups. In addition, bacterial diversity was not different between the vaccinated and unvaccinated samples. Accordingly, our results suggest that PCV10 vaccination promotes a specific response against its targets, thereby preserving the nosocomial microbiome. Although not statistically significant, Streptococcus and Haemophilus genera were increased in the vaccinated group, while Moraxella was decreased. Increases in Streptococcus may be associated with vaccine-target taxa replacement by non-pathogenic species. In sum, we observed that PCV10 vaccination acts by promoting a target-specific action against pathogenic bacteria and also induces commensal bacteria colonization without substantially changing the nasopharyngeal microbiome. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Salgado, Vanessa R.; Fukutani, Eduardo; Rossi, Erik A.; Barral, Aldina; de Oliveira, Camila I.; Queiroz, Artur T. L.] Oswaldo Cruz Fdn FIOCRUZ, Goncalo Moniz Inst, Salvador, BA, Brazil.
   [Fukutani, Kiyoshi F.; Queiroz, Artur T. L.] Fundacao Jose Silveira, MONSTER, Salvador, BA, Brazil.
   [Fukutani, Kiyoshi F.] Fac Tecnol & Ciencia, Salvador, BA, Brazil.
   [Fukutani, Eduardo; Lima, Joao V.; Queiroz, Artur T. L.] Oswaldo Cruz Fdn FIOCRUZ, Ctr Data & Knowledge Integrat Hlth, Goncalo Moniz Inst, Salvador, BA, Brazil.
   [Nascimento-Carvalho, Cristiana] Univ Fed Bahia, Postgrad Programme Hlth Sci, Sch Med, Salvador, BA, Brazil.
   [Nascimento-Carvalho, Cristiana] Univ Fed Bahia, Dept Pediat, Sch Med, Salvador, BA, Brazil.
   [Van Weyenbergh, Johan] Katholieke Univ Leuven, Dept Microbiol & Immunol, Rega Inst Med Res, Leuven, Belgium.
RP Van Weyenbergh, J; Queiroz, ATL (corresponding author), Oswaldo Cruz Fdn FIOCRUZ, Goncalo Moniz Inst, Salvador, BA, Brazil.
EM artur.queiroz@fiocruz.br
RI Van Weyenbergh, Johan/B-4187-2009
OI Van Weyenbergh, Johan/0000-0003-3234-8426; Nascimento-Carvalho,
   Cristiana/0000-0002-3942-2492
FU program Inova Fiocruz [VPPIS001-FIO18]; Pronex/FAPESB [PNX0019/2009]
FX We thank Ms. Suzane de Oliveira and Mr Olival Rocha for their
   assistance. We also are grateful to Dr. Pablo Ivan Pereira Ramos for his
   support and counsel during the modelling analysis. KFF thanks Dr. Alana
   Alves Farias for her inspiration. The authors would also like to thank
   Andris K. Walter for English language revision and manuscript
   copyediting assistance. AQ acknowledges financial support from the
   program Inova Fiocruz (Project number VPPIS001-FIO18). AB acknowledges
   financial support from the Pronex/FAPESB (Project number PNX0019/2009).
CR Abt MC, 2014, CURR OPIN IMMUNOL, V29, P16, DOI 10.1016/j.coi.2014.03.003
   Andrade DC, 2017, VACCINE, V35, P4105, DOI 10.1016/j.vaccine.2017.06.048
   Biesbroek G, 2014, AM J RESP CRIT CARE, V190, P1283, DOI 10.1164/rccm.201407-1240OC
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Brown EM, 2013, NAT IMMUNOL, V14, P660, DOI 10.1038/ni.2611
   Camilli R, 2015, VACCINE, V33, P4559, DOI 10.1016/j.vaccine.2015.07.009
   Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303
   Chaban B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069559
   Cremers AJH, 2014, MICROBIOME, V2, DOI 10.1186/2049-2618-2-44
   Dickson RP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097214
   Dunne EM, 2013, VACCINE, V31, P2333, DOI 10.1016/j.vaccine.2013.03.024
   Feazel LM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128064
   Folsgaard NV, 2013, AM J RESP CRIT CARE, V187, P589, DOI 10.1164/rccm.201207-1297OC
   Frank DN, 2011, TRENDS MICROBIOL, V19, P427, DOI 10.1016/j.tim.2011.06.005
   Fukutani KF, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02475
   Geer LY, 2010, NUCLEIC ACIDS RES, V38, pD492, DOI 10.1093/nar/gkp858
   Gritzfeld JF, 2013, JOVE-J VIS EXP, DOI 10.3791/50115
   Haas BJ, 2011, GENOME RES, V21, P494, DOI 10.1101/gr.112730.110
   Harris VC, 2017, J INFECT DIS, V215, P34, DOI 10.1093/infdis/jiw518
   Hibbing ME, 2010, NAT REV MICROBIOL, V8, P15, DOI 10.1038/nrmicro2259
   Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578
   Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048
   Ichinohe T, 2011, P NATL ACAD SCI USA, V108, P5354, DOI 10.1073/pnas.1019378108
   Kwambana-Adams B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08717-0
   Morris A, 2013, AM J RESP CRIT CARE, V187, P1067, DOI 10.1164/rccm.201210-1913OC
   Perez GF, 2017, J INVEST MED, V65, P984, DOI 10.1136/jim-2017-000414
   Peterson J, 2009, GENOME RES, V19, P2317, DOI 10.1101/gr.096651.109
   Piters WAAD, 2016, ISME J, V10, P97, DOI 10.1038/ismej.2015.99
   Pulendran B, 2014, P NATL ACAD SCI USA, V111, P12300, DOI 10.1073/pnas.1400476111
   Quast C, 2013, NUCLEIC ACIDS RES, V41, pD590, DOI 10.1093/nar/gks1219
   Reid G, 2011, NAT REV MICROBIOL, V9, P27, DOI 10.1038/nrmicro2473
   Salgado VR, 2016, MEM I OSWALDO CRUZ, V111, P241, DOI 10.1590/0074-02760150436
   Salk HM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162803
   Segal LN, 2013, MICROBIOME, V1, DOI 10.1186/2049-2618-1-19
   Shreiner AB, 2015, CURR OPIN GASTROEN, V31, P69, DOI 10.1097/MOG.0000000000000139
   Smit LAM, 2017, PNEUMONIA, V9, DOI 10.1186/s41479-017-0027-0
   Teo SM, 2015, CELL HOST MICROBE, V17, P704, DOI 10.1016/j.chom.2015.03.008
   van den Bergh MR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047711
   van Gils EJM, 2011, VACCINE, V29, P7595, DOI 10.1016/j.vaccine.2011.08.049
   Vangay P, 2015, CELL HOST MICROBE, V17, P553, DOI 10.1016/j.chom.2015.04.006
   Vesikari T, 2016, J PEDIAT INF DIS SOC, V5, P237, DOI 10.1093/jpids/piw010
   Xu QF, 2012, EMERG INFECT DIS, V18, P1738, DOI 10.3201/eid1811.111904
   Zarco MF, 2012, ORAL DIS, V18, P109, DOI 10.1111/j.1601-0825.2011.01851.x
NR 43
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1436
EP 1443
DI 10.1016/j.vaccine.2019.11.079
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900020
PM 31839468
OA Other Gold
DA 2020-12-17
ER

PT J
AU Ventura, PA
   Lage, MLC
   de Carvalho, AL
   Fernandes, AS
   Taguchi, TB
   Nascimento-Carvalho, CM
AF Ventura, Paloma A.
   Lage, Maria-Lucia C.
   de Carvalho, Alessandra L.
   Fernandes, Adriana S.
   Taguchi, Tania B.
   Nascimento-Carvalho, Cristiana M.
TI Early Gross Motor Development Among Brazilian Children with Microcephaly
   Born Right After Zika Virus Infection Outbreak
SO JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS
LA English
DT Article
DE Zika virus; cerebral palsy; congenital microcephaly; developmental
   delay; gross motor skills
ID CEREBRAL-PALSY; INFANTS
AB Objective: To assess the gross motor development of children with presumed congenital Zika virus (ZIKV) infection over the first 2 years of their lives. Methods: Seventy-seven children were assessed at the median ages of 11, 18, and 24 months, using the evaluative instrument Gross Motor Function Measure (GMFM-66). At the third assessment, the children with diagnoses of cerebral palsy (CP) were classified by severity through the Gross Motor Function Classification System (GMFCS) and stratified by topography indicating the predominantly affected limbs. With these instruments in combination and using the motor development curves as reference, the rate of development and functional ability were estimated. Results: At 2 years of age, all children had the diagnosis of CP. Seventy-four (96.1%) presented gross motor skills similar to those of children aged 4 months or younger, according to the World Health Organization's standard. The GMFM-66 median score among the 73 (94.8%) children with quadriplegia and GMFCS level V showed significant change between 11 and 18 months (p < 0.001) and between 11 and 24 months (p < 0.001). No significant difference (p = 0.076) was found between 18 and 24 months. Conclusion: Despite showing some gross motor progress during the initial 18 months of life, these children with presumed congenital ZIKV infection and CP experienced severe motor impairment by 2 years of age. According to the motor development curves, these children with quadriplegia have probably already reached about 90% of their motor development potential.
C1 [Ventura, Paloma A.; Lage, Maria-Lucia C.; Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Postgrad Program Hlth Sci, Salvador, BA, Brazil.
   [Ventura, Paloma A.; de Carvalho, Alessandra L.; Fernandes, Adriana S.; Taguchi, Tania B.] SARAH Network Rehabil Hosp, Salvador, BA, Brazil.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Dept Paediat, Sch Med, Salvador, BA, Brazil.
RP Ventura, PA (corresponding author), SARAH Salvador Hosp, Ave Tancredo Neves 2782, BR-41820900 Salvador, BA, Brazil.
EM molima2010@gmail.com
CR [Anonymous], 2016, PROT VIG RESP OC MIC, P55
   Ashwal S, 2009, NEUROLOGY, V73, P887, DOI 10.1212/WNL.0b013e3181b783f7
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Cardoso CW, 2015, EMERG INFECT DIS, V21, P2274, DOI 10.3201/eid2112.151167
   Cardoso TF, 2019, ARCH DIS CHILD, V104, P199, DOI 10.1136/archdischild-2018-314782
   Carvalho AL, 2019, CLIN MICROBIOL INFEC, V25, P524, DOI 10.1016/j.cmi.2018.12.021
   Ferreira HNC, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15061107
   de Oliveira-Szejnfeld PS, 2016, RADIOLOGY, V281, P203, DOI 10.1148/radiol.2016161584
   del Campo M, 2017, AM J MED GENET A, V173, P841, DOI 10.1002/ajmg.a.38170
   Delaney A, 2018, MMWR-MORBID MORTAL W, V67, P91, DOI 10.15585/mmwr.mm6703a2
   Gorter JW, 2004, DEV MED CHILD NEUROL, V46, P461, DOI 10.1017/S0012162204000763
   Hanna SE, 2008, PHYS THER, V88, P596, DOI 10.2522/ptj.20070314
   Kapogiannis BG, 2017, JAMA PEDIATR, V171, P478, DOI 10.1001/jamapediatrics.2017.0002
   Marques FJP, 2019, J CHILD NEUROL, V34, P81, DOI 10.1177/0883073818811234
   Martorell R, 2006, ACTA PAEDIATR, V95, P86, DOI 10.1080/08035320500495563
   Melo A, 2019, DEV MED CHILD NEUROL
   Moore CA, 2017, JAMA PEDIATR, V171, P288, DOI 10.1001/jamapediatrics.2016.3982
   da Silva AAM, 2016, EMERG INFECT DIS, V22, P1953, DOI 10.3201/eid2211.160956
   Mysorekar IU, 2016, NEW ENGL J MED, V375, P481, DOI 10.1056/NEJMcibr1605445
   Novak I, 2017, JAMA PEDIATR, V171, P897, DOI 10.1001/jamapediatrics.2017.1689
   Palisano R, 1997, DEV MED CHILD NEUROL, V39, P214, DOI 10.1111/j.1469-8749.1997.tb07414.x
   Pessoa A, 2018, PEDIATRICS, V141, pS167, DOI 10.1542/peds.2017-2038F
   Rosenbaum P, 2007, DEV MED CHILD NEUROL, V49, P8, DOI 10.1111/j.1469-8749.2007.tb12610.x
   Rosenbaum PL, 2002, JAMA-J AM MED ASSOC, V288, P1357, DOI 10.1001/jama.288.11.1357
   RUSSELL DJ, 1989, DEV MED CHILD NEUROL, V31, P341
   Satterfield-Nash A, 2017, MMWR-MORBID MORTAL W, V66, P1347, DOI 10.15585/mmwr.mm6649a2
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
   Soares-Marangoni DD, 2019, DEV NEUROREHABIL, V22, P71, DOI 10.1080/17518423.2018.1437843
   van der Linden V, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i3899
   Aragao MDV, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i1901
   Wheeler AC, 2018, PEDIATRICS, V141, pS154, DOI [10.1542/peds.2017-2038D, 10.1542/peds.2017-2038d]
   Zafeiriou DI, 2004, PEDIATR NEUROL, V31, P1, DOI 10.1016/j.pediatrneurol.2004.01.012
NR 32
TC 3
Z9 3
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0196-206X
EI 1536-7312
J9 J DEV BEHAV PEDIATR
JI J. Dev. Behav. Pediatr.
PD FEB-MAR
PY 2020
VL 41
IS 2
BP 134
EP 140
DI 10.1097/DBP.0000000000000722
PG 7
WC Behavioral Sciences; Psychology, Developmental; Pediatrics
SC Behavioral Sciences; Psychology; Pediatrics
GA LE6SH
UT WOS:000526852800080
PM 31453893
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, EC
   Vasconcellos, AG
   Clarencio, J
   Andrade, D
   Barral, A
   Barral-Netto, M
   Nascimento-Carvalho, CM
AF Nascimento-Carvalho, Eduardo C.
   Vasconcellos, Angela G.
   Clarencio, Jorge
   Andrade, Daniela
   Barral, Aldina
   Barral-Netto, Manoel
   Nascimento-Carvalho, Cristiana M.
TI Evolution of cytokines/chemokines in cases with community-acquired
   pneumonia and distinct etiologies
SO PEDIATRIC PULMONOLOGY
LA English
DT Article
DE acute respiratory infection; child; lower respiratory tract infection;
   lung disease; pneumococcal infection
ID STREPTOCOCCUS-PNEUMONIAE; PNEUMOCOCCAL PNEUMONIA; CHILDREN; INFECTION;
   DIAGNOSIS; BURDEN; ASSAYS; IL-6
AB C Aim: To compare the systemic cytokines/chemokines levels over time during the evolution of children hospitalized with community-acquired pneumonia (CAP) with and without pneumococcal infection.
   Methods: Children less than 5-years-old hospitalized with CAP were prospectively investigated in Salvador, Brazil. Clinical data and biological samples were collected to investigate 20 etiological agents and to determine serum cytokines/chemokines levels on admission and 2 to 4 weeks later. Cases with pneumococcal infection received this diagnosis irrespective of also having other etiologies.
   Results: A total of 277 patients were enrolled, however, serum sample was unavailable for cytokine measurement upon admission (n = 61) or upon follow-up visit (n = 36), etiology was undetected (n = 50) and one patient did not attend the follow-up visit. Therefore, this study group comprised of 129 cases with established etiology. The median (interquartile range) age and sampling interval was 18 (9-27) months and 18 (16-21) days, respectively. Established etiology was viral (52.0%), viral-bacterial (30.2%), and bacterial (17.8%). Pneumococcal infection was found in 31 (24.0%) patients. Overall, median interleukin-6 (IL-6; 10.6 [4.7-30.6] vs 21.0 [20.2-21.7]; P = .03), IL-10 (3.5 [3.1-4.5] vs 20.1 [19.8-20.4]; P < .001), and CCL2 (19.3 [12.4-23.2] vs 94.0 [67.2-117.8]; P < .001) were significantly higher in convalescent serum samples, whereas median CXCL10 (83.6 [36.4-182.9] vs 14.6 [0-116.6]; P < .001) was lower. Acute vs convalescent levels evolution of IL-10, CCL2, and CXCL10 did not differ among patients with or without pneumococcal infection. However, IL-6 decreased (27.8 [12.3-48.6] vs 20.8 [20.2-22.6]; P = .1) in patients with pneumococcal infection and increased (9.0 [4.2-22.6] vs 21.0 [20.2-21.7]; P = .001) in patients without it.
   Conclusion: The marked increase of IL-6 serum levels during the acute phase makes it a potential biomarker of pneumococcal infection among children with CAP.
C1 [Nascimento-Carvalho, Eduardo C.] Bahiana Fdn Sci Dev, Bahiana Sch Med & Publ Hlth, Salvador, BA, Brazil.
   [Nascimento-Carvalho, Eduardo C.; Clarencio, Jorge; Andrade, Daniela; Barral, Aldina; Barral-Netto, Manoel] Fundacao Oswaldo Cruz Fiocruz, Inst Goncalo Moniz, Salvador, BA, Brazil.
   [Vasconcellos, Angela G.; Barral, Aldina; Barral-Netto, Manoel; Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Postgrad Program Hlth Sci, Sch Med, Salvador, BA, Brazil.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Dept Pediat, Sch Med, Rua Prof Aristides Novis 105-1201B, BR-40210630 Salvador, BA, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia, Dept Pediat, Sch Med, Rua Prof Aristides Novis 105-1201B, BR-40210630 Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
RI Barral Netto, Manoel/B-3904-2009
OI Barral Netto, Manoel/0000-0002-5823-7903
FU Bahia State Agency for Research Funding [PNX 0019/2009]
FX Bahia State Agency for Research Funding, Grant/Award Number: PNX
   0019/2009
CR Andrade DC, 2016, J IMMUNOL METHODS, V433, P31, DOI 10.1016/j.jim.2016.02.021
   Atkinson TP, 2014, PEDIATR INFECT DIS J, V33, P92, DOI 10.1097/INF.0000000000000171
   Calbo E, 2008, ANTIMICROB AGENTS CH, V52, P2395, DOI 10.1128/AAC.00658-07
   Calbo E, 2010, INT J ANTIMICROB AG, V35, P107, DOI 10.1016/j.ijantimicag.2009.10.002
   El-Rashdi AS, 2006, ARCH DIS CHILD, V91, P351, DOI 10.1136/adc.2005.088831
   Fisher DT, 2014, SEMIN IMMUNOL, V26, P38, DOI 10.1016/j.smim.2014.01.008
   Fuchs A, 2018, CLIN MICROBIOL INFEC, V24, DOI 10.1016/j.cmi.2018.03.016
   Horn F, 2000, IMMUNOBIOLOGY, V202, P151, DOI 10.1016/S0171-2985(00)80061-3
   Hyypia T, 1998, J CLIN MICROBIOL, V36, P2081
   Katz SE, 2018, INFECT DIS CLIN N AM, V32, P47, DOI 10.1016/j.idc.2017.11.002
   Korppi M, 2010, PEDIATR INFECT DIS J, V29, P387, DOI 10.1097/INF.0b013e3181ce8e81
   Lieberman D, 1997, INFECTION, V25, P90, DOI 10.1007/BF02113582
   Liu L, 2015, LANCET, V385, P430, DOI 10.1016/S0140-6736(14)61698-6
   Makela MJ, 1998, J CLIN MICROBIOL, V36, P539
   Michelow IC, 2007, PEDIATR PULM, V42, P640, DOI 10.1002/ppul.20633
   Morre SA, 2002, J CLIN MICROBIOL, V40, P584, DOI 10.1128/JCM.40.2.584-587.2002
   Nair H, 2013, LANCET, V381, P1380, DOI 10.1016/S0140-6736(12)61901-1
   Nascimento-Carvalho CM, 2011, INFLUENZA OTHER RESP, V5, P285, DOI 10.1111/j.1750-2659.2011.00206.x
   NOHYNEK H, 1995, PEDIATR INFECT DIS J, V14, P478, DOI 10.1097/00006454-199506000-00003
   Padrones S, 2010, EUR J CLIN MICROBIOL, V29, P1243, DOI 10.1007/s10096-010-0993-0
   Saukkoriipi A, 2002, MOL CELL PROBE, V16, P385, DOI 10.1006/mcpr.2002.0443
   van der Poll T, 2009, LANCET, V374, P1543, DOI 10.1016/S0140-6736(09)61114-4
   Vasconcellos AG, 2018, CYTOKINE, V107, P1, DOI 10.1016/j.cyto.2017.11.005
   Wahl B, 2018, LANCET GLOB HEALTH, V6, pE744, DOI 10.1016/S2214-109X(18)30247-X
   Wang SP, 2000, J INFECT DIS, V181, pS421, DOI 10.1086/315622
   WHO UNICEF, 2008, INT MAN CHILDH ILLN
   World Health Organization, 2008, TRAIN COURS CHILD GR
   Yamaguchi T, 2005, FEMS IMMUNOL MED MIC, V43, P21, DOI 10.1016/j.femsim.2004.06.023
NR 28
TC 0
Z9 1
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8755-6863
EI 1099-0496
J9 PEDIATR PULM
JI Pediatr. Pulmonol.
PD JAN
PY 2020
VL 55
IS 1
BP 169
EP 176
DI 10.1002/ppul.24533
PG 8
WC Pediatrics; Respiratory System
SC Pediatrics; Respiratory System
GA KQ7QA
UT WOS:000517114100028
PM 31553527
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, AC
   Ruuskanen, O
   Nascimento-Carvalho, CM
AF Nascimento-Carvalho, Amanda C.
   Ruuskanen, Olli
   Nascimento-Carvalho, Cristiana M.
TI Wheezing independently predicts viral infection in children with
   community-acquired pneumonia
SO PEDIATRIC PULMONOLOGY
LA English
DT Article
DE acute respiratory infection; lower respiratory tract infection; lung
   disease; respiratory viruses; wheeze
ID DIAGNOSIS; ETIOLOGY; ASTHMA; ASSAYS
AB Aim To assess whether there was a difference in the frequency of symptoms and signs among children with community-acquired pneumonia (CAP) with viral or bacterial infection. Methods A prospective cross-sectional study was conducted in Salvador, Brazil. Children less than 5-years-old hospitalized with CAP were recruited. Viral or only bacterial infection was diagnosed by an investigation of 11 viruses and 8 bacteria. Bacterial infection was diagnosed by blood culture, detection of pneumococcal DNA in acute buffy coat, and serological tests. Viral infection was diagnosed by detection of respiratory virus in nasopharyngeal aspirate and serological tests. Viral infection comprised only viral or mixed viral-bacterial infection subgroups. Results One hundred and eighty-eight patients had a probable etiology established as only viral (51.6%), mixed viral-bacterial (30.9%), and only bacterial infection (17.5%). Asthma was registered for 21.4%. Report of wheezing (47.4% vs 21.2%; P = 0.006), rhonchi (38.0% vs 15.2%; P = 0.01), and wheezing detected on physical examination (51.0% vs 9.1%; P < 0.001) were the differences found. Among children with asthma, detected wheezing was the only different finding when children with viral infection were compared with those with only bacterial infection (75.0% vs 0%; P = 0.008). By multivariable analysis, viral infection (AdjOR [95% CI]: 9.6; 95%CI: 2.7-34.0), asthma (AdjOR [95% CI]: 4.6; 95%CI: 1.9-11.0), and age (AdjOR [95% CI]: 0.95; 95%CI: 0.92-0.97) were independently associated with wheezing on physical examination. The positive predictive value of detected wheezing for viral infection was 96.3% (95% CI: 90.4-99.1%). Conclusion Wheezing detected on physical examination is an independent predictor of viral infection.
C1 [Nascimento-Carvalho, Amanda C.] Bahiana Fdn Sci Dev, Bahiana Sch Med, Salvador, BA, Brazil.
   [Ruuskanen, Olli] Turku Univ, Dept Pediat, Turku, Finland.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
RP Nascimento-Carvalho, AC (corresponding author), Rua Prof Aristides Novis 105-1201B, BR-40210630 Salvador, BA, Brazil.
EM carvalhoacn@hotmail.com
FU Conselho Nacional de Desenvolvimento Cientifico e TecnologicoNational
   Council for Scientific and Technological Development (CNPq)
   [303551/2011-9]; Fundacao de Amparo a Pesquisa do Estado da Bahia
   [52/2004]; Brazilian Council for Scientific and Technological
   DevelopmentNational Council for Scientific and Technological Development
   (CNPq); Paediatric Research Foundation; Bahia State Agency for Research
   Funding
FX Conselho Nacional de Desenvolvimento Cientifico e Tecnologico,
   Grant/Award Number: 303551/2011-9; Fundacao de Amparo a Pesquisa do
   Estado da Bahia, Grant/Award Number: 52/2004; Bahia State Agency for
   Research Funding; Brazilian Council for Scientific and Technological
   Development; Paediatric Research Foundation
CR Atkinson TP, 2014, PEDIATR INFECT DIS J, V33, P92, DOI 10.1097/INF.0000000000000171
   Baumann P, 2017, FRONT PEDIATR, V5, DOI 10.3389/fped.2017.00183
   BROWNER WS, 1988, DESIGNING CLIN RES E, P139
   El-Rashdi AS, 2006, ARCH DIS CHILD, V91, P351, DOI 10.1136/adc.2005.088831
   Florin TA, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2017-0310
   Gilani Z, 2012, CLIN INFECT DIS, V54, pS102, DOI 10.1093/cid/cir1053
   Hyypia T, 1998, J CLIN MICROBIOL, V36, P2081
   Juven T, 2003, SCAND J PRIM HEALTH, V21, P52, DOI 10.1080/02813430310000573
   Koponen P, 2012, EUR RESPIR J, V39, P76, DOI 10.1183/09031936.00040211
   Korppi M, 2012, EUR RESPIR J, V39, P228, DOI 10.1183/09031936.00150811
   Korppi M, 2010, PEDIATR INFECT DIS J, V29, P387, DOI 10.1097/INF.0b013e3181ce8e81
   Kotaniemi-Syrjanen A, 2003, J ALLERGY CLIN IMMUN, V111, P66, DOI 10.1067/mai.2003.33
   Makela MJ, 1998, J CLIN MICROBIOL, V36, P539
   Morre SA, 2002, J CLIN MICROBIOL, V40, P584, DOI 10.1128/JCM.40.2.584-587.2002
   Nair H, 2013, LANCET, V381, P1380, DOI 10.1016/S0140-6736(12)61901-1
   Nascimento-Carvalho CM, 2008, PEDIATR INFECT DIS J, V27, P939, DOI 10.1097/INF.0b013e3181723751
   Nascimento-Carvalho CM, 2012, J MED VIROL, V84, P253, DOI 10.1002/jmv.22268
   Nascimento-Carvalho CM, 2011, INFLUENZA OTHER RESP, V5, P285, DOI 10.1111/j.1750-2659.2011.00206.x
   Nascimento-Carvalho CM, 2009, J INFECTION, V58, P250, DOI 10.1016/j.jinf.2009.01.008
   NOHYNEK H, 1995, PEDIATR INFECT DIS J, V14, P478, DOI 10.1097/00006454-199506000-00003
   Nolan VG, 2018, J INFECT DIS, V218, P179, DOI 10.1093/infdis/jix641
   Rhodes HL, 2001, J ALLERGY CLIN IMMUN, V108, P720, DOI 10.1067/mai.2001.119151
   Ruuskanen O, 2011, LANCET, V377, P1264, DOI 10.1016/S0140-6736(10)61459-6
   Saukkoriipi A, 2002, MOL CELL PROBE, V16, P385, DOI 10.1006/mcpr.2002.0443
   Self WH, 2018, CLIN INFECT DIS, V66, P1640, DOI 10.1093/cid/cix1090
   Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162
   World Health Organization, 2013, POCK BOOK HOSP CAR C
   Yamaguchi T, 2005, FEMS IMMUNOL MED MIC, V43, P21, DOI 10.1016/j.femsim.2004.06.023
NR 28
TC 3
Z9 3
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8755-6863
EI 1099-0496
J9 PEDIATR PULM
JI Pediatr. Pulmonol.
PD JUL
PY 2019
VL 54
IS 7
BP 1022
EP 1028
DI 10.1002/ppul.24339
PG 7
WC Pediatrics; Respiratory System
SC Pediatrics; Respiratory System
GA IE9FV
UT WOS:000472681200013
PM 31004407
DA 2020-12-17
ER

PT J
AU Souto, D
   Arajo-Neto, C
   Nascimento-Carvalho, CM
AF Souto, Debora
   Araujo-Neto, Cesar
   Nascimento-Carvalho, Cristiana M.
TI Radiological findings among children with community-acquired pneumonia
   with exclusively viral or bacterial infection: a prospective
   investigation
SO INFECTIOUS DISEASES
LA English
DT Letter
ID DIFFERENTIATION
C1 [Souto, Debora; Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Postgrad Program Hlth Sci, Salvador, BA, Brazil.
   [Araujo-Neto, Cesar] Univ Fed Bahia, Sch Med, Dept Image Diag, Salvador, BA, Brazil.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia, Sch Med, Postgrad Program Hlth Sci, Salvador, BA, Brazil.; Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
FU Bahia State Agency for Research Funding (FAPESB) [52/2004]; Brazilian
   Council for Scientific and Technological Development (CNPq)National
   Council for Scientific and Technological Development (CNPq)
   [03551-2011-9]
FX This study was supported by the Bahia State Agency for Research Funding
   (FAPESB) under Grant number 52/2004 and the Brazilian Council for
   Scientific and Technological Development (CNPq) under Grant number
   03551-2011-9. CMN-C is a senior investigator at CNPq.
CR Cevey-Macherel M, 2009, EUR J PEDIATR, V168, P1429, DOI 10.1007/s00431-009-0943-y
   Cherian T, 2005, B WORLD HEALTH ORGAN, V83, P353
   Don M, 2009, PEDIATR INT, V51, P91, DOI 10.1111/j.1442-200X.2008.02678.x
   Katsurada N, 2019, INFECT DIS-NOR, V51, P510, DOI 10.1080/23744235.2019.1600018
   Nascimento-Carvalho CM, 2015, PEDIATR INFECT DIS J, V34, P490, DOI 10.1097/INF.0000000000000622
   Ruuskanen O, 2011, LANCET, V377, P1264, DOI 10.1016/S0140-6736(10)61459-6
   Virkki R, 2002, THORAX, V57, P438, DOI 10.1136/thorax.57.5.438
NR 7
TC 0
Z9 0
U1 0
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 2374-4235
EI 2374-4243
J9 INFECT DIS-NOR
JI Infect. Dis.
PD AUG 3
PY 2019
VL 51
IS 8
BP 630
EP 632
DI 10.1080/23744235.2019.1627409
EA JUN 2019
PG 3
WC Infectious Diseases
SC Infectious Diseases
GA IM6HM
UT WOS:000475161200001
PM 31190592
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, AC
   Nascimento-Carvalho, CM
AF Nascimento-Carvalho, Amanda C.
   Nascimento-Carvalho, Cristiana M.
TI Clinical management of community-acquired pneumonia in young children
SO EXPERT OPINION ON PHARMACOTHERAPY
LA English
DT Review
DE Community-acquired pneumonia; antimicrobial therapy; children
ID ORAL AMOXICILLIN; ANTIBIOTIC-TREATMENT; DOUBLE-BLIND; ETIOLOGY;
   CHILDHOOD; GUIDELINES; PENICILLIN; BACTERIAL; EPIDEMIOLOGY; MORTALITY
AB Introduction: Community-acquired pneumonia (CAP) is the leading cause of mortality among children under 5 years worldwide. However, the choices of chemical therapy for the empirical treatment of CAP are frequently debated. Areas covered: The authors provide an update on the chemical management recommendations for childhood CAP. The authors have performed a MEDLINE literature search, using the keywords 'guidelines,' 'community-acquired pneumonia,' AND 'children.' Articles published in English, providing consensual recommendations on management of children >2 months and <5 years with CAP but without HIV infection, were included. Furthermore, the authors discuss the latest evidence guiding the rational use of antibiotics in young children with CAP. Expert opinion: For the chemical management of CAP, the first-line antibiotic options are amoxicillin (50 mg/kg/day, every 12 h) among ambulatory patients and aqueous penicillin G (200,000 IU/kg/day, every 6 h) or ampicillin (200 mg/kg/day, every 6 h) for hospitalized children. Ceftriaxone can be considered in the treatment of very severe cases. Oxacillin or macrolide may be added in specific situations, if Staphylococcus aureus or atypical bacteria, respectively, are potential etiological agents, although not deemed common. Penicillins remain the first-line choice of antibiotic for the treatment of CAP in young children.
C1 [Nascimento-Carvalho, Amanda C.] Bahiana Fdn Sci Dev, Bahiana Sch Med, Rua Prof Aristides Novis 105-1201B, BR-40210630 Salvador, BA, Brazil.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
RP Nascimento-Carvalho, AC (corresponding author), Bahiana Fdn Sci Dev, Bahiana Sch Med, Rua Prof Aristides Novis 105-1201B, BR-40210630 Salvador, BA, Brazil.
EM carvalhoacn@hotmail.com
CR Addo-Yobo E, 2004, LANCET, V364, P1141, DOI 10.1016/S0140-6736(04)17100-6
   [Anonymous], 2017, UN ANN INT GROUP COO
   Berg AS, 2017, EUR J PEDIATR, V176, P629, DOI 10.1007/s00431-017-2887-y
   Borges IC, 2015, EUR J CLIN MICROBIOL, V34, P1551, DOI 10.1007/s10096-015-2385-y
   Bradley JS, 2011, CLIN INFECT DIS, V53, pE25, DOI 10.1093/cid/cir531
   Brandao A, 2014, ANTIMICROB AGENTS CH, V58, P1343, DOI 10.1128/AAC.01951-13
   Esposito S, 2011, RESP MED, V105, P1939, DOI 10.1016/j.rmed.2011.09.003
   Fonseca TS, 2019, CLIN CHIM ACTA, V489, P212, DOI 10.1016/j.cca.2017.12.021
   Gessner BD, 2005, EPIDEMIOL INFECT, V133, P877, DOI 10.1017/S0950268805004449
   Greenberg D, 2014, PEDIATR INFECT DIS J, V33, P136, DOI 10.1097/INF.0000000000000023
   Haider BA, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005976.pub2
   Harris M, 2011, THORAX, V66, pII1, DOI 10.1136/thoraxjnl-2011-200598
   Hazir T, 2008, LANCET, V371, P49, DOI 10.1016/S0140-6736(08)60071-9
   Higdon MM, 2017, CLIN INFECT DIS, V64, pS378, DOI 10.1093/cid/cix150
   Jain S, 2015, NEW ENGL J MED, V372, P835, DOI 10.1056/NEJMoa1405870
   JIBRIL HB, 1989, CURR MED RES OPIN, V11, P585, DOI 10.1185/03007998909112675
   Juven T, 2003, SCAND J PRIM HEALTH, V21, P52, DOI 10.1080/02813430310000573
   Juven T, 2000, PEDIATR INFECT DIS J, V19, P293, DOI 10.1097/00006454-200004000-00006
   Katz SE, 2018, INFECT DIS CLIN N AM, V32, P47, DOI 10.1016/j.idc.2017.11.002
   Lavi E, 2015, CASE REP PEDIAT, DOI 10.1155/2015/186302
   Le Saux N, 2015, PAED CHILD HEALT-CAN, V20, P441, DOI 10.1093/pch/20.8.441
   Liu L, 2016, LANCET, V388, P3027, DOI 10.1016/S0140-6736(16)31593-8
   Madhi SA, 2013, PEDIATR INFECT DIS J, V32, pE119, DOI 10.1097/INF.0b013e3182784b26
   McIntosh K, 2002, NEW ENGL J MED, V346, P429, DOI 10.1056/NEJMra011994
   Nagy B, 2013, PEDIATR PULM, V48, P168, DOI 10.1002/ppul.22574
   Nascimento-Carvalho AC, 2018, J CLIN VIROL, V105, P77, DOI 10.1016/j.jcv.2018.06.003
   Nascimento-Carvalho AC, 2016, BMC PEDIATR, V16, DOI 10.1186/s12887-016-0645-3
   Nascimento-Carvalho CM, 2004, REV PANAM SALUD PUBL, V15, P380, DOI 10.1590/S1020-49892004000600003
   Nascimento-Carvalho CM, 2008, PEDIATR INFECT DIS J, V27, P939, DOI 10.1097/INF.0b013e3181723751
   Nascimento-Carvalho CM, 2017, J ANTIMICROB CHEMOTH, V72, P2378, DOI 10.1093/jac/dkx126
   Nascimento-Carvalho CM, 2016, EXPERT OPIN PHARMACO, V17, P53, DOI 10.1517/14656566.2016.1109633
   Nascimento-Carvalho CM, 2009, J MED MICROBIOL, V58, P1390, DOI 10.1099/jmm.0.007765-0
   Nascimento-Carvalho Cristiana M.C., 2002, Braz J Infect Dis, V6, P22, DOI 10.1590/S1413-86702002000100004
   Nolan VG, 2018, J INFECT DIS, V218, P179, DOI 10.1093/infdis/jix641
   Reese RE, 2000, HDB ANTIBIOTICS
   Rudan I, 2008, B WORLD HEALTH ORGAN, V86, P408, DOI 10.2471/BLT.07.048769
   Shah D, 2008, INDIAN PEDIATR, V45, P577
   SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017
   Simbalista R, 2011, CLINICS, V66, P95, DOI 10.1590/S1807-59322011000100017
   Srugo I, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2016-3453
   Tagarro A, 2017, J PEDIATR-US, V185, P117, DOI 10.1016/j.jpeds.2017.02.043
   Tapiainen T, 2016, ACTA PAEDIATR, V105, P39, DOI 10.1111/apa.13177
   Tramper-Stranders GA, 2018, PAEDIATR RESPIR REV, V26, P41, DOI 10.1016/j.prrv.2017.06.013
   Turner GDH, 2012, CLIN INFECT DIS, V54, pS165, DOI 10.1093/cid/cir1062
   Uehara S, 2011, PEDIATR INT, V53, P264, DOI 10.1111/j.1442-200X.2010.03316.x
   van Houten CB, 2017, LANCET INFECT DIS, V17, P431, DOI 10.1016/S1473-3099(16)30519-9
   Vasconcellos AG, 2018, CYTOKINE, V107, P1, DOI 10.1016/j.cyto.2017.11.005
   Vilas-Boas AL, 2014, J ANTIMICROB CHEMOTH, V69, P1954, DOI 10.1093/jac/dku070
   Vuori-Holopainen E, 2001, CLIN INFECT DIS, V32, P715, DOI 10.1086/319213
   World Health Organization, 2012, REC MAN COMM CHILD C
   World Health Organization, 2000, MAN CHILD SER INF SE
   World Health Organization, 2015, ANT RES MULT PUBL AW
   Yassour M, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad0917
   Zar HJ, 2005, SAMJ S AFR MED J, V95, P977
NR 54
TC 3
Z9 3
U1 0
U2 8
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1465-6566
EI 1744-7666
J9 EXPERT OPIN PHARMACO
JI Expert Opin. Pharmacother.
PD MAR 4
PY 2019
VL 20
IS 4
BP 435
EP 442
DI 10.1080/14656566.2018.1552257
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA HL4DD
UT WOS:000458664700009
PM 30507273
DA 2020-12-17
ER

PT J
AU Lage, MLC
   de Carvalho, AL
   Ventura, PA
   Taguchi, TB
   Fernandes, AS
   Pinho, SF
   Santos, OT
   Ramos, CL
   Nascimento-Carvalho, CM
AF Lage, Maria-Lucia C.
   de Carvalho, Alessandra L.
   Ventura, Paloma A.
   Taguchi, Tania B.
   Fernandes, Adriana S.
   Pinho, Suely F.
   Santos-Junior, Onildo T.
   Ramos, Clara L.
   Nascimento-Carvalho, Cristiana M.
TI Clinical, Neuroimaging, and Neurophysiological Findings in Children with
   Microcephaly Related to Congenital Zika Virus Infection
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE Zika virus; microcephaly; neuroimaging; neurologic examination
ID INFANTS; BRAZIL; STANDARDS; OUTBREAK; GROWTH; STATES; HEAD
AB Zika virus (ZIKV) infection appeared in Brazil in 2015, causing an epidemic outbreak with increased rates of microcephaly and other serious birth disorders. We reviewed 102 cases of children who were diagnosed with microcephaly at birth and who had gestational exposure to ZIKV during the outbreak. We describe the clinical, neuroimaging, and neurophysiological findings. Most mothers (81%) reported symptoms of ZIKV infection, especially cutaneous rash, during the first trimester of pregnancy. The microcephaly was severe in 54.9% of the cases. All infants presented with brain malformations. The most frequent neuroimaging findings were cerebral atrophy (92.1%), ventriculomegaly (92.1%), malformation of cortical development (85.1%), and cortical-subcortical calcifications (80.2%). Abnormalities in neurological exams were found in 97.0% of the cases, epileptogenic activity in 56.3%, and arthrogryposis in 10.8% of the infants. The sensorineural screening suggested hearing loss in 17.3% and visual impairment in 14.1% of the infants. This group of infants who presented with microcephaly and whose mothers were exposed to ZIKV early during pregnancy showed clinical and radiological criteria for congenital ZIKV infection. A high frequency of brain abnormalities and signs of early neurological disorders were found, and epileptogenic activity and signs of sensorineural alterations were common. This suggests that microcephaly can be associated with a worst spectrum of neurological manifestations.
C1 [Lage, Maria-Lucia C.; Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Postgrad Programme Hlth Sci, Praca 15 Novembro Largo Terreiro de Jesus, BR-40025010 Salvador, BA, Brazil.
   [de Carvalho, Alessandra L.; Ventura, Paloma A.; Taguchi, Tania B.; Fernandes, Adriana S.; Pinho, Suely F.] SARAH Network Rehabil Hosp, Salvador Hosp, Pediat Rehabil Ctr, Ave Tancredo Neves, BR-41820900 Salvador, BA, Brazil.
   [Santos-Junior, Onildo T.] SARAH Network Rehabil Hosp, Salvador Hosp, Dept Diagnost Imaging, Ave Tancredo Neves, BR-41820900 Salvador, BA, Brazil.
   [Ramos, Clara L.] Bahiana Fdn Sci Dev, Bahiana Sch Med, Dom Joao 6, BR-40290000 Salvador, BA, Brazil.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Paediat, Praca 15 Novembro Largo Terreiro de Jesus, BR-40025010 Salvador, BA, Brazil.
RP Lage, MLC (corresponding author), Univ Fed Bahia, Sch Med, Postgrad Programme Hlth Sci, Praca 15 Novembro Largo Terreiro de Jesus, BR-40025010 Salvador, BA, Brazil.
EM marylulage@hotmail.com; 13110@sarah.br; 701064@sarah.br; 11786@sarah.br;
   400868@sarah.br; 701053@sarah.br; 700991@sarah.br; ccclr1@gmail.com;
   nascimentocarvalho@hotmail.com
OI Lage, Maria-Lucia Costa/0000-0001-5571-8640
CR Adebanjo T, 2017, MMWR-MORBID MORTAL W, V66, P1089, DOI 10.15585/mmwr.mm6641a1
   Aragao MFVV, 2017, AM J NEURORADIOL, V38, P1427, DOI 10.3174/ajnr.A5216
   Ashwal S, 2009, NEUROLOGY, V73, P887, DOI 10.1212/WNL.0b013e3181b783f7
   de Franca TLB, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15091990
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Brazilian Ministry of Heath, MIN SAUD MIN SAUD DI
   Campos GS, 2015, EMERG INFECT DIS, V21, P1885, DOI 10.3201/eid2110.150847
   CDC Zika and Pregnancy, CONG ZIK SYNDR OTH B
   Ferreira HNC, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15061107
   de Araujo TVB, 2016, LANCET INFECT DIS, V16, P1356, DOI 10.1016/S1473-3099(16)30318-8
   de Noronha L, 2016, MEM I OSWALDO CRUZ, V111, P287, DOI 10.1590/0074-02760160085
   de Oliveira-Szejnfeld PS, 2016, RADIOLOGY, V281, P203, DOI 10.1148/radiol.2016161584
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Dosman CF, 2012, PAED CHILD HEALT-CAN, V17, P561, DOI 10.1093/pch/17.10.561
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Frenkel LD, 2018, EUR J CLIN MICROBIOL, V37, P209, DOI 10.1007/s10096-017-3111-8
   Garcez PP, 2016, SCIENCE, V352, P816, DOI 10.1126/science.aaf6116
   Hazin AN, 2016, NEW ENGL J MED, V374, P2193, DOI 10.1056/NEJMc1603617
   Honein MA, 2017, JAMA-J AM MED ASSOC, V317, P59, DOI 10.1001/jama.2016.19006
   Leal MC, 2017, EMERG INFECT DIS, V23, P1253, DOI 10.3201/eid2308.170354
   Leal MC, 2016, MMWR-MORBID MORTAL W, V65, P917, DOI 10.15585/mmwr.mm6534e3
   Li SX, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10010049
   Lowe R, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15010096
   da Silva AAM, 2016, EMERG INFECT DIS, V22, P1953, DOI 10.3201/eid2211.160956
   Oliveira J, 2018, AM J TROP MED HYG, V98, P1860, DOI 10.4269/ajtmh.17-1020
   Pessoa A, 2018, PEDIATRICS, V141, pS167, DOI 10.1542/peds.2017-2038F
   Rosenbaum P, 2007, DEV MED CHILD NEUROL, V49, P8, DOI 10.1111/j.1469-8749.2007.tb12610.x
   van der Linden V, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i3899
   Aragao MDV, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i1901
   Ventura LO, 2018, J AAPOS, V22, P218, DOI 10.1016/j.jaapos.2018.01.009
   Villar J, 2014, LANCET, V384, P857, DOI 10.1016/S0140-6736(14)60932-6
   Wood AM, 2018, CLIN PERINATOL, V45, P307, DOI 10.1016/j.clp.2018.01.005
NR 32
TC 6
Z9 7
U1 0
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD FEB 1
PY 2019
VL 16
IS 3
AR 309
DI 10.3390/ijerph16030309
PG 9
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA HM0CQ
UT WOS:000459113600015
PM 30678125
OA DOAJ Gold, Green Published
DA 2020-12-17
ER

PT J
AU Fonseca, TS
   Vasconcellos, AG
   Gendrel, D
   Ruuskanen, O
   Nascimento-Carvalho, CM
AF Fonseca, Taiane S.
   Vasconcellos, Angela G.
   Gendrel, Dominique
   Ruuskanen, Olli
   Nascimento-Carvalho, Cristiana M.
TI Recovery from childhood community-acquired pneumonia in a developing
   country: Prognostic value of serum procalcitonin
SO CLINICA CHIMICA ACTA
LA English
DT Article
DE Procalcitonin; Biornarker; Child; Lower respiratory tract infection;
   Pneumonia
ID CHILDREN; INFECTION; DIAGNOSIS
AB Background: Childhood community-acquired pneumonia is a common and potentially life-threatening illness in developing countries. We assessed the prognostic value of serum procalcitonin level upon admission on clinical response to antibiotic treatment.
   Methods: Out of 89 patients, the median (IQR) age was 19(12-29) months and 60% were boys. Viral (49.5%), typical bacterial (38%) and atypical bacterial (12.5%) infections as well as probable pneumococcal infection (26%) were diagnosed.
   Results: Seventy-five (84%) children became afebrile <= 48 h after treatment. In 14 children who remained febrile after 48 h of treatment, median[IQR] serum procalcitonin (ng/ml) level on admission was higher than in those with rapid recovery (2.1[0.8-3.7] vs 0.6[0.1-2.2]; P = 0.025). In the slow-responding children, pneumococcal infections were more common (71% vs 17%; P < 0.001). Procalcitonin concentrations on admission were higher in children with pneumococcal pneumonia compared to children with non-pneumococcal pneumonia (2[0.7-4.2] vs 0.5[0.08-2.1]; P = 0.002). The ROC curve found that < 0.25 ng/ml of serum procalcitonin had a high negative predictive value (93%[95%CI:80%-99%]) for pneumococcal infection. All children that remained febrile after 48 h of treatment had procalcitonin > 0.25 ng/ml on admission. The majority of children with pneumonia in a developing country become afebrile within 48 h after onset of antibiotic treatment.
   Conclusions: Serum procalcitonin at 0.25 ng/ml predicted rapid clinical response and non-pneumococcal etiology.
C1 [Fonseca, Taiane S.; Vasconcellos, Angela G.; Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Postgrad Program Hlth Sci, Praca 15 Novembro S-N, BR-40025010 Salvador, BA, Brazil.
   [Gendrel, Dominique] Univ Paris 05, St Vincent de Paul & Necker Enfants Malad Hosp, AP HP, Dept Pediat, Paris, France.
   [Ruuskanen, Olli] Univ Turku, Dept Pediat, Turku, Finland.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
RP Fonseca, TS (corresponding author), Univ Fed Bahia, Sch Med, Postgrad Program Hlth Sci, Praca 15 Novembro S-N, BR-40025010 Salvador, BA, Brazil.
EM taianesf@hotmail.com
OI Fonseca, Taiane/0000-0002-7457-1848
FU Bahia State Agency for Research Funding (FAPESB); Brazilian Council for
   Scientific and Technological Development in Brazil; Foundation for
   Pediatric Research, in Finland
FX The authors thank the pediatricians of the Emergency Room of the Federal
   University of Bahia Hospital, in Salvador, Brazil. This study was
   supported by the Bahia State Agency for Research Funding (FAPESB) and
   the Brazilian Council for Scientific and Technological Development in
   Brazil and the Foundation for Pediatric Research, in Finland.
CR Bradley JS, 2011, CLIN INFECT DIS, V53, pE25, DOI 10.1093/cid/cir531
   Cardinale F, 2013, EARLY HUM DEV, V89, pS49, DOI 10.1016/j.earlhumdev.2013.07.023
   Cherian T, 2005, B WORLD HEALTH ORGAN, V83, P353
   Clark JE, 2015, ARCH DIS CHILD, V100, P193, DOI 10.1136/archdischild-2013-305742
   Cohen JF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036927
   El-Rashdi AS, 2006, ARCH DIS CHILD, V91, P351, DOI 10.1136/adc.2005.088831
   Esposito S, 2011, RESP MED, V105, P1939, DOI 10.1016/j.rmed.2011.09.003
   Flyypia T., 1998, J CLIN MICROBIOL, V36, P2081
   Fonseca TS, 2015, PEDIATR INFECT DIS J, V34, P914, DOI 10.1097/INF.0000000000000763
   Giulia B, 2015, CLIN CHIM ACTA, V451, P215, DOI 10.1016/j.cca.2015.09.031
   Harris M, 2011, THORAX, V66, pII1, DOI 10.1136/thoraxjnl-2011-200598
   Izadnegahdar R, 2013, LANCET RESP MED, V1, P574, DOI 10.1016/S2213-2600(13)70075-4
   Juven T, 2004, EUR J PEDIATR, V163, P140, DOI 10.1007/s00431-003-1397-2
   Korppi M, 2006, RESPIROLOGY, V11, P80, DOI 10.1111/j.1440-1843.2006.00788.x
   Liu L, 2015, LANCET, V385, P430, DOI 10.1016/S0140-6736(14)61698-6
   Makela MJ, 1998, J CLIN MICROBIOL, V36, P539
   Morre SA, 2002, J CLIN MICROBIOL, V40, P584, DOI 10.1128/JCM.40.2.584-587.2002
   Moulin F, 2001, ARCH DIS CHILD, V84, P332, DOI 10.1136/adc.84.4.332
   Nascimento-Carvalho CM, 2013, PEDIATR INFECT DIS J, V32, P1281, DOI 10.1097/INF.0b013e3182a4dcfa
   Nascimento-Carvalho CM, 2011, INFLUENZA OTHER RESP, V5, P285, DOI 10.1111/j.1750-2659.2011.00206.x
   NOHYNEK H, 1995, PEDIATR INFECT DIS J, V14, P478, DOI 10.1097/00006454-199506000-00003
   Ruuskanen O, 2011, LANCET, V377, P1264, DOI 10.1016/S0140-6736(10)61459-6
   Saukkoriipi A, 2002, MOL CELL PROBE, V16, P385, DOI 10.1006/mcpr.2002.0443
   Soderlund-Venermo M, 2009, EMERG INFECT DIS, V15, P1423, DOI 10.3201/eid1509.090204
   Toikka P, 1999, CLIN INFECT DIS, V29, P568, DOI 10.1086/598635
   Wang SP, 2000, J INFECT DIS, V181, pS421, DOI 10.1086/315622
   WHO UNICEF, 2008, INT MAN CHILDH ILLN
NR 27
TC 4
Z9 4
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0009-8981
EI 1873-3492
J9 CLIN CHIM ACTA
JI Clin. Chim. Acta
PD FEB
PY 2019
VL 489
BP 212
EP 218
DI 10.1016/j.cca.2017.12.021
PG 7
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA HK1KQ
UT WOS:000457664200033
PM 29258745
DA 2020-12-17
ER

PT J
AU Fukutani, KF
   Nascimento-Carvalho, CM
   Bouzas, ML
   Oliveira, JR
   Barral, A
   Dierckx, T
   Khouri, R
   Nakaya, HI
   Andrade, BB
   Van Weyenbergh, J
   de Oliveira, CI
AF Fukutani, Kiyoshi F.
   Nascimento-Carvalho, Cristiana M.
   Bouzas, Maiara L.
   Oliveira, Juliana R.
   Barral, Aldina
   Dierckx, Tim
   Khouri, Ricardo
   Nakaya, Helder I.
   Andrade, Bruno B.
   Van Weyenbergh, Johan
   de Oliveira, Camila I.
TI In situ Immune Signatures and Microbial Load at the Nasopharyngeal
   Interface in Children With Acute Respiratory Infection
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Article
DE network analysis; ARI; immune response; nCounter; interferon; viral
   load; innate immunity; adaptive immunity
ID HAEMOPHILUS-INFLUENZAE; STREPTOCOCCUS-PNEUMONIAE; MORAXELLA-CATARRHALIS;
   EPITHELIAL-CELLS; SYNCYTIAL VIRUS; INDUCTION; BACTERIAL; PROTEIN;
   INTERFERONS; SYMPTOMS
AB Acute respiratory infection (ARI) is the most frequent cause for hospitalization in infants and young children. Using multiplexed nCounter technology to digitally quantify 600 human mRNAs in parallel with 14 virus- and 5 bacterium-specific RNAs, we characterized viral and bacterial presence in nasopharyngeal aspirates (NPA) of 58 children with ARI and determined the corresponding in situ immune profiles. NPA contained different groups of organisms and these were classified into bacterial (n = 27), viral (n = 5), codetection [containing both viral and bacterial transcripts (n = 21), or indeterminate intermediate where microbial load is below threshold (n = 5)]. We then identified differentially expressed immune transcripts (DEITs) comparing NPAs from symptomatic children vs. healthy controls, and comparing children presenting NPAs with detectable microbial load vs. indeterminate. We observed a strong innate immune response in NPAs, due to the presence of evolutionarily conserved type I Interferon (IFN)-stimulated genes (ISG), which was correlated with total bacterial and/or viral load. In comparison with indeterminate NPAs, adaptive immunity transcripts discriminated among viral, bacterial, and codetected microbial profiles. In viral NPAs, B cell transcripts were significantly enriched among DEITs, while only type III IFN was correlated with viral load. In bacterial NPAs, myeloid cells and coinhibitory transcripts were enriched and significantly correlated with bacterial load. In conclusion, digital nCounter transcriptomics provide a microbial and immunological in situ "snapshot" of the nasopharyngeal interface in children with ARI. This enabled discrimination among viral, bacterial, codetection, and indeterminate transcripts in the samples using non-invasive sampling.
C1 [Fukutani, Kiyoshi F.; Barral, Aldina; Khouri, Ricardo; Andrade, Bruno B.; de Oliveira, Camila I.] Fiocruz MS, Inst Goncalo Moniz, Salvador, BA, Brazil.
   [Nascimento-Carvalho, Cristiana M.; Bouzas, Maiara L.; Oliveira, Juliana R.; Barral, Aldina; Khouri, Ricardo; de Oliveira, Camila I.] Univ Fed Bahia, Sch Med, Salvador, BA, Brazil.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
   [Dierckx, Tim; Van Weyenbergh, Johan] Katholieke Univ Leuven, Rega Inst Med Res, Dept Microbiol & Immunol, Leuven, Belgium.
   [Nakaya, Helder I.] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin & Toxicol Anal, Sao Paulo, Brazil.
   [Andrade, Bruno B.] Fdn Jose Silveira, Multinatl Org Network Sponsoring Translat & Epide, Salvador, BA, Brazil.
RP de Oliveira, CI (corresponding author), Fiocruz MS, Inst Goncalo Moniz, Salvador, BA, Brazil.; de Oliveira, CI (corresponding author), Univ Fed Bahia, Sch Med, Salvador, BA, Brazil.; Van Weyenbergh, J (corresponding author), Katholieke Univ Leuven, Rega Inst Med Res, Dept Microbiol & Immunol, Leuven, Belgium.
EM j.vw@live.be; camila@bahia.fiocruz.br
RI Khouri, Ricardo/M-3184-2018; de Oliveira, Camila I/B-4358-2009; Andrade,
   Bruno/AAI-2248-2020; Fukutani, Kiyoshi/T-1630-2019; Nakaya,
   Helder/AAF-1738-2020; Nakaya, Helder I/A-1397-2010; Fukutani,
   Kiyoshi/N-7905-2016; Van Weyenbergh, Johan/Q-3829-2019; Van Weyenbergh,
   Johan/B-4187-2009
OI Khouri, Ricardo/0000-0001-5664-4436; de Oliveira, Camila
   I/0000-0002-7868-5164; Nakaya, Helder/0000-0001-5297-9108; Nakaya,
   Helder I/0000-0001-5297-9108; Fukutani, Kiyoshi/0000-0003-2223-0918; Van
   Weyenbergh, Johan/0000-0003-3234-8426; Van Weyenbergh,
   Johan/0000-0003-3234-8426; Dierckx, Tim/0000-0002-1969-7974; Andrade,
   Bruno/0000-0001-6833-3811
FU Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB)
   [PNX0019/2009]; Belgian FWOFWO [G0D6817N]; Science without Borders (PVE
   Anne-Mieke Vandamme); Institute for the Promotion of Innovation through
   Science and Technology Flanders (IWT-Vlaanderen)Institute for the
   Promotion of Innovation by Science and Technology in Flanders (IWT)
   [141614]; FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2012/19278-6, 2017/50137-3]; National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [U01AI115940]; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [U01AI115940,
   U01AI115940, U01AI115940, U01AI115940, U01AI115940, U01AI115940] Funding
   Source: NIH RePORTER
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado da
   Bahia (FAPESB; Grant PNX0019/2009 to AB) and Belgian FWO (Grant
   G0D6817N). KF was supported by a fellowship from Science without Borders
   (PVE Anne-Mieke Vandamme). TD was supported by the Institute for the
   Promotion of Innovation through Science and Technology Flanders
   (IWT-Vlaanderen), project 141614. CN-C, AB, and CO were senior
   investigators from Conselho Nacional de Pesquisa Cientifica (CNPq). HN
   was supported by FAPESP (Grant Nos. 2012/19278-6 and 2017/50137-3). BA
   was supported by the National Institutes of Health (U01AI115940).
CR Andrade DC, 2016, PEDIATR INFECT DIS J, V35, P683, DOI 10.1097/INF.0000000000001126
   Andreakos E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01232
   Andris F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00480
   Avadhanula V, 2006, J VIROL, V80, P1629, DOI 10.1128/JVI.80.4.1629-1636.2006
   Blondel VD, 2008, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2008/10/P10008
   Bogaert D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017035
   Bouzas ML, 2018, J CLIN VIROL, V106, P34, DOI 10.1016/j.jcv.2018.07.003
   Bouzas ML, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005142
   Chaussabel D, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-84
   Durbin RK, 2013, IMMUNOL REV, V255, P25, DOI 10.1111/imr.12101
   Fabregat A, 2016, NUCLEIC ACIDS RES, V44, pD481, DOI 10.1093/nar/gkv1351
   Fukutani KF, 2015, J CLIN VIROL, V69, P190, DOI 10.1016/j.jcv.2015.06.005
   Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385
   Hallstrom T, 2007, J IMMUNOL, V178, P6359, DOI 10.4049/jimmunol.178.10.6359
   Heinonen S, 2016, AM J RESP CRIT CARE, V193, P772, DOI 10.1164/rccm.201504-0749OC
   HOWARD AJ, 1988, EPIDEMIOL INFECT, V100, P193, DOI 10.1017/S0950268800067327
   Ishizuka S, 2003, J INFECT DIS, V188, P1928, DOI 10.1086/379833
   Jogdand GM, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00520
   Khaitov MR, 2009, ALLERGY, V64, P375, DOI 10.1111/j.1398-9995.2008.01826.x
   Liquet B, 2016, BIOINFORMATICS, V32, P35, DOI 10.1093/bioinformatics/btv535
   Maler MD, 2017, MBIO, V8, DOI 10.1128/mBio.00670-17
   Mejias A, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001549
   Metzemaekers M, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01970
   Moens B, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-171
   Nakaya HI, 2016, P NATL ACAD SCI USA, V113, P1853, DOI 10.1073/pnas.1519690113
   Nakaya HI, 2012, ARTHRITIS RHEUM-US, V64, P3553, DOI 10.1002/art.34631
   Nascimento-Carvalho CM, 2016, PEDIATR INFECT DIS J, V35, P338, DOI 10.1097/INF.0000000000001032
   Nascimento-Carvalho CM, 2013, SCAND J INFECT DIS, V45, P478, DOI 10.3109/00365548.2012.754106
   Nascimento-Carvalho CM, 2010, SCAND J INFECT DIS, V42, P839, DOI 10.3109/00365548.2010.498020
   Nolan VG, 2018, J INFECT DIS, V218, P179, DOI 10.1093/infdis/jix641
   Nordstrom T, 2004, J IMMUNOL, V173, P4598, DOI 10.4049/jimmunol.173.7.4598
   Parnell GP, 2012, CRIT CARE, V16, DOI 10.1186/cc11477
   R Core Team, 2013, R LANG ENV STAT COMP
   Ruohola A, 2013, J INFECTION, V66, P247, DOI 10.1016/j.jinf.2012.12.002
   Sadler AJ, 2008, NAT REV IMMUNOL, V8, P559, DOI 10.1038/nri2314
   Shaw AE, 2017, PLOS BIOL, V15, DOI 10.1371/journal.pbio.2004086
   Shoemaker JE, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-460
   Skevaki CL, 2015, PEDIATR INFECT DIS J, V34, P1296, DOI 10.1097/INF.0000000000000872
   Spann KM, 2004, J VIROL, V78, P4363, DOI 10.1128/JVI.78.8.4363-4369.2004
   Suarez NM, 2015, J INFECT DIS, V212, P213, DOI 10.1093/infdis/jiv047
   Subramanian A, 2007, BIOINFORMATICS, V23, P3251, DOI 10.1093/bioinformatics/btm369
   Sweeney TE, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf7165
   Tregoning JS, 2010, CLIN MICROBIOL REV, V23, P74, DOI 10.1128/CMR.00032-09
   Uitti JM, 2015, PEDIATR INFECT DIS J, V34, P1056, DOI 10.1097/INF.0000000000000800
   Waggott D, 2012, BIOINFORMATICS, V28, P1546, DOI 10.1093/bioinformatics/bts188
   Wiertsema SP, 2011, J MED VIROL, V83, P2008, DOI 10.1002/jmv.22221
   Zhai YJ, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004869
NR 47
TC 1
Z9 1
U1 0
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD NOV 9
PY 2018
VL 9
AR 2475
DI 10.3389/fmicb.2018.02475
PG 13
WC Microbiology
SC Microbiology
GA GZ7DP
UT WOS:000449637600001
PM 30473680
OA DOAJ Gold, Green Published
DA 2020-12-17
ER

PT J
AU Andrade, DC
   Nascimento-Carvalho, CM
AF Andrade, Dafne C.
   Nascimento-Carvalho, Cristiana Maria
TI Radiologic scales as a tool for the etiologic diagnosis of pediatric
   community-acquired pneumonia
SO JORNAL DE PEDIATRIA
LA English
DT Letter
ID BACTERIAL
C1 [Andrade, Dafne C.; Nascimento-Carvalho, Cristiana Maria] Univ Fed Bahia, Fac Med, Programa Posgrad Ciencias Saude, Salvador, BA, Brazil.
RP Andrade, DC (corresponding author), Univ Fed Bahia, Fac Med, Programa Posgrad Ciencias Saude, Salvador, BA, Brazil.
EM andradedafne@yahoo.com.br
CR Andrade DC, 2018, J PEDIAT-BRAZIL, V94, P23, DOI 10.1016/j.jped.2017.03.004
   Heinsohn DVB, 2018, J PEDIAT-BRAZIL, V94, P689, DOI 10.1016/j.jped.2018.05.018
   Cherian T, 2005, B WORLD HEALTH ORGAN, V83, P353
   Don M, 2009, PEDIATR INT, V51, P91, DOI 10.1111/j.1442-200X.2008.02678.x
   Korppi M, 2008, ACTA PAEDIATR, V97, P943, DOI 10.1111/j.1651-2227.2008.00789.x
   Moreno Laura, 2006, Arch. argent. pediatr., V104, P109
NR 6
TC 0
Z9 0
U1 0
U2 0
PU SOC BRASIL PEDIATRIA
PI RIO DE JANEIRO, RJ
PA RUA SANTA CLARA 292, RIO DE JANEIRO, RJ, CEP 22401-01, BRAZIL
SN 0021-7557
EI 1678-4782
J9 J PEDIAT-BRAZIL
JI J. Pediatr.
PD NOV-DEC
PY 2018
VL 94
IS 6
BP 690
EP 691
DI 10.1016/j.jped.2018.06.004
PG 3
WC Pediatrics
SC Pediatrics
GA HC2NA
UT WOS:000451637600017
PM 29990464
OA DOAJ Gold
DA 2020-12-17
ER

PT J
AU Bouzas, ML
   Oliveira, JR
   Queiroz, A
   Fukutani, KF
   Barral, A
   Rector, A
   Wollants, E
   Keyaertse, E
   Van der Gucht, W
   Van Ranst, M
   Beuselinck, K
   de Oliveira, CI
   Van Weyenbergh, J
   Nascimento-Carvalho, CM
AF Bouzas, Maiara L.
   Oliveira, Juliana R.
   Queiroz, Artur
   Fukutani, Kiyoshi F.
   Barral, Aldina
   Rector, Annabel
   Wollants, Elke
   Keyaertse, Els
   Van der Gucht, Winke
   Van Ranst, Marc
   Beuselinck, Kurt
   de Oliveira, Camila, I
   Van Weyenbergh, Johan
   Nascimento-Carvalho, Cristiana M.
CA Acute Resp Infect Wheeze Study Grp
TI Diagnostic accuracy of digital RNA quantification versus real-time PCR
   for the detection of respiratory syncytial virus in nasopharyngeal
   aspirates from children with acute respiratory infection
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Article
DE RSV; Diagnostics; Respiratory viruses; Virus detection; Viral
   respiratory infection; Transcriptomics
ID ALIGNMENT
AB Background: Virus-specific molecular assays such as real-time polymerase chain reaction (RT-PCR) are regularly used as the gold standard to diagnose viral respiratory tract infections, but simultaneous detection of multiple different pathogens is often challenging. A multiplex digital method of RNA quantification, nCounter (NanoString Technologies), can overcome this disadvantage and identify, in a single reaction, the presence of different respiratory viruses.
   Objectives: To evaluate the accuracy of nCounter to identify and quantify RSV-A and RSV-B in nasopharyngeal aspirates (NPA) of children (6-23-months-old) with acute respiratory infection.
   Study design: NPA was collected at enrolment in a prospective cross-sectional study conducted in Salvador, Brazil. A quantitative RT-PCR with a subgroup-specific primer and probeset for RSV-A and RSV-B was performed in parallel with a customized nCounter probeset containing viral targets in NPA.
   Results: Of 559 NPA tested, RSV was detected by RT-PCR in 139 (24.9%), by nCounter in 122 (21.8%) and by any method in 158 (28.3%) cases. Compared to the gold standard of qRT-PCR, sensitivity of nCounter was 74.3% (95%CI:63.3%-82.9% RSV-A) and 77.6% (95%CI:66.3%-85.9% RSV-B); specificity was 98.4% (95%CI:96.8%-99.2% RSV-A) and 97.8% (95%CI:96.0%-98.8% RSV-B); positive predictive value was 87.3% (95%CI:76.9%-93.4% RSV-A) and 82.5% (95%CI:71.4%-90.0% RSV-B) and negative predictive value was 96.1% (95%CI:94.1%-97.5% RSV-A), and 96.9% (95%CI:95.1%-98.2% RSV-B). Accuracy was 95.2% (95%CI:93.1%-96.7%) for RSV-A and 95.3% (95%CI:93.3%-96.9%) for RSV-B, while both methods significantly correlated for RSV-A (r = 0.44, p = 8 x 10(-5)) and RSV-B (r = 0.73, p = 3 x 10(-12)) quantification.
   Conclusions: nCounter is highly accurate in detecting RSV-A/B in NPA. Robustness and high-throughput multiplexing indicate its use in large-scale epidemiological studies.
C1 [Bouzas, Maiara L.; Oliveira, Juliana R.; Fukutani, Kiyoshi F.; Barral, Aldina; de Oliveira, Camila, I; Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Postgrad Program Hlth Sci, Salvador, BA, Brazil.
   [Queiroz, Artur; Barral, Aldina; de Oliveira, Camila, I] Fundacao Oswaldo Cruz FIOCRUZ, Ctr Pesquisas Goncalo Moniz CPqGM, Salvador, BA, Brazil.
   [Fukutani, Kiyoshi F.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Biochem Immunol & Cell Biol, Ribeirao Preto, Brazil.
   [Barral, Aldina] Univ Fed Bahia, Sch Med, Dept Pathol, Salvador, BA, Brazil.
   [Rector, Annabel; Wollants, Elke; Keyaertse, Els; Van der Gucht, Winke; Van Ranst, Marc; Van Weyenbergh, Johan] Katholieke Univ Leuven, Rega Inst Med Res, Lab Clin & Epidemiol Virol, Dept Microbiol & Immunol, Leuven, Belgium.
   [Keyaertse, Els; Van Ranst, Marc; Beuselinck, Kurt] Univ Hosp Leuven, Dept Lab Med, Leuven, Belgium.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
RP Bouzas, ML (corresponding author), Univ Fed Bahia, Sch Med, Program Hlth Sci, Ctr Hist, Largo Terreiro de Jesus S-N, BR-40025010 Salvador, BA, Brazil.
EM maiara.lanna@gmail.com
RI Fukutani, Kiyoshi/T-1630-2019; de Oliveira, Camila I/B-4358-2009; Van
   Weyenbergh, Johan/B-4187-2009; Van Ranst, Marc/P-7522-2017; Van
   Weyenbergh, Johan/Q-3829-2019; Rector, Annabel/E-7619-2018; Keyaerts,
   Els/F-2305-2018
OI de Oliveira, Camila I/0000-0002-7868-5164; Van Weyenbergh,
   Johan/0000-0003-3234-8426; Van Ranst, Marc/0000-0002-1674-4157; Van
   Weyenbergh, Johan/0000-0003-3234-8426; Fukutani,
   Kiyoshi/0000-0003-2223-0918; Rector, Annabel/0000-0003-3714-449X; de
   Queiroz, Artur Trancoso Lopo/0000-0003-4908-9993; Wollants,
   Elke/0000-0002-4057-2236; Keyaerts, Els/0000-0002-1849-3240
FU Fundacao de Amparo a pesquisa do Estado da Bahia (FAPESB)
   [PNX0019/2009]; FAPESB; Conselho Nacional de Desenvolvimento Cientifico
   e Tecnologico (CNPQ)National Council for Scientific and Technological
   Development (CNPq); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2017/03491-6]; Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES)CAPES; Research Foundation - Flanders FWOFWO [G0D6817N]
FX This work was supported by Fundacao de Amparo a pesquisa do Estado da
   Bahia (FAPESB; grant PNX0019/2009). MLB was supported by fellowships
   from FAPESB. KFF was supported by fellowships from Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPQ), FAPESB and Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP no. 2017/03491-6). JRO
   was supported by fellowships from FAPESB and Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES). AB, CIO, CMN-C are
   senior investigators from CNPQ. JVW was supported by (Research
   Foundation - Flanders FWO; grant G0D6817N).
CR ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2
   Andrade DC, 2017, VACCINE, V35, P4105, DOI 10.1016/j.vaccine.2017.06.048
   Bouzas ML, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005142
   Durigon GS, 2015, INT J INFECT DIS, V34, P3, DOI 10.1016/j.ijid.2015.03.003
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Fukutani KF, 2015, J CLIN VIROL, V69, P190, DOI 10.1016/j.jcv.2015.06.005
   Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385
   Houspie L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060416
   Khouri R, 2014, J INFECT DIS, V210, P306, DOI 10.1093/infdis/jiu087
   Kuypers J, 2004, J CLIN VIROL, V31, P123, DOI 10.1016/j.jcv.2004.03.018
   Moens B, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-171
   Nascimento-Carvalho CM, 2010, SCAND J INFECT DIS, V42, P839, DOI 10.3109/00365548.2010.498020
   Salez N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130378
   Speranza E, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15145-7
   Thorburn F, 2015, J CLIN VIROL, V69, P96, DOI 10.1016/j.jcv.2015.06.082
   Ye J, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-134
   Zlateva KT, 2007, J CLIN MICROBIOL, V45, P3022, DOI 10.1128/JCM.00339-07
   Zlateva KT, 2005, J VIROL, V79, P9157, DOI 10.1128/JVI.79.14.9157-9167.2005
NR 18
TC 5
Z9 5
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1386-6532
EI 1873-5967
J9 J CLIN VIROL
JI J. Clin. Virol.
PD SEP
PY 2018
VL 106
BP 34
EP 40
DI 10.1016/j.jcv.2018.07.003
PG 7
WC Virology
SC Virology
GA GR2AR
UT WOS:000442361000009
PM 30031351
DA 2020-12-17
ER

PT J
AU Borges, IC
   Andrade, DC
   Ekstrom, N
   Virta, C
   Melin, M
   Saukkoriipi, A
   Leinonen, M
   Ruuskanen, O
   Kayhty, H
   Nascimento-Carvalho, CM
AF Borges, Igor C.
   Andrade, Dafne C.
   Ekstrom, Nina
   Virta, Camilla
   Melin, Merit
   Saukkoriipi, Annika
   Leinonen, Maija
   Ruuskanen, Olli
   Kayhty, Helena
   Nascimento-Carvalho, Cristiana M.
TI Comparison of serological assays using pneumococcal proteins or
   polysaccharides for detection of Streptococcus pneumoniae infection in
   children with community-acquired pneumonia
SO JOURNAL OF IMMUNOLOGICAL METHODS
LA English
DT Article
DE Pediatric pneumonia; Pneumonia aetiology; Serological diagnosis;
   Pneumococcal protein antigens; Pneumococcal polysaccharide antigens
ID RESPIRATORY-TRACT INFECTION; ANTIMICROBIAL THERAPY; HOSPITALIZED
   CHILDREN; ETIOLOGY; DIAGNOSIS; ANTIGENS; CHILDHOOD; BACTERIAL; PCR
AB The aim of this study was to compare the results of serological assays using pneumococcal proteins or polysaccharides for the detection of pneumococcal infection in childhood pneumonia. Serological assays measured IgG against eight pneumococcal proteins (Ply,CbpA,PspAl,PspA2,PcpA,PhtD,StkP-C,PcsB-N), C-polysaccharide [in the whole study population, n = 183], or 19 pneumococcal capsular polysaccharides (1,2,4,5,6B,7F,8,9 V,10A,11A,12F,14,15B,17F,18C,19F,20,23F,33F) [only in a subgroup of patients, n = 53] in paired serum samples of children aged < 5 years-old hospitalized with clinical and radiological diagnosis of community-acquired pneumonia. We also performed an inhibition of binding test with the anti-capsular polysaccharide assay in order to confirm the specificity of the antibody responses detected. Invasive pneumococcal pneumonia was investigated by blood culture and PCR (ply-primer). Among 183 children, the anti-protein assay detected antibody response in 77/183(42.1%) patients and the anti-C-polysaccharide assay in 28/183(15.3%) patients. In a subgroup of 53 children, the anti-protein assay detected response in 32/53(60.4%) patients, the anti-C-polysaccharide assay in 11/53(20.8%) patients, and the anti-capsular polysaccharide in 25/53(47.2%) patients. Simultaneous antibody responses against 2 different capsular polysaccharides were detected in 11/53(20.8%) patients and this finding could not be explained by cross-reactivity between different serotypes. Among 13 patients with invasive pneumococcal pneumonia, the sensitivity of the anti-protein assay was 92.3%(12/13), of the anti-C-polysaccharide assay 30.8%(4/13), and of the anti-capsular polysaccharide assay 46.2%(6/13). The serological assay using pneumococcal proteins is more sensitive for the detection of pneumococcal infection in children with pneumonia than the assay using pneumococcal polysaccharides. Future studies on childhood pneumonia aetiology should consider applying serological assays using pneumococcal proteins.
C1 [Borges, Igor C.; Andrade, Dafne C.; Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Postgrad Program Hlth Sci, Salvador, BA, Brazil.
   [Ekstrom, Nina; Virta, Camilla; Melin, Merit; Kayhty, Helena] Natl Inst Hlth & Welf, Dept Hlth Secur, Helsinki, Finland.
   [Saukkoriipi, Annika; Leinonen, Maija] Natl Inst Hlth & Welf, Dept Publ Hlth Solut, Oulu, Finland.
   [Ruuskanen, Olli] Univ Turku, Dept Paediat & Adolescent Med, Turku, Finland.
   [Ruuskanen, Olli] Turku Univ Hosp, Turku, Finland.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Paediat, Salvador, BA, Brazil.
RP Borges, IC (corresponding author), Univ Fed Bahia, Sch Med, Postgrad Program Hlth Sci, Salvador, BA, Brazil.; Borges, IC (corresponding author), Univ Fed Bahia, Sch Med, Praca 15 Novembro S-N, BR-40025010 Salvador, BA, Brazil.
EM igor.borges@hc.fm.usp.br
RI Borges, Igor Carmo/AAG-8531-2019
OI Carmo Borges, Igor/0000-0003-2749-0313
FU Bahia State Agency for Research Funding (FAPESB), Brazil; Brazilian
   Council for Scientific and Technological Development (CNPq),
   BrazilNational Council for Scientific and Technological Development
   (CNPq); National Institute for Health and Welfare, Finland; Turku
   University Hospital Research Foundation, Finland; Rauno and Anne
   Puolimatka Foundation, Finland; Sohlberg Foundation, Finland; Academy of
   Finland, FinlandAcademy of Finland
FX This work was supported by: Bahia State Agency for Research Funding
   (FAPESB), Brazil; Brazilian Council for Scientific and Technological
   Development (CNPq), Brazil; National Institute for Health and Welfare,
   Finland; Turku University Hospital Research Foundation, Finland; Rauno
   and Anne Puolimatka Foundation, Finland; Sohlberg Foundation, Finland;
   Academy of Finland, Finland. Professor Cristiana M. Nascimento-Carvalho
   is a senior investigator at the CNPq.
CR Andrade DC, 2014, J IMMUNOL METHODS, V405, P130, DOI 10.1016/j.jim.2014.02.002
   Andrade DC, 2016, J IMMUNOL METHODS, V433, P31, DOI 10.1016/j.jim.2016.02.021
   Avni T, 2010, J CLIN MICROBIOL, V48, P489, DOI 10.1128/JCM.01636-09
   Borges IC, 2015, EUR J CLIN MICROBIOL, V34, P1551, DOI 10.1007/s10096-015-2385-y
   Cevey-Macherel M, 2009, EUR J PEDIATR, V168, P1429, DOI 10.1007/s00431-009-0943-y
   CLAESSON BA, 1989, PEDIATR INFECT DIS J, V8, P856, DOI 10.1097/00006454-198912000-00006
   Daniels Calvin C, 2016, J Pediatr Pharmacol Ther, V21, P27, DOI 10.5863/1551-6776-21.1.27
   De Schutter I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089013
   Don M, 2005, SCAND J INFECT DIS, V37, P806, DOI 10.1080/00365540500262435
   Juven T, 2000, PEDIATR INFECT DIS J, V19, P293, DOI 10.1097/00006454-200004000-00006
   Korppi M, 2008, EUR J CLIN MICROBIOL, V27, P167, DOI 10.1007/s10096-007-0436-8
   KORPPI M, 1993, EUR J PEDIATR, V152, P24, DOI 10.1007/BF02072512
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Liu L, 2016, LANCET, V388, P3027, DOI 10.1016/S0140-6736(16)31593-8
   Michelow IC, 2002, CLIN INFECT DIS, V34, pE1, DOI 10.1086/324358
   Nascimento-Carvalho C M, 2001, Braz J Infect Dis, V5, P87
   Nascimento-Carvalho CM, 2015, PEDIATR INFECT DIS J, V34, P490, DOI 10.1097/INF.0000000000000622
   NOHYNEK H, 1995, PEDIATR INFECT DIS J, V14, P478, DOI 10.1097/00006454-199506000-00003
   NOHYNEK H, 1991, AM J DIS CHILD, V145, P618, DOI 10.1001/archpedi.1991.02160060036016
   Nolan VG, 2018, J INFECT DIS, V218, P179, DOI 10.1093/infdis/jix641
   RUUSKANEN O, 1992, EUR J CLIN MICROBIOL, V11, P217, DOI 10.1007/BF02098083
   Salter SJ, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005975
   Saukkoriipi A, 2002, MOL CELL PROBE, V16, P385, DOI 10.1006/mcpr.2002.0443
   Schlottmann SA, 2006, J IMMUNOL METHODS, V309, P75, DOI 10.1016/j.jim.2005.11.019
   Timby N, 2015, J PEDIATR GASTR NUTR, V60, P384, DOI 10.1097/MPG.0000000000000624
   Turner P, 2013, CLIN MICROBIOL INFEC, V19, pE551, DOI [10.1111/1469-0691.12286, 10.1111/1469-0691.12431]
   Vuori E, 1998, CLIN INFECT DIS, V27, P566, DOI 10.1086/514697
NR 27
TC 0
Z9 1
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-1759
EI 1872-7905
J9 J IMMUNOL METHODS
JI J. Immunol. Methods
PD SEP
PY 2018
VL 460
BP 72
EP 78
DI 10.1016/j.jim.2018.06.011
PG 7
WC Biochemical Research Methods; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA GQ2LL
UT WOS:000441486400009
PM 29935210
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, AC
   Vilas-Boas, AL
   Fontoura, MSH
   Vuorinen, T
   Nascimento-Carvalho, CM
AF Nascimento-Carvalho, Amanda C.
   Vilas-Boas, Ana-Luisa
   Fontoura, Maria-Socorro H.
   Vuorinen, Tytti
   Nascimento-Carvalho, Cristiana M.
CA PNEUMOPAC-Efficacy Study Grp
TI Respiratory viruses among children with non-severe community-acquired
   pneumonia: A prospective cohort study
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Article
DE Acute respiratory infection; Children; Lower tract respiratory
   infection; Respiratory virus; Viral infection
ID CHILDHOOD PNEUMONIA; ETIOLOGY; INFECTIONS; DIAGNOSIS; ILLNESS; OLD
AB Background: Community-acquired pneumonia (CAP) causes a major burden to the health care system among children under-5 years worldwide. Information on respiratory viruses in non-severe CAP cases is scarce.
   Objectives: To estimate the frequency of respiratory viruses among non-severe CAP cases.
   Study design: Prospective study conducted in Salvador, Brazil. Out of 820 children aged 2-59 months with nonsevere CAP diagnosed by pediatricians (respiratory complaints and radiographic pulmonary infiltrate/consolidation), recruited in a clinical trial (ClinicalTrials. gov Identifier NCT01200706), nasopharyngeal aspirate samples were obtained from 774 (94.4%) patients and tested for 16 respiratory viruses by PCRs.
   Results: Viruses were detected in 708 (91.5%; 95% CI: 89.3-93.3) cases, out of which 491 (69.4%; 95% CI: 65.9-72.7) harbored multiple viruses. Rhinovirus (46.1%; 95% CI: 42.6-49.6), adenovirus (38.4%; 95% CI: 35.0-41.8), and enterovirus (26.5%; 95% CI: 23.5-29.7) were the most commonly found viruses. The most frequent combination comprised rhinovirus plus adenovirus. No difference was found in the frequency of RSVA (16.1% vs. 14.6%; P= 0.6), RSVB (10.9% vs. 13.2%; P= 0.4) influenza (Flu) A (6.3% vs. 5.1%; P= 0.5), FluB (4.5% vs. 1.8%; P= 0.09), parainfluenza virus (PIV) 1 (5.1% vs. 2.8%; P= 0.2), or PIV4 (7.7% vs. 4.1%; P= 0.08), when children with multiple or sole virus detection were compared. Conversely, rhinovirus, adenovirus, enterovirus, bocavirus, PIV2, PIV3, metapneumovirus, coronavirus OC43, NL63, 229E were significantly more frequent among cases with multiple virus detection.
   Conclusions: Respiratory viruses were detected in over 90% of the cases, out of which 70% had multiple viruses. Several viruses are more commonly found in multiple virus detection whereas other viruses are similarly found in sole and in multiple virus detection.
C1 [Nascimento-Carvalho, Amanda C.] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
   [Vilas-Boas, Ana-Luisa; Fontoura, Maria-Socorro H.; Nascimento-Carvalho, Cristiana M.] Bahiana Fdn Sci Dev, Bahiana Sch Med, Salvador, BA, Brazil.
   [Vuorinen, Tytti] Turku Univ, Turku Univ Hosp, Dept Virol, Dept Clin Virol, Turku, Finland.
RP Nascimento-Carvalho, AC (corresponding author), Rua Prof Aristides Novis 105-1201B, BR-40210630 Salvador, BA, Brazil.
EM carvalhoacn@hotmail.com; anapediatria@ig.com.br; fontora@uol.com.br;
   tyvuori@utu.fi; nascimentocarvalho@hotmail.com
FU Bahia State Agency for Research Funding (FAPESB) [SUS0023/2013]
FX This work was supported by a grant from the Bahia State Agency for
   Research Funding (FAPESB) (Grant No. PPSUS No. SUS0023/2013). CMN-C is a
   senior investigator at the Brazilian Council for Science and
   Technological Development (CNPq).
CR Benet T, 2017, CLIN INFECT DIS, V65, P604, DOI 10.1093/cid/cix378
   Cherian T, 2005, B WORLD HEALTH ORGAN, V83, P353
   Choi SH, 2015, J CLIN MICROBIOL, V53, P1172, DOI 10.1128/JCM.03298-14
   Deng Jikui, 2013, Virologica Sinica, V28, P97, DOI 10.1007/s12250-013-3312-y
   Gerretsen HE, 2017, J INFECTION, V74, pS143, DOI 10.1016/S0163-4453(17)30205-0
   Goka EA, 2014, PAEDIATR RESPIR REV, V15, P363, DOI 10.1016/j.prrv.2013.11.001
   Higdon MM, 2017, CLIN INFECT DIS, V64, pS205, DOI 10.1093/cid/cix076
   Honkinen M, 2012, CLIN MICROBIOL INFEC, V18, P300, DOI 10.1111/j.1469-0691.2011.03603.x
   Huh HJ, 2014, DIAGN MICR INFEC DIS, V79, P419, DOI 10.1016/j.diagmicrobio.2014.01.025
   Hulley S. B., 1988, DESIGNING CLIN RES
   Lieberman D, 2010, CHEST, V138, P811, DOI 10.1378/chest.09-2717
   Lu GL, 2013, J MED VIROL, V85, P138, DOI 10.1002/jmv.23438
   Garcia-Garcia ML, 2012, PEDIATR INFECT DIS J, V31, P808, DOI 10.1097/INF.0b013e3182568c67
   Nascimento-Carvalho AC, 2018, PEDIATR PULM, V53, P88, DOI 10.1002/ppul.23891
   Pavia AT, 2013, INFECT DIS CLIN N AM, V27, P157, DOI 10.1016/j.idc.2012.11.007
   Peltola V, 2008, J INFECT DIS, V197, P382, DOI 10.1086/525542
   Rhedin S, 2015, THORAX, V70, P847, DOI 10.1136/thoraxjnl-2015-206933
   Rudan I, 2008, B WORLD HEALTH ORGAN, V86, P408, DOI 10.2471/BLT.07.048769
   Ruuskanen O, 2011, LANCET, V377, P1264, DOI 10.1016/S0140-6736(10)61459-6
   Self WH, 2016, J INFECT DIS, V213, P584, DOI 10.1093/infdis/jiv323
   Stevens DA, 2016, J CLIN MICROBIOL, V54, P2707, DOI 10.1128/JCM.01224-16
   Turunen R, 2014, PEDIAT ALLERG IMM-UK, V25, P796, DOI 10.1111/pai.12318
   Vilas-Boas AL, 2014, J ANTIMICROB CHEMOTH, V69, P1954, DOI 10.1093/jac/dku070
   Vuori-Holopainen E, 2001, CLIN INFECT DIS, V32, P715, DOI 10.1086/319213
   Walker CLF, 2013, LANCET, V381, P1405, DOI 10.1016/S0140-6736(13)60222-6
   WHO UNICEF, 2008, INT MAN CHILDH ILLN
   World Health Organization, 2000, MAN CHILD SER INF SE, P20
   World Health Organization, 2008, TRAIN COURS CHILD GR
NR 28
TC 9
Z9 9
U1 1
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1386-6532
EI 1873-5967
J9 J CLIN VIROL
JI J. Clin. Virol.
PD AUG
PY 2018
VL 105
BP 77
EP 83
DI 10.1016/j.jcv.2018.06.003
PG 7
WC Virology
SC Virology
GA GN3GN
UT WOS:000438892300012
PM 29908521
OA Green Published
DA 2020-12-17
ER

PT J
AU Vasconcellos, AG
   Clarencio, J
   Andrade, D
   Cardoso, MRA
   Barral, A
   Nascimento-Carvalho, CM
AF Vasconcellos, Angela G.
   Clarencio, Jorge
   Andrade, Daniela
   Cardoso, Maria-Regina A.
   Barral, Aldina
   Nascimento-Carvalho, Cristiana M.
TI Systemic cytokines and chemokines on admission of children hospitalized
   with community-acquired pneumonia
SO CYTOKINE
LA English
DT Article
DE Acute respiratory infection; Child; Lower respiratory tract infection;
   Lung disease; Pneumococcal infection
ID INFECTIONS; DIAGNOSIS; ETIOLOGY; INTERLEUKIN-6; PATHOGENESIS; BACTERIAL;
   ASSAYS
AB Community-acquired pneumonia (CAP) is the main cause of death in children under-5 years worldwide and Streptococcus pneumoniae is the most common bacterial agent. However, it is difficult to identify pneumococcal infection among children with CAP. We aimed to assess association between any cytokine/chemokine and pneumococcal infection in childhood CAP. Furthermore, we evaluated the diagnostic value of cytokine/chemokine for pneumococcal infection. This prospective study was conducted at an Emergency Room, in Salvador, Brazil. Children < 5-years-old hospitalized with CAP in a 21-month period were evaluated. On admission, clinical and radiological data were collected along with biological samples to investigate 20 etiological agents and determine serum cytokines (interleukin (IL)-8, IL-6, IL-10, IL-1 beta, IL-12, TNF-alpha, IL-2, IL-4, IL-5, gamma-interferon), and chemokines (CCL2, CCL5, CXCL9, CXCL10) concentration. From 166 patients with etiology detected, pneumococcal infection was detected in 38 (22.9%) cases among which the median IL-6(pg/ml) was 31.2 (IQR: 12.4-54.1). The other 128 cases had other causative agents detected (Haemophilus influenzae, Moraxella catorrhalis, atypical bacteria and viruses) with the median IL-6 concentration being 9.0 (IQR: 4.1-22.0; p < 0.001). The area under the ROC curve for IL-6 to predict pneumococcal CAP was 0.74 (95%CI: 0.65-0.83; p < 0.001). By multivariate analysis, with pneumococcal CAP as dependent variable, IL-6 was an independent predictor for pneumococcal infection (OR = 5.56; 95%CI: 2.42-12.75, cut-off point = 12.5 pg/ml; p = 0.0001). The negative predictive value of IL-6 under 12.5 pg/ml for pneumococcal infection was 90% (95%CI: 82-95%). Independently significant difference was not found for any other cytokines/chemokines. Serum IL-6 concentration on admission is independently associated with pneumococcal infection among children under-5 years hospitalized with CAP.
C1 [Vasconcellos, Angela G.; Barral, Aldina; Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Postgrad Program Hlth Sci, Salvador, BA, Brazil.
   [Clarencio, Jorge; Andrade, Daniela; Barral, Aldina] Fundacao Oswaldo Cruz, Ctr Pesquisa Goncalo Moniz, Salvador, BA, Brazil.
   [Cardoso, Maria-Regina A.] Univ Sao Paulo, Sch Publ Hlth, Sao Paulo, Brazil.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Pediat, Rua Prof Aristides Novis 105-1201B, BR-40210630 Salvador, BA, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia, Sch Med, Dept Pediat, Rua Prof Aristides Novis 105-1201B, BR-40210630 Salvador, BA, Brazil.
EM angelavase@yahoo.com.br; jorgec@bahia.ficoruz.br;
   danirodriguesandrade@hotmail.com; rcardoso@usp.br;
   aldinabarral@gmail.com; nascimentocarvalho@hotmail.com
OI Clarencio, Jorge/0000-0002-4289-5450
FU Bahia State Agency for Research Funding (FAPESB) [PNX 0019/2009]
FX This study was supported by the Bahia State Agency for Research Funding
   (FAPESB) (grant no. PNX 0019/2009).
CR Antunes G, 2002, EUR RESPIR J, V20, P990, DOI 10.1183/09031936.02.00295102
   Atkinson TP, 2014, PEDIATR INFECT DIS J, V33, P92, DOI 10.1097/INF.0000000000000171
   Bradley JS, 2011, CLIN INFECT DIS, V53, pE25, DOI 10.1093/cid/cir531
   Calbo E, 2010, INT J ANTIMICROB AG, V35, P107, DOI 10.1016/j.ijantimicag.2009.10.002
   Christ-Crain M, 2010, CRIT CARE, V14, DOI 10.1186/cc8155
   El-Rashdi AS, 2006, ARCH DIS CHILD, V91, P351, DOI 10.1136/adc.2005.088831
   Endeman H, 2011, EUR RESPIR J, V37, P1431, DOI 10.1183/09031936.00074410
   Gillespie SH, 2000, J MED MICROBIOL, V49, P1057, DOI 10.1099/0022-1317-49-12-1057
   Hyypia T, 1998, J CLIN MICROBIOL, V36, P2081
   Iroh Tam Pui-Ying, 2015, Hosp Pediatr, V5, P324, DOI 10.1542/hpeds.2014-0138
   Korppi M, 2008, EUR J CLIN MICROBIOL, V27, P167, DOI 10.1007/s10096-007-0436-8
   Korppi M, 2010, PEDIATR INFECT DIS J, V29, P387, DOI 10.1097/INF.0b013e3181ce8e81
   Lieberman D, 1997, INFECTION, V25, P90, DOI 10.1007/BF02113582
   Liu L, 2015, LANCET, V385, P430, DOI 10.1016/S0140-6736(14)61698-6
   Makela MJ, 1998, J CLIN MICROBIOL, V36, P539
   Michelow IC, 2007, PEDIATR PULM, V42, P640, DOI 10.1002/ppul.20633
   Morre SA, 2002, J CLIN MICROBIOL, V40, P584, DOI 10.1128/JCM.40.2.584-587.2002
   Nair H, 2013, LANCET, V381, P1380, DOI 10.1016/S0140-6736(12)61901-1
   Nascimento-Carvalho CM, 2008, PEDIATR INFECT DIS J, V27, P939, DOI 10.1097/INF.0b013e3181723751
   Nascimento-Carvalho CM, 2012, J MED VIROL, V84, P253, DOI 10.1002/jmv.22268
   Nascimento-Carvalho CM, 2011, INFLUENZA OTHER RESP, V5, P285, DOI 10.1111/j.1750-2659.2011.00206.x
   Nascimento-Carvalho CM, 2009, J INFECTION, V58, P250, DOI 10.1016/j.jinf.2009.01.008
   NOHYNEK H, 1995, PEDIATR INFECT DIS J, V14, P478, DOI 10.1097/00006454-199506000-00003
   Pavare J., 1999, PEDIATRICS, V104, P1321
   Rudan I, 2013, J GLOB HEALTH, V3, DOI 10.7189/jogh.03.010401
   Said MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060273
   Saukkoriipi A, 2002, MOL CELL PROBE, V16, P385, DOI 10.1006/mcpr.2002.0443
   Scott JAG, 2012, CLIN INFECT DIS, V54, pS109, DOI 10.1093/cid/cir1065
   Toikka P, 2000, PEDIATR INFECT DIS J, V19, P598, DOI 10.1097/00006454-200007000-00003
   Tumgor G, 2006, ANN TROP PAEDIATR, V26, P285, DOI 10.1179/146532806X152809
   van der Poll T, 2009, LANCET, V374, P1543, DOI 10.1016/S0140-6736(09)61114-4
   Wang SP, 2000, J INFECT DIS, V181, pS421, DOI 10.1086/315622
   World Health Organization, 2013, POCK BOOK HOSP CAR C
   Yamaguchi T, 2005, FEMS IMMUNOL MED MIC, V43, P21, DOI 10.1016/j.femsim.2004.06.023
NR 34
TC 10
Z9 10
U1 0
U2 7
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-4666
EI 1096-0023
J9 CYTOKINE
JI Cytokine
PD JUL
PY 2018
VL 107
BP 1
EP 8
DI 10.1016/j.cyto.2017.11.005
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA GR6ZS
UT WOS:000442835300001
PM 29158121
DA 2020-12-17
ER

PT J
AU Ramos, CL
   Moreno-Carvalho, OA
   Nascimento-Carvalho, CM
AF Ramos, Clara L.
   Moreno-Carvalho, Otavio A.
   Nascimento-Carvalho, Cristiana M.
TI Cerebrospinal fluid aspects of neonates with or without microcephaly
   born to mothers with gestational Zika virus clinical symptoms
SO JOURNAL OF INFECTION
LA English
DT Letter
ID INFECTION
C1 [Ramos, Clara L.] Bahiana Sch Med, Bahiana Fdn Sci Dev, Ave Santa Luzia 400,Apt 2002, BR-40295050 Salvador, BA, Brazil.
   [Moreno-Carvalho, Otavio A.] Jose Silveira Fdn, Cerebrospinal Fluid Lab, BR-40170100 Salvador, BA, Brazil.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Postgrad Program Hlth Sci, BR-40025010 Salvador, BA, Brazil.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Paediat, BR-40025010 Salvador, BA, Brazil.
   [Nascimento-Carvalho, Cristiana M.] Brazilian Council Sci & Technol Dev, Brasilia, Brazil.
RP Ramos, CL (corresponding author), Bahiana Sch Med, Bahiana Fdn Sci Dev, Ave Santa Luzia 400,Apt 2002, BR-40295050 Salvador, BA, Brazil.
EM ccclr1@gmail.com
CR BOPPANA SB, 1992, PEDIATR INFECT DIS J, V11, P93, DOI 10.1097/00006454-199202000-00007
   Center for Diseases Control and Prevention, 2016, ZIK VIR TEST TREATM
   Chan JFW, 2016, J INFECTION, V72, P507, DOI 10.1016/j.jinf.2016.02.011
   Fernandes RCDC, 2016, LANCET INFECT DIS, V16, P772, DOI 10.1016/S1473-3099(16)30079-2
   Passemard S, 2013, HAND CLINIC, V111, P129, DOI 10.1016/B978-0-444-52891-9.00013-0
   Reiber H, 2003, RESTOR NEUROL NEUROS, V21, P79
   Shah SS, 2011, J HOSP MED, V6, P22, DOI 10.1002/jhm.711
   Sousa AQ, 2017, EMERG INFECT DIS, V23, P1164, DOI 10.3201/eid2307.162019
   Aragao MDV, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i1901
NR 9
TC 1
Z9 1
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0163-4453
EI 1532-2742
J9 J INFECTION
JI J. Infect.
PD JUN
PY 2018
VL 76
IS 6
BP 565
EP 567
DI 10.1016/j.jinf.2018.02.004
PG 3
WC Infectious Diseases
SC Infectious Diseases
GA GI0VL
UT WOS:000434088300010
PM 29432825
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, CM
AF Nascimento-Carvalho, Cristiana Maria
TI Children With or Without Radiologically Confirmed Pneumonia: Does
   Etiology Play Any Role?
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Letter
C1 [Nascimento-Carvalho, Cristiana Maria] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
   [Nascimento-Carvalho, Cristiana Maria] Brazilian Council Sci & Technol Dev, Brasilia, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Rua Prof Aristides Novis,105 Apto 1201B, BR-40210630 Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
CR Fancourt N, 2017, CLIN INFECT DIS, V64, pS262, DOI 10.1093/cid/cix089
   Fontoura MS, 2012, INDIAN PEDIATR, V49, P363, DOI 10.1007/s13312-012-0085-6
   Kelly MS, 2016, PEDIATR INFECT DIS J, V35, P257, DOI 10.1097/INF.0000000000000990
   Levine OS, 2012, CLIN INFECT DIS, V54, pS93, DOI 10.1093/cid/cir1052
   Nascimento-Carvalho CM, 2015, PEDIATR INFECT DIS J, V34, P490, DOI 10.1097/INF.0000000000000622
   Simbalista R, 2015, BMC PEDIATR, V15, DOI 10.1186/s12887-015-0485-6
NR 6
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAR 15
PY 2018
VL 66
IS 6
BP 980
EP 980
DI 10.1093/cid/cix919
PG 1
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA FY4TS
UT WOS:000426819800024
PM 29088430
OA Bronze
DA 2020-12-17
ER

PT J
AU Andrade, DC
   Borges, IC
   Vilas-Boas, AL
   Fontoura, MSH
   Araujo-Neto, CA
   Andrade, SC
   Brim, RV
   Meinke, A
   Barral, A
   Ruuskanen, O
   Kayhty, H
   Nascimento-Carvalho, CM
AF Andrade, Dafne C.
   Borges, Igor C.
   Vilas-Boas, Ana Luisa
   Fontoura, Maria S. H.
   Araujo-Neto, Cesar A.
   Andrade, Sandra C.
   Brim, Rosa V.
   Meinke, Andreas
   Barral, Aldina
   Ruuskanen, Olli
   Kayhty, Helena
   Nascimento-Carvalho, Cristiana M.
TI Infection by Streptococcus pneumoniae in children with or without
   radiologically confirmed pneumonia
SO JORNAL DE PEDIATRIA
LA English
DT Article
DE Bacterial infection; Etiology; Lower respiratory tract infection;
   Radiological study; Serological tests
ID COMMUNITY-ACQUIRED PNEUMONIA; RADIOGRAPHICALLY DIAGNOSED PNEUMONIA;
   PNEUMOCOCCAL CONJUGATE VACCINE; RESPIRATORY-TRACT INFECTION; RANDOMIZED
   CONTROLLED-TRIAL; HAEMOPHILUS-INFLUENZAE; MORAXELLA-CATARRHALIS; PROTEIN
   ANTIGENS; ANTIBODY-RESPONSES; CHEST RADIOGRAPH
AB Objective: Community-acquired pneumonia is an important cause of morbidity in childhood, but the detection of its causative agent remains a diagnostic challenge. The authors aimed to evaluate the role of the chest radiograph to identify cases of community-aquired pneumonia caused by typical bacteria.
   Methods: The frequency of infection by Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis was compared in non-hospitalized children with clinical diagnosis of community acquired pneumonia aged 2-59 months with or without radiological confirmation (n = 249 and 366, respectively). Infection by S. pneumoniae was diagnosed by the detection of a serological response against at least one of eight pneumococcal proteins (defined as an increase >= 2-fold in the IgG levels against Ply, CbpA, PspA1 and PspA2, PhtD, StkP-C, and PcsB-N, or an increase >= 1.5-fold against PcpA). Infection by H. influenzae and M. catarrhalis was defined as an increase >= 2-fold on the levels of microbe-specific IgG.
   Results: Children with radiologically confirmed pneumonia had higher rates of infection by S. pneumoniae. The presence of pneumococcal infection increased the odds of having radiologically confirmed pneumonia by 2.8 times (95% CI: 1.8-4.3). The negative predictive value of the normal chest radiograph for infection by S. pneumoniae was 86.3% (95% CI: 82.4-89.7%). There was no difference on the rates of infection by H. influenzae and M. catarrhalis between children with community-acquired pneumonia with and without radiological confirmation.
   Conclusions: Among children with clinical diagnosis of community-acquired pneumonia submitted to chest radiograph, those with radiologically confirmed pneumonia present a higher rate of infection by S. pneumoniae when compared with those with a normal chest radiograph. (C) 2017 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda.
C1 [Andrade, Dafne C.; Borges, Igor C.; Vilas-Boas, Ana Luisa; Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia UFBA, Fac Med, Programa Posgrad Ciencias Saude, Salvador, BA, Brazil.
   [Fontoura, Maria S. H.; Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia UFBA, Fac Med, Dept Pediat, Salvador, BA, Brazil.
   [Araujo-Neto, Cesar A.; Brim, Rosa V.] Univ Fed Bahia UFBA, Fac Med, Dept Med Interna & Apoio Diagnost, Salvador, BA, Brazil.
   [Andrade, Sandra C.] Univ Fed Bahia UFBA, Complexo Hosp Prof Edgard Santos HUPES, Salvador, BA, Brazil.
   [Meinke, Andreas] Valneva Austria GmbH, Campus Vienna Bioctr 3, Vienna, Austria.
   [Barral, Aldina] Univ Fed Bahia UFBA, Fac Med, Dept Patol, Salvador, BA, Brazil.
   [Barral, Aldina] Fundacao Oswaldo Cruz FIOCRUZ, Ctr Pesquisa Goncalo Moniz, Salvador, BA, Brazil.
   [Ruuskanen, Olli] Turku Univ, Turku, Finland.
   [Ruuskanen, Olli] Univ Hosp, Dept Pediat, Turku, Finland.
   [Kayhty, Helena] Natl Inst Hlth & Welf, Helsinki, Finland.
RP Andrade, DC (corresponding author), Univ Fed Bahia UFBA, Fac Med, Programa Posgrad Ciencias Saude, Salvador, BA, Brazil.
EM andradedafne@yahoo.com.br
RI Borges, Igor Carmo/AAG-8531-2019
OI Carmo Borges, Igor/0000-0003-2749-0313
FU Bahia State Agency for Research Funding (Fundacao de Amparo a Pesquisa
   do Estado da Bahia [FAPESB]); Brazilian Council for Scientific and
   Technological Development (Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico [CNPq])National Council for Scientific and
   Technological Development (CNPq)
FX This work was supported by the Bahia State Agency for Research Funding
   (Fundacao de Amparo a Pesquisa do Estado da Bahia [FAPESB]) and the
   Brazilian Council for Scientific and Technological Development (Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico [CNPq]).
CR Andrade DC, 2016, PEDIATR INFECT DIS J, V35, P683, DOI 10.1097/INF.0000000000001126
   Andrade DC, 2014, J IMMUNOL METHODS, V405, P130, DOI 10.1016/j.jim.2014.02.002
   Andrade DC, 2016, J IMMUNOL METHODS, V433, P31, DOI 10.1016/j.jim.2016.02.021
   [Anonymous], 2008, REDE INT INF SAUD IN
   Bahia. Secretaria de Saude do Estado da Bahia, 2010, INTR VAC PNEUM 10 VA
   Bogaert D, 2004, LANCET INFECT DIS, V4, P144, DOI 10.1016/S1473-3099(04)00938-7
   Borges IC, 2015, EUR J CLIN MICROBIOL, V34, P1551, DOI 10.1007/s10096-015-2385-y
   Bradley JS, 2011, CLIN INFECT DIS, V53, pE25, DOI 10.1093/cid/cir531
   Cardoso MRA, 2011, ARCH DIS CHILD, V96, P58, DOI 10.1136/adc.2010.189894
   Chappuy H, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-357
   Cherian T, 2005, B WORLD HEALTH ORGAN, V83, P353
   Chien YW, 2013, PEDIATR INFECT DIS J, V32, P72, DOI 10.1097/INF.0b013e318270d850
   Don M, 2009, PEDIATR INT, V51, P91, DOI 10.1111/j.1442-200X.2008.02678.x
   Fontoura MS, 2012, INDIAN PEDIATR, V49, P363, DOI 10.1007/s13312-012-0085-6
   Harris M, 2011, THORAX, V66, pII1, DOI 10.1136/thoraxjnl-2011-200598
   Johnson J, 2010, EMERG RADIOL, V17, P285, DOI 10.1007/s10140-009-0854-2
   Kelly MS, 2016, PEDIATR INFECT DIS J, V35, P257, DOI 10.1097/INF.0000000000000990
   Key NK, 2011, INDIAN PEDIATR, V48, P873, DOI 10.1007/s13312-011-0142-6
   Korppi M, 2008, ACTA PAEDIATR, V97, P943, DOI 10.1111/j.1651-2227.2008.00789.x
   Liu L, 2015, LANCET, V385, P430, DOI 10.1016/S0140-6736(14)61698-6
   Lucero MG, 2009, PEDIATR INFECT DIS J, V28, P455, DOI 10.1097/INF.0b013e31819637af
   Nascimento-Carvalho CM, 2008, PEDIATR INFECT DIS J, V27, P939, DOI 10.1097/INF.0b013e3181723751
   Nascimento-Carvalho CM, 2015, PEDIATR INFECT DIS J, V34, P490, DOI 10.1097/INF.0000000000000622
   Swingler GH, 1998, LANCET, V351, P404, DOI 10.1016/S0140-6736(97)07013-X
   Toikka P, 2000, PEDIATR INFECT DIS J, V19, P598, DOI 10.1097/00006454-200007000-00003
   Tregnaghi MW, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001657
   Vilas-Boas AL, 2014, J ANTIMICROB CHEMOTH, V69, P1954, DOI 10.1093/jac/dku070
   Virkki R, 2002, THORAX, V57, P438, DOI 10.1136/thorax.57.5.438
   World Health Organization, 2008, TRAIN COURS CHILD GR
   Xavier-Souza G, 2013, PEDIATR PULM, V48, P464, DOI 10.1002/ppul.22644
NR 30
TC 8
Z9 8
U1 0
U2 4
PU SOC BRASIL PEDIATRIA
PI RIO DE JANEIRO, RJ
PA RUA SANTA CLARA 292, RIO DE JANEIRO, RJ, CEP 22401-01, BRAZIL
SN 0021-7557
EI 1678-4782
J9 J PEDIAT-BRAZIL
JI J. Pediatr.
PD JAN-FEB
PY 2018
VL 94
IS 1
BP 23
EP 30
DI 10.1016/j.jped.2017.03.004
PG 8
WC Pediatrics
SC Pediatrics
GA FX9TH
UT WOS:000426447600004
PM 28668258
OA DOAJ Gold, Green Published
DA 2020-12-17
ER

PT J
AU Andrade, DC
   Borges, IC
   Bouzas, ML
   Oliveira, JR
   Kayhty, H
   Ruuskanen, O
   Nascimento-Carvalho, C
AF Andrade, Dafne C.
   Borges, Igor C.
   Bouzas, Maiara L.
   Oliveira, Juliana R.
   Kayhty, Helena
   Ruuskanen, Olli
   Nascimento-Carvalho, Cristiana
TI Antibody responses against Streptococcus pneumoniae, Haemophilus
   influenzae and Moraxella catarrhalis in children with acute respiratory
   infection with or without nasopharyngeal bacterial carriage
SO INFECTIOUS DISEASES
LA English
DT Article
DE Bacterial infection; Immune response; Nasopharynx; Pneumococcus;
   Vaccination
ID ACUTE OTITIS-MEDIA; PNEUMOCOCCAL CONJUGATE VACCINE; SURFACE ADHESIN-A;
   PROTEIN ANTIGENS; NATURAL ANTIBODIES; YOUNG-CHILDREN; COLONIZATION;
   SERUM; PNEUMOLYSIN; MUCOSAL
AB Background: We studied Immunoglobulin G (IgG) antibody responses against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in young children with acute viral type respiratory infection and analyzed the findings in a multivariate model including age, nasopharyngeal carriage of the tested bacteria and pneumococcal vaccination.
   Methods: We included 227 children aged 6-23 months with acute respiratory infection. Nasopharyngeal aspirates were tested for bacterial carriage through detection of messenger RNA (mRNA) transcript with nCounter analysis. Acute and convalescent serum samples were tested for IgG antibody response against eight pneumococcal proteins, three proteins from H. influenzae and five proteins from M. catarrhalis in a fluorescent multiplex immunoassay.
   Results: A two-fold or greater increase in antibodies to S. pneumoniae, H. influenzae and M. catarrhalis was detected in 27.8, 9.7 and 14.1%, respectively. Nasopharyngeal carriage of each of the studied bacteria was not associated with antibody response detection against each respective bacterium. Furthermore, neither age nor pneumococcal vaccination were independently associated to detection of antibody response against the studied bacteria. Children who carried H. influenzae had higher frequency of colonization by M. catarrhalis (175 [80.3%] vs. 2 [22.2%]; p < .001) than those without H. influenzae. Also, children with acute otitis media tended to have higher frequency of antibody response to S. pneumoniae.
   Conclusion: Nasopharyngeal colonization by S. pneumoniae, H. influenzae and M. catarrhalis did not induce significant increases in antibody levels to these bacteria. Carriage of pathogenic bacteria in the nasopharynx is not able to elicit antibody responses to protein antigens similar to those caused by symptomatic infections.
C1 [Andrade, Dafne C.; Borges, Igor C.; Bouzas, Maiara L.; Oliveira, Juliana R.] Univ Fed Bahia, Sch Med, Postgrad Programme Hlth Sci, Salvador, BA, Brazil.
   [Kayhty, Helena] Natl Inst Hlth & Welf, Dept Vaccinat & Immune Protect, Helsinki, Finland.
   [Ruuskanen, Olli] Turku Univ, Dept Paediat, Turku, Finland.
   [Ruuskanen, Olli] Univ Hosp, Turku, Finland.
   [Nascimento-Carvalho, Cristiana] Univ Fed Bahia, Sch Med, Postgrad Programme Hlth Sci, Dept Paediat, Salvador, BA, Brazil.
RP Andrade, DC (corresponding author), Univ Fed Bahia, Sch Med, Praca 15 Novembro,S-N Largo Terreiro Jesus, BR-40025010 Salvador, BA, Brazil.
EM andradedafne@yahoo.com.br
RI Borges, Igor Carmo/AAG-8531-2019
OI Carmo Borges, Igor/0000-0003-2749-0313
FU Bahia State Agency for Research Funding [FAPESB], Brazil [52/2004];
   Brazilian Council for Scientific and Technological Development [CNPq],
   BrazilNational Council for Scientific and Technological Development
   (CNPq) [400995/2005-0]; Turku University Hospital Research Foundation,
   Finland; Rauno and Anne Puolimatka Foundation, Finland; Sohlberg
   Foundation, Finland [2418/2014]
FX This work was supported by: Bahia State Agency for Research Funding
   [FAPESB, grant number 52/2004], Brazil; Brazilian Council for Scientific
   and Technological Development [CNPq, grant number 400995/2005-0],
   Brazil; Turku University Hospital Research Foundation, Finland; Rauno
   and Anne Puolimatka Foundation, Finland and Sohlberg Foundation [grant
   number 2418/2014], Finland.
CR Andrade DC, 2016, PEDIATR INFECT DIS J, V35, P683, DOI 10.1097/INF.0000000000001126
   Andrade DC, 2014, J IMMUNOL METHODS, V405, P130, DOI 10.1016/j.jim.2014.02.002
   Andrade DC, 2016, J IMMUNOL METHODS, V433, P31, DOI 10.1016/j.jim.2016.02.021
   Brandileone MCD, 2016, VACCINE, V34, P5604, DOI 10.1016/j.vaccine.2016.09.027
   Camilli R, 2015, VACCINE, V33, P4559, DOI 10.1016/j.vaccine.2015.07.009
   Chonmaitree T, 2015, CLIN INFECT DIS, V60, P1, DOI 10.1093/cid/ciu714
   Cripps AW, 2007, VACCINE, V25, P2471, DOI 10.1016/j.vaccine.2006.09.022
   Fukutani KF, 2015, J CLIN VIROL, V69, P190, DOI 10.1016/j.jcv.2015.06.005
   Hagerman A, 2013, EUR J CLIN MICROBIOL, V32, P43, DOI 10.1007/s10096-012-1712-9
   Hammitt LL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085459
   Holmlund E, 2006, VACCINE, V24, P57, DOI 10.1016/j.vaccine.2005.07.055
   Hulley S. B., 1988, DESIGNING CLIN RES
   Lebon A, 2011, INFECT IMMUN, V79, P1680, DOI 10.1128/IAI.01379-10
   Littorin N, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1750-5
   Marom T, 2012, CURR ALLERGY ASTHM R, V12, P551, DOI 10.1007/s11882-012-0303-2
   Navne JE, 2016, EPIDEMIOL INFECT, V144, P3226, DOI 10.1017/S0950268816001461
   Oliveira JR, 2016, VACCINE, V34, P2556, DOI 10.1016/j.vaccine.2016.04.015
   Pichichero ME, 2012, HUM VACC IMMUNOTHER, V8, P799, DOI 10.4161/hv.19820
   Pichichero ME, 2010, VACCINE, V28, P7184, DOI 10.1016/j.vaccine.2010.08.063
   Rapola S, 2001, PEDIATR INFECT DIS J, V20, P482, DOI 10.1097/00006454-200105000-00003
   Ren D, 2015, VACCINE, V33, P5809, DOI 10.1016/j.vaccine.2015.09.023
   Rudan I, 2013, J GLOB HEALTH, V3, DOI 10.7189/jogh.03.010401
   Samukawa T, 2000, INFECT IMMUN, V68, P1569, DOI 10.1128/IAI.68.3.1569-1573.2000
   Simell B, 2012, EXPERT REV VACCINES, V11, P841, DOI [10.1586/erv.12.53, 10.1586/ERV.12.53]
   Simell B, 2009, VACCINE, V27, P4615, DOI 10.1016/j.vaccine.2009.05.071
   Tan TT, 2007, J INFECT DIS, V195, P1661, DOI 10.1086/517611
   Tregnaghi MW, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001657
   Turner P, 2013, CLIN MICROBIOL INFEC, V19, pE551, DOI [10.1111/1469-0691.12286, 10.1111/1469-0691.12431]
   van den Bergh MR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047711
   Verhaegh SJC, 2011, MICROBIOL-SGM, V157, P169, DOI 10.1099/mic.0.042929-0
   Wolter N, 2014, J INFECT DIS, V210, P1649, DOI 10.1093/infdis/jiu326
   Xu QF, 2017, J INFECTION, V75, P26, DOI 10.1016/j.jinf.2017.04.003
   Xu QF, 2012, EMERG INFECT DIS, V18, P1738, DOI 10.3201/eid1811.111904
   Zhang QB, 2006, EUR J IMMUNOL, V36, P46, DOI 10.1002/eji.200535101
NR 34
TC 2
Z9 3
U1 0
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 2374-4235
EI 2374-4243
J9 INFECT DIS-NOR
JI Infect. Dis.
PY 2018
VL 50
IS 9
BP 705
EP 713
DI 10.1080/23744235.2018.1463451
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA GS7JH
UT WOS:000443876300008
PM 29688138
DA 2020-12-17
ER

PT J
AU Andrade, DC
   Borges, IC
   Ekstrom, N
   Jartti, T
   Puhakka, T
   Barral, A
   Kayhty, H
   Ruuskanen, O
   Nascimento-Carvalho, CM
AF Andrade, D. C.
   Borges, I. C.
   Ekstrom, N.
   Jartti, T.
   Puhakka, T.
   Barral, A.
   Kayhty, H.
   Ruuskanen, O.
   Nascimento-Carvalho, C. M.
TI Determination of avidity of IgG against protein antigens from
   Streptococcus pneumoniae: assay development and preliminary application
   in clinical settings
SO EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
LA English
DT Article
ID PNEUMOCOCCAL CONJUGATE VACCINE; HAEMOPHILUS-INFLUENZAE;
   MORAXELLA-CATARRHALIS; FUNCTIONAL ANTIBODIES; OTITIS-MEDIA; CHILDREN;
   DISEASE; PSPA; PROTECTION; INFECTION
AB The measurement of antibody levels is a common test for the diagnosis of Streptococcus pneumoniae infection in research. However, the quality of antibody response, reflected by avidity, has not been adequately evaluated. We aimed to evaluate the role of avidity of IgG against eight pneumococcal proteins in etiologic diagnosis. Eight pneumococcal proteins (Ply, CbpA, PspA1 and 2, PcpA, PhtD, StkP-C, and PcsB-N) were used to develop a multiplex bead-based avidity immunoassay. The assay was tested for effects of the chaotropic agent, multiplexing, and repeatability. The developed assay was applied to paired samples from children with or without pneumococcal disease (n = 38 for each group), determined by either serology, polymerase chain reaction (PCR), or blood culture. We found a good correlation between singleplex and multiplex assays, with r >0.94.The assay was reproducible, with mean inter-assay variation >9% and intra-assay variation < 6%. Children with pneumococcal disease had lower median avidity indexes in the acute phase of disease for PspA1 and 2 (p = 0.042), PcpA (p = 0.002), PhtD (p = 0.014), and StkP-C (p < 0.001). When the use of IgG avidity as a diagnostic tool for pneumococcal infection was evaluated, the highest discriminative power was found for StkP-C, followed by PcpA (area under the curve [95% confidence interval, CI]: 0.868 [0.759-0.977] and 0.743 [0.607-879], respectively). The developed assay was robust and had no deleterious influence from multiplexing. Children with pneumococcal disease had lower median avidity against five pneumococcal proteins in the acute phase of disease compared to children without disease.
C1 [Andrade, D. C.; Borges, I. C.; Barral, A.; Nascimento-Carvalho, C. M.] Univ Fed Bahia, Sch Med, Postgrad Programme Hlth Sci, Salvador, BA, Brazil.
   [Ekstrom, N.; Kayhty, H.] Natl Inst Hlth & Welf, Helsinki, Finland.
   [Jartti, T.; Ruuskanen, O.] Univ Turku, Dept Paediat, Turku, Finland.
   [Jartti, T.; Puhakka, T.; Ruuskanen, O.] Turku Univ Hosp, Turku, Finland.
   [Puhakka, T.] Univ Turku, Dept Otorhinolaryngol, Turku, Finland.
   [Puhakka, T.] Satakunta Cent Hosp, Dept Otorhinolaryngol, Pori, Finland.
   [Barral, A.] Univ Fed Bahia, Sch Med, Dept Pathol, Salvador, BA, Brazil.
   [Barral, A.] Fundacao Oswaldo Cruz, Ctr Pesquisa Goncalo Muniz, Salvador, BA, Brazil.
   [Nascimento-Carvalho, C. M.] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
RP Andrade, DC (corresponding author), Univ Fed Bahia, Sch Med, Postgrad Programme Hlth Sci, Salvador, BA, Brazil.
EM andradedafne@yahoo.com.br
RI Borges, Igor Carmo/AAG-8531-2019
OI Carmo Borges, Igor/0000-0003-2749-0313
FU Bahia State Agency for Research Funding (FAPESB), Brazil; Brazilian
   Council for Scientific and Technological Development (CNPq),
   BrazilNational Council for Scientific and Technological Development
   (CNPq); Turku University Hospital Research Foundation, Finland; Rauno
   and Anne Puolimatka Foundation, Finland; Sohlberg Foundation, Finland
FX This work was supported by: Bahia State Agency for Research Funding
   (FAPESB), Brazil; Brazilian Council for Scientific and Technological
   Development (CNPq), Brazil; Turku University Hospital Research
   Foundation, Finland; Rauno and Anne Puolimatka Foundation, Finland;
   Sohlberg Foundation, Finland.
CR Adamou JE, 2001, INFECT IMMUN, V69, P949, DOI 10.1128/IAI.69.2.949-958.2001
   Andrade DC, 2016, PEDIATR INFECT DIS J, V35, P683, DOI 10.1097/INF.0000000000001126
   Andrade DC, 2014, J IMMUNOL METHODS, V405, P130, DOI 10.1016/j.jim.2014.02.002
   Andrade DC, 2016, J IMMUNOL METHODS, V433, P31, DOI 10.1016/j.jim.2016.02.021
   Anttila M, 1999, CLIN EXP IMMUNOL, V118, P402
   Borges IC, 2016, CLIN VACCINE IMMUNOL, V23, P878, DOI 10.1128/CVI.00341-16
   Briles DE, 2000, VACCINE, V18, P1707, DOI 10.1016/S0264-410X(99)00511-3
   Brooks WA, 2015, VACCINE, V33, P4610, DOI 10.1016/j.vaccine.2015.06.078
   Brooks-Walter A, 1999, INFECT IMMUN, V67, P6533
   Chen A, 2015, CLIN VACCINE IMMUNOL, V22, P1079, DOI 10.1128/CVI.00293-15
   Chen TT, 2014, EMERG INFECT DIS, V20, P689, DOI 10.3201/eid2004.131015
   Croney CM, 2012, CLIN VACCINE IMMUNOL, V19, P891, DOI 10.1128/CVI.05671-11
   Ekstrom N, 2007, INFECT IMMUN, V75, P1794, DOI 10.1128/IAI.01673-06
   Ekstrom N, 2013, CLIN VACCINE IMMUNOL, V20, P1034, DOI 10.1128/CVI.00039-13
   Fried AJ, 2013, J CLIN IMMUNOL, V33, P847, DOI 10.1007/s10875-013-9870-9
   Giefing C, 2008, J EXP MED, V205, P117, DOI 10.1084/jem.20071168
   Giefing C, 2010, MICROBIOL-SGM, V156, P1697, DOI 10.1099/mic.0.036335-0
   Giefing-Kroll C, 2011, MICROBIOL-SGM, V157, P1897, DOI 10.1099/mic.0.045211-0
   Jimenez-Munguia I, 2015, J PROTEOMICS, V126, P228, DOI 10.1016/j.jprot.2015.06.011
   Khan MN, 2012, MICROBES INFECT, V14, P1102, DOI 10.1016/j.micinf.2012.06.007
   Khan MN, 2012, VACCINE, V30, P2900, DOI 10.1016/j.vaccine.2012.02.023
   Meriluoto M, 2012, EMERG INFECT DIS, V18, P264, DOI 10.3201/eid1802.111293
   Musher DM, 2000, J INFECT DIS, V182, P158, DOI 10.1086/315697
   O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6
   Ogunniyi AD, 2001, INFECT IMMUN, V69, P5997, DOI 10.1128/IAI.69.10.5997-6003.2001
   Oishi T, 2013, VACCINE, V31, P845, DOI 10.1016/j.vaccine.2012.11.010
   Olafsdottir TA, 2012, INFECT IMMUN, V80, P461, DOI 10.1128/IAI.05801-11
   Orihuela CJ, 2009, J CLIN INVEST, V119, P1638, DOI 10.1172/JCI36759
   Ota MOC, 2011, INT J INFECT DIS, V15, pE282, DOI 10.1016/j.ijid.2010.12.011
   Posfay-Barbe KM, 2011, CLIN MICROBIOL INFEC, V17, P1232, DOI 10.1111/j.1469-0691.2010.03389.x
   Principi N, 2011, HUM VACCINES, V7, P905, DOI 10.4161/hv.7.9.15986
   PULLEN GR, 1986, J IMMUNOL METHODS, V86, P83, DOI 10.1016/0022-1759(86)90268-1
   Rapola S, 2001, PEDIATR INFECT DIS J, V20, P482, DOI 10.1097/00006454-200105000-00003
   Salt P, 2007, CLIN VACCINE IMMUNOL, V14, P593, DOI 10.1128/CVI.00344-06
   SCHLESINGER Y, 1992, JAMA-J AM MED ASSOC, V267, P1489, DOI 10.1001/jama.267.11.1489
   Seiberling M, 2012, VACCINE, V30, P7455, DOI 10.1016/j.vaccine.2012.10.080
   Tai SS, 2006, CRIT REV MICROBIOL, V32, P139, DOI 10.1080/10408410600822942
   Usinger WR, 1999, INFECT IMMUN, V67, P2366, DOI 10.1128/IAI.67.5.2366-2370.1999
   van der Poll T, 2009, LANCET, V374, P1543, DOI 10.1016/S0140-6736(09)61114-4
NR 39
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0934-9723
EI 1435-4373
J9 EUR J CLIN MICROBIOL
JI Eur. J. Clin. Microbiol. Infect. Dis.
PD JAN
PY 2018
VL 37
IS 1
BP 77
EP 89
DI 10.1007/s10096-017-3103-8
PG 13
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA FR6AZ
UT WOS:000419149100010
PM 29027028
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, AC
   Vilas-Boas, AL
   Fontoura, MSH
   Xu, M
   Vuorinen, T
   Soderlund-Venermo, M
   Ruuskanen, O
   Nascimento-Carvalho, CM
AF Nascimento-Carvalho, Amanda C.
   Vilas-Boas, Ana-Luisa
   Fontoura, Maria-Socorro H.
   Xu, Man
   Vuorinen, Tytti
   Soderlund-Venermo, Maria
   Ruuskanen, Olli
   Nascimento-Carvalho, Cristiana M.
CA PNEUMOPAC-Efficacy Study Grp
TI Serologically diagnosed acute human bocavirus 1 infection in childhood
   community-acquired pneumonia
SO PEDIATRIC PULMONOLOGY
LA English
DT Article
DE acute respiratory infection; children; lower respiratory tract
   infection; respiratory virus; viral infection
ID RESPIRATORY VIRUS-INFECTIONS; CHILDREN; SEVERITY; INFANTS; DISEASE;
   SAMPLES; BURDEN
AB AimTo assess the role of human bocavirus 1 (HBoV1) as a causative agent of non-severe community-acquired pneumonia (CAP) in children.
   MethodsPatients aged 2-59 months with non-severe CAP (respiratory complaints and radiographic pulmonary infiltrate/consolidation) attending a University Hospital in Salvador, Brazil were enrolled in a prospective cohort. From 820 recruited children in a clinical trial ( NCT01200706), nasopharyngeal aspirate (NPA), and acute and convalescent serum samples were obtained from 759 (92.6%) patients. NPAs were tested for 16 respiratory viruses by PCR. Acute HBoV1 infection was confirmed by measuring specific IgM and IgG responses in paired serum samples.
   ResultsRespiratory viruses were detected in 693 (91.3%; 95%CI: 89.1-93.2) CAP cases by PCR. HBoV1-DNA was detected in 159 (20.9%; 95%CI: 18.2-24.0) cases. Of these 159 PCR positive cases, acute HBoV1 infection was confirmed serologically in 38 cases (23.9%; 95%CI: 17.8-31.0). Overall, acute HBoV1 infection was confirmed in 5.0% (38/759) of non-severe CAP patients. HBoV1 was detected in 151 cases with at least one other virus making 31.7% of all multiple virus (n=477) detections. Among all 759 cases, 216 had one respiratory virus detected, and sole HBoV1 was detected in only 8 (3.7%). Acute HBoV1 infection was serologically diagnosed in 34 (22.5%) HBoV1-DNA-positive cases with another virus, compared to 4 (50.0%) cases with sole virus detection (p=0.09).
   ConclusionHBoV1 was detected by PCR in one fifth of the children with non-severe CAP and acute HBoV1 infection was serologically confirmed in one quarter of these cases.
C1 [Nascimento-Carvalho, Amanda C.] Bahiana Fdn Sci Dev, Bahiana Sch Med, Rua Prof Aristides Novis,105-1201B, BR-40210630 Salvador, BA, Brazil.
   [Vilas-Boas, Ana-Luisa; Fontoura, Maria-Socorro H.; Nascimento-Carvalho, Cristiana M.; PNEUMOPAC-Efficacy Study Grp] Univ Fed Bahia, Dept Pediat, Sch Med, Salvador, BA, Brazil.
   [Xu, Man; Soderlund-Venermo, Maria] Univ Helsinki, Dept Virol, Helsinki, Finland.
   [Vuorinen, Tytti] Turku Univ Hosp, Dept Clin Virol, Turku, Finland.
   [Vuorinen, Tytti] Univ Turku, Dept Virol, Turku, Finland.
   [Ruuskanen, Olli] Univ Turku, Dept Pediat, Turku, Finland.
RP Nascimento-Carvalho, AC (corresponding author), Bahiana Fdn Sci Dev, Bahiana Sch Med, Rua Prof Aristides Novis,105-1201B, BR-40210630 Salvador, BA, Brazil.
EM carvalhoacn@hotmail.com
RI Soderlund-Venermo, Maria/AAX-2112-2020
FU Bahia State Agency for Research Funding (FAPESB), PPSUS [SUS0023/2013];
   Helsinki University; Sigrid Juselius FoundationSigrid Juselius
   Foundation
FX Bahia State Agency for Research Funding (FAPESB), Grant number: PPSUS
   No. SUS0023/2013; Helsinki University 375-year grant; Sigrid Juselius
   Foundation
CR Allander T, 2005, P NATL ACAD SCI USA, V102, P12891, DOI 10.1073/pnas.0504666102
   Allander T, 2007, CLIN INFECT DIS, V44, P904, DOI 10.1086/512196
   Choi SH, 2015, J CLIN MICROBIOL, V53, P1172, DOI 10.1128/JCM.03298-14
   Christensen A, 2013, EMERG INFECT DIS, V19, P574, DOI 10.3201/eid1904.121775
   Don M, 2010, PEDIATR PULM, V45, P120, DOI 10.1002/ppul.21151
   El-Rashdi AS, 2006, ARCH DIS CHILD, V91, P351, DOI 10.1136/adc.2005.088831
   Finianos M, 2016, J MED VIROL, V88, P1874, DOI 10.1002/jmv.24544
   Foulongne V, 2006, EMERG INFECT DIS, V12, P862, DOI 10.3201/eid1205.051523
   Goka EA, 2014, PAEDIATR RESPIR REV, V15, P363, DOI 10.1016/j.prrv.2013.11.001
   Hayward AC, 2014, LANCET RESP MED, V2, P445, DOI 10.1016/S2213-2600(14)70034-7
   Kantola K, 2008, CLIN INFECT DIS, V46, P540, DOI 10.1086/526532
   Kantola K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139096
   Korppi M, 2014, PEDIATR PULM, V49, P515, DOI 10.1002/ppul.22939
   Lu GL, 2013, J MED VIROL, V85, P138, DOI 10.1002/jmv.23438
   Lu XY, 2006, J CLIN MICROBIOL, V44, P3231, DOI 10.1128/JCM.00889-06
   Luoto R, 2016, ACTA PAEDIATR, V105, P1132, DOI 10.1111/apa.13519
   Martin ET, 2015, J INFECT DIS, V212, P516, DOI 10.1093/infdis/jiv044
   Meriluoto M, 2012, EMERG INFECT DIS, V18, P264, DOI 10.3201/eid1802.111293
   Nascimento-Carvalho CM, 2012, J MED VIROL, V84, P253, DOI 10.1002/jmv.22268
   Peltola V, 2008, J INFECT DIS, V197, P382, DOI 10.1086/525542
   Peltola V, 2013, PEDIATR INFECT DIS J, V32, P178, DOI 10.1097/INF.0b013e31827fef67
   Polverino E, 2011, MINERVA ANESTESIOL, V77, P196
   Rhedin S, 2015, THORAX, V70, P847, DOI 10.1136/thoraxjnl-2015-206933
   Ruuskanen O, 2011, LANCET, V377, P1264, DOI 10.1016/S0140-6736(10)61459-6
   Soderlund-Venermo M, 2009, EMERG INFECT DIS, V15, P1423, DOI 10.3201/eid1509.090204
   Stevens DA, 2016, J CLIN MICROBIOL, V54, P2707, DOI 10.1128/JCM.01224-16
   Vilas-Boas AL, 2014, J ANTIMICROB CHEMOTH, V69, P1954, DOI 10.1093/jac/dku070
   Walker CLF, 2013, LANCET, V381, P1405, DOI 10.1016/S0140-6736(13)60222-6
   World Health Organization, 2000, MAN CHILD SER INF SE
   World Health Organization, 2008, 5032 WHO WC
   World Health Organization, 2008, TRAIN COURS CHILD GR
   Xu M, 2017, J INFECT DIS, V215, P1551, DOI 10.1093/infdis/jix169
NR 32
TC 4
Z9 6
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8755-6863
EI 1099-0496
J9 PEDIATR PULM
JI Pediatr. Pulmonol.
PD JAN
PY 2018
VL 53
IS 1
BP 88
EP 94
DI 10.1002/ppul.23891
PG 7
WC Pediatrics; Respiratory System
SC Pediatrics; Respiratory System
GA FQ3HI
UT WOS:000418247800016
PM 29028159
OA Bronze, Green Published
DA 2020-12-17
ER

PT J
AU Barbosa, PFA
   Juliao, GS
   Souza, NMM
   Castiglioni, M
   Santos, CJN
   Castro, APBM
   Dorna, MB
   Pastorino, AC
   Nascimento-Carvalho, CM
AF Barbosa, P. F. A.
   Juliao, G. S.
   Souza, N. M. M.
   Castiglioni, M.
   Santos, C. J. N.
   Castro, A. P. B. M.
   Dorna, M. B.
   Pastorino, A. C.
   Nascimento-Carvalho, C. M.
TI G-CSF Treatment in Stat1 Gain-of-Function Mutation with Chronic
   Mucocutaneous Candidiasis - Case Report
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Meeting of the Latin-American-Society-for-Immunodeficiencies (LASID)
CY OCT 04-07, 2017
CL Sao Paulo, BRAZIL
SP Latin Amer Soc Immunodeficiencies
C1 [Barbosa, P. F. A.; Juliao, G. S.; Souza, N. M. M.; Castiglioni, M.; Santos, C. J. N.; Castro, A. P. B. M.; Dorna, M. B.; Pastorino, A. C.; Nascimento-Carvalho, C. M.] Univ Sao Paulo, Fac Med, Hosp Clin, Allergy & Immunol Unit,Pediat Dept, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
EI 1573-2592
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
PD OCT
PY 2017
VL 37
SU 1
MA PO - 146
BP S57
EP S58
PG 2
WC Immunology
SC Immunology
GA GP8XY
UT WOS:000441200700142
DA 2020-12-17
ER

PT J
AU de Santana, MC
   Amoedo, CDM
   Nascimento-Carvalho, CM
AF de Santana, Mariana Costa
   Mello Amoedo, Caroline Duarte
   Nascimento-Carvalho, Cristiana Maria
TI Clinical and epidemiological characteristics of children admitted with
   fever in emergency department with or without sepsis
SO JOURNAL OF INFECTION IN DEVELOPING COUNTRIES
LA English
DT Article
DE pediatric; sepsis; infection; etiology; outcome; mortality
ID SICKLE-CELL-DISEASE; MANAGEMENT; DIAGNOSIS; INFECTIONS; PREDICTORS;
   PNEUMONIA; ASSAYS
AB Introduction: Sepsis is a major cause of childhood death worldwide. In developing countries, epidemiological data about sepsis is scarce. This study describes and compares the frequency of etiological agents and initial sites of infection in children with or without sepsis, identifying risk factors and assessing outcomes.
   Methodology: Clinical and demographic data from patients < 13 years of age with reported fever in a pediatric emergency department were collected and registered in forms. Patients were classified as with or without sepsis according to Goldstein et al.'s criteria [6].
   Results: Of 254 patients, 120 (47%) did and 134 (53%) did not meet the sepsis definition. Overall, the median age (IQR) was 1.7 (0.8-3.9) years, and 153 (60%) were boys. Patients with sepsis were older (2.8 [1.1-5.3] versus 1.3 [0.6-2.9] years; p < 0.001) and had sickle-cell disease more frequently (7.6% versus 0.8%; p = 0.007). By multiple logistic regression, age and sickle-cell disease were independently associated with sepsis. The most frequent initial infections were pneumonia (43.7%), diarrhea (17.3%) and cellulitis/adenitis (13.0%). The frequency of these did not differ when patients with or without sepsis were compared. Etiology was established in 57 (22.4%) patients, 32 (26.7%), and 25 (18.7%) with or without sepsis, respectively. Four (3.3%) patients died in the sepsis subgroup, whereas none died in the other subgroup.
   Conclusions: Children who met the 2005 international consensus definition of sepsis showed differences in age and comorbidities (sickle-cell disease) upon admission and were more likely to die.
C1 [de Santana, Mariana Costa; Nascimento-Carvalho, Cristiana Maria] Univ Fed Bahia, Sch Med, Salvador, BA, Brazil.
   [Mello Amoedo, Caroline Duarte; Nascimento-Carvalho, Cristiana Maria] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
RP de Santana, MC (corresponding author), Univ Fed Bahia, Sch Med, Postgrad Program Hlth Sci, Ctr Hist, Largo Terreiro de Jesus S-N, BR-40025010 Salvador, BA, Brazil.
EM maricsantana14@gmail.com
CR Alpern ER, 2006, PEDIATR EMERG CARE, V22, P689, DOI 10.1097/01.pec.0000236830.39194.c0
   Bertagnolli NM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078913
   BRADLEY DW, 1979, J CLIN MICROBIOL, V9, P120
   Carcillo JA, 2006, ADV SEPSIS, V5, P118
   Castro O, 1999, BRIT J HAEMATOL, V107, P2, DOI 10.1046/j.1365-2141.1999.01565.x
   Cruz AT, 2011, PEDIATRICS, V127, pE758, DOI 10.1542/peds.2010-2895
   Dellinger RP, 2008, INTENS CARE MED, V34, P17, DOI 10.1007/s00134-007-0934-2
   Elhassanien AF, 2013, RISK MANAG HEALTHC P, V6, P7, DOI 10.2147/RMHP.S40553
   Felix Andreza Aparecida, 2010, Rev. Bras. Hematol. Hemoter., V32, P203
   Frederiksen MS, 2007, PEDIATR INFECT DIS J, V26, P398, DOI 10.1097/01.inf.0000261112.53035.4c
   Ganjoo S, 2015, INDIAN J PEDIATR, V82, P698, DOI 10.1007/s12098-014-1618-x
   Goldstein B, 2006, PEDIATR CRIT CARE ME, V7, P200, DOI 10.1097/01.PCC.0000217470.68764.36
   Heyworth MF, 2014, T ROY SOC TROP MED H, V108, P123, DOI 10.1093/trstmh/tru005
   Hyypia T, 1998, J CLIN MICROBIOL, V36, P2081
   Jaramillo-Bustamante JC, 2012, PEDIATR CRIT CARE ME, V13, P501, DOI 10.1097/PCC.0b013e31823c980f
   Knight-Madden J, 2001, J PEDIATR-US, V138, P65, DOI 10.1067/mpd.2001.109709
   Liu L, 2015, LANCET, V385, P430, DOI 10.1016/S0140-6736(14)61698-6
   Makela MJ, 1998, J CLIN MICROBIOL, V36, P539
   Morre SA, 2002, J CLIN MICROBIOL, V40, P584, DOI 10.1128/JCM.40.2.584-587.2002
   Murphy CG, 2007, ACAD EMERG MED, V14, P243, DOI 10.1197/j.aem.2006.08.022
   NOHYNEK H, 1995, PEDIATR INFECT DIS J, V14, P478, DOI 10.1097/00006454-199506000-00003
   Saukkoriipi A, 2002, MOL CELL PROBE, V16, P385, DOI 10.1006/mcpr.2002.0443
   Schutze GE, 2002, PEDIATR INFECT DIS J, V21, P278, DOI 10.1097/00006454-200204000-00004
   Singh S. P., 2013, PROGRAMME GRANTS APP, V1, P1, DOI [10.3310/pgfar01030, DOI 10.3310/PGFAR01030]
   Soderlund-Venermo M, 2009, EMERG INFECT DIS, V15, P1423, DOI 10.3201/eid1509.090204
   Thompson GC, 2015, J EMERG MED, V49, P391, DOI 10.1016/j.jemermed.2015.03.012
   van Hal SJ, 2012, CLIN MICROBIOL REV, V25, P362, DOI 10.1128/CMR.05022-11
   Walker CLF, 2013, LANCET, V381, P1405, DOI 10.1016/S0140-6736(13)60222-6
   Watson RS, 2005, PEDIAT CRIT CARE, V6, P3
   Wiens Matthew O, 2012, Clin Epidemiol, V4, P319, DOI 10.2147/CLEP.S35693
   World Health Organization, 2008, TRAIN COURS CHILD GR
   Yamaguchi T, 2005, FEMS IMMUNOL MED MIC, V43, P21, DOI 10.1016/j.femsim.2004.06.023
NR 32
TC 0
Z9 0
U1 0
U2 2
PU J INFECTION DEVELOPING COUNTRIES
PI TRAMANIGLIO
PA JIDC CENT OFF PORTO CONTE RICERCHE RES CTR, S P 55, PORTO CONTE CAPO
   CACCIA KM 8.400 LOC, TRAMANIGLIO, 07041, ITALY
SN 1972-2680
J9 J INFECT DEV COUNTR
JI J. Infect. Dev. Ctries.
PD AUG
PY 2017
VL 11
IS 8
BP 597
EP 603
DI 10.3855/jidc.9257
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA FJ7KL
UT WOS:000412935900003
PM 31085820
OA DOAJ Gold
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, CM
   Xavier-Souza, G
   Vilas-Boas, AL
   Fontoura, MSH
   Barral, A
   Puolakkainen, M
   Ruuskanen, O
AF Nascimento-Carvalho, Cristiana M.
   Xavier-Souza, Gabriel
   Vilas-Boas, Ana-Luisa
   Fontoura, Maria-Socorro H.
   Barral, Aldina
   Puolakkainen, Mirja
   Ruuskanen, Olli
CA PNEUMOPAC-Efficacy Study Grp
TI Evolution of acute infection with atypical bacteria in a prospective
   cohort of children with community-acquired pneumonia receiving
   amoxicillin
SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
LA English
DT Article
ID MYCOPLASMA-PNEUMONIAE; CHLAMYDIA-PNEUMONIAE; DEVELOPING-COUNTRIES;
   CHILDHOOD; COMBINATION; TRACHOMATIS; THERAPY
AB Background: Atypical bacteria are treatable causative agents of community-acquired pneumonia (CAP). However, there is no conclusive evidence that a child with CAP should receive empirical treatment against such agents.
   Objectives: We assessed the possibility of association between clinical failure and acute infection by these bacteria among children with CAP treated with amoxicillin.
   Patients and methods: Patients aged 2-59 months with non-severe CAP received amoxicillin during prospective follow-up. Acute and convalescent blood samples were collected. Probable acute infection by Mycoplasma pneumoniae (specific IgM antibodies), by Chlamydia pneumoniae or Chlamydia trachomatis (specific IgM antibodies and/or IgG/IgA titre change) was investigated. Outcomes were assessed during follow-up at 2, 5 and 14-28 days. Treatment failure included development of danger signs, persistent fever, tachypnoea or death. ClinicalTrials.gov: NCT01200706.
   Results: Of 787 children, 86 (10.9%; 95% CI = 8.9%-13.3%) had acute M. pneumoniae infection. C. pneumoniae acute infection was found in 79 of 733 (10.8%; 95% CI = 8.7%-13.2%) and C. trachomatis was found in 3 of 28 (10.7%; 95% CI = 2.8%-26.5%),<6months old. Among patients with or without treatment failure at 2 days, acute M. pneumoniae infection (11.7% versus 10.7%; P = 0.7), acute C. pneumoniae infection (8.5% versus 11.3%; P =0.3) and acute C. trachomatis infection (16.7% versus 9.1%; P = 0.5) were found. No significant differences were found with regard to treatment failure at the 5 day evaluation. Overall, amoxicillin was substituted in 3.5% versus 2.7% among patients with orwithout acute infection by one of these bacteria (P = 0.6).
   Conclusions: The overall substitution rate of amoxicillin was very low. It is not necessary to give an empirical non beta-lactam antibiotic as a first-line option to treat every child between 2 and 59 months old with non-severe CAP.
C1 [Nascimento-Carvalho, Cristiana M.; Xavier-Souza, Gabriel; Vilas-Boas, Ana-Luisa; Fontoura, Maria-Socorro H.] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
   [Barral, Aldina] Univ Fed Bahia, Sch Med, Dept Pathol, Salvador, BA, Brazil.
   [Barral, Aldina] Fundacao Oswaldo Cruz, Ctr Pesquisa Goncalo Moniz, Salvador, BA, Brazil.
   [Puolakkainen, Mirja] Univ Helsinki, Virol, Helsinki, Finland.
   [Puolakkainen, Mirja] Univ Cent Hosp, Helsinki, Finland.
   [Ruuskanen, Olli] Univ Turku, Dept Pediat, Turku, Finland.
RP Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
RI Puolakkainen, Mirja/F-1767-2011
OI Puolakkainen, Mirja/0000-0001-7413-6793
FU Bahia State Agency for Research Funding (FAPESB) [0127/2006]
FX This work was supported by a grant from the Bahia State Agency for
   Research Funding (FAPESB) (grant no. APR N. 0127/2006). C. M. N.- C. and
   A. B. are investigators at the Brazilian Council for Scientific and
   Technological Development (CNPq).
CR Ambroggio L, 2012, J PEDIATR-US, V161, P1097, DOI 10.1016/j.jpeds.2012.06.067
   Atkinson TP, 2014, PEDIATR INFECT DIS J, V33, P92, DOI 10.1097/INF.0000000000000171
   Biondi E, 2014, PEDIATRICS, V133, P1081, DOI 10.1542/peds.2013-3729
   Cherian T, 2005, B WORLD HEALTH ORGAN, V83, P353
   Colin AA, 2014, PEDIATRICS, V133, P1124, DOI 10.1542/peds.2014-0871
   Dowell SF, 2001, CLIN INFECT DIS, V33, P492, DOI 10.1086/322632
   El-Rashdi AS, 2006, ARCH DIS CHILD, V91, P351, DOI 10.1136/adc.2005.088831
   Gencay M, 2000, APMIS, V108, P584, DOI 10.1034/j.1600-0463.2000.d01-101.x
   Gilani Z, 2012, CLIN INFECT DIS, V54, pS102, DOI 10.1093/cid/cir1053
   Leyenaar JK, 2014, PEDIATR INFECT DIS J, V33, P387, DOI 10.1097/INF.0000000000000119
   Liu L, 2015, LANCET, V385, P430, DOI 10.1016/S0140-6736(14)61698-6
   Madhi SA, 2013, PEDIATR INFECT DIS J, V32, pE119, DOI 10.1097/INF.0b013e3182784b26
   Mills GD, 2005, BMJ-BRIT MED J, V330, P456, DOI 10.1136/bmj.38334.591586.82
   Nascimento-Carvalho CM, 2004, REV PANAM SALUD PUBL, V15, P380, DOI 10.1590/S1020-49892004000600003
   Nascimento-Carvalho CM, 2013, PEDIATR INFECT DIS J, V32, P1281, DOI 10.1097/INF.0b013e3182a4dcfa
   Nilsson AC, 2014, SCAND J INFECT DIS, V46, P315, DOI 10.3109/00365548.2013.866268
   Normann E, 1998, ACTA PAEDIATR, V87, P23, DOI 10.1080/08035259850157813
   Pan American Health Organization, 2012, REG REP SIREVA
   Principi Nicola, 2001, Clinical Infectious Diseases, V32, P1281, DOI 10.1086/319981
   SCHACHTER J, 1982, J INFECT DIS, V146, P530, DOI 10.1093/infdis/146.4.530
   SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017
   Spuesens EBM, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001444
   Vilas-Boas AL, 2014, J ANTIMICROB CHEMOTH, V69, P1954, DOI 10.1093/jac/dku070
   Volanen I, 2003, SCAND J INFECT DIS, V35, P471, DOI 10.1080/00365540310013351
   Walker CLF, 2013, LANCET, V381, P1405, DOI 10.1016/S0140-6736(13)60222-6
   Wood PR, 2013, ANN ALLERG ASTHMA IM, V110, P328, DOI 10.1016/j.anai.2013.01.022
   World Health Organization, 2013, POCK BOOK HOSP CAR C
   World Health Organization, 2008, TRAIN COURS CHILD GR
   Youn YS, 2014, INFECT CHEMOTHER, V46, P239, DOI 10.3947/ic.2014.46.4.239
   Zhou YL, 2014, ANTIMICROB AGENTS CH, V58, P1034, DOI 10.1128/AAC.01806-13
NR 30
TC 5
Z9 5
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-7453
EI 1460-2091
J9 J ANTIMICROB CHEMOTH
JI J. Antimicrob. Chemother.
PD AUG
PY 2017
VL 72
IS 8
BP 2378
EP 2384
DI 10.1093/jac/dkx126
PG 7
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA FB5BC
UT WOS:000406155400030
PM 28475737
OA Bronze
DA 2020-12-17
ER

PT J
AU Andrade, DC
   Borges, IC
   Bouzas, ML
   Oliveira, JR
   Fukutani, KF
   Queiroz, AT
   de Oliveira, CI
   Barral, A
   Van Weyenbergh, J
   Nascimento-Carvalho, C
AF Andrade, Dafne C.
   Borges, Igor C.
   Bouzas, Maiara L.
   Oliveira, Juliana R.
   Fukutani, Kiyoshi F.
   Queiroz, Artur T.
   de Oliveira, Camila Indiani
   Barral, Aldina
   Van Weyenbergh, Johan
   Nascimento-Carvalho, Cristiana
TI 10-valent pneumococcal conjugate vaccine (PCV10) decreases metabolic
   activity but not nasopharyngeal carriage of Streptococcus pneumoniae and
   Haemophilus influenzae
SO VACCINE
LA English
DT Article
DE Capsular polysaccharides; Metabolism; Nasopharyngeal colonization;
   Protein D
ID RESPIRATORY-TRACT INFECTION; YOUNG-CHILDREN; MORAXELLA-CATARRHALIS;
   BRAZIL; IDENTIFICATION; PATHOGENS; RNA
AB Background: The effect of pneumococcal vaccination is widely variable when measured by nasopharyngeal carriage of vaccine and non-vaccine targets. The aim of this study was to compare the carriage rates and metabolic activity of Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae and Moraxella catarrhalis among children who were or were not vaccinated with PCV10.
   Methods: We included children with acute respiratory infection aged 6-23 months from a cross-sectional study (CHIADO-IVAS). Nasopharyngeal aspirates were collected and respiratory pathogens were quantified by nCounter digital transcriptomics (Nanostririg) and metagenomic sequencing of 16S ribosomal RNA (Illumina). The metabolic rate was calculated by the ratio between RNA transcripts and 16S DNA reads.
   Results: Out of the 80 patients in this study, 53 were vaccinated with PCV10 and 27 were unvaccinated. There was no difference in nasopharyngeal carriage rates of S. pneumoniae, S. aureus, H. influenzae or M. catarrhalis by either transcriptomic analysis or 16S metagenomics. However, unvaccinated children presented a higher metabolic rate for S. pneumoniae compared to PCV10-vaccinated children (Median [25-75th percentiles]: 126 [22.75-218.41] vs. 0[0-47.83], p = 0.004). Furthermore, unvaccinated children presented a positive correlation between mRNA counts and 16S DNA reads for S. pneumoniae (r = 0.707; p < 0.001) and H. influenzae (r = 0.525; p = 0.005), in contrast to vaccinated children. No such effect was observed for S. aureus and M catarrhalis.
   Conclusions: Vaccination by PCV10 exerts a pathogen-specific effect on pneumococcal metabolic rate. Pathogen RNA/DNA ratio might represent a more sensitive readout for vaccine follow-up, as compared to nasopharyngeal carriage. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Andrade, Dafne C.; Borges, Igor C.; Bouzas, Maiara L.; Oliveira, Juliana R.; de Oliveira, Camila Indiani; Barral, Aldina; Nascimento-Carvalho, Cristiana] Univ Fed Bahia, Sch Med, Postgrad Programme Hlth Sci, Salvador, BA, Brazil.
   [Fukutani, Kiyoshi F.; Queiroz, Artur T.; de Oliveira, Camila Indiani; Barral, Aldina] Fundacao Oswaldo Cruz, Ctr Pesquisa Goncalo Moniz, Salvador, BA, Brazil.
   [de Oliveira, Camila Indiani; Barral, Aldina] Iii INCT, Sao Paulo, Brazil.
   [Van Weyenbergh, Johan] Katholieke Univ Leuven, Rega Inst Med Res, Dept Microbiol & Immunol, Leuven, Belgium.
   [Nascimento-Carvalho, Cristiana] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
RP Andrade, DC (corresponding author), Praca XV Novembro,S-N Largo Terreiro Jesus, BR-40025010 Salvador, BA, Brazil.
EM andradedafne@yahoo.com.br
RI Van Weyenbergh, Johan/B-4187-2009; de Oliveira, Camila I/B-4358-2009;
   Van Weyenbergh, Johan/Q-3829-2019; Borges, Igor Carmo/AAG-8531-2019;
   Fukutani, Kiyoshi/T-1630-2019
OI Van Weyenbergh, Johan/0000-0003-3234-8426; de Oliveira, Camila
   I/0000-0002-7868-5164; Van Weyenbergh, Johan/0000-0003-3234-8426; Carmo
   Borges, Igor/0000-0003-2749-0313; Fukutani, Kiyoshi/0000-0003-2223-0918
FU Bahia State Agency for Research Funding (FAPESB), in Brazil
   [APP0045/2009, PNX 0019/2009, PET 007/2012]; FWO in Belgium [G0D6817N]
FX The research project was supported by the Bahia State Agency for
   Research Funding (FAPESB) (grants APP0045/2009, PNX 0019/2009, PET
   007/2012), in Brazil; and FWO (grant G0D6817N) in Belgium. Aldina
   Barral, Camila I. de Oliveira, and Cristiana Nascimento-Carvalho are
   senior investigators at the Brazilian Council for Scientific and
   Technological Development (CNPq), Brazil.
CR Barczak AK, 2012, P NATL ACAD SCI USA, V109, P6217, DOI 10.1073/pnas.1119540109
   Brandileone MCD, 2016, VACCINE, V34, P5604, DOI 10.1016/j.vaccine.2016.09.027
   Camilli R, 2015, VACCINE, V33, P4559, DOI 10.1016/j.vaccine.2015.07.009
   Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303
   Fukutani KF, 2015, J CLIN VIROL, V69, P190, DOI 10.1016/j.jcv.2015.06.005
   Ilboudo H, 2015, J INFECT DIS, V212, P1996, DOI 10.1093/infdis/jiv337
   Jartti T, 2011, EUR J CLIN MICROBIOL, V30, P233, DOI 10.1007/s10096-010-1075-z
   Laval CB, 2006, CLIN MICROBIOL INFEC, V12, P50, DOI 10.1111/j.1469-0691.2005.01304.x
   Lindstrand A, 2016, VACCINE, V34, P4565, DOI 10.1016/j.vaccine.2016.07.031
   Meier PS, 2002, VACCINE, V20, P1754, DOI 10.1016/S0264-410X(02)00030-0
   Navne JE, 2016, EPIDEMIOL INFECT, V144, P3226, DOI 10.1017/S0950268816001461
   Oliveira JR, 2016, VACCINE, V34, P2556, DOI 10.1016/j.vaccine.2016.04.015
   Prymula R, 2009, VACCINE, V28, P71, DOI 10.1016/j.vaccine.2009.09.113
   Rodrigues HG, 2017, EPIDEMIOL INFECT, V145, P1720, DOI 10.1017/S0950268817000449
   Simell B, 2012, EXPERT REV VACCINES, V11, P841, DOI [10.1586/erv.12.53, 10.1586/ERV.12.53]
   Simoes AS, 2016, DIAGN MICR INFEC DIS, V85, P141, DOI 10.1016/j.diagmicrobio.2016.03.018
   Tenenbaum T, 2012, EUR J CLIN MICROBIOL, V31, P3173, DOI 10.1007/s10096-012-1682-y
   van den Bergh MR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047711
   van der Poll T, 2009, LANCET, V374, P1543, DOI 10.1016/S0140-6736(09)61114-4
   van Gils EJM, 2011, VACCINE, V29, P7595, DOI 10.1016/j.vaccine.2011.08.049
   Vesikari T, 2016, J PEDIAT INF DIS SOC, V5, P237, DOI 10.1093/jpids/piw010
   Watkins ER, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005034
   Xu QF, 2012, EMERG INFECT DIS, V18, P1738, DOI 10.3201/eid1811.111904
   Yu D, 2010, CLIN MICROBIOL INFEC, V16, P1399, DOI [10.1111/j.1469-0691.2010.03147.x, 10.1111/j.1469-0691.2009.03147.x]
   Zanella RC, 2015, MEM I OSWALDO CRUZ, V110, P755, DOI 10.1590/0074-02760150140
NR 25
TC 8
Z9 8
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 24
PY 2017
VL 35
IS 33
BP 4105
EP 4111
DI 10.1016/j.vaccine.2017.06.048
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA FC3JS
UT WOS:000406735500009
PM 28668567
DA 2020-12-17
ER

PT J
AU Safadi, MAP
   Nascimento-Carvalho, CM
AF Palazzi Safadi, Marco Aurelio
   Nascimento-Carvalho, Cristiana M.
TI Update on Zika: What You Need to Know
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Review
ID VIRUS-INFECTION; CASE SERIES; BRAZIL
C1 [Palazzi Safadi, Marco Aurelio] Santa Casa Sao Paulo Sch Med Sci, Dept Pediat, Sao Paulo, Brazil.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
RP Safadi, MAP (corresponding author), Santa Casa Sao Paulo Sch Med Sci, Alameda Indigenas 228, BR-04059060 Sao Paulo, Brazil.
EM masa-fadi@uol.com.br
RI safadi, marco aurelio palazzi/B-7157-2015
OI safadi, marco aurelio palazzi/0000-0002-4401-9446
CR Abbink P, 2016, SCIENCE, V353, P1129, DOI 10.1126/science.aah6157
   Brasil P, 2016, NEW ENGL J MED, V16, P742
   Brazilian Ministry of Health, 2016, EPIDEMIOLOGICAL B
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Cauchemez S, 2016, LANCET, V387, P2125, DOI 10.1016/S0140-6736(16)00651-6
   Centers for Disease Control and Prevention, 2016, ZIKA VIR
   Delvecchio R, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8120322
   dos Santos T, 2016, NEW ENGL J MED, V375, P1598, DOI 10.1056/NEJMc1609015
   Franca GVA, 2016, LANCET, V388, P891, DOI 10.1016/S0140-6736(16)30902-3
   Ioos S, 2014, MED MALADIES INFECT, V44, P302, DOI 10.1016/j.medmal.2014.04.008
   Kuno G, 1998, J VIROL, V72, P73, DOI 10.1128/JVI.72.1.73-83.1998
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Martines RB, 2016, MMWR-MORBID MORTAL W, V65, P159, DOI 10.15585/mmwr.mm6506e1
   Musso D, 2014, EUROSURVEILLANCE, V19, P6, DOI 10.2807/1560-7917.ES2014.19.14.20761
   Oliveira DBL, 2016, NEW ENGL J MED, V375, P1202, DOI 10.1056/NEJMc1607583
   World Health Organization, 2016, ZIK SIT REP
   World Health Organization, 2016, ZIK VIR VACC PROD DE
NR 17
TC 4
Z9 4
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD MAR
PY 2017
VL 36
IS 3
BP 333
EP 336
DI 10.1097/INF.0000000000001449
PG 4
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA EL1CE
UT WOS:000394357300021
PM 27977548
DA 2020-12-17
ER

PT J
AU Andrade, ES
   Gomes, RT
   Lyra, TG
   Nascimento-Carvalho, CM
AF Andrade, Eulina S.
   Gomes, Renata T.
   Lyra, Ticiana G.
   Nascimento-Carvalho, Cristiana M.
TI Community-acquired versus healthcare-associated Staphylococcus aureus
   bacteraemia among children in a tropical region
SO INFECTIOUS DISEASES
LA English
DT Letter
C1 [Andrade, Eulina S.; Gomes, Renata T.; Lyra, Ticiana G.; Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Paediat, Praca 15 Novembro, Salvador, BA, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia, Sch Med, Dept Paediat, Praca 15 Novembro, Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
FU Brazilian Council for Scientific and Technological Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq)
FX Ticiana G. Lyra was recipient of a fellowship from the Brazilian Council
   for Scientific and Technological Development (CNPq). Cristiana M.
   Nascimento-Carvalho is a senior investigator at CNPq.
CR CDC, 2010, DIAGN TEST MRSA MRSA
   Clinical and Laboratory Standards Institute, 2015, M100S25 CLIN LAB STA
   de Onis M, 2006, PUBLIC HEALTH NUTR, V9, P942, DOI 10.1017/PHN20062005
   Hakim H, 2007, AM J INFECT CONTROL, V35, P102, DOI 10.1016/j.ajic.2006.09.016
   Hill PC, 2001, PEDIATR INFECT DIS J, V20, P868, DOI 10.1097/00006454-200109000-00009
   Ladhani S, 2004, ARCH DIS CHILD, V89, P568, DOI 10.1136/adc.2003.026781
   Ning X, 2015, INFECT DIS-NOR, V47, P410, DOI 10.3109/00365548.2015.1006675
   Schaaf EM, 2016, INFECT DIS LOND
   Suryati BA, 2002, J PAEDIATR CHILD H, V38, P290, DOI 10.1046/j.1440-1754.2002.00787.x
   Vanderkooi OG, 2011, PAED CHILD HEALT-CAN, V16, P276, DOI 10.1093/pch/16.5.276
NR 10
TC 1
Z9 1
U1 0
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 2374-4235
EI 2374-4243
J9 INFECT DIS-NOR
JI Infect. Dis.
PY 2017
VL 49
IS 7
BP 549
EP 551
DI 10.1080/23744235.2017.1285047
PG 3
WC Infectious Diseases
SC Infectious Diseases
GA ES5CX
UT WOS:000399555100011
PM 28152654
DA 2020-12-17
ER

PT J
AU Borges, IC
   Andrade, DC
   Cardoso, MRA
   Meinke, A
   Barral, A
   Kayhty, H
   Ruuskanen, O
   Nascimento-Carvalho, CM
AF Borges, I. C.
   Andrade, D. C.
   Cardoso, M. -R. A.
   Meinke, A.
   Barral, A.
   Kayhty, H.
   Ruuskanen, O.
   Nascimento-Carvalho, C. M.
TI Seasonal patterns and association of meteorological factors with
   infection caused by Streptococcus pneumoniae, Haemophilus influenzae,
   and Moraxella catarrhalis in childhood community-acquired pneumonia in a
   tropical region, Infectious Disease (vol 49, pg 147, 2016)
SO INFECTIOUS DISEASES
LA English
DT Correction
RI Borges, Igor Carmo/AAG-8531-2019
CR Borges IC, 2017, INFECT DIS-NOR, V49, P147, DOI 10.1080/23744235.2016.1212170
NR 1
TC 0
Z9 0
U1 0
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 2374-4235
EI 2374-4243
J9 INFECT DIS-NOR
JI Infect. Dis.
PY 2017
VL 49
IS 2
BP I
EP I
DI 10.1080/23744235.2016.1222989
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA EK3FZ
UT WOS:000393813100001
OA Bronze
DA 2020-12-17
ER

PT J
AU Borges, IC
   Andrade, DC
   Cardoso, MRA
   Meinke, A
   Barral, A
   Kayhty, H
   Ruuskanen, O
   Nascimento-Carvalho, CM
AF Borges, Igor C.
   Andrade, Dafne C.
   Cardoso, Maria-Regina A.
   Meinke, Andreas
   Barral, Aldina
   Kayhty, Helena
   Ruuskanen, Olli
   Nascimento-Carvalho, Cristiana M.
TI Seasonal patterns and association of meteorological factors with
   infection caused by Streptococcus pneumoniae, Haemophilus influenzae,
   and Moraxella catarrhalis in childhood community-acquired pneumonia in a
   tropical region
SO INFECTIOUS DISEASES
LA English
DT Letter
ID INVASIVE PNEUMOCOCCAL DISEASE; CHILDREN; ANTIGENS; IMPACT
C1 [Borges, Igor C.; Andrade, Dafne C.; Barral, Aldina; Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Postgrad Program Hlth Sci, Salvador, BA, Brazil.
   [Cardoso, Maria-Regina A.] Univ Sao Paulo, Sch Publ Hlth, Dept Epidemiol, Sao Paulo, Brazil.
   [Meinke, Andreas] Valneva Austria GmbH, Campus Vienna Bioctr 3, Vienna, Austria.
   [Barral, Aldina] Univ Fed Bahia, Sch Med, Dept Pathol, Salvador, BA, Brazil.
   [Barral, Aldina] Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil.
   [Kayhty, Helena] Natl Inst Hlth & Welf, Helsinki, Finland.
   [Ruuskanen, Olli] Turku Univ, Dept Paediat, Turku, Finland.
   [Ruuskanen, Olli] Univ Hosp, Turku, Finland.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Paediat, Salvador, BA, Brazil.
RP Borges, IC (corresponding author), Univ Fed Bahia, Sch Med, Postgrad Program Hlth Sci, Salvador, BA, Brazil.
EM igorcms@gmail.com
RI Borges, Igor Carmo/AAG-8531-2019
OI Carmo Borges, Igor/0000-0003-2749-0313
FU Bahia State Agency for Research Funding (FAPESB), Brazil; Brazilian
   Council for Scientific and Technological Development (CNPq),
   BrazilNational Council for Scientific and Technological Development
   (CNPq); National Institute for Health and Welfare, Finland
FX This work was supported by: Bahia State Agency for Research Funding
   (FAPESB), Brazil; Brazilian Council for Scientific and Technological
   Development (CNPq), Brazil; and in part by National Institute for Health
   and Welfare, Finland.
CR Andrade DC, 2014, J IMMUNOL METHODS, V405, P130, DOI 10.1016/j.jim.2014.02.002
   Borges IC, 2015, EUR J CLIN MICROBIOL, V34, P1551, DOI 10.1007/s10096-015-2385-y
   Jain S, 2015, NEW ENGL J MED, V372, P835, DOI 10.1056/NEJMoa1405870
   Jiang WJ, 2016, INFECT DIS-NOR, V48, P82, DOI 10.3109/23744235.2015.1082621
   Nascimento-Carvalho CM, 2010, SCAND J INFECT DIS, V42, P839, DOI 10.3109/00365548.2010.498020
   Numminen E, 2015, SCI REP-UK, V5, DOI 10.1038/srep11344
   Tam PYI, 2015, PEDIATR INFECT DIS J, V34, P456, DOI 10.1097/INF.0000000000000620
   Vilas-Boas AL, 2014, J ANTIMICROB CHEMOTH, V69, P1954, DOI 10.1093/jac/dku070
   Weinberger DM, 2014, CLIN INFECT DIS, V58, P188, DOI 10.1093/cid/cit721
   White ANJ, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-196
NR 10
TC 7
Z9 7
U1 0
U2 6
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 2374-4235
EI 2374-4243
J9 INFECT DIS-NOR
JI Infect. Dis.
PY 2017
VL 49
IS 2
BP 147
EP 150
DI 10.1080/23744235.2016.1212170
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA EK3FZ
UT WOS:000393813100012
PM 27464260
DA 2020-12-17
ER

PT J
AU Borges, IC
   Andrade, DC
   Cardoso, MRA
   Toppari, J
   Vaha-Makila, M
   Ilonen, J
   Knip, M
   Hyoty, H
   Veijola, R
   Simell, O
   Jartti, T
   Kayhty, H
   Ruuskanen, O
   Nascimento-Carvalho, CM
AF Borges, Igor C.
   Andrade, Dafne C.
   Cardoso, Maria Regina A.
   Toppari, Jorma
   Vaha-Makila, Mari
   Ilonen, Jorma
   Knip, Mikael
   Hyoty, Heikki
   Veijola, Riitta
   Simell, Olli
   Jartti, Tuomas
   Kayhty, Helena
   Ruuskanen, Olli
   Nascimento-Carvalho, Cristiana M.
TI Natural Development of Antibodies against Streptococcus pneumoniae,
   Haemophilus influenzae, and Moraxella catarrhalis Protein Antigens
   during the First 13 Years of Life
SO CLINICAL AND VACCINE IMMUNOLOGY
LA English
DT Article
ID PNEUMOCOCCAL SURFACE ADHESIN; ACUTE OTITIS-MEDIA; CHILDREN YOUNGER;
   NASOPHARYNGEAL COLONIZATION; RESPIRATORY PATHOGENS; IMMUNE-RESPONSE;
   INFANTS; CARRIAGE; DISEASE; PNEUMOLYSIN
AB Conserved protein antigens have been investigated as vaccine candidates against respiratory pathogens. We evaluated the natural development of antibodies against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis proteins during childhood. Serum samples were collected from 50 healthy children from their first months to age 13 years (median sampling interval, 6 months). We also analyzed serum samples from 24 adults. Serum IgG antibodies against eight pneumococcal proteins (Ply, CbpA, PspA 1 and 2, PcpA, PhtD, StkP-C, and PcsB-N), three H. influenzae proteins, and five M. catarrhalis proteins were measured using a multiplexed bead-based immunoassay. Antibody levels were analyzed using multilevel mixed-effects regression and Spearman's correlation. Antibody levels against pneumococcal proteins peaked at 3 to 5 years of age and then reached a plateau. Antibody levels against H. influenzae proteins peaked during the second year and then stabilized. Antibody levels against M. catarrhalis proteins peaked during the first year and then slowly decreased. Peak antibody levels during childhood were higher than those of adults. Correlations among pneumococcal antibody levels were highest among anti-CbpA, anti-PcpA, and anti-PhtD antibodies (r = 0.71 to 0.75; P < 0.001). The children presented 854 symptomatic respiratory infections on 586 occasions. Symptomatic respiratory infections did not improve prediction of antibody levels in the regression model. The maturation of immune responses against the investigated pneumococcal proteins shares similarities, especially among CbpA, PcpA, and PhtD. Antibody production against H. influenzae and M. catarrhalis proteins starts early in life and reaches peak levels earlier than antibody production against the pneumococcal proteins. Basal antibody levels are not related to the occurrence of symptomatic respiratory infections.
C1 [Borges, Igor C.; Andrade, Dafne C.] Univ Fed Bahia, Sch Med, Postgrad Program Hlth Sci, Salvador, BA, Brazil.
   [Cardoso, Maria Regina A.] Univ Sao Paulo, Sch Publ Hlth, Dept Epidemiol, Sao Paulo, Brazil.
   [Toppari, Jorma] Univ Turku, Dept Physiol, Turku, Finland.
   [Toppari, Jorma] Turku Univ Hosp, Dept Pediat, Turku, Finland.
   [Vaha-Makila, Mari; Simell, Olli; Jartti, Tuomas; Ruuskanen, Olli] Univ Turku, Dept Pediat, Turku, Finland.
   [Vaha-Makila, Mari; Ilonen, Jorma; Simell, Olli; Jartti, Tuomas; Ruuskanen, Olli] Turku Univ Hosp, Turku, Finland.
   [Ilonen, Jorma] Univ Turku, Immunogenet Lab, Turku, Finland.
   [Knip, Mikael] Univ Helsinki, Childrens Hosp, Helsinki, Finland.
   [Knip, Mikael] Helsinki Univ Hosp, Helsinki, Finland.
   [Knip, Mikael] Tampere Univ Hosp, Dept Pediat, Tampere, Finland.
   [Hyoty, Heikki] Univ Tampere, Dept Virol, Tampere, Finland.
   [Hyoty, Heikki] Pirkanmaa Hosp Dist, Fimlab Labs, Tampere, Finland.
   [Veijola, Riitta] Oulu Univ Hosp, Dept Pediat, Med Res Ctr, PEDEGO Res Unit, Oulu, Finland.
   [Veijola, Riitta] Univ Oulu, Oulu, Finland.
   [Kayhty, Helena] Natl Inst Hlth & Welf, Helsinki, Finland.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, Bahia, Brazil.
RP Borges, IC (corresponding author), Univ Fed Bahia, Sch Med, Postgrad Program Hlth Sci, Salvador, BA, Brazil.
EM igorcms@gmail.com
RI Borges, Igor Carmo/AAG-8531-2019; Knip, Mikael/AAL-3773-2020
OI Vaha-Makila, Mari/0000-0003-2216-4607; Hyoty,
   Heikki/0000-0003-0370-4145; Carmo Borges, Igor/0000-0003-2749-0313;
   Ilonen, Jorma/0000-0002-9973-2062; Knip, Mikael/0000-0003-0474-0033
FU Bahia State Agency for Research Funding (FAPESB); Brazilian Council for
   Scientific and Technological Development (CNPq)National Council for
   Scientific and Technological Development (CNPq); National Institute for
   Health and Welfare; Turku University Hospital Research Foundation; Rauno
   and Anne Puolimatka Foundation; Sohlberg Foundation; Academy of
   FinlandAcademy of Finland
FX This work, including the efforts of Cristiana M. Nascimento-Carvalho,
   was funded by Bahia State Agency for Research Funding (FAPESB). This
   work, including the efforts of Cristiana M. Nascimento-Carvalho, was
   funded by Brazilian Council for Scientific and Technological Development
   (CNPq). This work, including the efforts of Helena Kayhty, was funded by
   National Institute for Health and Welfare. This work, including the
   efforts of Igor C. Borges, was funded by Turku University Hospital
   Research Foundation. This work, including the efforts of Igor C. Borges,
   was funded by Rauno and Anne Puolimatka Foundation. This work, including
   the efforts of Helena Kayhty, was funded by Sohlberg Foundation. This
   work, including the efforts of Helena Kayhty, was funded by Academy of
   Finland.
CR Andrade DC, 2014, J IMMUNOL METHODS, V405, P130, DOI 10.1016/j.jim.2014.02.002
   Andrade DC, 2016, J IMMUNOL METHODS, V433, P31, DOI 10.1016/j.jim.2016.02.021
   Berglund J, 2014, CLIN VACCINE IMMUNOL, V21, P56, DOI 10.1128/CVI.00430-13
   Bogaert D, 2004, LANCET INFECT DIS, V4, P144, DOI 10.1016/S1473-3099(04)00938-7
   Brooks WA, 2015, VACCINE, V33, P4610, DOI 10.1016/j.vaccine.2015.06.078
   Chen A, 2015, CLIN VACCINE IMMUNOL, V22, P1079, DOI 10.1128/CVI.00293-15
   Feldman C, 2014, J INFECTION, V69, P309, DOI 10.1016/j.jinf.2014.06.006
   Garcia-Rodriguez JA, 2002, J ANTIMICROB CHEMOTH, V50, P59, DOI 10.1093/jac/dkf506
   Goldblatt D, 2011, CLIN VACCINE IMMUNOL, V18, P1728, DOI 10.1128/CVI.05252-11
   Holmlund E, 2006, VACCINE, V24, P57, DOI 10.1016/j.vaccine.2005.07.055
   Hua CZ, 2016, CLIN VACCINE IMMUNOL, V23, P155, DOI 10.1128/CVI.00506-15
   Jartti T, 2014, ALLERGY, V69, P658, DOI 10.1111/all.12396
   Kwambana BA, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-175
   Laine C, 2004, INFECT IMMUN, V72, P3331, DOI 10.1128/IAI.72.6.3331-3335.2004
   LEACH AJ, 1994, PEDIATR INFECT DIS J, V13, P983, DOI 10.1097/00006454-199411000-00009
   Lebon A, 2011, INFECT IMMUN, V79, P1680, DOI 10.1128/IAI.01379-10
   LloydEvans N, 1996, PEDIATR INFECT DIS J, V15, P866, DOI 10.1097/00006454-199610000-00007
   Meriluoto M, 2012, EMERG INFECT DIS, V18, P264, DOI 10.3201/eid1802.111293
   Murphy TF, 2015, CLIN VACCINE IMMUNOL, V22, P459, DOI 10.1128/CVI.00089-15
   Murphy TF, 2009, CLIN INFECT DIS, V49, P124, DOI 10.1086/599375
   Nejentsev S, 1999, DIABETIC MED, V16, P985, DOI 10.1046/j.1464-5491.1999.00186.x
   O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6
   Ogunniyi AD, 2001, INFECT IMMUN, V69, P5997, DOI 10.1128/IAI.69.10.5997-6003.2001
   Pichichero ME, 2010, VACCINE, V28, P7184, DOI 10.1016/j.vaccine.2010.08.063
   Rapola S, 2000, J INFECT DIS, V182, P1146, DOI 10.1086/315822
   Ren DB, 2016, EXPERT OPIN THER TAR, V20, P19, DOI 10.1517/14728222.2015.1081686
   Ren DB, 2015, HUM VACC IMMUNOTHER, V11, P489, DOI 10.4161/21645515.2014.990861
   Samukawa T, 2000, INFECT IMMUN, V68, P1569, DOI 10.1128/IAI.68.3.1569-1573.2000
   Syrjanen RK, 2001, J INFECT DIS, V184, P451, DOI 10.1086/322048
   Turner P, 2013, CLIN MICROBIOL INFEC, V19, pE551, DOI [10.1111/1469-0691.12286, 10.1111/1469-0691.12431]
   Verhaegh SJC, 2011, VACCINE, V29, P5603, DOI 10.1016/j.vaccine.2011.06.019
   Walker CLF, 2013, LANCET, V381, P1405, DOI 10.1016/S0140-6736(13)60222-6
   Watt JP, 2009, LANCET, V374, P903, DOI 10.1016/S0140-6736(09)61203-4
NR 33
TC 4
Z9 4
U1 0
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1556-6811
EI 1556-679X
J9 CLIN VACCINE IMMUNOL
JI Clin. Vaccine Immunol.
PD NOV
PY 2016
VL 23
IS 11
BP 878
EP 883
DI 10.1128/CVI.00341-16
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA EC1HM
UT WOS:000387855500005
PM 27581439
OA Green Published, Bronze
DA 2020-12-17
ER

PT J
AU Bouzas, ML
   Oliveira, JR
   Fukutani, KF
   Borges, IC
   Barral, A
   Van der Gucht, W
   Wollants, E
   Van Ranst, M
   de Oliveira, CI
   Van Weyenbergh, J
   Nascimento-Carvalho, CM
AF Bouzas, Maiara L.
   Oliveira, Juliana R.
   Fukutani, Kiyoshi F.
   Borges, Igor C.
   Barral, Aldina
   Van der Gucht, Winke
   Wollants, Elke
   Van Ranst, Marc
   de Oliveira, Camila I.
   Van Weyenbergh, Johan
   Nascimento-Carvalho, Cristiana M.
TI Respiratory syncytial virus a and b display different temporal patterns
   in a 4-year prospective cross-sectional study among children with acute
   respiratory infection in a tropical city
SO MEDICINE
LA English
DT Article
DE acute respiratory infection; immunoprophylaxis; palivizumab; RSV; RSVA;
   RSVB; seasonality
ID COMMUNITY-ACQUIRED PNEUMONIA; TRACT INFECTIONS; BRAZIL; SEASONALITY;
   PREVALENCE; EPIDEMIOLOGY; FREQUENCY; GENOTYPES; DYNAMICS; FEATURES
AB Respiratory syncytial virus (RSV) is one of the most common etiological agents of childhood respiratory infections globally. Information on seasonality of different antigenic groups is scarce. We aimed to describe the frequency, seasonality, and age of children infected by RSV antigenic groups A (RSVA) and B (RSVB) among children with ARI in a 4-year period.Children (6-23 months old) with respiratory infection for 7 days were enrolled in a prospective cross-sectional study, from September, 2009 to October, 2013, in Salvador, in a tropical region of Brazil. Upon recruitment, demographic, clinical data, and nasopharyngeal aspirates (NPA) were collected. A multiplex quantitative real-time polymerase chain reaction (RT-PCR) with a group-specific primer and probeset for RSVA and RSVB was used. Seasonal distribution of infection by RSV different antigenic groups was evaluated by Prais-Wisten regression.Of 560 cases, the mean age was 11.44.5 months and there were 287 (51.3%) girls. Overall, RSV was detected in 139 (24.8%; 95% CI: 21.4%-28.5%) cases, RSVA in 74 (13.2%; 95% CI: 10.6%-16.2%) cases, and RSVB in 67 (12.0%; 95% CI: 9.5%-14.9%) cases. Two (0.4%; 95% CI: 0.06%-1.2%) cases had coinfection. RSVA frequency was 9.6%, 18.4%, 21.6%, and 3.1% in 2010, 2011, 2012, and 2013, respectively. RSVB frequency was 19.2%, 0.7%, 1.4%, and 35.4% in the same years. RSVA was more frequently found from August to January than February to July (18.2% vs. 6.4%, P<0.001). RSVB was more frequently found (P<0.001) between March and June (36.0%) than July to October (1.0%) or November to February (1.6%). RSVB infection showed seasonal distribution and positive association with humidity (P = 0.02) whereas RSVA did not. RSVA was more common among children 1-year-old (17.8% vs. 1.8%; P = 0.02), as opposed to RSVB (11.5% vs. 12.2%; P = 0.8).One quarter of patients had RSV infection. RSVA compromised more frequently children aged 1 year. RSVA predominated in 2011 and 2012 whereas RSVB predominated in 2010 and 2013. In regard to months, RSVA was more frequent from August to January whereas RSVB was more often detected between March and June. Markedly different monthly as well as yearly patterns for RSVA and RSVB reveal independent RSV antigenic groups' epidemics.
C1 [Bouzas, Maiara L.; Oliveira, Juliana R.; Fukutani, Kiyoshi F.; Borges, Igor C.; Barral, Aldina; de Oliveira, Camila I.; Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Postgrad Program Hlth Sci, Salvador, BA, Brazil.
   [Barral, Aldina; de Oliveira, Camila I.] Fundacao Oswaldo Cruz FIOCRUZ, Ctr Pesquisas Goncalo Moniz CPqGM, Salvador, BA, Brazil.
   [Barral, Aldina] Univ Fed Bahia, Sch Med, Dept Pathol, Salvador, BA, Brazil.
   [Van der Gucht, Winke; Wollants, Elke; Van Ranst, Marc; Van Weyenbergh, Johan] KU, Rega Inst Med Res, Lab Clin & Epidemiol Virol, Dept Microbiol & Immunol, Leuven, Belgium.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Pediat, Rua Prof Aristides Novis,105-1201B, BR-40210630 Salvador, BA, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia, Sch Med, Dept Pediat, Rua Prof Aristides Novis,105-1201B, BR-40210630 Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
RI Borges, Igor Carmo/AAG-8531-2019; Van Ranst, Marc/P-7522-2017; Van
   Weyenbergh, Johan/B-4187-2009; de Oliveira, Camila I/B-4358-2009; Van
   Weyenbergh, Johan/Q-3829-2019; Fukutani, Kiyoshi/T-1630-2019
OI Van Ranst, Marc/0000-0002-1674-4157; Van Weyenbergh,
   Johan/0000-0003-3234-8426; de Oliveira, Camila I/0000-0002-7868-5164;
   Van Weyenbergh, Johan/0000-0003-3234-8426; Carmo Borges,
   Igor/0000-0003-2749-0313; Wollants, Elke/0000-0002-4057-2236; Fukutani,
   Kiyoshi/0000-0003-2223-0918
FU Bahia State Agency for Research Funding (FAPESB) [APP0045/2009,
   PNX0019/2009]
FX This work was supported by the Bahia State Agency for Research Funding
   (FAPESB) [grant numbers APP0045/2009 and PNX0019/2009]. FAPESB had no
   role in study design, data collection, data analysis, data
   interpretation, or writing of the report.
CR Aamir UB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074018
   Gardinassi LGA, 2012, VIRUSES-BASEL, V4, P2432, DOI 10.3390/v4112432
   Arbiza J, 2005, MEM I OSWALDO CRUZ, V100, P221, DOI 10.1590/S0074-02762005000300001
   Borchers AT, 2013, CLIN REV ALLERG IMMU, V45, P331, DOI 10.1007/s12016-013-8368-9
   Brady MT, 2014, PEDIATRICS, V134, P415, DOI 10.1542/peds.2014-1665
   Brazilian Ministry of Health, 2015, 052015 BRAZ MIN HLTH
   Calegari Tatiany, 2005, Braz J Infect Dis, V9, P156, DOI 10.1590/S1413-86702005000200006
   Cuevas LE, 2003, EMERG INFECT DIS, V9, P1626, DOI 10.3201/eid0912.030522
   Durigon GS, 2015, INT J INFECT DIS, V34, P3, DOI 10.1016/j.ijid.2015.03.003
   El-Rashdi AS, 2006, ARCH DIS CHILD, V91, P351, DOI 10.1136/adc.2005.088831
   Ferone EA, 2014, J PEDIAT-BRAZIL, V90, P42, DOI 10.1016/j.jped.2013.05.005
   Gurgel RQ, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003090
   Hacimustafaoglu M, 2013, TURKISH J PEDIATR, V55, P130
   Hara M, 2014, PEDIATR INFECT DIS J, V33, P687, DOI 10.1097/INF.0000000000000227
   Harris M, 2011, THORAX, V66, pII1, DOI 10.1136/thoraxjnl-2011-200598
   Haynes AK, 2013, J INFECT DIS, V208, pS246, DOI 10.1093/infdis/jit515
   Houspie L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060416
   Kimberlin DW, 2015, AM ACAD PEDIATRICSRE, P672
   Lamarao LM, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-119
   McCracken JP, 2013, J INFECT DIS, V208, pS197, DOI 10.1093/infdis/jit517
   Moore HC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100422
   Nair H, 2013, LANCET, V381, P1380, DOI 10.1016/S0140-6736(12)61901-1
   Nascimento-Carvalho CM, 2010, SCAND J INFECT DIS, V42, P839, DOI 10.3109/00365548.2010.498020
   Nolan T, 2015, CLIN INFECT DIS, V60, pE80, DOI 10.1093/cid/civ065
   Oliveira TFM, 2008, MEM I OSWALDO CRUZ, V103, P417, DOI 10.1590/S0074-02762008000500002
   Panayiotou C, 2014, EPIDEMIOL INFECT, V142, P2406, DOI 10.1017/S0950268814000028
   Sloan C, 2011, CTS-CLIN TRANSL SCI, V4, P48, DOI 10.1111/j.1752-8062.2010.00257.x
   White LJ, 2005, EPIDEMIOL INFECT, V133, P279, DOI 10.1017/S0950268804003450
   World Health Organization, 2008, 5032 WC WHO
   Zhang ZY, 2010, J CLIN MICROBIOL, V48, P1201, DOI 10.1128/JCM.02258-09
NR 30
TC 8
Z9 9
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD OCT
PY 2016
VL 95
IS 41
AR e5142
DI 10.1097/MD.0000000000005142
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA EA1LV
UT WOS:000386354700048
PM 27741144
OA DOAJ Gold, Green Published
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, AC
   Ruuskanen, O
   Nascimento-Carvalho, CM
AF Nascimento-Carvalho, Amanda C.
   Ruuskanen, Olli
   Nascimento-Carvalho, Cristiana M.
TI Comparison of the frequency of bacterial and viral infections among
   children with community-acquired pneumonia hospitalized across distinct
   severity categories: a prospective cross-sectional study
SO BMC PEDIATRICS
LA English
DT Article
DE Acute respiratory infection; Lower respiratory tract infection; Lung
   disease; Respiratory viruses; Severity assessment
ID HUMAN BOCAVIRUS INFECTION; CHILDHOOD PNEUMONIA;
   STREPTOCOCCUS-PNEUMONIAE; HUMAN METAPNEUMOVIRUS; SIMKANIA-NEGEVENSIS;
   TROPICAL REGION; DIAGNOSIS; ETIOLOGY; ANTIBODIES; OUTCOMES
AB Background: The comparison of the frequencies of bacterial and viral infections among children with community-acquired pneumonia (CAP) admitted in distinct severity categories, in an original study, is lacking in literature to-date. We aimed to achieve this goal.
   Methods: Children aged 2-59-months-old hospitalized with CAP were included in this prospective study in Salvador, Brazil. Clinical data and biological samples were collected to investigate 11 viruses and 8 bacteria. Severity was assessed by using the World Health Organization criteria.
   Results: One hundred eighty-one patients were classified as "non-severe" (n = 53; 29.3 %), "severe" (n = 111; 61.3 %), or "very severe" (n = 17; 9.4 %) CAP. Overall, aetiology was detected among 156 (86.2 %) cases; viral (n = 84; 46.4 %), bacterial (n = 26; 14.4 %) and viral-bacterial (n = 46; 25.4 %) infections were identified. Viral infection frequency was similar in severe/very severe and non-severe cases (46.1 % vs. 47.2 %; p = 0.9). Pneumococcal infection increased across "non-severe" (13.2 %), "severe" (23.4 %), and "very severe" (35.3 %) cases (qui-squared test for trend p = 0.04). Among patients with detected aetiology, after excluding cases with co-infection, the frequency of sole bacterial infection was different (p = 0.04) among the categories; non-severe (12.5 %), severe (29.3 %) or very severe (55.6 %). Among these patients, sole bacterial infection was independently associated with severity (OR = 4.4 [95 % CI:1.1-17. 6]; p = 0.04) in a model controlled for age (OR = 0.7 [95 % CI:0.5-1.1]; p = 0.1).
   Conclusions: A substantial proportion of cases in distinct severity subgroups had respiratory viral infections, which did not differ between severity categories. Bacterial infection, particularly pneumococcal infection, was more likely among severe/very severe cases.
C1 [Nascimento-Carvalho, Amanda C.] Bahiana Fdn Sci Dev, Bahiana Sch Med, Salvador, BA, Brazil.
   [Ruuskanen, Olli] Turku Univ, Dept Paediat, Turku, Finland.
   [Ruuskanen, Olli] Turku Univ Hosp, Turku, Finland.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Dept Paediat, Sch Med, Salvador, BA, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia, Dept Paediat, Sch Med, Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
FU Bahia State Agency for Research Funding (FAPESB) [52/2004]; Brazilian
   Council for Scientific and Technological Development (CNPq)National
   Council for Scientific and Technological Development (CNPq)
   [303551/2011-9]
FX This study was supported by the Bahia State Agency for Research Funding
   (FAPESB) [grant number 52/2004] and the Brazilian Council for Scientific
   and Technological Development (CNPq) [grant number 303551/2011-9]. CMN-C
   is an investigator at CNPq. The funding agencies had no role in the
   design of the study and collection, analysis and interpretation of data
   and in writing the manuscript.
CR Atkinson TP, 2014, PEDIATR INFECT DIS J, V33, P92, DOI 10.1097/INF.0000000000000171
   Bogaert D, 2006, MICROBIOL-SGM, V152, P377, DOI 10.1099/mic.0.28394-0
   Bordon J, 2008, CHEST, V133, P618, DOI 10.1378/chest.07-1322
   Gilani Z, 2012, CLIN INFECT DIS, V54, pS102, DOI 10.1093/cid/cir1053
   Howie SRC, 2014, CLIN INFECT DIS, V59, P682, DOI 10.1093/cid/ciu384
   Ishimine P, 2006, PEDIATR CLIN N AM, V53, P167, DOI 10.1016/j.pcl.2005.09.012
   Jain S, 2015, NEW ENGL J MED, V372, P835, DOI 10.1056/NEJMoa1405870
   Johansson N, 2010, CLIN INFECT DIS, V50, P202, DOI 10.1086/648678
   Korppi M, 2008, EUR J CLIN MICROBIOL, V27, P167, DOI 10.1007/s10096-007-0436-8
   Korppi M, 2010, PEDIATR INFECT DIS J, V29, P387, DOI 10.1097/INF.0b013e3181ce8e81
   Lin SH, 2011, EPIDEMIOL INFECT, V139, P1307, DOI 10.1017/S0950268810002402
   Makela MJ, 1998, J CLIN MICROBIOL, V36, P539
   Mameli C, 2013, CURR INFECT DIS REP, V15, P197, DOI 10.1007/s11908-013-0339-z
   Morre SA, 2002, J CLIN MICROBIOL, V40, P584, DOI 10.1128/JCM.40.2.584-587.2002
   Nascimento-Carvalho CM, 2008, PEDIATR INFECT DIS J, V27, P939, DOI 10.1097/INF.0b013e3181723751
   Nascimento-Carvalho CM, 2012, J MED VIROL, V84, P253, DOI 10.1002/jmv.22268
   Nascimento-Carvalho CM, 2011, INFLUENZA OTHER RESP, V5, P285, DOI 10.1111/j.1750-2659.2011.00206.x
   Nascimento-Carvalho CM, 2009, J INFECTION, V58, P250, DOI 10.1016/j.jinf.2009.01.008
   NOHYNEK H, 1995, PEDIATR INFECT DIS J, V14, P478, DOI 10.1097/00006454-199506000-00003
   Nolte FS, 2008, CLIN INFECT DIS, V47, pS123, DOI 10.1086/591392
   Principi N, 2014, J CLIN VIROL, V59, P141, DOI 10.1016/j.jcv.2014.01.003
   Rudan I, 2013, J GLOB HEALTH, V3, DOI 10.7189/jogh.03.010401
   Ruuskanen O, 2014, CLIN INFECT DIS, V59, P71, DOI 10.1093/cid/ciu242
   Ruuskanen O, 2011, LANCET, V377, P1264, DOI 10.1016/S0140-6736(10)61459-6
   Saukkoriipi A, 2002, MOL CELL PROBE, V16, P385, DOI 10.1006/mcpr.2002.0443
   SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017
   Spuesens EBM, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001444
   Vuori-Holopainen E, 2001, CLIN INFECT DIS, V32, P715, DOI 10.1086/319213
   Walker CLF, 2013, LANCET, V381, P1405, DOI 10.1016/S0140-6736(13)60222-6
   Wolf DG, 2010, J PEDIATR-US, V156, P115, DOI 10.1016/j.jpeds.2009.07.014
   Woods CR, 2013, CURR INFECT DIS REP, V15, P177, DOI 10.1007/s11908-013-0324-6
   World Health Organization, 2000, MAN CHILD SER INF SE, P20
   World Health Organization, 2013, POCK BOOK HOSP CAR C, P81
   Yamaguchi T, 2005, FEMS IMMUNOL MED MIC, V43, P21, DOI 10.1016/j.femsim.2004.06.023
NR 34
TC 9
Z9 10
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2431
J9 BMC PEDIATR
JI BMC Pediatr.
PD JUL 22
PY 2016
VL 16
AR 105
DI 10.1186/s12887-016-0645-3
PG 10
WC Pediatrics
SC Pediatrics
GA DR9US
UT WOS:000380242200002
PM 27449898
OA DOAJ Gold, Green Published
DA 2020-12-17
ER

PT J
AU Andrade, DC
   Borges, IC
   Adrian, PV
   Meinke, A
   Barral, A
   Ruuskanen, O
   Kayhty, H
   Nascimento-Carvalho, CM
AF Andrade, Dafne C.
   Borges, Igor C.
   Adrian, Peter V.
   Meinke, Andreas
   Barral, Aldina
   Ruuskanen, Olli
   Kayhty, Helena
   Nascimento-Carvalho, Cristiana M.
TI Effect of Pneumococcal Conjugate Vaccine on the Natural Antibodies and
   Antibody Responses Against Protein Antigens From Streptococcus
   pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in Children
   With Community-acquired Pneumonia
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE humoral antibody response; immune factors; lower respiratory tract
   infection; polysaccharides; serological tests
ID RANDOMIZED CONTROLLED-TRIAL; LUNG EPITHELIAL-CELLS; ACUTE OTITIS-MEDIA;
   NASOPHARYNGEAL COLONIZATION; FUNCTIONAL ANTIBODIES;
   STAPHYLOCOCCUS-AUREUS; CARRIAGE; PHTD; PCPA; CANDIDATES
AB Background: Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis are common causative agents of respiratory infections. Pneumococcal conjugate vaccines have been introduced recently, but their effect on the natural immunity against protein antigens from these pathogens has not been elucidated.
   Methods: This was an age-matched observational controlled study that evaluated the influence of 10-valent pneumococcal conjugate vaccines on the levels of antibodies and frequencies of antibody responses against proteins from S. pneumoniae, H. influenzae and M. catarrhalis in serum samples of children with community-acquired pneumonia. Eight pneumococcal proteins (pneumolysin, choline-binding protein A, pneumococcal surface protein A families 1 and 2, pneumococcal choline-binding protein A, pneumococcal histidine triad protein D, serine/threonine protein kinase, protein required for cell wall separation of group B streptococcus), 3 proteins from H. influenzae (including protein D) and 5 M. catarrhalis proteins were investigated.
   Results: The study group comprised 38 vaccinated children and 114 age-matched controls (median age: 14.5 vs. 14.6 months, respectively; P = 0.997), all with community-acquired pneumonia. There was no difference on clinical baseline characteristics between vaccinated and unvaccinated children. Vaccinated children had significantly lower levels of antibodies against 4 of the studied pneumococcal antigens (P = 0.048 for Ply, P = 0.018 for pneumococcal surface protein A, P = 0.001 for StkP and P = 0.028 for PcsB) and higher levels of antibodies against M. catarrhalis (P = 0.015). Nevertheless, the vaccination status did not significantly affect the rates of antibody responses against S. pneumoniae, H. influenzae and M. catarrhalis.
   Conclusions: In spite of the differences that have been found on the level of natural antibodies, no effect from pneumococcal vaccination was observed on the rate of immune responses associated with community-acquired pneumonia against protein antigens from S. pneumoniae, H. influenzae and M. catarrhalis.
C1 [Andrade, Dafne C.; Borges, Igor C.; Barral, Aldina] Univ Fed Bahia, Sch Med, Postgrad Program Hlth Sci, BR-40025010 Salvador, BA, Brazil.
   [Barral, Aldina] Univ Fed Bahia, Sch Med, Postgrad Program Human Pathol, BR-40025010 Salvador, BA, Brazil.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Paediat, BR-40025010 Salvador, BA, Brazil.
   [Adrian, Peter V.] Univ Witwatersrand, DST NRF Vaccine Preventable Dis, Resp & Meningeal Pathogens Res Unit, Johannesburg, South Africa.
   [Meinke, Andreas] Valneva Austria GmbH, Campus Vienna Bioctr 3, Vienna, Austria.
   [Barral, Aldina] Fundacao Oswaldo Cruz FIOCRUZ, Ctr Pesquisa Goncalo, Salvador, BA, Brazil.
   [Ruuskanen, Olli] Turku Univ, Dept Paediat, Turku, Finland.
   [Ruuskanen, Olli] Univ Hosp, Turku, Finland.
   [Kayhty, Helena] Natl Inst Hlth & Welf, Helsinki, Finland.
RP Andrade, DC (corresponding author), Univ Fed Bahia, Sch Med, Praca 15 Novembro,S-N Largo Terreiro Jesus, BR-40025010 Salvador, BA, Brazil.
EM andradedafne@yahoo.com.br
RI Borges, Igor Carmo/AAG-8531-2019
OI Carmo Borges, Igor/0000-0003-2749-0313
FU Bahia State Agency for Research Funding (FAPESB), Brazil; Brazilian
   Council for Scientific and Technological Development (CNPq),
   BrazilNational Council for Scientific and Technological Development
   (CNPq)
FX This study was supported by Bahia State Agency for Research Funding
   (FAPESB), Brazil; Brazilian Council for Scientific and Technological
   Development (CNPq), Brazil. Andreas Meinke is an employee at Valneva
   Austria GmbH. The authors have no conflicts of interest to disclose.
CR Adamou JE, 2001, INFECT IMMUN, V69, P949, DOI 10.1128/IAI.69.2.949-958.2001
   Andrade DC, 2014, J IMMUNOL METHODS, V405, P130, DOI 10.1016/j.jim.2014.02.002
   Bahia. Secretaria de Saude do Estado da Bahia, 2010, INTR VAC PNEUM 10 VA
   Bogaert D, 2004, LANCET INFECT DIS, V4, P144, DOI 10.1016/S1473-3099(04)00938-7
   Borges IC, 2015, EUR J CLIN MICROBIOL, V34, P1551, DOI 10.1007/s10096-015-2385-y
   Bradley JS, 2011, CLIN INFECT DIS, V53, P617, DOI 10.1093/cid/cir625
   Brooks-Walter A, 1999, INFECT IMMUN, V67, P6533
   Casey JR, 2010, PEDIATR INFECT DIS J, V29, P304, DOI 10.1097/INF.0b013e3181c1bc48
   Croney CM, 2012, CLIN VACCINE IMMUNOL, V19, P891, DOI 10.1128/CVI.05671-11
   Ditse Z, 2013, VACCINE, V31, P4421, DOI 10.1016/j.vaccine.2013.06.097
   Dunne EM, 2012, J CLIN MICROBIOL, V50, P1034, DOI 10.1128/JCM.06589-11
   Flasche S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001017
   Giefing C, 2008, J EXP MED, V205, P117, DOI 10.1084/jem.20071168
   Holmlund E, 2009, CLIN VACCINE IMMUNOL, V16, P916, DOI 10.1128/CVI.00050-09
   Kaur R, 2014, INFECT IMMUN, V82, P5069, DOI 10.1128/IAI.02124-14
   Khan MN, 2012, MICROBES INFECT, V14, P1102, DOI 10.1016/j.micinf.2012.06.007
   Khan MN, 2012, VACCINE, V30, P2900, DOI 10.1016/j.vaccine.2012.02.023
   Lebon A, 2011, INFECT IMMUN, V79, P1680, DOI 10.1128/IAI.01379-10
   Madhi SA, 2007, J INFECT DIS, V196, P1662, DOI 10.1086/522164
   Murphy TF, 2009, CLIN INFECT DIS, V49, P124, DOI 10.1086/599375
   NOHYNEK H, 1995, PEDIATR INFECT DIS J, V14, P478, DOI 10.1097/00006454-199506000-00003
   Pichichero ME, 2012, HUM VACC IMMUNOTHER, V8, P799, DOI 10.4161/hv.19820
   Poolman JT, 2000, VACCINE, V19, pS108, DOI 10.1016/S0264-410X(00)00288-7
   Prevaes SMPJ, 2012, INFECT IMMUN, V80, P2186, DOI 10.1128/IAI.00037-12
   Prymula R, 2009, VACCINE, V28, P71, DOI 10.1016/j.vaccine.2009.09.113
   Rede Interagencial de Informacoes para a Saude, 2008, REDE INTERAGENCIAL I
   Rodgers G.L., 2011, VACCINE, V29, P43
   Rudan I, 2008, B WORLD HEALTH ORGAN, V86, P408, DOI 10.2471/BLT.07.048769
   Ruuskanen O, 2011, LANCET, V377, P1264, DOI 10.1016/S0140-6736(10)61459-6
   Spijkerman J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039730
   Tai SS, 2006, CRIT REV MICROBIOL, V32, P139, DOI 10.1080/10408410600822942
   van der Poll T, 2009, LANCET, V374, P1543, DOI 10.1016/S0140-6736(09)61114-4
   van Gils EJM, 2011, VACCINE, V29, P7595, DOI 10.1016/j.vaccine.2011.08.049
   van Gils EJM, 2009, JAMA-J AM MED ASSOC, V302, P159, DOI 10.1001/jama.2009.975
   Verhaegh SJC, 2010, CLIN MICROBIOL INFEC, V16, P992, DOI 10.1111/j.1469-0691.2009.03008.x
   Verhaegh SJC, 2012, CLIN VACCINE IMMUNOL, V19, P914, DOI 10.1128/CVI.05630-11
   Vilas-Boas AL, 2014, J ANTIMICROB CHEMOTH, V69, P1954, DOI 10.1093/jac/dku070
   World Health Organization, 2008, TRAIN COURS CHILD GR
NR 38
TC 7
Z9 7
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD JUN
PY 2016
VL 35
IS 6
BP 683
EP 689
DI 10.1097/INF.0000000000001126
PG 7
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA DQ6VN
UT WOS:000379343700019
PM 26954601
OA Green Published
DA 2020-12-17
ER

PT J
AU Andrade, DC
   Borges, IC
   Ivaska, L
   Peltola, V
   Meinke, A
   Barral, A
   Kayhty, H
   Ruuskanen, O
   Nascimento-Carvalho, CM
AF Andrade, Dafne Carvalho
   Borges, Igor Carmo
   Ivaska, Lauri
   Peltola, Ville
   Meinke, Andreas
   Barral, Aldina
   Kayhty, Helena
   Ruuskanen, Olli
   Nascimento-Carvalho, Cristiana Maria
TI Serological diagnosis of pneumococcal infection in children with
   pneumonia using protein antigens: A study of cut-offs with positive and
   negative controls
SO JOURNAL OF IMMUNOLOGICAL METHODS
LA English
DT Article
DE Immune response; Luminex; Invasive pneumococcal disease; Bacteremia;
   Respiratory infection; Fluorescent multiplex microsphere immunoassay
   (FMIA)
ID COMMUNITY-ACQUIRED PNEUMONIA; RESPIRATORY VIRAL-INFECTIONS; FILIPINO
   PREGNANT-WOMEN; STREPTOCOCCUS-PNEUMONIAE; SURFACE ADHESIN;
   ANTIBODY-RESPONSES; CARRIAGE; SERUM; COLONIZATION; PNEUMOLYSIN
AB The etiological diagnosis of infection by Streptococcus pneumoniae in children is difficult, and the use of indirect techniques is frequently warranted. We aimed to study the use of pneumococcal proteins for the serological diagnosis of pneumococcal infection in children with pneumonia. We analyzed paired serum samples from 13 Brazilian children with invasive pneumococcal pneumonia (positive control group) and 23 Finnish children with viral pharyngitis (negative control group), all aged <5 years-old. Children with pharyngitis were evaluated for oropharyngeal colonization, and none of them carried S. pneumoniae. We used a multiplex bead-based assay with eight proteins: Ply, CbpA, PspA1 and 2, PcpA, PhtD, StkP and PcsB. The optimal cut-off for increase in antibody level for the diagnosis of pneumococcal infection was determined for each antigen by ROC curve analysis. The positive control group had a significantly higher rate of >= 2-fold rise in antibody levels against all pneumococcal proteins, except Ply, compared to the negative controls. The cut-off of >= 2-fold increase in antibody levels was accurate for pneumococcal infection diagnosis for all investigated antigens. However, there was a substantial increase in the accuracy of the test with a cut-off of >= 1.52-fold rise in antibody levels for PcpA. When using the investigated protein antigens for the diagnosis of pneumococcal infection, the detection of response against at least one antigen was highly sensitive (92.3.1%) and specific (91.30%). The use of serology with pneumococcal proteins is a promising method for the diagnosis of pneumococcal infection in children with pneumonia. The use of a >= 2-fold increase cut-off is adequate for most pneumococcal proteins. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Andrade, Dafne Carvalho; Borges, Igor Carmo; Barral, Aldina; Nascimento-Carvalho, Cristiana Maria] Univ Fed Bahia, Sch Med, Postgrad Programme Hlth Sci, BR-40025010 Salvador, BA, Brazil.
   [Ivaska, Lauri; Peltola, Ville; Ruuskanen, Olli] Turku Univ Hosp, Dept Pediat & Adolescent Med, FIN-20520 Turku, Finland.
   [Ivaska, Lauri; Ruuskanen, Olli] Univ Turku, Turku, Finland.
   [Meinke, Andreas] Valneva Austria GmbH, Campus Vienna Bioctr 3, Vienna, Austria.
   [Barral, Aldina] Univ Fed Bahia, Sch Med, Dept Pathol, BR-40025010 Salvador, BA, Brazil.
   [Barral, Aldina] Fundacao Oswaldo Cruz FIOCRUZ, Ctr Pesquisa Goncalo Moniz, Salvador, BA, Brazil.
   [Kayhty, Helena] Natl Inst Hlth & Welf, Helsinki, Finland.
   [Nascimento-Carvalho, Cristiana Maria] Univ Fed Bahia, Sch Med, Dept Pediat, BR-40025010 Salvador, BA, Brazil.
RP Andrade, DC (corresponding author), Univ Fed Bahia, Sch Med, Praca 15 Novembro S-N, BR-40025010 Salvador, BA, Brazil.
EM andradedafne@yahoo.com.br
RI Borges, Igor Carmo/AAG-8531-2019
OI Carmo Borges, Igor/0000-0003-2749-0313; Ivaska,
   Lauri/0000-0001-8935-5032
FU Bahia State Agency for Research Funding (FAPESB), Brazil [52/2004];
   Brazilian Council for Scientific and Technological Development (CNPq),
   BrazilNational Council for Scientific and Technological Development
   (CNPq) [400995/2005-0]; Turku University Hospital Research Foundation,
   Finland; Rauno and Anne Puolimatka Foundation, Finland; Sohlberg
   Foundation, Finland [2418/2014]
FX This work was supported by: Bahia State Agency for Research Funding
   (FAPESB, grant number 52/2004), Brazil; Brazilian Council for Scientific
   and Technological Development (CNPq, grant number 400995/2005-0),
   Brazil; Turku University Hospital Research Foundation, Finland; Rauno
   and Anne Puolimatka Foundation, Finland; and Sohlberg Foundation (grant
   number 2418/2014), Finland. Profs. Aldina Barral and Cristiana M.
   Nascimento-Carvalho are investigators at the CNPq.
CR Andrade D.C., 2016, PEDIAT INFE IN PRESS
   Andrade DC, 2014, J IMMUNOL METHODS, V405, P130, DOI 10.1016/j.jim.2014.02.002
   Bogaert D, 2004, LANCET INFECT DIS, V4, P144, DOI 10.1016/S1473-3099(04)00938-7
   Borges I.C., 2015, EUR J CLIN MICROBIOL
   De Schutter I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089013
   FREIJD A, 1984, CLIN EXP IMMUNOL, V55, P204
   Giefing C, 2008, J EXP MED, V205, P117, DOI 10.1084/jem.20071168
   Goldblatt D, 2011, CLIN VACCINE IMMUNOL, V18, P1728, DOI 10.1128/CVI.05252-11
   Hagerman A, 2013, EUR J CLIN MICROBIOL, V32, P43, DOI 10.1007/s10096-012-1712-9
   Holmlund E, 2006, VACCINE, V24, P57, DOI 10.1016/j.vaccine.2005.07.055
   Holmlund E, 2009, CLIN VACCINE IMMUNOL, V16, P916, DOI 10.1128/CVI.00050-09
   Hsieh TH, 2011, J MICROBIOL IMMUNOL, V44, P328, DOI 10.1016/j.jmii.2010.08.009
   Jimenez-Munguia I, 2015, J PROTEOMICS, V126, P228, DOI 10.1016/j.jprot.2015.06.011
   Korppi M, 2008, EUR J CLIN MICROBIOL, V27, P167, DOI 10.1007/s10096-007-0436-8
   Lebon A, 2011, INFECT IMMUN, V79, P1680, DOI 10.1128/IAI.01379-10
   Nascimento-Carvalho CM, 2008, PEDIATR INFECT DIS J, V27, P939, DOI 10.1097/INF.0b013e3181723751
   Nascimento-Carvalho CM, 2013, SCAND J INFECT DIS, V45, P478, DOI 10.3109/00365548.2012.754106
   NOHYNEK H, 1995, PEDIATR INFECT DIS J, V14, P478, DOI 10.1097/00006454-199506000-00003
   O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6
   Olaya-Abril A, 2015, MOL CELL PROTEOMICS, V14, P2591, DOI 10.1074/mcp.M115.049544
   Posfay-Barbe KM, 2011, CLIN MICROBIOL INFEC, V17, P1232, DOI 10.1111/j.1469-0691.2010.03389.x
   Prevaes SMPJ, 2012, INFECT IMMUN, V80, P2186, DOI 10.1128/IAI.00037-12
   Rapola S, 2000, J INFECT DIS, V182, P1146, DOI 10.1086/315822
   Satzke C, 2013, VACCINE, V32, P165, DOI 10.1016/j.vaccine.2013.08.062
   Scott JAG, 2005, CLIN DIAGN LAB IMMUN, V12, P1195, DOI 10.1128/CDLI.12.10.1195-1201.2005
   Shah SS, 2011, PEDIATR INFECT DIS J, V30, P475, DOI 10.1097/INF.0b013e31820a5adb
   Simell B, 2009, VACCINE, V27, P4615, DOI 10.1016/j.vaccine.2009.05.071
   Tai SS, 2006, CRIT REV MICROBIOL, V32, P139, DOI 10.1080/10408410600822942
   Turner P, 2013, CLIN MICROBIOL INFEC, V19, pE551, DOI [10.1111/1469-0691.12286, 10.1111/1469-0691.12431]
   van der Poll T, 2009, LANCET, V374, P1543, DOI 10.1016/S0140-6736(09)61114-4
   Zhang QB, 2006, EUR J IMMUNOL, V36, P46, DOI 10.1002/eji.200535101
NR 31
TC 8
Z9 8
U1 0
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-1759
EI 1872-7905
J9 J IMMUNOL METHODS
JI J. Immunol. Methods
PD JUN
PY 2016
VL 433
BP 31
EP 37
DI 10.1016/j.jim.2016.02.021
PG 7
WC Biochemical Research Methods; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA DM9QK
UT WOS:000376700600005
PM 26928648
OA Green Published
DA 2020-12-17
ER

PT J
AU Oliveira, JR
   Bouzas, ML
   Cardoso, MRA
   Barral, A
   Nascimento-Carvalho, C
AF Oliveira, Juliana R.
   Bouzas, Maiara L.
   Cardoso, Maria-Regina A.
   Barral, Aldina
   Nascimento-Carvalho, Cristiana
CA Acute Resp Infect Wheeze Study Grp
TI Frequency of complications and the effects of pneumococcal vaccination
   in young children with acute respiratory tract infection
SO VACCINE
LA English
DT Article
DE Pneumococcal conjugate vaccine; Children; Common cold; Viruses
ID BURDEN; INFLUENZA; PNEUMONIA; COMMUNITY
AB Background: Acute respiratory infection (ARI) is the most frequent reason for children being seen by doctors worldwide. We aimed to estimate the frequency of complications in children aged 6-23 months during ARI episode and to evaluate risk factors present on recruitment associated with complications after the universal implementation of pneumococcal vaccine (PCV10) in our region.
   Methods: This prospective cohort enrolled children who had shown ARI for up to 7 days and who were subsequently followed up 14-21 days after, in Salvador, Brazil. Data on recruitment were registered. The vaccine card was personally checked. Complication was defined when hospitalization, pneumonia or acute otitis media (AOM) were informed during the follow-up visit. Pneumonia and AOM were diagnosed by a doctor. Multiple logistic regression analysis was performed.
   Results: Of 576 children, 422 (73%) returned and 79 (19%; 95%CI: 15-23%) had complications. The mean interval between admission and follow-up was 23 +/- 13 days. Pneumonia (n = 47; 11%), hospitalization (n = 28; 7%), and AOM (n = 17; 4%) were reported. Most of the patients presented one complication (n = 66; 84%) followed by two (n = 13; 16%). Report of fever (92% versus 79%; OR [95%CI]: 2.90 [1.18-7.14]), bird at home (24% versus 14%; OR [95%CI]: 2.13 [1.07-4.26]), ronchi (48% versus 36%; OR [95%CI]: 2.06 [1.16-3.67]) or crackles (17% versus 7%; OR [95%CI]: 2.36 [1.04-5.38]) on auscultation were directly associated with complications whereas PCV10 (59% versus 75%; OR [95%CI]: 0.46 [0.26-0.82]) was inversely associated. Bird at home (OR [95%CI]: 5.80 [1.73-19.38]) and ronchi (OR [95%CI]: 6.39 [1.96-20.85]) were associated with AOM; PCV10 was inversely associated with AOM (OR [95%CI]: 0.16 [0.05-0.52]). Crackles were associated with pneumonia (OR [95%CI]: 2.55 [1.01-6.40]).
   Conclusions: One fifth of the children presented complications. PCV10 was independently associated with lower odds of development of AOM. Bird at home and ronchi are risk factors of otitis. Crackles are associated with pneumonia. (C) 2016 Published by Elsevier Ltd.
C1 [Oliveira, Juliana R.; Bouzas, Maiara L.; Barral, Aldina; Nascimento-Carvalho, Cristiana] Univ Fed Bahia, Sch Med, Postgrad Program Hlth Sci, Salvador, BA, Brazil.
   [Cardoso, Maria-Regina A.] Univ Sao Paulo, Sch Publ Hlth, Dept Epidemiol, Sao Paulo, Brazil.
   [Barral, Aldina] Fundacao Oswaldo Cruz, Goncalo Moniz Res Ctr, Salvador, BA, Brazil.
   [Nascimento-Carvalho, Cristiana; Acute Resp Infect Wheeze Study Grp] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
   [Barral, Aldina] Univ Fed Bahia, Sch Med, Dept Pathol, Salvador, BA, Brazil.
RP Oliveira, JR (corresponding author), Largo Terreiro de Jesus S-N, BR-40025010 Salvador, BA, Brazil.
EM juliamar1@ig.com.br
FU Bahia State Agency for Research Funding (FAPESB), in Salvador, Brazil
FX This study was supported by funding from the Bahia State Agency for
   Research Funding (FAPESB), in Salvador, Brazil.
CR Afonso ET, 2013, EMERG INFECT DIS, V19, P589, DOI 10.3201/eid1904.121198
   Antonova EN, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-968
   Budge PJ, 2014, PEDIATR INFECT DIS J, V33, P443, DOI 10.1097/INF.0000000000000135
   Chonmaitree T, 2008, CLIN INFECT DIS, V46, P815, DOI 10.1086/528685
   Department of Health of the State of Bahia [Secretaria de Saude do Estado da Bahia], 2010, INTR 10 VAL PNEUM CO
   El-Rashdi AS, 2006, ARCH DIS CHILD, V91, P351, DOI 10.1136/adc.2005.088831
   Fortanier AC, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001480.pub4
   Hazir T, 2006, BMJ-BRIT MED J, V333, P629, DOI 10.1136/bmj.38915.673322.80
   Heikkinen T, 2004, J INFECT DIS, V190, P1369, DOI 10.1086/424527
   Homaira N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032056
   Janahi IA, 2006, AEROBIOLOGIA, V22, P305, DOI 10.1007/s10453-006-9044-9
   Klugman KP, 2007, SCIENCE, V316, P49
   Klugman KP, 2009, VACCINE, V27, pC9, DOI 10.1016/j.vaccine.2009.06.007
   Komakhidze T, 2015, VACCINE, V33, pA219, DOI 10.1016/j.vaccine.2014.12.070
   Mir E, 2012, ASIA PAC ALLERGY, V2, P93, DOI 10.5415/apallergy.2012.2.2.93
   Nair H, 2013, LANCET, V381, P1380, DOI 10.1016/S0140-6736(12)61901-1
   Nascimento-Carvalho CM, 2004, REV PANAM SALUD PUBL, V15, P380, DOI 10.1590/S1020-49892004000600003
   Marcone DN, 2013, PEDIATR INFECT DIS J, V32, pE105, DOI 10.1097/INF.0b013e31827cd06f
   Neuzil KM, 2002, J INFECT DIS, V185, P147, DOI 10.1086/338363
   Palmu AA, 2015, PEDIATR INFECT DIS J, V34, P1230, DOI 10.1097/INF.0000000000000857
   Ploin D, 2007, PEDIATR INFECT DIS J, V26, P142, DOI 10.1097/01.inf.0000253062.41648.60
   Ujunwa FA, 2014, ANN MED HEALTH SCI R, V4, P95, DOI 10.4103/2141-9248.126610
   WHO UNICEF, 2008, INT MAN CHILDH ILLN
   Winther B, 2002, PEDIATRICS, V109, P826, DOI 10.1542/peds.109.5.826
   World Factbook, HOSP BED DENS BEDS 1
   World Health Organization, 2008, TRAIN COURS CHILD GR
NR 26
TC 5
Z9 5
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 17
PY 2016
VL 34
IS 23
BP 2556
EP 2561
DI 10.1016/j.vaccine.2016.04.015
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA DM9SC
UT WOS:000376705000005
PM 27102819
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, CM
   Ruuskanen, O
AF Nascimento-Carvalho, Cristiana M.
   Ruuskanen, Olli
TI Clinical Significance of Multiple Respiratory Virus Detection
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Editorial Material
DE viral infection; respiratory infection; respiratory virus coinfection;
   respiratory virus
ID INTERFERENCE; ETIOLOGY; CHILDREN
C1 [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Pediat, Rua Prof Aristides Novis,105-1201B, BR-40210630 Salvador, BA, Brazil.
   [Ruuskanen, Olli] Turku Univ Hosp, Dept Pediat, FIN-20520 Turku, Finland.
RP Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia, Sch Med, Dept Pediat, Rua Prof Aristides Novis,105-1201B, BR-40210630 Salvador, BA, Brazil.
EM nascimentocarv-alho@hotmail.com
CR Asner SA, 2015, CLIN MICROBIOL INFEC, V21, DOI 10.1016/j.cmi.2014.08.024
   Asner SA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099392
   Bin Seo Y, 2014, INFECT CHEMOTHER, V46, P67, DOI 10.3947/ic.2014.46.2.67
   Choi SH, 2015, J CLIN MICROBIOL, V53, P1172, DOI 10.1128/JCM.03298-14
   Deng Jikui, 2013, Virologica Sinica, V28, P97, DOI 10.1007/s12250-013-3312-y
   Drews AL, 1997, CLIN INFECT DIS, V25, P1421, DOI 10.1086/516137
   Esposito S, 2013, INFLUENZA OTHER RESP, V7, P18, DOI 10.1111/j.1750-2659.2012.00340.x
   Goka EA, 2014, PAEDIATR RESPIR REV, V15, P363, DOI 10.1016/j.prrv.2013.11.001
   Heinonen S, 2016, AM J RESP CRIT CARE, V193, P772, DOI 10.1164/rccm.201504-0749OC
   ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048
   Jain S, 2015, NEW ENGL J MED, V372, P835, DOI 10.1056/NEJMoa1405870
   Jartti T, 2012, REV MED VIROL, V22, P46, DOI 10.1002/rmv.720
   Laurie KL, 2015, J INFECT DIS, V212, P1701, DOI 10.1093/infdis/jiv260
   Lisco A, 2007, J VIROL, V81, P708, DOI 10.1128/JVI.01367-06
   Lukkarinen H, 2014, J ALLERGY CLIN IMMUN, V133, P256, DOI 10.1016/j.jaci.2013.10.014
   Mansbach JM, 2012, ARCH PEDIAT ADOL MED, V166, P700, DOI 10.1001/archpediatrics.2011.1669
   Schultz-Cherry S, 2015, J INFECT DIS, V212, P1690, DOI 10.1093/infdis/jiv261
   Turunen R, 2014, PEDIAT ALLERG IMM-UK, V25, P796, DOI 10.1111/pai.12318
NR 18
TC 2
Z9 2
U1 2
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD MAR
PY 2016
VL 35
IS 3
BP 338
EP 339
DI 10.1097/INF.0000000000001032
PG 2
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA DF6WY
UT WOS:000371499900020
PM 26658624
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, CM
   Andrade, DC
   Vilas-Boas, AL
AF Nascimento-Carvalho, Cristiana M.
   Andrade, Dafne C.
   Vilas-Boas, Ana-Luisa
TI An update on antimicrobial options for childhood community-acquired
   pneumonia: a critical appraisal of available evidence
SO EXPERT OPINION ON PHARMACOTHERAPY
LA English
DT Review
DE acute respiratory infection; antibacterials; lower respiratory tract
   infection; lung disease
ID AGED 2-59 MONTHS; RANDOMIZED CONTROLLED-TRIAL; ORAL AMOXICILLIN;
   CASE-MANAGEMENT; DOUBLE-BLIND; STREPTOCOCCUS-PNEUMONIAE;
   ANTIBIOTIC-TREATMENT; BACTERIAL PNEUMONIA; PROCAINE PENICILLIN;
   CLINICAL-TRIAL
AB Introduction: Community-acquired pneumonia (CAP) is a leading cause of death and a major cause of morbidity in children under the age of 5. Appropriate antimicrobial use is one crucial tool in controlling childhood CAP mortality and suffering.Areas covered: Structured search of current literature. PubMed was consulted for published trials conducted in children with CAP. We aimed to provide a comprehensive evaluation of antimicrobials used to treat childhood CAP, including a critical appraisal of the methodological aspects of these clinical trials.Expert opinion: Amoxicillin is the preferred option to treat non-severe non-complicated CAP among children aged 2 months. Amoxicillin may be used to treat children in this age group with severe CAP if they do not require hospital assistance. If the patient warrants hospitalization, intravenous penicillin is the chosen option. Heterogeneity was high in the included trials, in regard to clinical inclusion criteria, use of radiological inclusion criteria, placebo use and masking. Higher quality evidence was found in the studies which included amoxicillin. There is a clear dearth of randomized, placebo-controlled, well-performed clinical trials evaluating children with CAP aged under 2 months, or aged 2 months and above with very severe or complicated CAP, or in specific age groups like teenagers.
C1 [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Paediat, BR-40210630 Salvador, BA, Brazil.
   [Andrade, Dafne C.; Vilas-Boas, Ana-Luisa] Univ Fed Bahia, Sch Med, Postgrad Program Hlth Sci, BR-40025010 Salvador, BA, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia, Sch Med, Dept Paediat, BR-40210630 Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
CR Abgueguen P, 2007, ANTIMICROB AGENTS CH, V51, P208, DOI 10.1128/AAC.00004-06
   Addo-Yobo E, 2004, LANCET, V364, P1141, DOI 10.1016/S0140-6736(04)17100-6
   ALBAN J, 1975, CURR THER RES CLIN E, V18, P539
   Altman DG, 1996, BRIT MED J, V313, P570
   Amir J, 1996, CLIN PEDIATR, V35, P629, DOI 10.1177/000992289603501204
   Asghar R, 2008, BMJ-BRIT MED J, V336, P80, DOI 10.1136/bmj.39421.435949.BE
   Atkinson M, 2007, THORAX, V62, P1102, DOI 10.1136/thx.2006.074906
   Aurangzeb Brekhna, 2003, J Coll Physicians Surg Pak, V13, P704
   Awasthi S, 2004, BMJ-BRIT MED J, V328, P791
   Awasthi S, 2008, J TROP PEDIATRICS, V54, P382, DOI 10.1093/tropej/fmn050
   Awasthi S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001991
   Bansal Arun, 2006, Indian Journal of Pediatrics, V73, P305, DOI 10.1007/BF02825824
   Bari A, 2011, LANCET, V378, P1796, DOI 10.1016/S0140-6736(11)61140-9
   Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637
   Berti E, 2013, ACTA PAEDIATR, V102, P4, DOI 10.1111/apa.12501
   BLOCK S, 1995, PEDIATR INFECT DIS J, V14, P471, DOI 10.1097/00006454-199506000-00002
   Blum CA, 2015, LANCET, V385, P1511, DOI 10.1016/S0140-6736(14)62447-8
   Boccazzi A, 1998, DIAGN MICR INFEC DIS, V32, P265, DOI 10.1016/S0732-8893(98)00110-2
   Bradley JS, 2007, PEDIATR INFECT DIS J, V26, P868, DOI 10.1097/INF.0b013e3180cbd2c7
   Bradley JS, 2011, CLIN INFECT DIS, V53, pE25, DOI 10.1093/cid/cir531
   Brandao A, 2014, ANTIMICROB AGENTS CH, V58, P1343, DOI 10.1128/AAC.01951-13
   CALDERON E, 1991, CLIN THER, V13, P699
   Camargos PAM, 1997, J TROP PEDIATRICS, V43, P353, DOI 10.1093/tropej/43.6.353
   CAMPBELL H, 1988, LANCET, V2, P1182
   Cardoso MRA, 2008, ARCH DIS CHILD, V93, P221, DOI 10.1136/adc.2006.111625
   Cetinkaya Feyzullah, 2004, Indian Journal of Pediatrics, V71, P969, DOI 10.1007/BF02828108
   Clinical and Laboratory Standards Institute, 2008, PERF STAND ANT SUSC
   Cook RC, 1996, BRIT J CLIN PRACT, V50, P125
   DAGAN R, 1994, DRUGS, V47, P43, DOI 10.2165/00003495-199400473-00008
   DASCHNER FD, 1981, J INT MED RES, V9, P274, DOI 10.1177/030006058100900407
   Deivanayagam N, 1996, Indian Pediatr, V33, P813
   Dowell SF, 2000, NEW ENGL J MED, V342, P1399, DOI 10.1056/NEJM200005113421904
   Duke T, 2002, LANCET, V359, P474, DOI 10.1016/S0140-6736(02)07677-8
   Ferwerda A, 2001, J ANTIMICROB CHEMOTH, V47, P441, DOI 10.1093/jac/47.4.441
   Franco GCN, 2014, INT J CLIN PHARM TH, V52, P425, DOI 10.5414/CP202039
   Gessner BD, 2005, EPIDEMIOL INFECT, V133, P877, DOI 10.1017/S0950268805004449
   Gilani Z, 2012, CLIN INFECT DIS, V54, pS102, DOI 10.1093/cid/cir1053
   Greenberg D, 2014, PEDIATR INFECT DIS J, V33, P136, DOI 10.1097/INF.0000000000000023
   Gupta D, 1996, Indian Pediatr, V33, P41
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   Harris JAS, 1998, PEDIATR INFECT DIS J, V17, P865, DOI 10.1097/00006454-199810000-00004
   Hasali MAA, 2005, PHARM WORLD SCI, V27, P249, DOI 10.1007/s11096-004-7039-6
   Hazir T, 2002, LANCET, V360, P835
   Hazir T, 2008, LANCET, V371, P49, DOI 10.1016/S0140-6736(08)60071-9
   Hazir T, 2007, ARCH DIS CHILD, V92, P291, DOI 10.1136/adc.2005.092494
   Hazir T, 2011, CLIN INFECT DIS, V52, P293, DOI 10.1093/cid/ciq142
   Ishiwada N, 2014, VACCINE, V32, P5425, DOI 10.1016/j.vaccine.2014.07.100
   JIBRIL HB, 1989, CURR MED RES OPIN, V11, P585, DOI 10.1185/03007998909112675
   KEELEY DJ, 1990, B WORLD HEALTH ORGAN, V68, P185
   Klein M, 1995, PEDIATR INFECT DIS J, V14, P19
   Kogan R, 2003, PEDIATR PULM, V35, P91, DOI 10.1002/ppul.10180
   KRAMER RI, 1982, J ANTIMICROB CHEMOTH, V10, P105, DOI 10.1093/jac/10.suppl_B.105
   Lassi ZS, 2014, ARCH DIS CHILD, V99, P687, DOI 10.1136/archdischild-2013-304023
   Lee KY, 2015, INFECT CHEMOTHER, V47, P12, DOI 10.3947/ic.2015.47.1.12
   Lee PI, 2008, J MICROBIOL IMMUNOL, V41, P54
   Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700
   Lines D R, 1967, Med J Aust, V1, P551
   Liu L, 2015, LANCET, V385, P430, DOI 10.1016/S0140-6736(14)61698-6
   Liu L, 2012, LANCET, V379, P2151, DOI 10.1016/S0140-6736(12)60560-1
   Lodha R, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004874.pub4
   Lovera D, 2005, J CHEMOTHERAPY, V17, P283, DOI 10.1179/joc.2005.17.3.283
   MAHON WA, 1967, CAN MED ASSOC J, V96, P265
   McIntosh K, 2002, NEW ENGL J MED, V346, P429, DOI 10.1056/NEJMra011994
   MULHOLLAND EK, 1995, PEDIATR INFECT DIS J, V14, P959, DOI 10.1097/00006454-199511000-00007
   Nascimento-Carvalho AC, 2014, 32 ANN M EUR SOC PAE
   Nascimento-Carvalho C M, 2001, Braz J Infect Dis, V5, P87
   Nascimento-Carvalho CM, 2004, REV PANAM SALUD PUBL, V15, P380, DOI 10.1590/S1020-49892004000600003
   Nascimento-Carvalho CM, 2015, PEDIATR INFECT DIS J, V34, P490, DOI 10.1097/INF.0000000000000622
   Nascimento-Carvalho CM, 2013, PEDIATR INFECT DIS J, V32, P1281, DOI 10.1097/INF.0b013e3182a4dcfa
   Nascimento-Carvalho Cristiana M.C., 2002, Braz J Infect Dis, V6, P22, DOI 10.1590/S1413-86702002000100004
   Pio A, 2003, B WORLD HEALTH ORGAN, V81, P298
   Qazi SA, 2002, ARCH DIS CHILD, V86, P113
   Queen MA, 2014, PEDIATRICS, V133, pE23, DOI 10.1542/peds.2013-1773
   Rasmussen ZA, 2005, B WORLD HEALTH ORGAN, V83, P10
   Ribeiro CF, 2011, REV PANAM SALUD PUBL, V29, P444
   Roord JJ, 1996, ANTIMICROB AGENTS CH, V40, P2765, DOI 10.1128/AAC.40.12.2765
   Rudan I, 2004, B WORLD HEALTH ORGAN, V82, P895
   Rudan I, 2008, B WORLD HEALTH ORGAN, V86, P408, DOI 10.2471/BLT.07.048769
   Rudan I, 2013, J GLOB HEALTH, V3, DOI 10.7189/jogh.03.010401
   RUHRMANN H, 1982, INFECTION, V10, pS86
   SHANN F, 1985, LANCET, V2, P684
   SIDAL M, 1994, J TROP PEDIATRICS, V40, P301, DOI 10.1093/tropej/40.5.301
   Soofi S, 2012, LANCET, V379, P729, DOI 10.1016/S0140-6736(11)61714-5
   Straus WL, 1998, LANCET, V352, P270, DOI 10.1016/S0140-6736(97)10294-X
   Theodoratou E, 2010, INT J EPIDEMIOL, V39, P155, DOI 10.1093/ije/dyq032
   Torres A, 2015, JAMA-J AM MED ASSOC, V313, P677, DOI 10.1001/jama.2015.88
   Tsarouhas N, 1998, PEDIATR EMERG CARE, V14, P338
   Vilas-Boas AL, 2014, J ANTIMICROB CHEMOTH, V69, P1954, DOI 10.1093/jac/dku070
   Walker CLF, 2013, LANCET, V381, P1405, DOI 10.1016/S0140-6736(13)60222-6
   Williams DJ, 2013, PEDIATRICS, V132, pE1141, DOI 10.1542/peds.2013-1614
   World Health Organisation, 2011, INT MAN CHILDH ILLN
   World Health Organization, 2013, POCK BOOK HOSP CAR C
   Wubbel L, 1999, PEDIATR INFECT DIS J, V18, P98, DOI 10.1097/00006454-199902000-00004
   Zar Heather J, 2005, Paediatr Drugs, V7, P103, DOI 10.2165/00148581-200507020-00003
NR 94
TC 3
Z9 3
U1 0
U2 4
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1465-6566
EI 1744-7666
J9 EXPERT OPIN PHARMACO
JI Expert Opin. Pharmacother.
PD JAN 2
PY 2016
VL 17
IS 1
BP 53
EP 78
DI 10.1517/14656566.2016.1109633
PG 26
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DC5RH
UT WOS:000369277600003
PM 26549167
DA 2020-12-17
ER

PT J
AU Leite, CR
   Azevedo, J
   Galvao, VS
   Moreno-Carvalho, O
   Reis, JN
   Nascimento-Carvalho, C
AF Leite, Carolina Regis
   Azevedo, Jailton
   Galvao, Vivian Santos
   Moreno-Carvalho, Otvio
   Reis, Joice Neves
   Nascimento-Carvalho, Cristiana
TI Clinical and bacteriological characteristics of invasive pneumococcal
   disease after pneumococcal 10-valent conjugate vaccine implementation in
   Salvador, Brazil
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Streptococcus pneumoniae; Vaccine; Epidemiology
ID STREPTOCOCCUS-PNEUMONIAE; CHILDREN; SEROTYPE
AB Invasive pneumococcal disease is a relevant public health problem in Brazil, especially among children and the elderly. In July/2010 a 10-valent pneumococcal conjugate vaccine was introduced to the immunization schedule of Brazilian children under two years of age. Between July/2010 and December/2013 we conducted a case-series study on invasive pneumococcal disease in Salvador, Brazil to describe the clinical and bacteriological profile of invasive pneumococcal disease cases during the post-implementation period. Eighty-two cases were eligible. Mean age was 31 years (interquartile range, 3-42); 17.1% and 30.5% were under 2 years and 5 years, respectively. Pneumococcal meningitis (n = 64, 78.1%), bacteraemic pneumococcal pneumonia (n = 12, 14.6%) and bacteraemia (n = 6, 7.3%) were the clinical syndromes identified. Thirty-three different serotypes were found. Of these, serotype 14 (n = 12, 14.6%) was the most common, followed by 23F (n = 10, 12.2%), 12F (n = 8, 9.8%), 18 C (n = 5, 6.1%) and 6B (n = 5, 6.1%). Investigations conducted in Salvador in the pre-vaccine period did not identify serotype 12F as one of the most prevalent serotypes. Increase of serotype 12F was observed in different regions of Brazil, in the post-vaccine period. Among children under two years of age, the target group for 10-valent pneumococcal conjugate vaccine, 11 (78.6%) of the 14 isolated strains of Streptococcus pneumoniae belonged to vaccine serotypes; at least 50% of these children were not vaccinated. The relatively recent implementation of 10-yalent pneumococcal conjugate vaccine in Brazil reinforces the need to maintain an active surveillance of invasive pneumococcal disease cases, considering the possible increase of invasive pneumococcal disease cases related to non-vaccine serotypes and the changes on the clinical presentation of the disease. (C) 2015 Elsevier Editora Ltda. All rights reserved.
C1 [Leite, Carolina Regis; Nascimento-Carvalho, Cristiana] Univ Fed Bahia, Fac Med Bahia, Salvador, BA, Brazil.
   [Azevedo, Jailton; Galvao, Vivian Santos; Reis, Joice Neves] Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil.
   [Moreno-Carvalho, Otvio] Fdn Jose Silveira, Lab Liquor SINPEL, Salvador, BA, Brazil.
   [Reis, Joice Neves] Univ Fed Bahia, Fac Farm, Salvador, BA, Brazil.
RP Leite, CR (corresponding author), Univ Fed Bahia, Fac Med Bahia, Salvador, BA, Brazil.
EM carolr.leite2@gmail.com
RI Reis, Joice N/H-9227-2013
OI Azevedo, Jailton/0000-0002-0801-8673
CR Afonso ET, 2013, EMERG INFECT DIS, V19, P589, DOI 10.3201/eid1904.121198
   [Anonymous], 2007, J. bras. pneumol., V33, ps31, DOI 10.1590/S1806-37132007000700002
   Bogaert D, 2004, LANCET INFECT DIS, V4, P144, DOI 10.1016/S1473-3099(04)00938-7
   Brasil Ministerio da Saude Secretaria de Vigilancia em Saude Departamento de Vigilancia Epidemiologica, 2010, COORD GER PROGR NAC
   Brasil Ministerio da Saude Secretaria de Vigilancia em Saude Departamento de Vigilancia Epidemiologica, 2009, GUIA VIG EP
   Brasil Ministerio da Saude Secretaria de Vigilancia em Saude Departamento de Vigilancia Epidemiologica, 2006, MAN CENTR REF IM ESP
   Carvalho MD, 2010, J CLIN MICROBIOL, V48, P1611, DOI 10.1128/JCM.02243-09
   Carvalho MD, 2009, J CLIN MICROBIOL, V47, P554, DOI 10.1128/JCM.01919-08
   Castaneda E, 2009, PEDIATR INFECT DIS J, V28, pe265
   Centers for Disease Control Prevention (CDC), 2014, PCR DED PNEUM SER
   dos Santos SR, 2013, VACCINE, V31, P6150, DOI 10.1016/j.vaccine.2013.05.042
   Novaes HMD, 2011, REV SAUDE PUBL, V45, P539, DOI 10.1590/S0034-89102011005000028
   FINLAND M, 1977, J CLIN MICROBIOL, V5, P154
   Foster D, 2008, J MED MICROBIOL, V57, P480, DOI 10.1099/jmm.0.47690-0
   Gladstone RA, 2011, J MED MICROBIOL, V60, P1, DOI 10.1099/jmm.0.020016-0
   Hausdorff WP, 2005, LANCET INFECT DIS, V5, P83, DOI 10.1016/S1473-3099(05)01280-6
   Hausdorff WP, 2000, CLIN INFECT DIS, V30, P100, DOI 10.1086/313608
   Kaplan SL, 2010, PEDIATRICS, V125, P429, DOI 10.1542/peds.2008-1702
   Lovgren M, 2007, J CLIN MICROBIOL, V45, P3184, DOI 10.1128/JCM.00789-07
   Menezes APD, 2011, VACCINE, V29, P1139, DOI 10.1016/j.vaccine.2010.12.021
   Mott M, 2014, INT J INFECT DIS, V20, P47, DOI 10.1016/j.ijid.2013.11.009
   Nascimento-Carvalho CM, 2006, J PEDIAT RIO J, V79, P209
   O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6
   Azevedo LCP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064524
   Vesikari T, 2009, PEDIATR INFECT DIS J, V28, pS66, DOI 10.1097/INF.0b013e318199f8ef
   Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823
   WHO Publication, 2012, VACCINE, V30, P4717, DOI 10.1016/j.vaccine.2012.04.093
NR 27
TC 6
Z9 7
U1 0
U2 4
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD JAN-FEB
PY 2016
VL 20
IS 1
BP 56
EP 60
DI 10.1016/j.bjid.2015.10.005
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA DB5SO
UT WOS:000368574100009
PM 26706019
OA DOAJ Gold, Green Published
DA 2020-12-17
ER

PT J
AU Simbalista, R
   Andrade, DC
   Borges, IC
   Arajo, M
   Nascimento-Carvalho, CM
AF Simbalista, Raquel
   Andrade, Dafne C.
   Borges, Igor C.
   Arajo, Marcelo
   Nascimento-Carvalho, Cristiana M.
TI Differences upon admission and in hospital course of children
   hospitalized with community-acquired pneumonia with or without
   radiologically-confirmed pneumonia: a retrospective cohort study
SO BMC PEDIATRICS
LA English
DT Article
ID RADIOGRAPHICALLY DIAGNOSED PNEUMONIA; CHEST RADIOGRAPHS; INFECTION
AB Background: The use of chest radiograph (CXR) for the diagnosis of childhood community-acquired pneumonia (CAP) is controversial. We assessed if children with CAP diagnosed on clinical grounds, with or without radiologically-confirmed pneumonia on admission, evolved differently.
   Methods: Children aged >= 2 months, hospitalized with CAP diagnosed on clinical grounds, treated with 200,000 IU/Kg/day of aqueous penicillin G for >= 48 h and with CXR taken upon admission, without pleural effusion, were included in this retrospective cohort. One researcher, blinded to the radiological diagnosis, collected data on demographics, clinical history and physical examination on admission, daily hospital course during the first 2 days of treatment, and outcome, all from medical charts. Radiological confirmation of pneumonia was based on presence of pulmonary infiltrate detected by a paediatric radiologist who was also blinded to clinical data. Variables were initially compared by bivariate analysis. Multi-variable logistic regression analysis assessed independent association between radiologically-confirmed pneumonia and factors which significantly differed during hospital course in the bivariate analysis. The multi-variable analysis was performed in a model adjusted for age and for the same factor present upon admission.
   Results: 109 (38.5 %) children had radiologically-confirmed pneumonia, 143 (50.5 %) had normal CXR and 31 (11.0 %) had atelectasis or peribronchial thickening. Children without radiologically-confirmed pneumonia were younger than those with radiologically-confirmed pneumonia (median [IQR]: 14 [7-28 months versus 21 [12-44] months; P = 0.001). None died. The subgroup with radiologically-confirmed pneumonia presented fever on D1 (33.7 vs. 19.1; P = 0.015) and on D2 (31.6 % vs. 16.2 %; P = 0.004) more frequently. The subgroup without radiologically-confirmed pneumonia had chest indrawing on D1 (22.4 % vs. 11.9 %; P = 0.027) more often detected. By multi-variable analysis, Fever on D2 (OR [95 % CI]: 2.16 [1.15-4.06]) was directly and independently associated with radiologically-confirmed pneumonia upon admission.
   Conclusion: The compared subgroups evolved differently.
C1 [Simbalista, Raquel; Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Postgrad Program Pathol, Salvador, BA, Brazil.
   [Andrade, Dafne C.; Borges, Igor C.; Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Postgrad Program Hlth Sci, Salvador, BA, Brazil.
   [Arajo, Marcelo] Image Mem Unit, Image Diag, Salvador, BA, Brazil.
   [Arajo, Marcelo] Bahia Hosp, Salvador, BA, Brazil.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Paediat, Salvador, BA, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia, Sch Med, Postgrad Program Pathol, Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
RI Borges, Igor Carmo/AAG-8531-2019
OI Carmo Borges, Igor/0000-0003-2749-0313
CR Bradley JS, 2011, CLIN INFECT DIS, V53, pE25, DOI 10.1093/cid/cir531
   Cardoso MRA, 2011, ARCH DIS CHILD, V96, P58, DOI 10.1136/adc.2010.189894
   Castro AV, 2005, INDIAN PEDIATR, V42, P773
   Cherian T, 2005, B WORLD HEALTH ORGAN, V83, P353
   El-Rashdi AS, 2006, ARCH DIS CHILD, V91, P351, DOI 10.1136/adc.2005.088831
   Fontoura MS, 2012, INDIAN PEDIATR, V49, P363, DOI 10.1007/s13312-012-0085-6
   Gentile A, 2012, INT J INFECT DIS, V16, pE5, DOI 10.1016/j.ijid.2011.09.013
   Harris M, 2011, THORAX, V66, pII1, DOI 10.1136/thoraxjnl-2011-200598
   Hazir T, 2006, BMJ-BRIT MED J, V333, P629, DOI 10.1136/bmj.38915.673322.80
   Johnson J, 2010, EMERG RADIOL, V17, P285, DOI 10.1007/s10140-009-0854-2
   Key NK, 2011, INDIAN PEDIATR, V48, P873, DOI 10.1007/s13312-011-0142-6
   Korppi M, 2008, ACTA PAEDIATR, V97, P943, DOI 10.1111/j.1651-2227.2008.00789.x
   Lynch T, 2004, PEDIATRICS, V113, pE186, DOI 10.1542/peds.113.3.e186
   Mathews B, 2009, PEDIATRICS, V124, pE29, DOI 10.1542/peds.2008-2062
   Nascimento-Carvalho C M, 2001, Indian Pediatr, V38, P307
   Nascimento-Carvalho CM, 2004, REV PANAM SALUD PUBL, V15, P380, DOI 10.1590/S1020-49892004000600003
   Nascimento-Carvalho CM, 2015, PEDIATR INFECT DIS J, V34, P490, DOI 10.1097/INF.0000000000000622
   Simbalista R, 2011, CLINICS, V66, P95, DOI 10.1590/S1807-59322011000100017
   Swingler GH, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001268.pub3
   Swingler GH, 1998, LANCET, V351, P404, DOI 10.1016/S0140-6736(97)07013-X
   Walker CLF, 2013, LANCET, V381, P1405, DOI 10.1016/S0140-6736(13)60222-6
   WHO UNICEF, 2008, INT MAN CHILDH ILLN
   World Health Organization, 1990, PROGR CONTR AC RESP
   World Health Organization, 2008, TRAIN COURS CHILD GR
   World Health Organization TUNCsF, 2009, GLOB ACT PLAN PREV C
   Zorc JJ, 2010, PEDIATRICS, V125, P342, DOI 10.1542/peds.2009-2092
NR 26
TC 5
Z9 6
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2431
J9 BMC PEDIATR
JI BMC Pediatr.
PD OCT 23
PY 2015
VL 15
AR 166
DI 10.1186/s12887-015-0485-6
PG 9
WC Pediatrics
SC Pediatrics
GA CU3QX
UT WOS:000363441000001
PM 26496953
OA DOAJ Gold, Green Published
DA 2020-12-17
ER

PT J
AU Borges, IC
   Andrade, DC
   Vilas-Boas, AL
   Fontoura, MSH
   Laitinen, H
   Ekstrom, N
   Adrian, PV
   Meinke, A
   Cardoso, MRA
   Barral, A
   Ruuskanen, O
   Kayhty, H
   Nascimento-Carvalho, CM
AF Borges, I. C.
   Andrade, D. C.
   Vilas-Boas, A. -L.
   Fontoura, M. -S. H.
   Laitinen, H.
   Ekstrom, N.
   Adrian, P. V.
   Meinke, A.
   Cardoso, M. -R. A.
   Barral, A.
   Ruuskanen, O.
   Kayhty, H.
   Nascimento-Carvalho, C. M.
TI Detection of antibody responses against Streptococcus pneumoniae,
   Haemophilus influenzae, and Moraxella catarrhalis proteins in children
   with community-acquired pneumonia: effects of combining pneumococcal
   antigens, pre-existing antibody levels, sampling interval, age, and
   duration of illness
SO EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
LA English
DT Article
ID CHILDHOOD PNEUMONIA
AB We evaluated the effects of combining different numbers of pncumococcal antigens, pre-existing antibody levels, sampling interval, age, and duration of illness on the detection of IgG responses against eight Streptococcus pneumoniae proteins, three Haeniophihts influenzae proteins, and five Moraxella catarrhalis proteins in 690 children aged <5 years with pneumonia. Serological tests were performed on acute and convalescent serum samples with a multiplexed bead-based immunoassay. The median sampling interval was 19 days, the median age was 26.7 months, and the median duration of illness was 5 days. The rate of antibody responses was 15.4 A for at least one pneumococcal antigen, 5.8 % for IL influenzae, and 2.3 ')/0 for M. catarrhalis. The rate of antibody responses against each pneumococcal antigen varied from 3.5 to 7.1 %" By multivariate analysis, pre-existing antibody levels showed a negative association with the detection of antibody responses against pneumococcal and IL influenzae antigens; the sampling interval was positively associated with the detection of antibody responses against pncumococcal and H. influenzae antigens. A sampling interval of 3 weeks was the optimal cut-off for the detection of antibody responses against pneumococcal and H. influenzae proteins. Duration of illness was negatively associated with antibody responses against PspA. Age did not influence antibody responses against the investigated antigens. In conclusion, serological assays using combinations of different pneumococcal proteins detect a higher rate of antibody responses against pneumoniae compared to assays using a single pneumococcal protein. Pre-existing antibody levels and sampling interval influence the detection of antibody responses against pneumococcal and 11. influenzae proteins. These factors should be considered when determining pneumonia etiology by serological methods in children.
C1 [Borges, I. C.; Andrade, D. C.; Vilas-Boas, A. -L.; Barral, A.; Nascimento-Carvalho, C. M.] Univ Fed Bahia, Sch Med, Postgrad Programme Hlth Sci, BR-40025010 Salvador, BA, Brazil.
   [Fontoura, M. -S. H.; Nascimento-Carvalho, C. M.] Univ Fed Bahia, Sch Med, Dept Paediat, BR-40025010 Salvador, BA, Brazil.
   [Laitinen, H.; Ekstrom, N.; Kayhty, H.] Natl Inst Hlth & Welf, Helsinki, Finland.
   [Adrian, P. V.] Univ Witwatersrand, MRC Resp & Meningeal Pathogens Res Unit, DST NRF Vaccine Preventable Dis, Johannesburg, South Africa.
   [Meinke, A.] Valneva Austria GmbH, Vienna, Austria.
   [Cardoso, M. -R. A.] Univ Sao Paulo, Sch Publ Hlth, Dept Epidemiol, Sao Paulo, Brazil.
   [Barral, A.] Univ Fed Bahia, Sch Med, Dept Pathol, BR-40025010 Salvador, BA, Brazil.
   [Barral, A.] Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil.
   [Ruuskanen, O.] Turku Univ, Dept Paediat, Turku, Finland.
   [Ruuskanen, O.] Turku Univ Hosp, FIN-20520 Turku, Finland.
RP Borges, IC (corresponding author), Univ Fed Bahia, Sch Med, Postgrad Programme Hlth Sci, Praca 15 Novembro S-N, BR-40025010 Salvador, BA, Brazil.
EM igorcms@gmail.com
RI Borges, Igor Carmo/AAG-8531-2019
FU Bahia State Agency for Research Funding (FAPESB), Brazil; Brazilian
   Council for Scientific and Technological Development (CNPq),
   BrazilNational Council for Scientific and Technological Development
   (CNPq); National Institute for Health and Welfare, Finland
FX This work was supported by Bahia State Agency for Research Funding
   (FAPESB), Brazil; Brazilian Council for Scientific and Technological
   Development (CNPq), Brazil; and, in part, by National Institute for
   Health and Welfare, Finland. Profs. Aldina Banal, Maria Regina A.
   Cardoso, and Cristiana M. Nascimento-Carvalho are investigators at CNPq.
CR Andrade DC, 2014, J IMMUNOL METHODS, V405, P130, DOI 10.1016/j.jim.2014.02.002
   Bhat N, 2012, CLIN INFECT DIS, V54, pS146, DOI 10.1093/cid/cir1073
   Cevey-Macherel M, 2009, EUR J PEDIATR, V168, P1429, DOI 10.1007/s00431-009-0943-y
   Hare ND, 2009, J ALLERGY CLIN IMMUN, V123, P195, DOI 10.1016/j.jaci.2008.09.021
   Heiskanen-Kosma T, 1998, PEDIATR INFECT DIS J, V17, P986, DOI 10.1097/00006454-199811000-00004
   Juven T, 2001, PEDIATR INFECT DIS J, V20, P1028, DOI 10.1097/00006454-200111000-00005
   Korppi M, 2008, EUR J CLIN MICROBIOL, V27, P167, DOI 10.1007/s10096-007-0436-8
   Nascimento-Carvalho C M, 2001, Braz J Infect Dis, V5, P87
   Nascimento-Carvalho CM, 2010, SCAND J INFECT DIS, V42, P644, DOI 10.3109/00365541003796775
   Posfay-Barbe KM, 2011, CLIN MICROBIOL INFEC, V17, P1232, DOI 10.1111/j.1469-0691.2010.03389.x
   Vilas-Boas AL, 2014, J ANTIMICROB CHEMOTH, V69, P1954, DOI 10.1093/jac/dku070
   Walker CLF, 2013, LANCET, V381, P1405, DOI 10.1016/S0140-6736(13)60222-6
   WHO (World Health Organization), 2008, WHO CHILD GROWTH STA
NR 13
TC 6
Z9 6
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0934-9723
EI 1435-4373
J9 EUR J CLIN MICROBIOL
JI Eur. J. Clin. Microbiol. Infect. Dis.
PD AUG
PY 2015
VL 34
IS 8
BP 1551
EP 1557
DI 10.1007/s10096-015-2385-y
PG 7
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA CN6LI
UT WOS:000358545900009
PM 25894988
OA Green Published
DA 2020-12-17
ER

PT J
AU Fukutani, KF
   Nascimento-Carvalho, CM
   Van der Gucht, W
   Wollants, E
   Khouri, R
   Dierckx, T
   Van Ranst, M
   Houspie, L
   Bouzas, ML
   Oliveira, JR
   Barral, A
   Van Weyenbergh, J
   de Oliveira, CI
AF Fukutani, Kiyoshi F.
   Nascimento-Carvalho, Cristiana M.
   Van der Gucht, Winke
   Wollants, Elke
   Khouri, Ricardo
   Dierckx, Tim
   Van Ranst, Marc
   Houspie, Lieselot
   Bouzas, Maiara L.
   Oliveira, Juliana R.
   Barral, Aldina
   Van Weyenbergh, Johan
   de Oliveira, Camila I.
TI Pathogen transcriptional profile in nasopharyngeal aspirates of children
   with acute respiratory tract infection
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Article
DE ARI; nCounter; Diagnostics; RSV
ID MESSENGER-RNA ABUNDANCE; RSV BRONCHIOLITIS; QUANTIFICATION; PULMONARY;
   VIRUSES; RISK
AB Background: Acute respiratory tract infections (ARI) present a significant morbidity and pose a global health burden. Patients are frequently treated with antibiotics although ARI are most commonly caused by virus, strengthening the need for improved diagnostic methods.
   Objectives: Detect viral and bacterial RNA in nasopharyngeal aspirates (NPA) from children aged 6-23 months with ARI using nCounter.
   Study design: A custom-designed nCounter probeset containing viral and bacterial targets was tested in NPA of ARI patients.
   Results: Initially, spiked control viral RNAs were detectable in >= 6.25 ng input RNA, indicating absence of inhibitors in NPA. nCounter applied to a larger NPA sample (n = 61) enabled the multiplex detection of different pathogens: RNA viruses Parainfluenza virus (PIV 1-3) and RSV A-B in 21%, Human metapneumovirus (hMPV) in 5%, Bocavirus (BoV), CoV, Influenza virus (IV) A in 3% and, Rhinovirus (RV) in 2% of samples, respectively. RSV A-B was confirmed by Real Time PCR (86.2-96.9% agreement). DNA virus (AV) was detected at RNAlevel, reflecting viral replication, in 10% of samples. Bacterial transcripts from Staphylococcus aureus, Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis, Mycoplasma pneumoniae and Chlamydophila pneumoniae were detected in 77, 69, 26, 8, 3 and 2% of samples, respectively.
   Conclusion: nCounter is robust and sensitive for the simultaneous detection of viral (both RNA and DNA) and bacterial transcripts in NPA with low RNA input (< 10 ng). This medium-throughput technique will increase our understanding of ARI pathogenesis and may provide an evidence-based approach for the targeted and rational use of antibiotics in pediatric ARI. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Fukutani, Kiyoshi F.; Khouri, Ricardo; Barral, Aldina; de Oliveira, Camila I.] Ctr Pesquisas Goncalo Moniz CPqGM FIOCRUZ, Salvador, BA, Brazil.
   [Fukutani, Kiyoshi F.; Nascimento-Carvalho, Cristiana M.; Khouri, Ricardo; Bouzas, Maiara L.; Oliveira, Juliana R.; Barral, Aldina; de Oliveira, Camila I.] Univ Fed Bahia, Sch Med, Postgrad Program Hlth Sci, Salvador, BA, Brazil.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
   [Van der Gucht, Winke; Wollants, Elke; Dierckx, Tim; Van Ranst, Marc; Houspie, Lieselot; Van Weyenbergh, Johan] Katholieke Univ Leuven, Rega Inst Med Res, Dept Microbiol & Immunol, Leuven, Belgium.
   [Barral, Aldina] Univ Fed Bahia, Sch Med, Dept Pathol, Salvador, BA, Brazil.
   [Barral, Aldina; de Oliveira, Camila I.] Inst Invest Imunol, Sao Paulo, SP, Brazil.
RP de Oliveira, CI (corresponding author), LIP CPqGM FIOCRUZ, Rua Waldemar Falcao 121, BR-40296710 Salvador, BA, Brazil.
EM camila@bahia.fiocruz.br
RI de Oliveira, Camila I/B-4358-2009; Khouri, Ricardo/M-3184-2018; Van
   Ranst, Marc/P-7522-2017; Van Weyenbergh, Johan/Q-3829-2019; Fukutani,
   Kiyoshi/N-7905-2016; Fukutani, Kiyoshi/T-1630-2019; Van Weyenbergh,
   Johan/B-4187-2009
OI de Oliveira, Camila I/0000-0002-7868-5164; Khouri,
   Ricardo/0000-0001-5664-4436; Van Ranst, Marc/0000-0002-1674-4157; Van
   Weyenbergh, Johan/0000-0003-3234-8426; Fukutani,
   Kiyoshi/0000-0003-2223-0918; Van Weyenbergh, Johan/0000-0003-3234-8426;
   Dierckx, Tim/0000-0002-1969-7974; Wollants, Elke/0000-0002-4057-2236
FU Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB)
   [PNX0019/2009]; Science without Borders (Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico; CNPQ); FAPESB; CNPqNational
   Council for Scientific and Technological Development (CNPq)
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado da
   Bahia (FAPESB; grant PNX0019/2009). KFF was supported by fellowships
   from Science without Borders (Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico; CNPQ) and FAPESB. RK was supported by a
   fellowship from CNPq. AB, CN-C and CIO are senior investigators from
   CNPq.
CR Barczak AK, 2012, P NATL ACAD SCI USA, V109, P6217, DOI 10.1073/pnas.1119540109
   Bouzas ML, 2014, PEDIAT ALLERG IMM-UK, V25, P198, DOI 10.1111/pai.12141
   Duttweiler L, 2004, ARCH DIS CHILD, V89, P1155, DOI 10.1136/adc.2004.049551
   Fahey T, 1998, ARCH DIS CHILD, V79, P225, DOI 10.1136/adc.79.3.225
   Fang RD, 2011, J IMMUNOL, V187, P4890, DOI 10.4049/jimmunol.1100381
   Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385
   Hishiki H, 2011, J INFECT CHEMOTHER, V17, P87, DOI 10.1007/s10156-010-0097-x
   Houspie L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060416
   Mahony JB, 2008, CLIN MICROBIOL REV, V21, P716, DOI 10.1128/CMR.00037-07
   Moens B, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-171
   Pavia AT, 2011, CLIN INFECT DIS, V52, pS284, DOI 10.1093/cid/cir043
   Payton JE, 2009, J CLIN INVEST, V119, P1714, DOI 10.1172/JCI38248
   Pettigrew MM, 2011, J CLIN MICROBIOL, V49, P3750, DOI 10.1128/JCM.01186-11
   Prokopec SD, 2013, RNA, V19, P51, DOI 10.1261/rna.034710.112
   Rde C. Silva, 2014, MEM I O CRUZ, V109, P229
   Resch B, 2007, ACTA PAEDIATR, V96, P495, DOI 10.1111/j.1651-2227.2007.00226.x
   Robinson Joan, 2004, Paediatr Child Health, V9, P21
   Segovia J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029695
   Thorburn K, 2006, THORAX, V61, P611, DOI 10.1136/thx.2005.048397
   Waggott D, 2012, BIOINFORMATICS, V28, P1546, DOI 10.1093/bioinformatics/bts188
   Yang S, 2004, LANCET INFECT DIS, V4, P337, DOI 10.1016/S1473-3099(04)01044-8
NR 21
TC 10
Z9 12
U1 0
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1386-6532
EI 1873-5967
J9 J CLIN VIROL
JI J. Clin. Virol.
PD AUG
PY 2015
VL 69
BP 190
EP 196
DI 10.1016/j.jcv.2015.06.005
PG 7
WC Virology
SC Virology
GA CN3IH
UT WOS:000358318400039
PM 26209405
OA Green Published
DA 2020-12-17
ER

PT J
AU Fonseca, TS
   Gendrel, D
   Ruuskanen, O
   Nascimento-Carvalho, CM
AF Fonseca, Taiane S.
   Gendrel, Dominique
   Ruuskanen, Olli
   Nascimento-Carvalho, Cristiana M.
TI Pleural Effusion Increases Serum Procalcitonin Values in Children with
   Community-acquired Pneumonia
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Letter
ID EMPYEMA
C1 [Fonseca, Taiane S.; Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Postgrad Program Hlth Sci, Salvador, BA, Brazil.
   [Gendrel, Dominique] Univ Paris 05, St Vincent de Paul & Necker Enfants Malades Hosp, AP HP, Dept Pediat, Paris, France.
   [Ruuskanen, Olli] Univ Turku, Dept Pediat, Turku, Finland.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
RP Fonseca, TS (corresponding author), Univ Fed Bahia, Sch Med, Postgrad Program Hlth Sci, Salvador, BA, Brazil.
EM taianesf@hotmail.com
CR Chiu CY, 2008, PEDIATR INFECT DIS J, V27, P699, DOI 10.1097/INF.0b013e318170b678
   Cohen JF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036927
   Esposito S, 2011, RESP MED, V105, P1939, DOI 10.1016/j.rmed.2011.09.003
   Lahti E, 2007, ACTA PAEDIATR, V96, P1686, DOI 10.1111/j.1651-2227.2007.00511.x
   Michelow IC, 2004, PEDIATRICS, V113, P701, DOI 10.1542/peds.113.4.701
   Yu D, 2014, ACTA PAEDIATR, V103, P93, DOI 10.1111/apa.12426
NR 6
TC 4
Z9 4
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD AUG
PY 2015
VL 34
IS 8
BP 914
EP 915
DI 10.1097/INF.0000000000000763
PG 2
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA CN4PE
UT WOS:000358411500030
PM 26020411
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, CM
   Araujo-Neto, CA
   Ruuskanen, O
AF Nascimento-Carvalho, Cristiana M.
   Araujo-Neto, Cesar A.
   Ruuskanen, Olli
TI Association Between Bacterial Infection and Radiologically Confirmed
   Pneumonia Among Children
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE acute respiratory infection; child; lower respiratory tract infection;
   lung disease; pneumonia radiography
ID COMMUNITY-ACQUIRED PNEUMONIA; HUMAN BOCAVIRUS INFECTION; CHEST
   RADIOGRAPHS; CHILDHOOD PNEUMONIA; SIMKANIA-NEGEVENSIS; DIAGNOSIS;
   DIFFERENTIATION; ETIOLOGY; ASSAYS
AB Background: The role of chest radiograph (CXR) among children with community-acquired pneumonia is controversial. We aimed to assess if there is association between a specific etiology and radiologically confirmed pneumonia.
   Methods: This was a prospective cross-sectional study. Based on report of respiratory complaints and fever/difficulty breathing plus the detection of pulmonary infiltrate/pleural effusion on the CXR taken upon admission read by the pediatrician on duty, children <5-year-old hospitalized with community-acquired pneumonia were enrolled. On admission, clinical data and biological samples were collected to investigate 19 etiological agents (11 viruses and 8 bacteria). CXR taken upon admission was independently read by a pediatric radiologist blinded to clinical data.
   Results: The study group comprised 209 cases with evaluated CXR and establishment of a probable etiology. Radiologically confirmed pneumonia, normal CXR and other radiographic diagnoses were described for 165 (79.0%), 36 (17.2%) and 8 (3.8%) patients, respectively. Viral infection was significantly more common among patients without radiologically confirmed pneumonia (68.2% vs. 47.9%; P = 0.02), particularly among those with normal CXR (66.7% vs. 47.9%; P = 0.04) when compared with patients with radiologically confirmed pneumonia. Bacterial infection was more frequent among cases with radiologically confirmed pneumonia (52.1% vs. 31.8%; P = 0.02). Likewise, pneumococcal infection was more frequently detected among children with radiologically confirmed pneumonia in regard to children with normal CXR (24.2% vs. 8.3%; P = 0.04). Sensitivity (95% confidence interval) of radiologically confirmed pneumonia for pneumococcal infection was 93% (80-98%), and negative predictive value (95% confidence interval) of normal CXR for pneumococcal infection was 92% (77-98%).
   Conclusion: Bacterial infection, especially pneumococcal one, is associated with radiologically confirmed pneumonia.
C1 [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Pediat, BR-40210630 Salvador, BA, Brazil.
   [Araujo-Neto, Cesar A.] Univ Fed Bahia, Sch Med, Dept Image Diag, BR-40210630 Salvador, BA, Brazil.
   [Ruuskanen, Olli] Univ Turku, Dept Pediat, Turku, Finland.
RP Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia, Sch Med, Dept Pediat, Rua Prof Aristides Novis 105-1201B, BR-40210630 Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
FU Bahia State Agency for Research Funding (FAPESB) [52/2004]; Brazilian
   Council for Scientific and Technological Development (CNPq) in
   BrazilNational Council for Scientific and Technological Development
   (CNPq) [03551/2011-9]; Pediatric Research Foundation, in Finland
FX This study was supported by the Bahia State Agency for Research Funding
   (FAPESB; grant number 52/2004) and the Brazilian Council for Scientific
   and Technological Development (CNPq; grant number 03551/2011-9) in
   Brazil and the Pediatric Research Foundation, in Finland.
CR Atkinson TP, 2014, PEDIATR INFECT DIS J, V33, P92, DOI 10.1097/INF.0000000000000171
   Ben Shimol S, 2012, EUR J PEDIATR, V171, P369, DOI 10.1007/s00431-011-1543-1
   Bradley JS, 2011, CLIN INFECT DIS, V53, pE25, DOI 10.1093/cid/cir531
   Browner WS, 1988, DESIGNING CLIN RES E, P91
   Cherian T, 2005, B WORLD HEALTH ORGAN, V83, P353
   COURTOY I, 1989, CLIN PEDIATR, V28, P261, DOI 10.1177/000992288902800604
   Ecochard-Dugelay E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096189
   Greenberg D, 2014, PEDIATR INFECT DIS J, V33, P136, DOI 10.1097/INF.0000000000000023
   Hall J. E., 2011, GUYTON HALL TXB MED
   Harris M, 2011, THORAX, V66, pII1, DOI 10.1136/thoraxjnl-2011-200598
   HUSAIN AN, 2010, ROBBINS COTRAN PATHO, P677
   Johnson J, 2010, EMERG RADIOL, V17, P285, DOI 10.1007/s10140-009-0854-2
   KORPPI M, 1993, ACTA PAEDIATR, V82, P360, DOI 10.1111/j.1651-2227.1993.tb12697.x
   Korppi M, 2010, PEDIATR INFECT DIS J, V29, P387, DOI 10.1097/INF.0b013e3181ce8e81
   Makela MJ, 1998, J CLIN MICROBIOL, V36, P539
   Marostica P JC, 2012, KENDIG CHERNICKS DIS, P461
   MCCARTHY PL, 1981, CLIN PEDIATR, V20, P686, DOI 10.1177/000992288102001101
   Morre SA, 2002, J CLIN MICROBIOL, V40, P584, DOI 10.1128/JCM.40.2.584-587.2002
   Nascimento-Carvalho CM, 2008, PEDIATR INFECT DIS J, V27, P939, DOI 10.1097/INF.0b013e3181723751
   Nascimento-Carvalho CM, 2012, J MED VIROL, V84, P253, DOI 10.1002/jmv.22268
   Nascimento-Carvalho CM, 2011, INFLUENZA OTHER RESP, V5, P285, DOI 10.1111/j.1750-2659.2011.00206.x
   Nascimento-Carvalho CM, 2009, J INFECTION, V58, P250, DOI 10.1016/j.jinf.2009.01.008
   NOHYNEK H, 1995, PEDIATR INFECT DIS J, V14, P478, DOI 10.1097/00006454-199506000-00003
   Patel AB, 2007, INDIAN PEDIATR, V44, P675
   Saukkoriipi A, 2002, MOL CELL PROBE, V16, P385, DOI 10.1006/mcpr.2002.0443
   Swingler George H, 2001, BMC Med Imaging, V1, P1, DOI 10.1186/1471-2342-1-1
   Swingler GH, 1998, LANCET, V351, P404, DOI 10.1016/S0140-6736(97)07013-X
   Tregnaghi MW, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001657
   Virkki R, 2002, THORAX, V57, P438, DOI 10.1136/thorax.57.5.438
   WAHLGREN H, 1995, PEDIATR RADIOL, V25, P627, DOI 10.1007/BF02011833
   Walker CLF, 2013, LANCET, V381, P1405, DOI 10.1016/S0140-6736(13)60222-6
   World Health Organization, 2012, REC MAN COMM CHILDH
   Yamaguchi T, 2005, FEMS IMMUNOL MED MIC, V43, P21, DOI 10.1016/j.femsim.2004.06.023
NR 33
TC 18
Z9 20
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD MAY
PY 2015
VL 34
IS 5
BP 490
EP 493
DI 10.1097/INF.0000000000000622
PG 4
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA CG5PH
UT WOS:000353344500012
PM 25879649
DA 2020-12-17
ER

PT J
AU Reis, GG
   Miranda, VM
   Cardoso, MRA
   Sole, D
   Barral, A
   Nascimento-Carvalho, CM
AF Reis, G. G.
   Miranda, V. M.
   Cardoso, M. -R. A.
   Sole, D.
   Barral, A.
   Nascimento-Carvalho, C. M.
TI Prevalence and risk factors for wheezing in Salvador, Brazil: a
   population-based study
SO QJM-AN INTERNATIONAL JOURNAL OF MEDICINE
LA English
DT Article
ID 1ST YEAR; INFANTS; PATTERNS; LIFE; SYMPTOMS; CHILDREN; ASTHMA
AB Background: Wheezing is one of the most frequent causes of visit to emergency rooms among children. However, data on wheezing burden are mostly provided at healthcare setting, and particularly only for infants.
   Aims: We sought to estimate the prevalence of wheezing in children under 4 years and to assess potential risk factors in the community.
   Design: This was a cross-sectional analysis of a population-based cohort study.
   Methods: The sample comprised children aged <4 years living in Salvador, Brazil. Data were collected via home visits when the parents/guardians were interviewed. Data were recorded on standardized forms.
   Results: Of 1534 children, mean age was 21 +/- 14 months (minimum 3 days; maximum 47 months; 6% <2 months); 780 (51%) were males and 501 [33%; 95% confidence interval (95% CI): 30-35%] reported wheezing in the last 12 months. Among wheezers, 321 (64%) had occasional wheezing. Overall, 180 (12%; 95% CI: 10-14%) had recurrent wheezing and 157 (10%; 95% CI: 9-12%) had asthma. For children in the first, second, third and fourth year of life wheezing was reported in 23, 41, 34 and 37%, respectively. Mother atopic-related disease was independently associated with recurrent wheezing (AdjPR[95% CI]: 1.54 [1.12-2.11]) and asthma (AdjPR[95% CI]: 1.54 [1.10-2.16]). Smoker at home (AdjPR[95% CI]: 1.34 [1.07-1.67]) and low birth weight (AdjPR[95% CI]: 1.38 [1.05-1.81]) were independently associated with occasional wheezing.
   Conclusions: One-third of under 4 years reported wheezing; history of mother's atopic-related disease was an independent risk factor for recurrent wheezing and asthma; smoker at home and low birth weight were independent risk factors for occasional wheezing.
C1 [Reis, G. G.; Nascimento-Carvalho, C. M.] Univ Fed Bahia, Sch Med, Postgrad Program Hlth Sci, Salvador, BA, Brazil.
   [Miranda, V. M.; Nascimento-Carvalho, C. M.] Univ Fed Bahia, Sch Med, Dept Paediat, Salvador, BA, Brazil.
   [Cardoso, M. -R. A.] Univ Sao Paulo, Sch Publ Hlth, Dept Epidemiol, Sao Paulo, Brazil.
   [Sole, D.] Univ Fed Sao Paulo, Dept Paediat, Div Allergy Clin Immunol & Rheumatol, Sao Paulo, Brazil.
   [Barral, A.] Univ Fed Bahia, Sch Med, Dept Pathol, Salvador, BA, Brazil.
   [Barral, A.] Fundacao Oswaldo Cruz, Ctr Pesquisa Goncalo Moniz, Salvador, BA, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Rua Prof Aristides Novis 105-1201B, BR-40210630 Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
FU Brazilian Council for Scientific and Technological Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [303398/2005-1]
FX This study was supported by the Brazilian Council for Scientific and
   Technological Development (CNPq) [grant number 303398/2005-1]. MRA
   Cardoso, D Sole, A Barral and CM Nascimento-Carvalho are investigators
   from the CNPq.
CR Akinbami Lara J, 2012, NCHS Data Brief, P1
   Bisgaard H, 2007, PEDIATR PULM, V42, P723, DOI 10.1002/ppul.20644
   Cardoso MRA, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-19
   Chong HJ, 2007, J PEDIAT-BRAZIL, V83, P357, DOI 10.2223/JPED.1679
   de Jong BM, 2007, MED CARE, V45, P746, DOI 10.1097/MLR.0b013e3180546879
   de Sousa CA, 2012, REV SAUDE PUBL, V46, P825, DOI 10.1590/s0034-89102012000500009
   Dijk FN, 2013, CURR OPIN ALLERGY CL, V13, P193, DOI 10.1097/ACI.0b013e32835eb707
   Garcia-Marcos L, 2010, PEDIAT ALLERG IMM-UK, V21, P878, DOI 10.1111/j.1399-3038.2010.01035.x
   Hafkamp-de Groen E, 2013, EUR RESPIR J, V41, P952, DOI 10.1183/09031936.00015712
   Local Council's Department of Health in Salvador, 2006, HLTH INF
   Mallol J, 2010, THORAX, V65, P1004, DOI 10.1136/thx.2009.115188
   Martinez FD, 2002, PEDIATRICS, V109, P362
   Martinez FD, 2013, LANCET, V382, P1360, DOI 10.1016/S0140-6736(13)61536-6
   Martinez Fernando D, 2002, Paediatr Respir Rev, V3, P193, DOI 10.1016/S1526-0542(02)00188-4
   Matricardi PM, 2008, EUR RESPIR J, V32, P585, DOI 10.1183/09031936.00066307
   Medeiros D, 2011, CAD SAUDE PUBLICA, V27, P1551, DOI 10.1590/S0102-311X2011000800010
   Pellegrini-Belinchon J, 2012, ALLERGOL IMMUNOPATH, V40, P164, DOI 10.1016/j.aller.2011.03.014
   Prietsch SOM, 2006, REV PANAM SALUD PUBL, V20, P331, DOI 10.1590/S1020-49892006001000006
   Venero-Fernandez SJ, 2013, QJM-INT J MED, V106, P1023, DOI 10.1093/qjmed/hct143
   Visser CAN, 2010, PEDIATR PULM, V45, P149, DOI 10.1002/ppul.21161
NR 20
TC 2
Z9 3
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1460-2725
EI 1460-2393
J9 QJM-INT J MED
JI QJM-An Int. J. Med.
PD MAR 1
PY 2015
VL 108
IS 3
BP 213
EP 218
DI 10.1093/qjmed/hcu194
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA CE0UN
UT WOS:000351522900006
PM 25208893
OA Bronze, Green Published
DA 2020-12-17
ER

PT J
AU Vilas-Boas, AL
   Nascimento-Carvalho, CM
AF Vilas-Boas, Ana-Luisa
   Nascimento-Carvalho, Cristiana M.
CA PNEUMOPAC-Efficacy Study Grp
TI Comparison of oral amoxicillin given thrice or twice daily to children
   between 2 and 59 months old with non-severe pneumonia: a randomized
   controlled trial-authors' response
SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
LA English
DT Letter
DE acute respiratory infections; antibacterials; antimicrobial therapy;
   lower tract respiratory infections
C1 [Vilas-Boas, Ana-Luisa; Nascimento-Carvalho, Cristiana M.; PNEUMOPAC-Efficacy Study Grp] Univ Fed Bahia, Sch Med, Dept Paediat, Salvador, BA, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia, Sch Med, Dept Paediat, Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
RI Santos, Pablo/W-7141-2019
OI Matutino Kahn, Adriana/0000-0002-5306-0571
CR Bradley JS, 2011, CLIN INFECT DIS, V53, pE25, DOI 10.1093/cid/cir531
   Cherian T, 2005, B WORLD HEALTH ORGAN, V83, P353
   Fonseca W, 2003, ANTIMICROB AGENTS CH, V47, P997, DOI 10.1128/AAC.47.3.997-1001.2003
   Gilani Z, 2012, CLIN INFECT DIS, V54, pS102, DOI 10.1093/cid/cir1053
   Hazir T, 2007, ARCH DIS CHILD, V92, P291, DOI 10.1136/adc.2005.092494
   Johnson J, 2010, EMERG RADIOL, V17, P285, DOI 10.1007/s10140-009-0854-2
   Kardas P, 2002, J ANTIMICROB CHEMOTH, V49, P897, DOI 10.1093/jac/dkf046
   Osowicki J, 2015, J ANTIMICROB CHEMOTH, V70, P635, DOI 10.1093/jac/dku398
   Vilas-Boas AL, 2014, J ANTIMICROB CHEMOTH, V69, P1954, DOI 10.1093/jac/dku070
   World Health Organization, 2013, POCK BOOK HOSP CAR C
NR 10
TC 2
Z9 3
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-7453
EI 1460-2091
J9 J ANTIMICROB CHEMOTH
JI J. Antimicrob. Chemother.
PD FEB
PY 2015
VL 70
IS 2
BP 636
EP 638
DI 10.1093/jac/dku440
PG 4
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA CC2YR
UT WOS:000350211600052
PM 25362570
OA Bronze
DA 2020-12-17
ER

PT J
AU Vilas-Boas, AL
   Fontoura, MSH
   Xavier-Souza, G
   Araujo-Neto, CA
   Andrade, SC
   Brim, RV
   Noblat, L
   Barral, A
   Cardoso, MRA
   Nascimento-Carvalho, CM
AF Vilas-Boas, Ana-Luisa
   Fontoura, Maria-Socorro H.
   Xavier-Souza, Gabriel
   Araujo-Neto, Cesar A.
   Andrade, Sandra C.
   Brim, Rosa V.
   Noblat, Lucia
   Barral, Aldina
   Cardoso, Maria-Regina A.
   Nascimento-Carvalho, Cristiana M.
CA PNEUMOPAC-Efficacy Study Grp
TI Comparison of oral amoxicillin given thrice or twice daily to children
   between 2 and 59 months old with non-severe pneumonia: a randomized
   controlled trial
SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
LA English
DT Article
DE acute respiratory infections; antibacterials; antimicrobial therapy;
   lower respiratory tract infection
ID RESPIRATORY-TRACT INFECTION; AGED 2-59 MONTHS; DOUBLE-BLIND;
   MULTICENTER; THERAPY
AB Objectives: Oral amoxicillin (50 mg/kg/day) thrice daily is the first-line therapy for non-severe childhood pneumonia. Compliance could be enhanced if two daily doses are employed. We assessed the equivalence of oral amoxicillin (50 mg/kg/day) thrice or twice daily in those patients.
   Patients and methods: This randomized (1: 1), controlled, triple-blinded investigation conducted at one centre in Brazil included children aged 2-59 months with non-severe pneumonia diagnosed by trained paediatricians based on respiratory complaints and radiographic pulmonary infiltrate/consolidation. Participants were randomly assigned to receive one bottle (Amoxicillin 1) at 6 am, 2 pm and 10 pm and the other bottle (Amoxicillin 2) at 8 am and 8 pm: one bottle contained amoxicillin and the other placebo and vice versa. Only the pharmacist knew patients' allocation. Follow-up assessments were done at 2, 5 and 14 days after enrolment. Chest radiographs were read by three independent radiologists. Primary outcome was treatment failure (development of danger signs, persistence of fever, tachypnoea, development of serious adverse reactions, death and withdrawal from the trial) at 48 h. ClinicalTrials.gov: identifier NCT01200706.
   Results: Four hundred and twelve and 408 participants received amoxicillin thrice or twice daily, respectively. Treatment failure was detected in 94 (22.8%) and 94 (23.0%) patients in intention-to-treat analysis (risk difference 0.2%; 95% CI: -5.5%-6.0%) and in 80 (20.1%) and 85 (21.3%) patients in per-protocol analysis (risk difference 1.2%; 95% CI: -4.4%-6.8%). Pneumonia was radiologically confirmed by concordant reading in 277 (33.8%) cases, among whom treatment failure was registered in 25/133 (18.8%) and 27/144 (18.8%) participants from the thrice and twice daily doses subgroups, respectively (risk difference -0.05%; 95% CI: -9.3%-9.2%).
   Conclusions: Oral amoxicillin (50 mg/kg/day) twice daily is as efficacious as thrice daily.
C1 [Vilas-Boas, Ana-Luisa; Fontoura, Maria-Socorro H.; Xavier-Souza, Gabriel; Nascimento-Carvalho, Cristiana M.; PNEUMOPAC-Efficacy Study Grp] Univ Fed Bahia, Sch Med, Dept Paediat, Salvador, BA, Brazil.
   [Araujo-Neto, Cesar A.; Brim, Rosa V.] Univ Fed Bahia, Sch Med, Dept Image Diag, Salvador, BA, Brazil.
   [Andrade, Sandra C.] Fed Univ Bahia Hosp, Image Diag Unit, Salvador, BA, Brazil.
   [Noblat, Lucia] Fed Univ Bahia Hosp, Pharm Unit, Salvador, BA, Brazil.
   [Barral, Aldina] Univ Fed Bahia, Sch Med, Dept Pathol, Salvador, BA, Brazil.
   [Barral, Aldina] Fundacao Oswaldo Cruz, Ctr Pesquisa Goncalo Moniz, Salvador, BA, Brazil.
   [Cardoso, Maria-Regina A.] Univ Sao Paulo, Sch Publ Hlth, Dept Epidemiol, Sao Paulo, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia, Sch Med, Dept Paediat, Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
RI Santos, Pablo/W-7141-2019
OI Matutino Kahn, Adriana/0000-0002-5306-0571
FU Bahia State Agency for Research Funding (FAPESB) [0127/2006]
FX This work was supported by a grant from the Bahia State Agency for
   Research Funding (FAPESB) (Grant No. APR No. 0127/2006). A. B., M.-R. A.
   C. and C. M. N.-C. are investigators from the Brazilian Council for
   Scientific and Technological Development (CNPq).
CR Addo-Yobo E, 2004, LANCET, V364, P1141, DOI 10.1016/S0140-6736(04)17100-6
   Andes D, 2004, CLIN LAB MED, V24, P477, DOI 10.1016/j.cll.2004.03.009
   Awasthi S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001991
   Castaneda Elizabeth, 2009, Pediatr Infect Dis J, V28, pe265, DOI 10.1097/INF.0b013e3181a74b22
   Cherian T, 2005, B WORLD HEALTH ORGAN, V83, P353
   Clinical and Laboratory Standards Institute, 2014, M100S24 CLSI
   Dagan R, 2001, J ANTIMICROB CHEMOTH, V47, P129, DOI 10.1093/jac/47.2.129
   El-Rashdi AS, 2006, ARCH DIS CHILD, V91, P351, DOI 10.1136/adc.2005.088831
   Friedman LM, 1996, FUNDAMENTALS CLIN TR
   Hazir T, 2006, INT J TUBERC LUNG D, V10, P924
   Hazir T, 2002, LANCET, V360, P835
   Hazir T, 2007, ARCH DIS CHILD, V92, P291, DOI 10.1136/adc.2005.092494
   Hazir T, 2011, CLIN INFECT DIS, V52, P293, DOI 10.1093/cid/ciq142
   Kardas P, 2002, J ANTIMICROB CHEMOTH, V49, P897, DOI 10.1093/jac/dkf046
   Nascimento-Carvalho CM, 2004, REV PANAM SALUD PUBL, V15, P380, DOI 10.1590/S1020-49892004000600003
   Nascimento-Carvalho CM, 2013, PEDIATR INFECT DIS J, V32, P1281, DOI 10.1097/INF.0b013e3182a4dcfa
   PRICE JD, 1975, BRIT J CLIN PRACT, V29, P203
   Rudan I, 2008, B WORLD HEALTH ORGAN, V86, P408, DOI 10.2471/BLT.07.048769
   Walker CLF, 2013, LANCET, V381, P1405, DOI 10.1016/S0140-6736(13)60222-6
   World Health Organization, 2013, POCK BOOK HOSP CAR C
   World Health Organization, 2008, TRAIN COURS CHILD GR
NR 21
TC 18
Z9 18
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-7453
EI 1460-2091
J9 J ANTIMICROB CHEMOTH
JI J. Antimicrob. Chemother.
PD JUL
PY 2014
VL 69
IS 7
BP 1954
EP 1959
DI 10.1093/jac/dku070
PG 6
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA AK0TS
UT WOS:000338129000032
PM 24648506
OA Green Published, Bronze
DA 2020-12-17
ER

PT J
AU Bouzas, ML
   Sole, D
   Cardoso, MRA
   Barral, A
   Nascimento-Carvalho, CM
AF Bouzas, Maiara Lanna
   Sole, Dirceu
   Cardoso, Maria-Regina A.
   Barral, Aldina
   Nascimento-Carvalho, Cristiana M.
CA Acute Resp Infect Wheezing Study
TI Environmental factors independently associated with the first episode of
   wheezing among children
SO PEDIATRIC ALLERGY AND IMMUNOLOGY
LA English
DT Letter
ID RESPIRATORY SYNCYTIAL VIRUS; INFECTION; ILLNESSES; ASTHMA
C1 [Bouzas, Maiara Lanna; Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Postgrad Program Hlth Sci, Salvador, BA, Brazil.
   [Sole, Dirceu] Univ Fed Sao Paulo, Dept Pediat, Div Allergy Clin Immunol & Rheumatol, Sao Paulo, Brazil.
   [Cardoso, Maria-Regina A.] Univ Sao Paulo, Fac Publ Hlth, Dept Epidemiol, Sao Paulo, Brazil.
   [Barral, Aldina] Univ Fed Bahia, Sch Med, Dept Pathol, Salvador, BA, Brazil.
   [Barral, Aldina] Fundacao Oswaldo Cruz, Ctr Pesquisa Goncalo Muniz, Salvador, BA, Brazil.
   [Nascimento-Carvalho, Cristiana M.; Acute Resp Infect Wheezing Study] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
RP Bouzas, ML (corresponding author), Univ Fed Bahia, Sch Med, Postgrad Program Hlth Sci, Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
CR Bitko V, 2004, BMC MICROBIOL, V4, DOI 10.1186/1471-2180-4-28
   Bitko V, 2007, J VIROL, V81, P783, DOI 10.1128/JVI.01437-06
   Celedon JC, 2002, ARCH PEDIAT ADOL MED, V156, P241, DOI 10.1001/archpedi.156.3.241
   Gern JE, 2006, J ALLERGY CLIN IMMUN, V117, P72, DOI 10.1016/j.jaci.2005.10.002
   Mallol J, 2010, THORAX, V65, P1004, DOI 10.1136/thx.2009.115188
   Mortelliti MP, 2002, AM FAM PHYSICIAN, V65, P1823
   Narita A, 2011, JPN J INFECT DIS, V64, P433
   von Linstow ML, 2008, PEDIATR PULM, V43, P584, DOI 10.1002/ppul.20828
NR 8
TC 1
Z9 1
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0905-6157
EI 1399-3038
J9 PEDIAT ALLERG IMM-UK
JI Pediatr. Allergy Immunol.
PD JUN
PY 2014
VL 25
IS 4
BP 407
EP 410
DI 10.1111/pai.12171
PG 5
WC Allergy; Immunology; Pediatrics
SC Allergy; Immunology; Pediatrics
GA AJ9NB
UT WOS:000338037100017
PM 24289248
DA 2020-12-17
ER

PT J
AU Silva, RD
   Siqueira, MAM
   Netto, EM
   Bastos, JS
   Nascimento-Carvalho, CM
   Vilas-Boas, AL
   Bouzas, ML
   Motta, FD
   Brites, C
AF Silva, Rosangela de Castro
   Mendonca Siqueira, Marilda Agudo
   Netto, Eduardo Martins
   Bastos, Jacione Silva
   Nascimento-Carvalho, Cristiana Maria
   Vilas-Boas, Ana Luisa
   Bouzas, Maiara Lana
   Motta, Fernando do Couto
   Brites, Carlos
TI Epidemiological aspects of influenza A related to climatic conditions
   during and after a pandemic period in the city of Salvador, northeastern
   Brazil
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE influenza; A(H1N1)pdm09; children; epidemiology; seasonality; climate
ID VITAMIN-D; TRANSMISSION; H1N1; SEASONALITY; INFECTIONS; EPIDEMICS;
   VIRUS; WAVE
AB During the influenza pandemic of 2009, the A(H1N1)pdm09, A/H3N2 seasonal and influenza B viruses were observed to be co-circulating with other respiratory viruses. To observe the epidemiological pattern of the influenza virus between May 2009-August 2011, 467 nasopharyngeal aspirates were collected from children less than five years of age in the city of Salvador. In addition, data on weather conditions were obtained. Indirect immunofluorescence, real-time transcription reverse polymerase chain reaction (RT-PCR), and sequencing assays were performed for influenza virus detection. Of all 467 samples, 34 (7%) specimens were positive for influenza A and of these, viral characterisation identified Flu A/H3N2 in 25/34 (74%) and A(H1N1) pdm09 in 9/34 (26%). Influenza B accounted for a small proportion (0.8%) and the other respiratory viruses for 27.2% (127/467). No deaths were registered and no pattern of seasonality or expected climatic conditions could be established. These observations are important for predicting the evolution of epidemics and in implementing future anti-pandemic measures.
C1 [Silva, Rosangela de Castro; Netto, Eduardo Martins; Bastos, Jacione Silva; Brites, Carlos] Univ Fed Bahia, Complexo Hosp Prof Edgard Santos, Lab Pesquisa Infectol, Salvador, BA, Brazil.
   [Nascimento-Carvalho, Cristiana Maria] Univ Fed Bahia, Fac Med Bahia, Dept Pediat, Salvador, BA, Brazil.
   [Vilas-Boas, Ana Luisa; Bouzas, Maiara Lana] Univ Fed Bahia, Programa Posgrad Ciencias Saude, Salvador, BA, Brazil.
   [Mendonca Siqueira, Marilda Agudo; Motta, Fernando do Couto] Fiocruz MS, Inst Oswaldo Cruz, Lab Virus Resp & Influenza, BR-21045900 Rio De Janeiro, RJ, Brazil.
RP Silva, RD (corresponding author), Univ Fed Bahia, Complexo Hosp Prof Edgard Santos, Lab Pesquisa Infectol, Salvador, BA, Brazil.
EM rosangel@ufba.br
RI Netto, Eduardo/D-1432-2013; Brites, Carlos/D-1353-2013
OI Netto, Eduardo/0000-0003-1691-6761; Brites, Carlos/0000-0002-4673-6991
FU FAPESB [159/2007]
FX Financial support: FAPESB (159/2007)
CR Adams JS, 2008, NAT CLIN PRACT ENDOC, V4, P80, DOI 10.1038/ncpendmet0716
   Alonso WJ, 2007, AM J EPIDEMIOL, V165, P1434, DOI 10.1093/aje/kwm012
   Amato-Gauci A, 2011, EURO SURVEILL, V16, P19903
   [Anonymous], 2009, Wkly Epidemiol Rec, V84, P481
   Watanabe ASA, 2011, BRAZ J INFECT DIS, V15, P220, DOI [10.1590/S1413-86702011000300007, 10.1016/S1413-8670(11)70179-9]
   Bautista E, 2010, NEW ENGL J MED, V362, P1708, DOI 10.1056/NEJMra1000449
   Bellei N, 2007, BRAZ J INFECT DIS, V11, P399, DOI 10.1590/S1413-86702007000400005
   Brankston G, 2007, LANCET INFECT DIS, V7, P257, DOI 10.1016/S1473-3099(07)70029-4
   Chowell G, 2010, P ROY SOC B-BIOL SCI, V277, P1857, DOI 10.1098/rspb.2009.1897
   Cortese Margaret M., 2009, Morbidity and Mortality Weekly Report, V58, P1
   Dowse GK, 2011, MED J AUSTRALIA, V194, P68, DOI 10.5694/j.1326-5377.2011.tb04170.x
   Peters BSE, 2009, ANN NUTR METAB, V54, P15, DOI 10.1159/000199454
   Iskander M, 2007, CURR OPIN INFECT DIS, V20, P259, DOI 10.1097/QCO.0b013e3280ad4687
   Libster R, 2010, NEW ENGL J MED, V362, P45, DOI 10.1056/NEJMoa0907673
   Mello WA, 2009, PLOS ONE, V4, P1
   Moura FEA, 2009, AM J TROP MED HYG, V81, P180, DOI 10.4269/ajtmh.2009.81.180
   MS - Ministerio da Saude-Brasil, 2012, INF TECN INFL 2012
   Neuzil KM, 2002, ARCH PEDIAT ADOL MED, V156, P986, DOI 10.1001/archpedi.156.10.986
   OLIVEIRA WK, 2009, EURO SURVEILL, V14
   Sagripanti JL, 2007, PHOTOCHEM PHOTOBIOL, V83, P1278, DOI 10.1111/j.1751-1097.2007.00177.x
   Schout D, 2009, CLINICS, V64, P1025, DOI 10.1590/S1807-59322009001000014
   Shaman J, 2009, P NATL ACAD SCI USA, V106, P3243, DOI 10.1073/pnas.0806852106
   Simonsen L, 2011, BIRKHAUSER ADV INFEC, P27, DOI 10.1007/978-3-0346-0279-2_2
   Steel J, 2011, J VIROL, V85, P1400, DOI 10.1128/JVI.02186-10
   Straliotto Selir M., 2002, Rev. Soc. Bras. Med. Trop., V35, P283, DOI 10.1590/S0037-86822002000400002
   SUVISA/DIVEP - Superintendencia de Vigilancia e Protecao da Saude/Secretaria de Saude do Estado da Bahia, 2012, B INFL BAH 2012
   Tellier R, 2006, EMERG INFECT DIS, V12, P1657, DOI 10.3201/eid1211.060426
   Viboud C, 2004, EUR J EPIDEMIOL, V19, P1055, DOI 10.1007/s10654-004-2450-9
   Viboud C, 2006, PLOS MED, V3, P468, DOI 10.1371/journal.pmed.0030089
   Vidal LRR, 2008, MEM I OSWALDO CRUZ, V103, P180, DOI 10.1590/S0074-02762008000200009
   WHO/CDC - World Health Organization/Center for Disease Control and Prevention, 2009, CDC PROT REAL TIM RT
   WHO - World Health Organization, 2011, STAND TERM PAND H1N1
   WHO - World Health Organization, 2009, GLOB INFL SURV NETW
   World Health Organization, 2009, CLIN MAN HUM INF PAN
   World Health Organization Global Influenza Surveillance Network-WHO GISN, 2011, MAN LAB DIAGN VIR SU
   World Health Organization (WHO), 2009, SEQ PRIM PROT
NR 36
TC 6
Z9 6
U1 0
U2 5
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD APR
PY 2014
VL 109
IS 2
BP 229
EP 235
DI 10.1590/0074-0276140273
PG 7
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA AJ7VQ
UT WOS:000337908500014
PM 24714967
OA DOAJ Gold, Green Published
DA 2020-12-17
ER

PT J
AU Bouzas, ML
   Cardoso, MRA
   Sole, D
   Barral, A
   Nascimento-Carvalho, CM
AF Bouzas, Maiara Lanna
   Cardoso, Maria-Regina A.
   Sole, Dirceu
   Barral, Aldina
   Nascimento-Carvalho, Cristiana M.
CA Acute Resp Infection Wheezing
TI Validating report of first episode of wheezing with
   pediatrician-detected wheezing among children
SO PEDIATRIC ALLERGY AND IMMUNOLOGY
LA English
DT Letter
ID INFECTIONS
C1 [Bouzas, Maiara Lanna; Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Postgrad Program Hlth Sci, Salvador, BA, Brazil.
   [Cardoso, Maria-Regina A.] Univ Sao Paulo, Fac Publ Hlth, Dept Epidemiol, Sao Paulo, Brazil.
   [Sole, Dirceu] Univ Fed Sao Paulo, Div Allergy Clin Immunol & Rheumatol, Dept Pediat, Sao Paulo, Brazil.
   [Barral, Aldina] Univ Fed Bahia, Sch Med, Dept Pathol, Ctr Pesquisa Goncalo Muniz,Fundacao Oswaldo Cruz, Salvador, BA, Brazil.
   [Nascimento-Carvalho, Cristiana M.; Acute Resp Infection Wheezing] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
RP Bouzas, ML (corresponding author), Univ Fed Bahia, Sch Med, Postgrad Program Hlth Sci, Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
CR El-Rashdi AS, 2006, ARCH DIS CHILD, V91, P351, DOI 10.1136/adc.2005.088831
   Fernandes RM, 2011, BMC PEDIATR, V11, DOI 10.1186/1471-2431-11-112
   Gern JE, 2006, J ALLERGY CLIN IMMUN, V117, P72, DOI 10.1016/j.jaci.2005.10.002
   Gern JE, 2005, J ALLERGY CLIN IMMUN, V115, P668, DOI 10.1016/j.jaci.2005.01.057
   Lowe L, 2004, ARCH DIS CHILD, V89, P540, DOI 10.1136/adc.2003.038539
   Mommers M, 2010, PEDIAT ALLERG IMM-UK, V21, P983, DOI 10.1111/j.1399-3038.2010.01042.x
   Tregoning JS, 2010, CLIN MICROBIOL REV, V23, P74, DOI 10.1128/CMR.00032-09
   von Linstow ML, 2008, PEDIATR PULM, V43, P584, DOI 10.1002/ppul.20828
   World Health Organization, 2008, 5032 WC WHO
NR 9
TC 2
Z9 2
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0905-6157
EI 1399-3038
J9 PEDIAT ALLERG IMM-UK
JI Pediatr. Allergy Immunol.
PD MAR
PY 2014
VL 25
IS 2
SI SI
BP 198
EP 200
DI 10.1111/pai.12141
PG 3
WC Allergy; Immunology; Pediatrics
SC Allergy; Immunology; Pediatrics
GA AD1BE
UT WOS:000332968000015
PM 24118128
OA Green Published
DA 2020-12-17
ER

PT J
AU Andrade, DC
   Borges, IC
   Laitinen, H
   Ekstrom, N
   Adrian, PV
   Meinke, A
   Barral, A
   Nascimento-Carvalho, CM
   Kayhty, H
AF Andrade, Dafne C.
   Borges, Igor C.
   Laitinen, Hanna
   Ekstrom, Nina
   Adrian, Peter V.
   Meinke, Andreas
   Barral, Aldina
   Nascimento-Carvalho, Cristiana M.
   Kayhty, Helena
TI A fluorescent multiplexed bead-based immunoassay (FMIA) for quantitation
   of IgG against Streptococcus pneumoniae, Haemophilus influenzae and
   Moraxella catarrhalis protein antigens
SO JOURNAL OF IMMUNOLOGICAL METHODS
LA English
DT Article
DE Antibody; Multiplex; Etiological diagnosis; Recombinant proteins;
   Serology; Validation
ID HUMORAL IMMUNE-RESPONSE; ACUTE OTITIS-MEDIA; PNEUMOCOCCAL PROTEINS;
   FUNCTIONAL ANTIBODIES; VACCINE CANDIDATES; SERUM ANTIBODIES; PSPA;
   IMMUNOGENICITY; PROTECTION; SAFETY
AB Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis are pathogens commonly associated with infectious diseases in childhood. This study aimed to develop a fluorescent multiplexed bead-based immunoassay (FMIA) using recombinant proteins for the quantitation of serum IgG antibodies against these bacteria. Eight pneumococcal proteins (Ply, CbpA, PspA1, PspA2, PcpA, PhtD, 5P1732-3 and SP2216-1), 3 proteins of H. influenzae (NTHi Protein D, NTHiO371-1, NTHi0830), and 5 proteins of M. catarrhalis (MC Omp CD, MC_RH4_2506, MC_RH4_1701, MC_RH4_3729-1, MC_RH4_4730) were used to develop the FMIA. Optimal coupling concentrations for each protein, comparison of singleplex and multiplex assays, specificity, reproducibility, and correlation to ELISA for six pneumococcal antigens were determined for validation. FMIA was then used to analyze acute and convalescent paired serum samples of 50 children with non-severe pneumonia. The coupling concentrations varied for different antigens, ranging from 1.6 to 32 mu g of protein/million beads. Correlation between singleplexed and multiplexed assays was excellent, with R >= 0.987. The FMIA was specific, reaching > 92% homologous inhibition for all specificities; heterologous inhibition >= 20% was found only in six cases. The assay was repeatable, with averages of intra-assay variation <= 10.5%, day-to-day variation <= 9.7% and variation between technicians <= 9.1%. Comparison with ELISA for pneumococcal antigens demonstrated good correlation with R ranging from 0.854 (PspA2) to 0.976 (PcpA). The samples from children showed a wide range of antibody concentrations and increases in convalescent samples. In conclusion, the FMIA was sensitive, specific, and repeatable, using small amounts of recombinant proteins and sera to detect antibodies against S. pneumoniae, H. influenzae and M. catarrhalis. The methodology would be suitable for studies investigating etiological diagnosis and in experimental vaccine studies. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Andrade, Dafne C.; Borges, Igor C.] Univ Fed Bahia, Sch Med, Salvador, BA, Brazil.
   [Laitinen, Hanna; Ekstrom, Nina; Kayhty, Helena] Natl Inst Hlth & Welf, Helsinki, Finland.
   [Adrian, Peter V.] Univ Witwatersrand, Resp & Meningeal Pathogens Res Unit, DST NRF Vaccine Preventable Dis, Johannesburg, South Africa.
   [Meinke, Andreas] Valneva Austria GmbH, Vienna, Austria.
   [Barral, Aldina] Univ Fed Bahia, Sch Med, Dept Pathol, Salvador, BA, Brazil.
   [Barral, Aldina] Ctr Pesquisa Goncalo Moniz, Fdn Oswaldo Cruz, Salvador, BA, Brazil.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
RP Andrade, DC (corresponding author), Praca 15 Novembro S-N, BR-40025010 Salvador, BA, Brazil.
EM andradedafne@yahoo.com.br
RI Borges, Igor Carmo/AAG-8531-2019
OI Carmo Borges, Igor/0000-0003-2749-0313
FU Bahia State Agency for Research Funding (FAPESB); Brazilian Council for
   Scientific and Technological Development (CNPq), BrazilNational Council
   for Scientific and Technological Development (CNPq); National Institute
   for Health and Welfare, Finland
FX This work was supported by: Bahia State Agency for Research Funding
   (FAPESB); Brazilian Council for Scientific and Technological Development
   (CNPq), Brazil, and in part by National Institute for Health and
   Welfare, Finland. Profs Aldina Barral and Cristiana M.
   Nascimento-Carvalho are investigators of the CNPq.
CR Adamou JE, 2001, INFECT IMMUN, V69, P949, DOI 10.1128/IAI.69.2.949-958.2001
   Akkoyunlu M, 1996, INFECT IMMUN, V64, P4586, DOI 10.1128/IAI.64.11.4586-4592.1996
   Bologa M, 2012, VACCINE, V30, P7461, DOI 10.1016/j.vaccine.2012.10.076
   Briles DE, 2000, VACCINE, V18, P1707, DOI 10.1016/S0264-410X(99)00511-3
   Brooks-Walter A, 1999, INFECT IMMUN, V67, P6533
   Casey JR, 2010, PEDIATR INFECT DIS J, V29, P304, DOI 10.1097/INF.0b013e3181c1bc48
   CRAIN MJ, 1990, INFECT IMMUN, V58, P3293, DOI 10.1128/IAI.58.10.3293-3299.1990
   Croney CM, 2012, CLIN VACCINE IMMUNOL, V19, P891, DOI 10.1128/CVI.05671-11
   De Wals P, 2009, VACCINE, V27, P2877, DOI 10.1016/j.vaccine.2009.02.102
   Giefing C, 2008, J EXP MED, V205, P117, DOI 10.1084/jem.20071168
   Holmlund E, 2009, CLIN VACCINE IMMUNOL, V16, P916, DOI 10.1128/CVI.00050-09
   Kaminski RW, 2013, J IMMUNOL METHODS, V393, P18, DOI 10.1016/j.jim.2013.04.002
   Kamtchoua T, 2013, VACCINE, V31, P327, DOI 10.1016/j.vaccine.2012.11.005
   Khan MN, 2012, MICROBES INFECT, V14, P1102, DOI 10.1016/j.micinf.2012.06.007
   Khan MN, 2012, VACCINE, V30, P2900, DOI 10.1016/j.vaccine.2012.02.023
   Kilpi T, 2001, PEDIATR INFECT DIS J, V20, P654, DOI 10.1097/00006454-200107000-00004
   Korppi M, 2008, EUR J CLIN MICROBIOL, V27, P167, DOI 10.1007/s10096-007-0436-8
   Lal G, 2005, J IMMUNOL METHODS, V296, P135, DOI 10.1016/j.jim.2004.11.006
   Lebon A, 2011, INFECT IMMUN, V79, P1680, DOI 10.1128/IAI.01379-10
   MCDANIEL LS, 1994, MICROB PATHOGENESIS, V17, P323, DOI 10.1006/mpat.1994.1078
   Murphy TF, 2009, CLIN INFECT DIS, V49, P124, DOI 10.1086/599375
   Ogunniyi AD, 2001, INFECT IMMUN, V69, P5997, DOI 10.1128/IAI.69.10.5997-6003.2001
   Orihuela CJ, 2009, J CLIN INVEST, V119, P1638, DOI 10.1172/JCI36759
   Pickering JW, 2002, AM J CLIN PATHOL, V117, P589
   Pickering JW, 2002, CLIN DIAGN LAB IMMUN, V9, P872, DOI 10.1128/CDLI.9.4.872-876.2002
   Poolman JT, 2000, VACCINE, V19, pS108, DOI 10.1016/S0264-410X(00)00288-7
   Posfay-Barbe KM, 2011, CLIN MICROBIOL INFEC, V17, P1232, DOI 10.1111/j.1469-0691.2010.03389.x
   Prevaes SMPJ, 2012, INFECT IMMUN, V80, P2186, DOI 10.1128/IAI.00037-12
   Principi N, 2011, HUM VACCINES, V7, P905, DOI 10.4161/hv.7.9.15986
   Rodgers G.L., 2011, VACCINE, V29, P43
   Rudan I, 2008, B WORLD HEALTH ORGAN, V86, P408, DOI 10.2471/BLT.07.048769
   Saito R, 2013, RES MICROBIOL, V164, P236, DOI 10.1016/j.resmic.2012.12.005
   Seiberling M, 2012, VACCINE, V30, P7455, DOI 10.1016/j.vaccine.2012.10.080
   Shaper M, 2004, INFECT IMMUN, V72, P5031, DOI 10.1128/IAI.72.9.5031-5040.2004
   Shoma S, 2011, EUR J CLIN MICROBIOL, V30, P521, DOI 10.1007/s10096-010-1113-x
   Simell B, 2008, CLIN VACCINE IMMUNOL, V15, P1391, DOI 10.1128/CVI.00110-08
   Smidt M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064422
   Tai SS, 2006, CRIT REV MICROBIOL, V32, P139, DOI 10.1080/10408410600822942
   van der Poll T, 2009, LANCET, V374, P1543, DOI 10.1016/S0140-6736(09)61114-4
   van Gageldonk PGM, 2008, J IMMUNOL METHODS, V335, P79, DOI 10.1016/j.jim.2008.02.018
   Verhaegh SJC, 2012, CLIN VACCINE IMMUNOL, V19, P914, DOI 10.1128/CVI.05630-11
   Verkaik N, 2008, J IMMUNOL METHODS, V335, P121, DOI 10.1016/j.jim.2008.02.022
   Verkaik NJ, 2009, J INFECT DIS, V199, P625, DOI 10.1086/596743
   Waterboer T, 2006, J IMMUNOL METHODS, V309, P200, DOI 10.1016/j.jim.2005.11.008
NR 44
TC 21
Z9 21
U1 0
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-1759
EI 1872-7905
J9 J IMMUNOL METHODS
JI J. Immunol. Methods
PD MAR
PY 2014
VL 405
BP 130
EP 143
DI 10.1016/j.jim.2014.02.002
PG 14
WC Biochemical Research Methods; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA AG7PA
UT WOS:000335608900014
PM 24530690
OA Green Published
DA 2020-12-17
ER

PT J
AU Brandao, A
   Simbalista, R
   Borges, IC
   Andrade, DC
   Araujo, M
   Nascimento-Carvalho, CM
AF Brandao, Alyson
   Simbalista, Raquel
   Borges, Igor C.
   Andrade, Dafne C.
   Araujo, Marcelo
   Nascimento-Carvalho, Cristiana M.
TI Retrospective Analysis of the Efficacies of Two Different Regimens of
   Aqueous Penicillin G Administered to Children with Pneumonia
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID RESISTANT PNEUMOCOCCUS; THERAPY
AB Community-acquired pneumonia (CAP) is an important childhood health problem. Penicillin remains appropriate for treating children with CAP. Clinical data are lacking on disease evolution in children treated with different posologic schemes of aqueous penicillin G. To assess if there were differences in disease evolution between children with CAP treated with 6 or 4 daily doses of aqueous penicillin G, we reviewed the medical charts of hospitalized patients 2 months to 11.5 years of age. Pneumonia was radiologically confirmed based on the detection of pulmonary infiltrate or pleural effusion on the chest radiograph taken on admission and read by a pediatric radiologist blinded to the clinical data. The total daily dose of aqueous penicillin G was 200,000 IU/kg of body weight. Data were recorded on admission, during disease evolution up to the 7th day of treatment, and at the final outcome. The results of hospitalization and the daily frequency of physical signs suggestive of pneumonia were assessed. The subgroups comprised 120 and 144 children who received aqueous penicillin G in 6 or 4 daily doses, respectively. Children >= 5 years of age were more frequent in the 4-daily-doses subgroup (16.0% versus 4.2%; respectively, P = 0.02). There were no differences between the compared subgroups in terms of final outcomes, lengths of hospitalization, durations of aqueous penicillin G use, frequencies of aqueous penicillin G substitution, or daily frequencies of tachypnea, fever, chest retraction, lower chest recession, nasal flaring, and cyanosis up to the 7th day of treatment. The studied posologic regimens were similarly effective in treating children hospitalized with a radiologically confirmed CAP diagnosis. Aqueous penicillin G (200,000 IU/kg/day) may be given in 4 daily doses to children with CAP.
C1 [Brandao, Alyson] Fed Univ Bahia Hosp, Pharm Unit, Salvador, BA, Brazil.
   [Simbalista, Raquel; Borges, Igor C.; Andrade, Dafne C.] Univ Fed Bahia, Sch Med, Salvador, BA, Brazil.
   [Araujo, Marcelo] Image Mem Unit, Salvador, BA, Brazil.
   [Araujo, Marcelo] Bahia Hosp, Salvador, BA, Brazil.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Dept Pediat, Sch Med, Salvador, BA, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia, Dept Pediat, Sch Med, Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
RI Borges, Igor Carmo/AAG-8531-2019
OI Carmo Borges, Igor/0000-0003-2749-0313
CR Aguado-Garcia JM, 2004, ENFERM INFEC MICR CL, V22, P230, DOI 10.1157/13059054
   Bradley JS, 2011, CLIN INFECT DIS, V53, pE25, DOI 10.1093/cid/cir531
   Cardoso MRA, 2008, ARCH DIS CHILD, V93, P221, DOI 10.1136/adc.2006.111625
   Cherian T, 2005, B WORLD HEALTH ORGAN, V83, P353
   Deiros Bronte L, 2006, An Pediatr (Barc), V64, P40
   El-Rashdi AS, 2006, ARCH DIS CHILD, V91, P351, DOI 10.1136/adc.2005.088831
   Giachetto G, 2004, PEDIATR INFECT DIS J, V23, P625, DOI 10.1097/01.inf.0000128783.11218.c9
   Goldbart AD, 2009, SCAND J INFECT DIS, V41, P182, DOI 10.1080/00365540802688378
   Harris M, 2011, THORAX, V66, pII1, DOI 10.1136/thoraxjnl-2011-200598
   Jacobs Michael R., 1999, American Journal of Medicine, V106, p19S, DOI 10.1016/S0002-9343(98)00351-9
   Jacobs MR, 2001, CLIN MICROBIOL INFEC, V7, P589, DOI 10.1046/j.1198-743x.2001.00295.x
   Kabra SK, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004874.pub3
   Liu L, 2012, LANCET, V379, P2151, DOI 10.1016/S0140-6736(12)60560-1
   Madhi SA, 2013, PEDIATR INFECT DIS J, V32, pE119, DOI 10.1097/INF.0b013e3182784b26
   Nascimento-Carvalho C M, 2001, Braz J Infect Dis, V5, P87
   Nascimento-Carvalho C M, 2001, Indian Pediatr, V38, P307
   Nascimento-Carvalho CM, 2009, J MED MICROBIOL, V58, P1390, DOI 10.1099/jmm.0.007765-0
   Niemi E, 2011, ACTA PAEDIATR, V100, P1230, DOI 10.1111/j.1651-2227.2011.02290.x
   Ponte C, 1996, ANTIMICROB AGENTS CH, V40, P2698, DOI 10.1128/AAC.40.12.2698
   Rudan I, 2008, B WORLD HEALTH ORGAN, V86, P408, DOI 10.2471/BLT.07.048769
   WHO UNICEF, 2008, INT MAN CHILDH ILLN
   World Health Organization, 2008, TRAIN COURS CHILD GR
   Zhang LJ, 2008, INDIAN PEDIATR, V45, P554
NR 23
TC 5
Z9 5
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD MAR
PY 2014
VL 58
IS 3
BP 1343
EP 1347
DI 10.1128/AAC.01951-13
PG 5
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA AC0HJ
UT WOS:000332175100010
PM 24342647
OA Green Published, Bronze
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, CM
   Madhi, SA
   O'Brien, KL
AF Nascimento-Carvalho, Cristiana M.
   Madhi, Shabir A.
   O'Brien, Katherine L.
TI Is Pneumonia Among Children in Developing Countries a Different Disease
   From the 1 Among Patients in the Same Age Group in Developed Countries?
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Letter
C1 [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
   [Madhi, Shabir A.] Univ Witwatersrand, Resp & Meningeal Pathogens Res Unit, MRC, ZA-2050 Johannesburg, South Africa.
   [Madhi, Shabir A.] Univ Witwatersrand, Fac Hlth Sci, Natl Res Fdn, ZA-2050 Johannesburg, South Africa.
   [O'Brien, Katherine L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA.
RP Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
OI O'Brien, Katherine/0000-0002-0164-4030
CR [Anonymous], 2002, STAT METHODS DIAGNOS
   Cherian T, 2005, B WORLD HEALTH ORGAN, V83, P353
   Griffin MR, 2013, NEW ENGL J MED, V369, P155, DOI 10.1056/NEJMoa1209165
   Principi N, 2011, THORAX, V66, P815, DOI 10.1136/thx.2010.142604
   Wingerter SL, 2012, PEDIATR INFECT DIS J, V31, P561, DOI 10.1097/INF.0b013e31824da716
   World Health Organization, 1990, PROGR CONTR AC RESP
   Xavier-Souza G, 2013, PEDIATR PULM, V48, P464, DOI 10.1002/ppul.22644
NR 7
TC 3
Z9 3
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD FEB
PY 2014
VL 33
IS 2
BP 229
EP 230
DI 10.1097/INF.0000000000000121
PG 2
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA AA5KZ
UT WOS:000331139100037
PM 24413414
DA 2020-12-17
ER

PT J
AU Cardoso, MRA
   Nascimento-Carvalho, CMC
   Ferrero, F
   Berezin, EN
   Ruvinsky, R
   Sant'Anna, CC
   Brandileone, MCD
   March, MDBP
   Maggi, R
   Feris-lglesias, J
   Benguigui, Y
   Camargos, PAM
AF Alves Cardoso, Maria Regina
   Costa Nascimento-Carvalho, Cristiana Maria
   Ferrero, Fernando
   Berezin, Eitan Naaman
   Ruvinsky, Raul
   Sant'Anna, Clemax Couto
   de Cunto Brandileone, Maria Cristina
   Bazhuni Pombo March, Maria de Ftima
   Maggi, Ruben
   Feris-lglesias, Jesus
   Benguigui, Yehuda
   Moreira Camargos, Paulo Augusto
CA CARIBE Group
TI Empyema and bacteremic pneumococcal pneumonia in children under five
   years of age
SO JORNAL BRASILEIRO DE PNEUMOLOGIA
LA English
DT Article
DE Empyema, pleural; Pneumonia, pneumococcal; Pneumococcal infections
ID COMMUNITY-ACQUIRED PNEUMONIA; COMPLICATIONS; RISK
AB We compared bacteremic pneumococcal pneumonia (BPP) and pneumococcal empyema (PE), in terms of clinical, radiological, and laboratory findings, in under-fives. A cross-sectional nested cohort study, involving under-fives (102 with PE and 128 with BPP), was conducted at 12 centers in Argentina, Brazil, and the Dominican Republic. Among those with PE, mean age was higher; disease duration was longer; and tachypnea, dyspnea, and high leukocyte counts were more common. Among those with BPP, fever and lethargy were more common. It seems that children with PE can be distinguished from those with BPP on the basis of clinical and laboratory findings. Because both conditions are associated with high rates of morbidity and mortality, prompt diagnosis is crucial.
C1 [Alves Cardoso, Maria Regina] Univ Sao Paulo, Sch Publ Hlth, Dept Epidemiol, Sao Paulo, Brazil.
   [Costa Nascimento-Carvalho, Cristiana Maria] Univ Fed Sao Paulo, Paulista Sch Med, Sao Paulo, Brazil.
   [Ferrero, Fernando] Pedro Elizalde Childrens Hosp, Buenos Aires, DF, Argentina.
   [Berezin, Eitan Naaman] Santa Casa Sch Med Sci Sao Paulo, Dept Pediat, Sao Paulo, Brazil.
   [Ruvinsky, Raul] Durand Municipal Hosp, Dept Maternal & Child Hlth, Buenos Aires, DF, Argentina.
   [Sant'Anna, Clemax Couto] Univ Fed Rio de Janeiro, Sch Med, Dept Pediat, Rio De Janeiro, Brazil.
   [de Cunto Brandileone, Maria Cristina] Adolfo Lutz Inst, Sao Paulo, Brazil.
   [Bazhuni Pombo March, Maria de Ftima] Univ Fed Fluminense, Niteroi, RJ, Brazil.
   [Maggi, Ruben] Fernando Figueira Inst Integrat Med, Recife, PE, Brazil.
   [Feris-lglesias, Jesus] Dr Robert Reid Cabral Childrens Hosp, Dept Infect Dis, Santo Domingo, Dominican Rep.
   [Benguigui, Yehuda] WHO, Pan Amer Hlth Org, Washington, DC USA.
   [Moreira Camargos, Paulo Augusto] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
   Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
RP Camargos, PAM (corresponding author), Univ Fed Minas Gerais, Fac Med, Dept Pediat, Ave Alfredo Balena 190,Sala 267, BR-30130100 Belo Horizonte, MG, Brazil.
EM paulo.camargos@pq.cnpq.br
RI Anna, Clemax Sant/H-7923-2019; Ferrero, Fernando/AAE-1886-2020
OI Anna, Clemax Sant/0000-0001-8732-8065; Ferrero,
   Fernando/0000-0001-6335-0102; Cardoso, Maria Regina/0000-0001-6092-9215
FU Canadian International Development Agency (CIDA); Pan American Health
   Organization; World Health Organization Department of Child and
   Adolescent Health and DevelopmentWorld Health Organization; Boston
   University Applied Research on Child Health (ARCH) Project (United
   States Agency for International Development)United States Agency for
   International Development (USAID) [HRN-A-00-960010-00]
FX This study received financial support from the Canadian International
   Development Agency (CIDA); the Pan American Health Organization; the
   World Health Organization Department of Child and Adolescent Health and
   Development; and the Boston University Applied Research on Child Health
   (ARCH) Project (United States Agency for International Development
   cooperative agreement no. HRN-A-00-960010-00).
CR Amorim PG, 2012, J BRAS PNEUMOL, V38, P614, DOI 10.1590/S1806-37132012000500011
   Calado C, 2010, REV PORT PNEUMOL, V16, P287
   Cardoso MRA, 2008, ARCH DIS CHILD, V93, P221, DOI 10.1136/adc.2006.111625
   Francois P, 2010, ACTA PAEDIATR, V99, P861, DOI 10.1111/j.1651-2227.2010.01734.x
   Grijalva CG, 2010, CLIN INFECT DIS, V50, P805, DOI 10.1086/650573
   Roxburgh CSD, 2008, ARCH DIS CHILD, V93, P316, DOI 10.1136/adc.2007.126540
NR 6
TC 2
Z9 2
U1 0
U2 1
PU SOC BRASILEIRA PNEUMOLOGIA TISIOLOGIA
PI BRASILIA DF
PA SEPS 714-719, BLOCO E ASA SUL, SALAS 220-223, BRASILIA DF, CEP70390-145,
   BRAZIL
SN 1806-3713
EI 1806-3756
J9 J BRAS PNEUMOL
JI J. Bras. Pneumol.
PD JAN-FEB
PY 2014
VL 40
IS 1
BP 69
EP 72
DI 10.1590/S1806-37132014000100010
PG 4
WC Respiratory System
SC Respiratory System
GA AB1ZY
UT WOS:000331594000010
PM 24626272
OA DOAJ Gold, Green Published
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, CM
   Madhi, SA
   O'Brien, KL
AF Nascimento-Carvalho, Cristiana M.
   Madhi, Shabir A.
   O'Brien, Katherine L.
TI Review of Guidelines for Evidence-based Management for Childhood
   Community-acquired Pneumonia in Under-5 Years From Developed and
   Developing Countries
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Editorial Material
ID LOWER RESPIRATORY-INFECTIONS; SIMPLE CLINICAL SIGNS; SYSTEMATIC
   ANALYSIS; ANTIBIOTIC-THERAPY; DIAGNOSIS; CHILDREN; ETIOLOGY; CRITERIA
C1 [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
   [Madhi, Shabir A.] Univ Witwatersrand, Fac Hlth Sci, MRC, Resp & Meningeal Pathogens Res Unit, Johannesburg, South Africa.
   [Madhi, Shabir A.] Univ Witwatersrand, Natl Res Fdn Vaccine Preventable Dis, Fac Hlth Sci, Dept Sci & Technol, Johannesburg, South Africa.
   [O'Brien, Katherine L.] Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA.
RP Nascimento-Carvalho, CM (corresponding author), Rua Prof Aristides Novis 105-1201B, BR-40210630 Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
OI O'Brien, Katherine/0000-0002-0164-4030
CR Ayieko P, 2007, PEDIATR INFECT DIS J, V26, P432, DOI 10.1097/01.inf.0000260107.79355.7d
   Bradley JS, 2011, CLIN INFECT DIS, V53, pE25, DOI 10.1093/cid/cir531
   CAMPBELL H, 1988, LANCET, V2, P742
   CHERIAN T, 1988, LANCET, V2, P125
   Esposito S, 2012, PEDIATR INFECT DIS J, V31, pE78, DOI 10.1097/INF.0b013e318255dc5b
   Jadavji T, 1997, CAN MED ASSOC J, V156, pS703
   LEVENTHAL JM, 1982, CLIN PEDIATR, V21, P730, DOI 10.1177/000992288202101205
   Levine OS, 2012, CLIN INFECT DIS, V54, pS93, DOI 10.1093/cid/cir1052
   Liu L, 2012, LANCET, V379, P2151, DOI 10.1016/S0140-6736(12)60560-1
   Madhi SA, 2013, PEDIATR INFECT DIS J, V32, pE119, DOI 10.1097/INF.0b013e3182784b26
   Nair H, 2013, LANCET, V381, P1380, DOI 10.1016/S0140-6736(12)61901-1
   Nascimento-Carvalho CM, 2010, EXPERT OPIN PHARMACO, V11, P225, DOI 10.1517/14656560903433714
   Principi N, 2011, THORAX, V66, P815, DOI 10.1136/thx.2010.142604
   Rudan I, 2008, B WORLD HEALTH ORGAN, V86, P408, DOI 10.2471/BLT.07.048769
   SHANN F, 1984, B WORLD HEALTH ORGAN, V62, P749
   SPOONER V, 1989, J TROP PEDIATRICS, V35, P295, DOI 10.1093/tropej/35.6.295
   Theodoratou E, 2010, INT J EPIDEMIOL, V39, P155, DOI 10.1093/ije/dyq032
   United Nations Statistics Division, 2013, COMP MACR CONT REG G
   *WHO, PROGR CONTR AC RESP
   Wingerter SL, 2012, PEDIATR INFECT DIS J, V31, P561, DOI 10.1097/INF.0b013e31824da716
   World Health Organisation, 2011, INT MAN CHILDH ILLN
   World Health Organization, 2013, POCK BOOK HOSP CHILD
   Zar HJ, 2005, SAMJ S AFR MED J, V95, P977
NR 23
TC 12
Z9 13
U1 0
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD NOV
PY 2013
VL 32
IS 11
BP 1281
EP 1282
DI 10.1097/INF.0b013e3182a4dcfa
PG 2
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA AA1BY
UT WOS:000330832500024
PM 24141800
DA 2020-12-17
ER

PT J
AU Gomes, RT
   Lyra, TG
   Alves, NN
   Caldas, RM
   Barberino, MG
   Nascimento-Carvalho, CM
AF Gomes, Renata Tavares
   Lyra, Ticiana Goyanna
   Alves, Noraney Nunes
   Caldas, Renilza Menezes
   Barberino, Maria-Goreth
   Nascimento-Carvalho, Cristiana Maria
TI Methicillin-resistant and methicillin-susceptible community-acquired
   Staphylococcus aureus infection among children
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Antibacterial agents; Community-acquired infection; Methicillin
   resistance; Staphylococcal infections; Staphylococcus aureus
   antimicrobial; resistance
ID BLOOD-STREAM INFECTIONS; SURVEILLANCE; DEFINITIONS
AB Methicillin-resistant Staphylococcus aureus has emerged as a pathogen associated with community-acquired infections worldwide. We report the spectrum of community-acquired S. aureus infections and compare the patients infected with methicillin-susceptible or methicillin-resistant strains among patients aged <20 years. Overall, 90 cases of community-acquired S. aureus were detected in an 11-year period. Clinical and microbiological data were registered. Fifty-nine (66%) patients were male and the median age was two years. The majority (87%) of the patients were hospitalized and chronic underlying illnesses were detected in 27 (30%) cases. Overall, 34 (37.8%) patients had skin/soft tissue infections and 56 (62.2%) patients had deep-seated infection. Four (5.1%) patients were transferred to the intensive care unit and two (2.6%) died. Complications were detected in 17 (18.9%) cases, such as pleural effusion (41.2%), osteomyelitis (23.5%), and sepsis (17.6%). Six (6.7%) methicillin-resistant strains were detected. Patients infected with methicillin-susceptible or methicillin-resistant strains had similar baseline characteristics and treatment outcomes. Approximately 93% of the cases received systemic antibiotics, out of which 59 (65.5%) used oxacillin or cefalotin. Both methicillin-susceptible and methicillin-resistant S. aureus strains resulted in morbidity and death among children in this setting where methicillin-resistant strains are infrequent. (C) 2013 Elsevier Editora Ltda. All rights reserved.
C1 [Gomes, Renata Tavares; Lyra, Ticiana Goyanna; Nascimento-Carvalho, Cristiana Maria] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
   [Alves, Noraney Nunes; Caldas, Renilza Menezes; Barberino, Maria-Goreth] Fed Univ Bahia Hosp, Bacteriol Lab, Salvador, BA, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Rua Prof Aristides Novis 105-1201B, BR-40210630 Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
CR CDC, 2010, DIAGN TEST MRSA MRSA
   CDC, 1999, MMWR-MORBID MORTAL W, V48, P707
   Chambers HF, 2001, EMERG INFECT DIS, V7, P178, DOI 10.3201/eid0702.010204
   Clinical and Laboratory Standards Institute, 2007, M100S17 CLIN LAB STA
   Corey GR, 2009, CLIN INFECT DIS, V48, pS254, DOI 10.1086/598186
   Cosgrove SE, 2003, CLIN INFECT DIS, V36, P53, DOI 10.1086/345476
   de Onis M, 2006, PUBLIC HEALTH NUTR, V9, P942, DOI 10.1017/PHN20062005
   Folden DV, 2005, J HOSP INFECT, V60, P329, DOI 10.1016/j.jhin.2004.12.025
   Fowler VG, 2003, ARCH INTERN MED, V163, P2066, DOI 10.1001/archinte.163.17.2066
   Ibrahim EH, 2000, CHEST, V118, P146, DOI 10.1378/chest.118.1.146
   JORGENSEN JH, 1991, INFECT CONT HOSP EP, V12, P14, DOI 10.2307/30147084
   Kang CI, 2010, J INFECTION, V61, P299, DOI 10.1016/j.jinf.2010.07.011
   Kaplan SL, 2005, CLIN INFECT DIS, V40, P1785, DOI 10.1086/430312
   Len KA, 2010, PEDIATR PULM, V45, P898, DOI 10.1002/ppul.21269
   Martinez-Aguilar G, 2004, PEDIATR INFECT DIS J, V23, P701, DOI 10.1097/01.inf.0000133044.79130.2a
   Mera RM, 2011, MICROB DRUG RESIST, V17, P321, DOI 10.1089/mdr.2010.0193
   Miller LG, 2009, INFECT DIS CLIN N AM, V23, P35, DOI 10.1016/j.idc.2008.10.002
   Mongkolrattanothai K, 2003, CLIN INFECT DIS, V37, P1050, DOI 10.1086/378277
   Mongkolrattanothai K, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-112
   Nascimento-Carvalho C, 2000, J PEDIAT RIO J, V79, P209
   Nascimento-Carvalho CM, 2008, MICROB DRUG RESIST, V14, P129, DOI 10.1089/mdr.2008.0790
   Rybak MJ, 2005, PHARMACOTHERAPY, V25, P74, DOI 10.1592/phco.25.1.74.55620
   Salgado CD, 2003, CLIN INFECT DIS, V36, P131, DOI 10.1086/345436
   Sattler CA, 2002, PEDIATR INFECT DIS J, V21, P910, DOI 10.1097/00006454-200210000-00005
   Seybold U, 2006, CLIN INFECT DIS, V42, P647, DOI 10.1086/499815
   Sievert DM, 2010, AM J PUBLIC HEALTH, V100, P1777, DOI 10.2105/AJPH.2009.181958
   Taiwo S S, 2009, West Afr J Med, V28, P281
   Thomas B, 2009, ACTA PAEDIATR, V98, P1372, DOI 10.1111/j.1651-2227.2009.01293.x
   Wu DJ, 2010, DIAGN MICR INFEC DIS, V67, P1, DOI 10.1016/j.diagmicrobio.2009.12.006
NR 29
TC 7
Z9 7
U1 0
U2 4
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD SEP-OCT
PY 2013
VL 17
IS 5
BP 573
EP 578
DI 10.1016/j.bjid.2013.02.010
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA 244OJ
UT WOS:000326398600010
PM 24055391
OA DOAJ Gold, Green Published
DA 2020-12-17
ER

PT J
AU Simbalista, R
   Araujo, M
   Nascimento-Carvalho, CM
AF Simbalista, Raquel
   Araujo, Marcelo
   Nascimento-Carvalho, Cristiana M.
TI Radiologically confirmed pneumonia among neonates and very young infants
SO ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION
LA English
DT Letter
C1 [Simbalista, Raquel] Univ Fed Bahia, Sch Med, Postgrad Program, BR-40210630 Salvador, BA, Brazil.
   [Araujo, Marcelo] Bahia Hosp, Image Mem Unit, Salvador, BA, Brazil.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Paediat, BR-40210630 Salvador, BA, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia, Sch Med, Dept Paediat, Rua Prof Aristides Novis 105-1201B, BR-40210630 Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
CR Cherian T, 2005, B WORLD HEALTH ORGAN, V83, P353
   Duke T, 2005, ARCH DIS CHILD-FETAL, V90, P211, DOI 10.1136/adc.2003.048108
   Harris M, 2011, THORAX, V66, pII1, DOI 10.1136/thoraxjnl-2011-200598
   WHO UNICEF, 2008, INT MAN CHILDH ILLN
NR 4
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1359-2998
EI 1468-2052
J9 ARCH DIS CHILD-FETAL
JI Arch. Dis. Child.-Fetal Neonatal Ed.
PD JUL
PY 2013
VL 98
IS 4
BP F373
EP +
DI 10.1136/archdischild-2013-304087
PG 2
WC Pediatrics
SC Pediatrics
GA 301EG
UT WOS:000330515000021
PM 23632314
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, CM
   Oliveira, JR
   Cardoso, MRA
   Araujo-Neto, C
   Barral, A
   Saukkoriipi, A
   Paldanius, M
   Leinonen, M
   Lappalainen, M
   Soderlund-Venermo, M
   Vainionpaa, R
   Ruuskanen, O
AF Nascimento-Carvalho, Cristiana M.
   Oliveira, Juliana R.
   Cardoso, Maria-Regina A.
   Araujo-Neto, Cesar
   Barral, Aldina
   Saukkoriipi, Annika
   Paldanius, Mika
   Leinonen, Maija
   Lappalainen, Maija
   Soderlund-Venermo, Maria
   Vainionpaa, Raija
   Ruuskanen, Olli
TI Respiratory viral infections among children with community-acquired
   pneumonia and pleural effusion
SO SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Acute respiratory infection; lower respiratory tract infection; pleural
   fluid; respiratory viruses; viral infection
ID TIME QUANTITATIVE PCR; DIAGNOSIS; TRACT; EPIDEMIOLOGY; ETIOLOGY; ASSAYS
AB Pleural effusion (PE), a complication of community-acquired pneumonia (CAP), is usually attributed to a bacterial infection. Nonetheless, viral infections have not been investigated routinely. We searched for bacterial and viral infections among 277 children hospitalized with CAP. Among these children 206 (74%) had radiographic confirmation, of whom 25 (12%) had PE. The aetiology was established in 18 (72%) PE cases: bacterial (n = 5; 28%), viral (n = 9; 50%), and viral-bacterial (n = 4; 22%) infections were found. Infection by rhinovirus (n = 3), enterovirus, Streptococcus pneumoniae (n = 2 each), Haemophilus influenzae, Moraxella catarrhalis, Mycoplasma pneumoniae, influenza A virus, and respiratory syncytial virus (RSV)(n = 1 each) were detected as probable sole infections. Parainfluenza virus 1/3 + influenza A virus and RSV + influenza A virus (n = 1 each) were identified as mixed viral-viral infections. Probable viral non-bacterial infection was identified in a third of the cases with CAP and PE. It is advisable to investigate viral as well as bacterial infections among children with CAP and PE.
C1 [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Paediat, BR-40210630 Salvador, BA, Brazil.
   [Oliveira, Juliana R.] Univ Fed Bahia, Prof Hosannah de Oliveira Paediat Ctr, BR-40210630 Salvador, BA, Brazil.
   [Cardoso, Maria-Regina A.] Univ Sao Paulo, Fac Publ Hlth, Dept Epidemiol, Sao Paulo, Brazil.
   [Araujo-Neto, Cesar] Univ Fed Bahia, Sch Med, Image Diag Dept, BR-40210630 Salvador, BA, Brazil.
   [Barral, Aldina] Univ Fed Bahia, Sch Med, Dept Pathol, BR-40210630 Salvador, BA, Brazil.
   [Saukkoriipi, Annika; Paldanius, Mika; Leinonen, Maija] Natl Inst Hlth & Welf, Bacterial Lab, Oulu, Finland.
   [Paldanius, Mika] Oulu Univ Hosp, Clin Microbiol Lab, Oulu, Finland.
   [Lappalainen, Maija] Univ Cent Hosp Lab Div, Virol Lab, Helsinki, Finland.
   [Soderlund-Venermo, Maria] Univ Helsinki, Haartman Inst, Helsinki, Finland.
   [Vainionpaa, Raija] Univ Turku, Dept Virol, Turku, Finland.
   [Ruuskanen, Olli] Univ Turku, Dept Paediat, Turku, Finland.
RP Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia, Sch Med, Dept Paediat, Rua Prof Aristides Novis 105-1201B, BR-40210630 Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
RI Soderlund-Venermo, Maria/AAX-2112-2020
OI Lappalainen, Maija/0000-0001-5400-1250
FU Fundacao de Amparo a Pesquisa no Estado da Bahia (FAPESB), Salvador,
   Brazil; Paediatric Research Foundation; Helsinki University Central
   Hospital Research and Development Fund; Academy of FinlandAcademy of
   Finland [1122539]; Helsinki University; Medical Society of Finland;
   Sigrid Juselius Foundation, Helsinki, FinlandSigrid Juselius Foundation
FX This study was supported by the Fundacao de Amparo a Pesquisa no Estado
   da Bahia (FAPESB), Salvador, Brazil, the Paediatric Research Foundation,
   the Helsinki University Central Hospital Research and Development Fund,
   the Academy of Finland (project 1122539), the Helsinki University Funds,
   the Medical Society of Finland, and the Sigrid Juselius Foundation,
   Helsinki, Finland. C. M. Nascimento-Carvalho, M.-R. A. Cardoso, and A.
   Barral are investigators of the Brazilian Council for Science and
   Technology Development (CNPq).
CR Baron EJ, 2007, MANUAL OF CLINICAL MICROBIOLOGY, 9TH ED, P1
   Chetty Krishne, 2007, Paediatr Drugs, V9, P401, DOI 10.2165/00148581-200709060-00007
   Deiros Bronte L, 2006, An Pediatr (Barc), V64, P40
   Galama JMD, 1996, CLIN INFECT DIS, V22, P1004, DOI 10.1093/clinids/22.6.1004
   Gerna G, 2009, J MED VIROL, V81, P1498, DOI 10.1002/jmv.21548
   Hijazi Z, 1997, ANN TROP PAEDIATR, V17, P127, DOI 10.1080/02724936.1997.11747875
   Hyypia T, 1998, J CLIN MICROBIOL, V36, P2081
   Kantola K, 2010, J CLIN MICROBIOL, V48, P4044, DOI 10.1128/JCM.00686-10
   Korppi M, 2006, RESPIROLOGY, V11, P80, DOI 10.1111/j.1440-1843.2006.00788.x
   Liu L, 2012, LANCET, V379, P2151, DOI 10.1016/S0140-6736(12)60560-1
   Makela MJ, 1998, J CLIN MICROBIOL, V36, P539
   Michelow IC, 2004, PEDIATRICS, V113, P701, DOI 10.1542/peds.113.4.701
   Morre SA, 2002, J CLIN MICROBIOL, V40, P584, DOI 10.1128/JCM.40.2.584-587.2002
   Nascimento-Carvalho CM, 2008, PEDIATR INFECT DIS J, V27, P939, DOI 10.1097/INF.0b013e3181723751
   Nascimento-Carvalho CM, 2012, J MED VIROL, V84, P253, DOI 10.1002/jmv.22268
   NOHYNEK H, 1995, PEDIATR INFECT DIS J, V14, P478, DOI 10.1097/00006454-199506000-00003
   Rudan I, 2008, B WORLD HEALTH ORGAN, V86, P408, DOI 10.2471/BLT.07.048769
   Ruuskanen O, 2011, LANCET, V377, P1264, DOI 10.1016/S0140-6736(10)61459-6
   Saglani S, 2005, ARCH DIS CHILD, V90, P70, DOI 10.1136/adc.2003.042176
   Saukkoriipi A, 2002, MOL CELL PROBE, V16, P385, DOI 10.1006/mcpr.2002.0443
   Soderlund-Venermo M, 2009, EMERG INFECT DIS, V15, P1423, DOI 10.3201/eid1509.090204
   Wang SP, 2000, J INFECT DIS, V181, pS421, DOI 10.1086/315622
   Waris ME, 1998, J CLIN MICROBIOL, V36, P3155, DOI 10.1128/JCM.36.11.3155-3159.1998
NR 23
TC 5
Z9 7
U1 0
U2 8
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0036-5548
EI 1651-1980
J9 SCAND J INFECT DIS
JI Scand. J. Infect. Dis.
PD JUN
PY 2013
VL 45
IS 6
BP 478
EP 483
DI 10.3109/00365548.2012.754106
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA 144LI
UT WOS:000318940400009
PM 23286738
DA 2020-12-17
ER

PT J
AU Xavier-Souza, G
   Vilas-Boas, AL
   Fontoura, MSH
   Araujo-Neto, CA
   Andrade, SCS
   Cardoso, MRA
   Nascimento-Carvalho, CM
AF Xavier-Souza, Gabriel
   Vilas-Boas, Ana Luisa
   Fontoura, Maria-Socorro Heitz
   Araujo-Neto, Cesar Augusto
   Andrade, Sandra C. S.
   Cardoso, Maria-Regina Alves
   Nascimento-Carvalho, Cristiana Maria
CA PNEUMOPAC-Efficacy Study Grp
TI The inter-observer variation of chest radiograph reading in acute lower
   respiratory tract infection among children
SO PEDIATRIC PULMONOLOGY
LA English
DT Article
DE acute respiratory infection; child; community-acquired infection; lower
   respiratory tract disease; lung disease; pneumonia radiography;
   reproducibility of results
ID PNEUMONIA; DIAGNOSIS; AGREEMENT; VARIABILITY
AB This study assessed the inter-observer agreement in the interpretation of several radiographic features in the chest radiographs (CXR) of 803 children aged 259 months with non-severe acute lower respiratory tract infection (ALRI). Inclusion criteria comprised: report of respiratory complaints, detection of lower respiratory findings, and presence of pulmonary infiltrate on the CXR taken on admission and read by the pediatrician on duty. Data on demographic and clinical findings on admission were collected from children included in a clinical trial on the use of amoxicillin (ClinicalTrials.gov Identifier NCT01200706). CXR was later read by two independent pediatric radiologists blinded to clinical information and pneumonia was finally diagnosed if there was agreement on the presence of pulmonary infiltrate or pleural effusion. The kappa index () of agreement was calculated. The radiologists agreed that 774 (96.4%) and 3 (0.4%) CXR were appropriate or inappropriate for reading, respectively, and that 222 (28.7%) and 459 (59.3%) CXR presented or did not present pneumonia. In intent to treat analysis, that is, considering the 803 enrolled patients, for the presence of pneumonia was 0.725 (95% CI: 0.6750.775). The overall agreement was 78.7% (normal CXR [n=385, 60.9%], pneumonia [n=222, 35.1%], other radiological diagnosis [n=22, 3.5%], inappropriate for reading [n=3, 0.5%]). The most frequent radiological findings were alveolar infiltrate (33.2%) and consolidation (32.9%) by radiologist 1 and consolidation (28.3%) and alveolar infiltrate (19.3%) by radiologist 2. Concordance for consolidation was 86.7% (k=0.683, 95%CI: 0.6310.741). Agreement was good between two pediatric radiologists when diagnosis of pneumonia among children with non-severe ALRI was compared. Pediatr Pulmonol. 2013; 48:464469. (c) 2012 Wiley Periodicals, Inc.
C1 [Xavier-Souza, Gabriel; Vilas-Boas, Ana Luisa; Fontoura, Maria-Socorro Heitz; Nascimento-Carvalho, Cristiana Maria] Univ Fed Bahia, Dept Pediat, Sch Med, Salvador, Bahia, Brazil.
   [Araujo-Neto, Cesar Augusto] Univ Fed Bahia, Dept Image Diag, Sch Med, Salvador, Bahia, Brazil.
   [Andrade, Sandra C. S.] Fed Univ, Image Diag Unit, Bahia Hosp, Salvador, Bahia, Brazil.
   [Cardoso, Maria-Regina Alves] Univ Sao Paulo, Fac Publ Hlth, Dept Epidemiol, Sao Paulo, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Rua Prof Aristides Novis 105-1201B, BR-40210630 Salvador, Bahia, Brazil.
EM nascimentocarvalho@hotmail.com
OI Cardoso, Maria Regina/0000-0001-6092-9215; Matutino Kahn,
   Adriana/0000-0002-5306-0571
FU Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB)
FX Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB).
CR Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1
   Cherian T, 2005, B WORLD HEALTH ORGAN, V83, P353
   Coakley FV, 1996, CLIN RADIOL, V51, P614, DOI 10.1016/S0009-9260(96)80053-5
   CRAIN EF, 1991, PEDIATRICS, V88, P821
   Davies HD, 1996, PEDIATR INFECT DIS J, V15, P600, DOI 10.1097/00006454-199607000-00008
   El-Rashdi AS, 2006, ARCH DIS CHILD, V91, P351, DOI 10.1136/adc.2005.088831
   FEINSTEIN AR, 1990, J CLIN EPIDEMIOL, V43, P543, DOI 10.1016/0895-4356(90)90158-L
   Hazir T, 2006, BMJ-BRIT MED J, V333, P629, DOI 10.1136/bmj.38915.673322.80
   Johnson J, 2010, EMERG RADIOL, V17, P285, DOI 10.1007/s10140-009-0854-2
   Kiekara O, 1996, ANN MED, V28, P69, DOI 10.3109/07853899608999077
   KRAMER MS, 1992, PEDIATRICS, V90, P11
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Madhi SA, 2007, VACCINE, V25, P2413, DOI 10.1016/j.vaccine.2006.09.010
   MCCARTHY PL, 1981, CLIN PEDIATR, V20, P686, DOI 10.1177/000992288102001101
   MELBYE H, 1992, ACTA RADIOL, V33, P79
   Neuman MI, 2012, J HOSP MED, V7, P294, DOI 10.1002/jhm.955
   Patel AB, 2007, INDIAN PEDIATR, V44, P675
   Pauls S, 2007, ROFO-FORTSCHR RONTG, V179, P1152, DOI 10.1055/s-2007-963286
   SIMPSON W, 1974, PEDIATR RADIOL, V2, P97, DOI 10.1007/BF01314938
   Swingler George H, 2001, BMC Med Imaging, V1, P1, DOI 10.1186/1471-2342-1-1
   WHO UNICEF, 2008, INT MAN CHILDH ILLN
NR 21
TC 17
Z9 19
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8755-6863
J9 PEDIATR PULM
JI Pediatr. Pulmonol.
PD MAY
PY 2013
VL 48
IS 5
BP 464
EP 469
DI 10.1002/ppul.22644
PG 6
WC Pediatrics; Respiratory System
SC Pediatrics; Respiratory System
GA 130PN
UT WOS:000317930800005
PM 22888091
DA 2020-12-17
ER

PT J
AU Madhi, SA
   De Wals, P
   Grijalva, CG
   Grimwood, K
   Grossman, R
   Ishiwada, N
   Lee, PI
   Nascimento-Carvalho, C
   Nohynek, H
   O'Brien, KL
   Vergison, A
   Wolter, J
AF Madhi, Shabir A.
   De Wals, Philippe
   Grijalva, Carlos G.
   Grimwood, Keith
   Grossman, Ronald
   Ishiwada, Naruhiko
   Lee, Ping-Ing
   Nascimento-Carvalho, Cristiana
   Nohynek, Hanna
   O'Brien, Katherine L.
   Vergison, Anne
   Wolter, Joanne
TI The Burden of Childhood Pneumonia in the Developed World: A Review of
   the Literature
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Review
DE children; epidemiology; mortality; morbidity; pneumonia; hospitalization
ID PNEUMOCOCCAL CONJUGATE VACCINE; COMMUNITY-ACQUIRED PNEUMONIA;
   RESPIRATORY-TRACT INFECTIONS; RADIOLOGICALLY-CONFIRMED PNEUMONIA;
   PEDIATRIC PARAPNEUMONIC EMPYEMA; INFLUENZAE TYPE-B;
   HAEMOPHILUS-INFLUENZAE; HOSPITAL ADMISSIONS; HEALTH-ORGANIZATION;
   CHILDREN YOUNGER
AB Background: Estimates of the disease burden from childhood pneumonia are available for most developed countries, but they are based mainly on models. Measured country-specific pneumonia burden data are limited to a few nations and differ in case definitions and case ascertainment methods. This review describes pneumonia disease burden in developed countries.
   Methods: We reviewed studies describing childhood pneumonia incidence in North America, Europe, Australia, New Zealand and Japan. Available estimates suggest that each year in developed countries there are up to 2.6 million cases of pneumonia, including 1.5 million hospitalized cases and around 3000 pneumonia deaths (compared with approximately 640 annual deaths from meningitis) in children <5 years of age.
   Results: Data to inform policy decisions would be improved by information on burden and etiology of severe pneumonia, population-based incidence of ambulatory visits and hospitalizations and prevalence of complications and sequelae.
C1 [Madhi, Shabir A.] Univ Witwatersrand, MRC, Resp & Meningeal Pathogens Res Unit, ZA-2050 Johannesburg, South Africa.
   [Madhi, Shabir A.] Univ Witwatersrand, Dept Sci & Technol, Natl Res Fdn, ZA-2050 Johannesburg, South Africa.
   [De Wals, Philippe] Univ Laval, Dept Social & Prevent Med, Quebec City, PQ, Canada.
   [Grijalva, Carlos G.] Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37212 USA.
   [Grimwood, Keith] Univ Queensland, Royal Childrens Hosp, Queensland Childrens Med Res Inst, Brisbane, Qld, Australia.
   [Grossman, Ronald] Univ Toronto, Mississauga, ON L5L 1C6, Canada.
   [Grossman, Ronald] Credit Valley Hosp, Mississauga, ON, Canada.
   [Ishiwada, Naruhiko] Chiba Univ, Grad Sch Med, Dept Pediat, Chiba, Japan.
   [Lee, Ping-Ing] Natl Taiwan Univ Hosp, Taipei, Taiwan.
   [Nascimento-Carvalho, Cristiana] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
   [Nohynek, Hanna] Natl Inst Hlth & Welf, Dept Vaccines & Immune Protect, Helsinki, Finland.
   [O'Brien, Katherine L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA.
   [Vergison, Anne] Univ Libre Bruxelles, Pediat Infect Dis,Infect Control & Epidemiol Unit, Brussels, Belgium.
EM shabirm@nicd.ac.za
RI Grimwood, Keith/F-9334-2011
OI Grijalva, Carlos/0000-0002-2329-7797; Grimwood,
   Keith/0000-0003-3174-9834; O'Brien, Katherine/0000-0002-0164-4030; LEE,
   PING-ING/0000-0002-7299-2825
FU GlaxoSmithKline Vaccines; PfizerPfizer; GlaxoSmithKlineGlaxoSmithKline;
   Merck Sharp and DohmeMerck & Company; NovartisNovartis; Sanofi Pasteur
FX GlaxoSmithKline Vaccines funded all costs associated with the
   development and the publishing of the present article. S. A. M. received
   an honorarium and travel support from GlaxoSmithKline to attend the
   Pneumonia Advisory Board on the 13th and 14th October 2010 in Leuven,
   Belgium. He has received consultancy fees for participation in expert
   boards from Pfizer, GlaxoSmithKline, Merck Sharp and Dohme and Novartis,
   and payment for lectures from Pfizer and GlaxoSmithKline. P. D. W.
   received consulting fees and travel support from GlaxoSmithKline to
   attend the Pneumonia Advisory Board on the 13th and 14th October 2010 in
   Leuven, Belgium. P. D. W. has received consulting fees for board
   memberships and research grants from GlaxoSmithKline, Pfizer and
   Novartis. C. G. G. received an honorarium and travel support from
   GlaxoSmithKline to attend the Pneumonia Advisory Board on the 13th and
   14th October 2010 in Leuven, Belgium. K. G. received consulting fees and
   travel support from GlaxoSmithKline to attend the Pneumonia Advisory
   Board on the 13th and 14th October 2010 in Leuven, Belgium. He has also
   received lectures fees from GlaxoSmithKline for presentations on
   pneumococcal conjugate vaccines. R. G. is a member of Advisory Boards
   for the following companies: Merck, GlaxoSmithKline, Bayer Pharma,
   Novartis, Nycomed and Abbott Laboratories. He has received research
   support from GlaxoSmithKline and Novartis, payment for lectures from
   GlaxoSmithKline, Bayer Pharma, Novartis, Nycomed and Abbott
   Laboratories, payment for development of educational presentations from
   Bayer Pharma and GlaxoSmithKline, and payment for travel expenses
   unrelated to the activities listed from Bayer, Novartis and
   GlaxoSmithKline. C. N.-C. received money for expert testimony from
   GlaxoSmithKline, specifically to present data on the burden of pneumonia
   in Brazil and neighboring countries during the Pneumonia Advisory Board
   on the 13th and 14th October 2010 in Leuven, Belgium. H.N. received
   consulting fees from GlaxoSmithKline to attend the Pneumonia Advisory
   Board on the 13th and 14th October 2010 in Leuven, Belgium. She has
   received money for board memberships and payment for lectures relating
   to pneumococcal vaccines from Pfizer, has served as technical advisor in
   pneumococcal conjugate vaccine development issues for GlaxoSmithKline
   and Pfizer and as a scientific consultant for Encorium. She was the
   coordinator of a phase III trial on 11-valent pneumococcal conjugate
   vaccine, which received funding support from Sanofi Pasteur. K.L.O.B.
   has current research grant support from GlaxoSmithKline and has
   participated in ad hoc external expert committees on pneumococcal
   vaccines for Merck, Sanofi Pasteur, GlaxoSmithKline and Pfizer. A. V.
   has received support from GlaxoSmithKline for travel to attend
   scientific meetings and has participated in advisory boards and given
   lectures on pneumococcal disease for Pfizer and GlaxoSmithKline. She has
   received institutional support and grants from Merck Sharp and Dohme for
   unrelated board memberships and research activities. J.W. is an
   independent consultant and medical writer who received funding from
   GlaxoSmithKline Vaccines to perform the literature review and write the
   first draft of this article. The authors have no other funding or
   conflicts of interest to disclose.
CR Adam D, 2008, VACCINE, V26, P5944, DOI 10.1016/j.vaccine.2008.08.058
   Alaghehbandan R, 2007, INT J INFECT DIS, V11, P23, DOI 10.1016/j.ijid.2005.09.003
   Alfaro C, 2005, PEDIATR INFECT DIS J, V24, P274, DOI 10.1097/01.inf.0000154332.66085.de
   Ampofo K, 2010, PEDIATR INFECT DIS J, V29, P905, DOI 10.1097/INF.0b013e3181df2c70
   ANDERSON HR, 1986, BRIT MED BULL, V42, P167, DOI 10.1093/oxfordjournals.bmb.a072116
   Ansaldi F, 2008, J INT MED RES, V36, P1255, DOI 10.1177/147323000803600612
   Bjor O, 2003, BMC PUBLIC HEALTH, V3, DOI 10.1186/1471-2458-3-22
   Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1
   Black SB, 2002, PEDIATR INFECT DIS J, V21, P810, DOI 10.1097/00006454-200209000-00005
   Byington CL, 2010, J CLIN MICROBIOL, V48, P520, DOI 10.1128/JCM.01200-09
   Byington CL, 2002, CLIN INFECT DIS, V34, P434, DOI 10.1086/338460
   Calado C, 2010, REV PORT PNEUMOL, V16, P287
   Calbo E, 2006, CLIN MICROBIOL INFEC, V12, P867, DOI 10.1111/j.1469-0691.2006.1502_1.x
   Clark JE, 2007, EPIDEMIOL INFECT, V135, P262, DOI 10.1017/S0950268806006741
   Comes Castellano A M, 2005, An Med Interna, V22, P118
   Dallaire F, 2006, CAN J PUBLIC HEALTH, V97, P362, DOI 10.1007/BF03405343
   De Wals P, 2008, PEDIATR INFECT DIS J, V27, P963, DOI 10.1097/INF.0b013e31817cf76f
   Deiros Bronte L, 2006, An Pediatr (Barc), V64, P40
   Esposito S, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-12
   EVERS SE, 1982, CAN MED ASSOC J, V126, P249
   Feikin DR, 2013, PEDIATR INFECT DIS J, V32, pE14, DOI 10.1097/INF.0b013e31826fd39b
   Finley C, 2008, CAN RESPIR J, V15, P85, DOI 10.1155/2008/975312
   Fletcher M, 2006, PEDIATR INFECT DIS J, V25, P559, DOI 10.1097/01.inf.0000219535.14201.1b
   FOY HM, 1973, AM J EPIDEMIOL, V97, P80, DOI 10.1093/oxfordjournals.aje.a121492
   FOY HM, 1979, JAMA-J AM MED ASSOC, V241, P253, DOI 10.1001/jama.241.3.253
   Francois P, 2010, ACTA PAEDIATR, V99, P861, DOI 10.1111/j.1651-2227.2010.01734.x
   Garces-Sanchez M D, 2005, An Pediatr (Barc), V63, P125
   Garcia-Cobos S, 2008, ANTIMICROB AGENTS CH, V52, P2760, DOI 10.1128/AAC.01674-07
   Gil A, 2002, J INFECTION, V44, P84, DOI 10.1053/jinf.2002.0966
   Gimenez Sanchez F, 2007, An Pediatr (Barc), V66, P578
   Grant CC, 1998, J PAEDIATR CHILD H, V34, P355, DOI 10.1046/j.1440-1754.1998.00237.x
   Grant CC, 1999, NEW ZEAL MED J, V112, P345
   Grijalva C. G., 2009, Morbidity and Mortality Weekly Report, V58, P1
   Grijalva CG, 2007, LANCET, V369, P1179, DOI 10.1016/S0140-6736(07)60564-9
   Grijalva CG, 2010, CLIN INFECT DIS, V50, P805, DOI 10.1086/650573
   Gupta R, 2006, THORAX, V61, P179, DOI 10.1136/thx.2005.049510
   Hammitt LL, 2012, CLIN INFECT DIS, V54, pS190, DOI 10.1093/cid/cir1071
   Hanquet G, 2010, EMERG INFECT DIS, V16, P1428, DOI 10.3201/eid1609.100102
   Hansen J, 2006, PEDIATR INFECT DIS J, V25, P779, DOI 10.1097/01.inf.0000232706.35674.2f
   Heilmann KP, 2005, ANTIMICROB AGENTS CH, V49, P2561, DOI 10.1128/aac.49.6.2561-2564.2005
   Jardine A, 2010, PEDIATR INFECT DIS J, V29, P607, DOI 10.1097/INF.0b013e3181d7d09c
   Jensen-Fangel S, 2004, SCAND J INFECT DIS, V36, P31, DOI 10.1080/00365540310017618
   JOKINEN C, 1993, AM J EPIDEMIOL, V137, P977, DOI 10.1093/oxfordjournals.aje.a116770
   Kolnaar B G, 1994, Fam Med, V26, P106
   Koshy E, 2010, THORAX, V65, P770, DOI 10.1136/thx.2010.137802
   Kronman MP, 2011, PEDIATRICS, V127, P411, DOI 10.1542/peds.2010-2008
   Lanata CF, 2004, INT J EPIDEMIOL, V33, P1362, DOI 10.1093/ije/dyh229
   Lee GE, 2010, PEDIATRICS, V126, P204, DOI 10.1542/peds.2009-3109
   Levine OS, 2012, CLIN INFECT DIS, V54, pS93, DOI 10.1093/cid/cir1052
   Li STT, 2010, PEDIATRICS, V125, P26, DOI 10.1542/peds.2009-0184
   Lynch T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011989
   MacIntyre CR, 2003, EPIDEMIOL INFECT, V131, P1091, DOI 10.1017/S0950268803001365
   Madhi SA, 2008, VACCINE, V26, pB9, DOI 10.1016/j.vaccine.2008.06.001
   Madhi SA, 2007, VACCINE, V25, P2413, DOI 10.1016/j.vaccine.2006.09.010
   Madhi Shabir A, 2008, Expert Rev Respir Med, V2, P663, DOI 10.1586/17476348.2.5.663
   Martinon-Torres F, 2008, An Pediatr (Barc), V68, P158
   MCCONNOCHIE KM, 1988, AM J PUBLIC HEALTH, V78, P34, DOI 10.2105/AJPH.78.1.34
   Michelow IC, 2004, PEDIATRICS, V113, P701, DOI 10.1542/peds.113.4.701
   Milne RJ, 2010, APPL HEALTH ECON HEA, V8, P281, DOI 10.2165/11535710-000000000-00000
   Monge V, 2001, INFECTION, V29, P3, DOI 10.1007/s15010-001-0024-2
   Moore H, 2007, J PAEDIATR CHILD H, V43, P451, DOI 10.1111/j.1440-1754.2007.01110.x
   Moore HC, 2012, J EPIDEMIOL COMMUN H, V66, P489, DOI 10.1136/jech.2010.122762
   MURPHY TF, 1981, AM J EPIDEMIOL, V113, P12, DOI 10.1093/oxfordjournals.aje.a113061
   Myles PR, 2009, EPIDEMIOL INFECT, V137, P709, DOI 10.1017/S0950268808001428
   Nair H, 2011, LANCET, V378, P1917, DOI 10.1016/S0140-6736(11)61051-9
   Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1
   Nelson JC, 2008, VACCINE, V26, P4947, DOI 10.1016/j.vaccine.2008.07.016
   Nohynek H, 2009, PEDIATR INFECT DIS J, V28, pS127, DOI 10.1097/INF.0b013e3181b6d800
   O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6
   O'Brien KL, 2000, CLIN INFECT DIS, V30, P784, DOI 10.1086/313772
   O'Grady KAF, 2010, J PAEDIATR CHILD H, V46, P461, DOI 10.1111/j.1440-1754.2010.01845.x
   O'Grady KAF, 2010, MED J AUSTRALIA, V192, P592, DOI 10.5694/j.1326-5377.2010.tb03644.x
   Obando I, 2008, EMERG INFECT DIS, V14, P1390, DOI 10.3201/eid1409.071094
   Ogita Junko, 2008, Kansenshogaku Zasshi, V82, P624
   OSEASOHN R, 1978, AM REV RESPIR DIS, V117, P1003
   Patrzalek M, 2010, EUR J CLIN MICROBIOL, V29, P787, DOI 10.1007/s10096-010-0928-9
   Peck AJ, 2005, PEDIATR INFECT DIS J, V24, P342, DOI 10.1097/01.inf.0000157250.95880.91
   Petit Genevieve, 2003, Can J Infect Dis, V14, P215
   Read AW, 1996, PAEDIATR PERINAT EP, V10, P175, DOI 10.1111/j.1365-3016.1996.tb00041.x
   Rees JHM, 1997, LANCET, V349, P402, DOI 10.1016/S0140-6736(97)80022-0
   Rosychuk RJ, 2010, CHEST, V138, P1363, DOI 10.1378/chest.09-2829
   Roxburgh CSD, 2008, ARCH DIS CHILD, V93, P316, DOI 10.1136/adc.2007.126540
   Rudan I, 2004, B WORLD HEALTH ORGAN, V82, P895
   Rudan I, 2008, B WORLD HEALTH ORGAN, V86, P408, DOI 10.2471/BLT.07.048769
   Ruuskanen O, 2011, LANCET, V377, P1264, DOI 10.1016/S0140-6736(10)61459-6
   Sabuncu E, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000084
   Schneeweiss S, 2007, CLIN PHARMACOL THER, V82, P143, DOI 10.1038/sj.clpt.6100249
   Schultz KD, 2004, PEDIATRICS, V113, P1735, DOI 10.1542/peds.113.6.1735
   See H, 2010, PEDIATR INFECT DIS J, V29, P786, DOI 10.1097/INF.0b013e3181e6c317
   Sheppard CL, 2011, J MED MICROBIOL, V60, P1879, DOI 10.1099/jmm.0.034975-0
   Simonsen L, 2011, MBIO, V2, DOI 10.1128/mBio.00309-10
   Singleton RJ, 2012, J PEDIAT, V161, p[296, e2]
   Strachan R, 2009, J PAEDIATR CHILD H, V45, P431, DOI 10.1111/j.1440-1754.2009.01533.x
   Tan Tina Q, 2002, Pediatrics, V110, P1, DOI 10.1542/peds.110.1.1
   Theodoratou E, 2010, INT J EPIDEMIOL, V39, P172, DOI 10.1093/ije/dyq033
   United Nations Population Division, WORLD POP PROSP 2010
   United Nations Statistics Division, 2011, COMP MACR GEOGR CONT
   Van Ackere T, 2009, EUR J PEDIATR, V168, P51, DOI 10.1007/s00431-008-0708-z
   Van den Bruel Ann, 2006, BMC Fam Pract, V7, P23, DOI 10.1186/1471-2296-7-23
   van Gageldonk-Lafeber AB, 2009, EPIDEMIOL INFECT, V137, P1472, DOI 10.1017/S0950268809002258
   Washington EL, 2004, J HEALTH CARE POOR U, V15, P462, DOI 10.1353/hpu.2004.0050
   Watt JP, 2009, LANCET, V374, P903, DOI 10.1016/S0140-6736(09)61203-4
   Weigl JAI, 2005, KLIN PADIATR, V217, P211, DOI 10.1055/s-2004-822699
   Weigl JAI, 2005, KLIN PADIATR, V217, P259, DOI 10.1055/s-2004-820352
   Weigl JAI, 2003, EUR J PEDIATR, V162, P309, DOI 10.1007/s00431-002-1140-4
   Wickman M, 1998, EUR RESPIR J, V11, P366, DOI 10.1183/09031936.98.11020366
   Williams P, 1997, INT J EPIDEMIOL, V26, P797, DOI 10.1093/ije/26.4.797
   Wingerter SL, 2012, PEDIATR INFECT DIS J, V31, P561, DOI 10.1097/INF.0b013e31824da716
   Woodhead M, 2009, SEMIN RESP CRIT CARE, V30, P136, DOI 10.1055/s-0029-1202932
   World Health Organization, 1984, CAS MAN AC RESP INF
   WRIGHT AL, 1989, AM J EPIDEMIOL, V129, P1232, DOI 10.1093/oxfordjournals.aje.a115243
   Zhou FJ, 2007, ARCH PEDIAT ADOL MED, V161, P1162, DOI 10.1001/archpedi.161.12.1162
NR 112
TC 45
Z9 46
U1 1
U2 23
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD MAR
PY 2013
VL 32
IS 3
BP E119
EP E127
DI 10.1097/INF.0b013e3182784b26
PG 9
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 089TK
UT WOS:000314932700005
PM 23099423
DA 2020-12-17
ER

PT J
AU Bouzas, ML
   Sole, D
   Cardoso, MRA
   Silva, EEV
   Miranda, KS
   Neri, LR
   Silva, PFC
   Amoedo, RS
   Meneses, RB
   Barral, A
   Nascimento-Carvalho, CM
AF Bouzas, Maiara Lanna
   Sole, Dirceu
   Cardoso, Maria Regina A.
   Silva, Eliana E. V.
   Miranda, Karen S.
   Neri, Laise R.
   Silva, Patricia F. C.
   Amoedo, Ramon S.
   Meneses, Romulo B.
   Barral, Aldina
   Nascimento-Carvalho, Cristiana M.
TI Wheezing in infants: frequency, clinical characteristics and treatment
SO JORNAL DE PEDIATRIA
LA English
DT Article
ID 1ST YEAR; RISK-FACTORS; VIRAL-INFECTIONS; LIFE; PREVALENCE
AB Objective: To estimate the frequency and describe the clinical characteristics and respective treatments of previous history of wheezing.
   Methods: Infants aged 6-23 months with upper respiratory tract complaints and reporting previous wheezing were followed-up retrospectively. Data were registered on a validated standardized form.
   Results: Out of 451 infants, 164 (36.4%; 95%CI: 31.9-41.0) had a report of prior history of wheezing, 148 (32.8%; 95%CI: 28.5-37.4) during the first year of life. The mean age at the first episode of wheezing was 5.3 +/- 3.9 months. Among those who had had their first episode before 12 months of age, 38.5% reported 3 to 6 episodes and 14.2% > 6 episodes. Mean age at first episode was lower for those with a >= 3 episodes in comparison with those with <= 2 episodes (3.2 +/- 2.7 vs. 5.7 +/- 2.5 months, p < 0.001).
   Conclusion: One third of the infants reported wheezing during the first year of life. The earlier the first episode occurs, the more frequently wheezing recurs.
C1 [Bouzas, Maiara Lanna] Univ Fed Bahia UFBA, Programa Posgrad Ciencias Saude, Fac Med Bahia, Salvador, BA, Brazil.
   [Sole, Dirceu] Univ Fed Sao Paulo, Discipline Alergia Imunol Clin & Reumatol, Dept Pediat, Escola Paulista Med,UNIFESP EPM, Sao Paulo, Brazil.
   [Cardoso, Maria Regina A.] Univ Sao Paulo, Dept Epidemiol, Fac Saude Publ, BR-09500900 Sao Paulo, Brazil.
   [Silva, Eliana E. V.; Miranda, Karen S.; Neri, Laise R.; Silva, Patricia F. C.; Meneses, Romulo B.] EBMSP, Salvador, BA, Brazil.
   [Barral, Aldina] Univ Fed Bahia, Dept Anat Patol & Med Legal, Fac Med Bahia, Salvador, BA, Brazil.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Dept Pediat, Fac Med Bahia, Salvador, BA, Brazil.
RP Bouzas, ML (corresponding author), Univ Fed Bahia, Programa Posgrad Ciencias Saude, Fac Med Bahia, Largo Terreiro de Jesus S-N, BR-40025010 Salvador, BA, Brazil.
EM maiara.lanna@gmail.com
RI Cardoso, Maria Regina A/J-7280-2012; Sole, Dirceu/D-7789-2013
FU Fundacao de Amparo Pesquisa do Estado da Bahia (FAPESB); Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)National
   Council for Scientific and Technological Development (CNPq)
FX Fundacao de Amparo Pesquisa do Estado da Bahia (FAPESB) and Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq).
CR Lima JAB, 2010, J BRAS PNEUMOL, V36, P525, DOI 10.1590/S1806-37132010000500002
   Brasil. Ministerio da Saude, PROP INT HOSP SUS GR
   Dela Bianca ACC, 2010, J BRAS PNEUMOL, V36, P402, DOI 10.1590/S1806-37132010000400003
   Neto HJC, 2011, J PEDIAT-BRAZIL, V87, P547, DOI [10.1590/S0021-75572011000600015, 10.2223/JPED.2107]
   Neto HJC, 2010, J PEDIAT-BRAZIL, V86, P171, DOI [10.2223/JPED.1977, 10.1590/S0021-75572010000300003]
   Neto HJC, 2009, J PEDIAT-BRAZIL, V85, P170, DOI [10.2223/JPED.1854, 10.1590/S0021-75572009000200014]
   da Cunha SS, 2010, REV PANAM SALUD PUBL, V28, P405, DOI 10.1590/S1020-49892010001200001
   Garcia-Marcos L, 2010, PEDIAT ALLERG IMM-UK, V21, P878, DOI 10.1111/j.1399-3038.2010.01035.x
   Garcia-Marques L, 2006, ESTUDIO INT SIBILANC
   Global Initiative for Asthma (GINA), 2019, GLOB STRAT ASTHM MAN
   Jackson DJ, 2010, IMMUNOL ALLERGY CLIN, V30, P513, DOI 10.1016/j.iac.2010.08.004
   Jartti T, 2008, EUR RESPIR J, V32, P314, DOI 10.1183/09031936.00161907
   Jartti T, 2007, PEDIAT ALLERG IMM-UK, V18, P326, DOI 10.1111/j.1399-3038.2007.00512.x
   Mallol J, 2010, THORAX, V65, P1004, DOI 10.1136/thx.2009.115188
   Martinez FD, 2009, ALLERGOL IMMUNOPATH, V37, P249, DOI 10.1016/j.aller.2009.06.008
   Tregoning JS, 2010, CLIN MICROBIOL REV, V23, P74, DOI 10.1128/CMR.00032-09
   Visser CAN, 2010, PEDIATR PULM, V45, P149, DOI 10.1002/ppul.21161
NR 17
TC 3
Z9 6
U1 0
U2 0
PU SOC BRASIL PEDIATRIA
PI RIO DE JANEIRO, RJ
PA RUA SANTA CLARA 292, RIO DE JANEIRO, RJ, CEP 22401-01, BRAZIL
SN 0021-7557
EI 1678-4782
J9 J PEDIAT-BRAZIL
JI J. Pediatr.
PD JUL-AUG
PY 2012
VL 88
IS 4
BP 361
EP 365
DI 10.2223/JPED.2187
PG 5
WC Pediatrics
SC Pediatrics
GA 000LY
UT WOS:000308389000015
PM 22782490
OA Bronze, Green Published
DA 2020-12-17
ER

PT J
AU Ferrero, F
   Nascimento-Carvalho, CM
AF Ferrero, Fernando
   Nascimento-Carvalho, Cristiana M.
TI Clinical Prediction Rules and Pediatric Infectious Diseases
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE clinical prediction rule; predictive value of tests; decision support
   techniques
ID COMMUNITY-ACQUIRED PNEUMONIA; DISTINGUISH BACTERIAL; CHILDREN;
   MANAGEMENT; AGE; VALIDATION; INFANTS; FEVER; RISK
AB Clinical prediction rules (CPR) are tools including appropriately weighted clinical aspects (history, physical examination and/or complementary tests) showing the odds for a specific diagnosis or prognosis. Their development includes a complex and strict process to achieve the scientific strength which supports use in clinical settings. Although CPR may be developed for almost any clinical situation, they are particularly useful in complex decision making, high-risk situations and for health cost reduction. Most CPR in pediatrics are devoted to infectious diseases, but only a few of them are used in daily practice. Reluctance in using them may be related to the most pediatrician's expectation of 100% sensitivity, when only a few CPR have sensitivity >90%. It is important to take into account that even a less-than-perfect CPR may be more sensitive than the physician's clinical judgment alone.
C1 [Ferrero, Fernando] Hosp Ninos Pedro de Elizalde, Buenos Aires, DF, Argentina.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Dept Pediat, Sch Med, Salvador, BA, Brazil.
RP Ferrero, F (corresponding author), Hosp Ninos Pedro de Elizalde, Amenabar 1935 PB 3,C1428CQC, Buenos Aires, DF, Argentina.
EM fferrero@intramed.net
RI Ferrero, Fernando/AAE-1886-2020
OI Ferrero, Fernando/0000-0001-6335-0102
CR Aujesky D, 2008, CLIN INFECT DIS, V47, pS133, DOI 10.1086/591394
   BARAFF LJ, 1993, ANN EMERG MED, V22, P1198, DOI 10.1016/S0196-0644(05)80991-6
   Bradley JS, 2011, CLIN INFECT DIS, V53, pE25, DOI 10.1093/cid/cir531
   Harris M, 2011, THORAX, V66, pII1, DOI 10.1136/thoraxjnl-2011-200598
   Kronman MP, 2011, PEDIATRICS, V127, P411, DOI 10.1542/peds.2010-2008
   Lacour AG, 2008, PEDIATR INFECT DIS J, V27, P654, DOI 10.1097/INF.0b013e318168d2b4
   Laupacis A, 1997, JAMA-J AM MED ASSOC, V277, P488, DOI 10.1001/jama.277.6.488
   Maguire JL, 2011, PEDIATRICS, V128, pE666, DOI 10.1542/peds.2011-0043
   McGinn T, 2001, USE ARTICLES CLIN PR
   Moreno L, 2006, PEDIATR PULM, V41, P331, DOI 10.1002/ppul.20364
   Nascimento-Carvalho CM, 2008, PEDIATR INFECT DIS J, V27, P939, DOI 10.1097/INF.0b013e3181723751
   National Institute for Health and Clinical Excellence, 2007, 47 NICE
   Nigrovic LE, 2002, PEDIATRICS, V110, P712, DOI 10.1542/peds.110.4.712
   Nigrovic LE, 2007, JAMA-J AM MED ASSOC, V297, P52, DOI 10.1001/jama.297.1.52
   Pollack MM, 1997, J PEDIATR-US, V131, P575, DOI 10.1016/S0022-3476(97)70065-9
   Reilly BM, 2006, ANN INTERN MED, V144, P201, DOI 10.7326/0003-4819-144-3-200602070-00009
   Stiell I, 1996, CAN FAM PHYSICIAN, V42, P478
   TEELE DW, 1975, J PEDIATR-US, V87, P227, DOI 10.1016/S0022-3476(75)80584-1
   Torres FA, 2010, ARCH ARGENT PEDIATR, V108, P511, DOI 10.1590/S0325-00752010000600006
   Walker CLF, 2006, J PEDIATR-US, V149, P64, DOI 10.1016/j.jpeds.2006.03.005
   WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306
   World Health Organization, 2009, PNEUM FACT SHEET 31
NR 22
TC 6
Z9 6
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD JUN
PY 2012
VL 31
IS 6
BP 628
EP 629
DI 10.1097/INF.0b013e31825670f2
PG 2
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 950SH
UT WOS:000304668700019
PM 22592488
DA 2020-12-17
ER

PT J
AU Fontoura, MS
   Matutino, AR
   Silva, CC
   Santana, MC
   Nobre-Bastos, M
   Oliveira, F
   Barreto, BB
   Araujo-Neto, CA
   Andrade, SC
   Brim, RV
   Cardoso, MRA
   Nascimento-Carvalho, CM
AF Fontoura, M-Sh
   Matutino, A. R.
   Silva, C. C.
   Santana, M. C.
   Nobre-Bastos, M.
   Oliveira, F.
   Barreto, B. B.
   Araujo-Neto, C. A.
   Andrade, S. C.
   Brim, R. V.
   Cardoso, M-R A.
   Nascimento-Carvalho, C. M.
CA PNEUMOPAC-Efficacy Study Grp
TI Differences in Evolution of Children with Non-severe Acute Lower
   Respiratory Tract Infection With and Without Radiographically Diagnosed
   Pneumonia
SO INDIAN PEDIATRICS
LA English
DT Article
DE Acute respiratory infection; Children; Fever; Lower respiratory tract
   disease; Lung disease; Respiratory discomfort
ID CLINICAL SIGNS; CASE-MANAGEMENT; IDENTIFICATION
AB Objective: To identify differences in the evolution of children with non-severe acute lower respiratory tract infection between those with and without radiographically diagnosed pneumonia.
   Design: Prospective cohort study.
   Setting: A public university pediatric hospital in Salvador, Northeast Brazil.
   Patients: Children aged 2-59 months.
   Methods: By active surveillance, the pneumonia cases were prospectively identified in a 2-year period. Each case was followed-up for changes in various clinical symptoms and signs. Demographic, clinical and radiographic data were recorded in standardized forms. Exclusion was due to antibiotic use in the previous 48 hours, signs of severe disease, refusal to give informed consent, underlying chronic illness, hospitalization in the previous 7 days or amoxicillin allergy. Chest X-ray (CXR) was later read by at least 2 independent pediatric radiologists.
   Main Outcome Measures: Radiographic diagnosed pneumonia based on agreed detection of pulmonary infiltrate or pleural effusion in 2 assessments.
   Results: A total of 382 patients receiving amoxicillin were studied, of whom, 372 (97.4%) had concordant radiographic diagnosis which was pneumonia (52%), normal CXR (41%). and others (7%). By multivariate analysis, age (OR=1.03; 95% CI: 1.02-1.05), disease >= 5days (OR = 1.04; 95% CI: 1.001-1.08), reduced pulmonary expansion (OR = 3.3; 95% CI: 1.4-8.0), absence of wheezing (OR = 0.5; 95% CI: 0.3-0.9), crackles on admission (OR = 2.0; 95% CI: 1.2-3.5), inability to drink on day 1 (OR = 4.2; 95% CI: 1.05-17.3), consolidation percussion sign (OR = 7.0; 95% CI: 1.5-32.3), tachypnea (OR = 2.0; 95% CI: 1.09-3.6) and fever (OR = 3.6; 95% CI: 1.4-9.4) on day 2 were independently associated with pneumonia. The highest positive predictive value was at the 2nd day of evolution for tachypnea (71.0%) and fever (81.1%).
   Conclusion: Persistence of fever or tachypnea up to the second day of amoxicillin treatment is predictive of radiographically diagnosed pneumonia among children with non-severe lower respiratory tract diseases.
C1 [Fontoura, M-Sh; Matutino, A. R.; Silva, C. C.; Santana, M. C.; Nobre-Bastos, M.; Oliveira, F.; Barreto, B. B.; Araujo-Neto, C. A.; Nascimento-Carvalho, C. M.; PNEUMOPAC-Efficacy Study Grp] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
   [Brim, R. V.] Bahiana Fdn Sci Dev, Bahiana Sch Med, Salvador, BA, Brazil.
   [Brim, R. V.] Univ Fed Bahia, Sch Med, Dept Image Diag, Salvador, BA, Brazil.
   [Andrade, S. C.] Fed Univ Bahia Hosp, Image Diag Unit, Salvador, BA, Brazil.
   [Cardoso, M-R A.] Univ Sao Paulo, Fac Publ Hlth, Dept Epidemiol, Sao Paulo, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Rua Prof Aristides Novis 105-1201B, BR-40210630 Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
RI Cardoso, Maria Regina A/J-7280-2012
OI Matutino Kahn, Adriana/0000-0002-5306-0571
FU Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB), Salvador,
   Brazil
FX This research was funded by the the Fundacao de Amparo a Pesquisa do
   Estado da Bahia (FAPESB), Salvador, Brazil. Maria-Regina A Cardoso and
   Cristiana M Nascimento-Carvalho are investigators of the Brazilian
   Council for Science and Technology Development (CNPq). Neither FAPESB
   nor CNPq had any role in handling or completing the research. The
   authors had full control of all primary data.
CR Awasthi S, 2004, BMJ-BRIT MED J, V328, P791
   Cardoso MRA, 2011, ARCH DIS CHILD, V96, P58, DOI 10.1136/adc.2010.189894
   Cherian T, 2005, B WORLD HEALTH ORGAN, V83, P353
   El-Rashdi AS, 2006, ARCH DIS CHILD, V91, P351, DOI 10.1136/adc.2005.088831
   FALADE AG, 1995, B WORLD HEALTH ORGAN, V73, P299
   Fontoura MSH, 2010, EXPERT OPIN PHARMACO, V11, P1451, DOI 10.1517/14656561003777034
   Graham SM, 2008, B WORLD HEALTH ORGAN, V86, P349, DOI 10.2471/BLT.07.048512
   Grant GB, 2009, LANCET INFECT DIS, V9, P185, DOI 10.1016/S1473-3099(09)70044-1
   Haider BA, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005976.pub2
   HARARI M, 1991, LANCET, V338, P928, DOI 10.1016/0140-6736(91)91785-S
   Hazir T, 2002, LANCET, V360, P835
   Hazir T, 2007, ARCH DIS CHILD, V92, P291, DOI 10.1136/adc.2005.092494
   Mahabee-Gittens EM, 2005, CLIN PEDIATR, V44, P427, DOI 10.1177/000992280504400508
   MULHOLLAND EK, 1992, PEDIATR INFECT DIS J, V11, P77, DOI 10.1097/00006454-199202000-00004
   Nascimento-Carvalho CM, 2004, REV PANAM SALUD PUBL, V15, P380, DOI 10.1590/S1020-49892004000600003
   Puumalainen T, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-95
   Ranganathan SC, 2009, PEDIATR CLIN N AM, V56, P135, DOI 10.1016/j.pcl.2008.10.005
   REDD SC, 1994, B WORLD HEALTH ORGAN, V72, P113
   Sazawal S, 2003, LANCET INFECT DIS, V3, P547, DOI 10.1016/S1473-3099(03)00737-0
   Shah S, 2010, PEDIATR INFECT DIS J, V29, P406, DOI 10.1097/INF.0b013e3181cb45a7
   SINGHI S, 1994, ANN TROP PAEDIATR, V14, P53, DOI 10.1080/02724936.1994.11747692
   WHO UNICEF, 2008, INT MAN CHILDH ILLN
   Wilkins Tyler R, 2005, Radiol Technol, V77, P106
   World Health Organization, 1990, AC RESP INF CHILDR C
   Zorc JJ, 2010, PEDIATRICS, V125, P342, DOI 10.1542/peds.2009-2092
NR 25
TC 7
Z9 8
U1 0
U2 2
PU SPRINGER INDIA
PI NEW DELHI
PA 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001,
   INDIA
SN 0019-6061
EI 0974-7559
J9 INDIAN PEDIATR
JI Indian Pediatrics
PD MAY
PY 2012
VL 49
IS 5
BP 363
EP 369
AR PII S0974755911000108-1
DI 10.1007/s13312-012-0085-6
PG 7
WC Pediatrics
SC Pediatrics
GA 949MJ
UT WOS:000304580000004
PM 22080618
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, CM
   Cardoso, MRA
   Meriluoto, M
   Kemppainen, K
   Kantola, K
   Ruuskanen, O
   Hedman, K
   Soderlund-Venermo, M
AF Nascimento-Carvalho, Cristiana M.
   Cardoso, Maria-Regina A.
   Meriluoto, Mira
   Kemppainen, Kaisa
   Kantola, Kalle
   Ruuskanen, Olli
   Hedman, Klaus
   Soderlund-Venermo, Maria
TI Human bocavirus infection diagnosed serologically among children
   admitted to hospital with community-acquired pneumonia in a tropical
   region
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE acute respiratory infection; lower respiratory tract infection;
   respiratory virus; respiratory tract infection
ID RESPIRATORY-TRACT INFECTIONS; PARVOVIRUS; INFANTS
AB Human bocavirus (HBoV) is a human virus associated with respiratory disease in children. Limited information is available on acute infection with HBoV among children admitted to hospital with community-acquired pneumonia in tropical regions and the current diagnosis is inadequate. The aims were to diagnose and describe acute HBoV infections among children hospitalized for community-acquired pneumonia. In Salvador, Brazil, 277 children with community-acquired pneumonia were prospectively enrolled. Paired serum samples were tested by IgG, IgM, and IgG-avidity enzyme immunoassays (EIAs) using recombinant HBoV VP2. HBoV DNA was detected in nasopharyngeal aspirates and serum by a quantitative polymerase-chain reaction (PCR). HBoV DNA was detected in nasopharyngeal aspirates of 62/268 (23%) children and 156/273 (57%) were seropositive. Acute primary HBoV infection was reliably diagnosed (bearing at least two acute markers: Positive IgM, a fourfold increase/conversion of IgG, low IgG avidity or viremia) in 21 (8%) of 273 patients, 90% of 20 had HBoV DNA in nasopharyngeal aspirates, 83% with a high DNA load. The median age of infection with HBoV was 16 months, range 5-36.Community-acquired pneumonia was confirmed radiographically in 85% of 20 patients with acute HBoV infection diagnosed serologically. HBoV DNA was found in nasopharyngeal aspirates of 42/246(17%) children without an acute primary HBoV infection and available nasopharyngeal aspirate. Four children with HBoV secondary immune responses were detected, lacking both IgM and viremia. HBoV infection was diagnosed accurately in children aged 5-36 months with community-acquired pneumonia confirmed radiographically. PCR of nasopharyngeal aspirates is not a reliable marker of acute HBoV infection. J. Med. Virol. 84:253-258, 2012. (C) 2011 Wiley Periodicals, Inc.
C1 [Cardoso, Maria-Regina A.] Univ Sao Paulo, Fac Publ Hlth, Dept Epidemiol, Sao Paulo, Brazil.
   [Meriluoto, Mira; Kemppainen, Kaisa; Kantola, Kalle; Hedman, Klaus; Soderlund-Venermo, Maria] Univ Helsinki, Dept Virol, Haartman Inst, Helsinki, Finland.
   [Ruuskanen, Olli] Univ Turku, Dept Pediat, Turku, Finland.
   [Hedman, Klaus] Helsinki Univ Hosp, Dept Virol, Lab Div, Helsinki, Finland.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Rua Prof Aristides Novis,105-1201B, BR-40210630 Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
RI Soderlund-Venermo, Maria/AAX-2112-2020; Cardoso, Maria Regina
   A/J-7280-2012
OI Hedman, Klaus/0000-0003-1779-7960
FU Fundacao de Amparo a Pesquisa no Estado da Bahia (FAPESB), Salvador,
   Brazil; Academy of FinlandAcademy of Finland [1122539]; Medical Society
   of Finland; University of Helsinki; Sigrid Juselius Foundation,
   Helsinki, FinlandSigrid Juselius Foundation
FX We thank Lea Hedman for the IgG-avidity determinations. This study was
   supported by the Fundacao de Amparo a Pesquisa no Estado da Bahia
   (FAPESB), Salvador, Brazil and the Academy of Finland (project 1122539),
   the Medical Society of Finland, the Research Fund of the University of
   Helsinki and the Sigrid Juselius Foundation, Helsinki, Finland.
CR Albuquerque MCM, 2007, EMERG INFECT DIS, V13, P1756, DOI 10.3201/eid1311.070671
   Allander T, 2005, P NATL ACAD SCI USA, V102, P12891, DOI 10.1073/pnas.0504666102
   Allander T, 2008, J CLIN VIROL, V41, P29, DOI 10.1016/j.jcv.2007.10.026
   Allander T, 2007, CLIN INFECT DIS, V44, P904, DOI 10.1086/512196
   Arthur JL, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000391
   Berkley JA, 2010, JAMA-J AM MED ASSOC, V303, P2051, DOI 10.1001/jama.2010.675
   Bezerra PGM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018928
   Blessing K, 2009, PEDIATR INFECT DIS J, V28, P1018, DOI 10.1097/INF.0b013e3181a854ae
   Carrol ED, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021042
   Christensen A, 2010, J CLIN VIROL, V49, P158, DOI 10.1016/j.jcv.2010.07.016
   Cilla G, 2008, J MED VIROL, V80, P1843, DOI 10.1002/jmv.21271
   Don M, 2010, PEDIATR PULM, V45, P120, DOI 10.1002/ppul.21151
   El-Rashdi AS, 2006, ARCH DIS CHILD, V91, P351, DOI 10.1136/adc.2005.088831
   Fry AM, 2007, J INFECT DIS, V195, P1038, DOI 10.1086/512163
   Gagliardi TB, 2009, EPIDEMIOL INFECT, V137, P1032, DOI 10.1017/S0950268808001842
   Hedman K, 1993, REV MED MICROBIOL, V4, P123, DOI DOI 10.1097/00013542-199307000-00001
   Hedman L, 2010, J CLIN VIROL, V48, P44, DOI 10.1016/j.jcv.2010.02.003
   Kantola K, 2008, CLIN INFECT DIS, V46, P540, DOI 10.1086/526532
   Kantola K, 2010, J CLIN MICROBIOL, V48, P4044, DOI 10.1128/JCM.00686-10
   Kapoor A, 2009, J INFECT DIS, V199, P196, DOI 10.1086/595831
   Kapoor A, 2010, J INFECT DIS, V201, P1633, DOI 10.1086/652416
   Karalar L, 2010, CLIN MICROBIOL INFEC, V16, P633, DOI 10.1111/j.1469-0691.2009.02889.x
   Margaret IP, 2008, J CLIN VIROL, V42, P72, DOI 10.1016/j.jcv.2007.12.016
   Martin ET, 2010, J INFECT DIS, V201, P1625, DOI 10.1086/652405
   Martin ET, 2009, J CLIN MICROBIOL, V47, P4131, DOI 10.1128/JCM.01508-09
   Nascimento-Carvalho CM, 2008, PEDIATR INFECT DIS J, V27, P939, DOI 10.1097/INF.0b013e3181723751
   Nascimento-Carvalho CM, 2011, INFLUENZA OTHER RESP, V5, P285, DOI 10.1111/j.1750-2659.2011.00206.x
   Pozo F, 2007, J CLIN VIROL, V40, P224, DOI 10.1016/j.jcv.2007.08.010
   Schildgen O, 2008, CLIN MICROBIOL REV, V21, P291, DOI 10.1128/CMR.00030-07
   Soderlund-Venermo M, 2009, EMERG INFECT DIS, V15, P1423, DOI 10.3201/eid1509.090204
   von Linstow ML, 2008, PEDIATR INFECT DIS J, V27, P897, DOI 10.1097/INF.0b013e3181757b16
   Wang K, 2010, J CLIN VIROL, V47, P148, DOI 10.1016/j.jcv.2009.11.015
   WHO UNICEF, 2008, INT MAN CHILDH ILLN
   World Health Organization, 2008, TRAIN COURS CHILD GR
NR 34
TC 38
Z9 41
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0146-6615
J9 J MED VIROL
JI J. Med. Virol.
PD FEB
PY 2012
VL 84
IS 2
BP 253
EP 258
DI 10.1002/jmv.22268
PG 6
WC Virology
SC Virology
GA 861ZQ
UT WOS:000298060000011
PM 22170545
DA 2020-12-17
ER

PT J
AU de Vasconcellos, AG
   Leal, RD
   Silvany-Neto, A
   Nascimento-Carvalho, CM
AF de Vasconcellos, Angela Gomes
   Leal, Renata Dorea
   Silvany-Neto, Annibal
   Nascimento-Carvalho, Cristiana Maria
TI Oxacillin or Cefalotin Treatment of Hospitalized Children with
   Cellulitis
SO JAPANESE JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID RESISTANT STAPHYLOCOCCUS-AUREUS; SOFT-TISSUE INFECTIONS; ANTIMICROBIAL
   THERAPY; METHICILLIN; SKIN; MANAGEMENT
AB Cellulitis is an important cause of hospitalization in pediatrics. Because Staphylococcus aureus is the main pathogen of cellulitis, medicinal therapeutics should take the changing resistance profile of this organism into consideration. The aim of this study was to evaluate the progression and outcomes of children hospitalized for cellulitis and treated with oxacillin or cefalotin. This retrospective cohort study enrolled 218 children, hospitalized between 2001 and 2008 in Salvador, Northeast Brazil. All were diagnosed with cellulitis and treated with oxacillin or cefalotin (>= 100 mg/kg/day). The median age was 2 years and 56.9% were males. Frequencies of signs and symptoms used in the clinical diagnoses were as follows: swelling (91.3%), redness (81.7%), warmth (47.2%), and tenderness (31.7%). All patients were discharged due to clinical recovery and the mean length of hospitalization was 7 +/- 4 days. None of the patients died, needed intensive care, or had sequelae. By comparing the daily frequency of clinical findings during hospitalization, significant decreases were found in the frequencies of fever (admission day [42.2%], first day [20.8%], second day [12.9%], third day [8.3%], fourth day [6.1%]), toxemia, irritability, somnolence, vomiting, tachycardia, and need for intravenous hydration. In conclusion, oxacillin or cefalotin remain the drugs of choice for treating uncomplicated cellulitis in regions where community-acquired methicillin-resistant S. aureus is infrequent (< 10%).
C1 [de Vasconcellos, Angela Gomes; Leal, Renata Dorea] Univ Fed Bahia, Sch Med, Salvador, BA, Brazil.
   [Silvany-Neto, Annibal] Univ Fed Bahia, Dept Prevent & Social Med, Salvador, BA, Brazil.
   [Nascimento-Carvalho, Cristiana Maria] Univ Fed Bahia, Dept Pediat, Salvador, BA, Brazil.
RP de Vasconcellos, AG (corresponding author), Rua Graca,15,Edf Mirante, BR-40150055 Salvador, BA, Brazil.
EM angelavasc@yahoo.com.br
CR Abrahamian FM, 2008, INFECT DIS CLIN N AM, V22, P89, DOI 10.1016/j.idc.2007.12.001
   Babar TF, 2009, JCPSP-J COLL PHYSICI, V19, P39, DOI 01.2009/JCPSP.3942
   Chaudhry IA, 2007, OPHTHALMOLOGY, V114, P345, DOI 10.1016/j.ophtha.2006.07.059
   Cohen PR, 2004, J AM ACAD DERMATOL, V50, P277, DOI 10.1016/j.jaad.2003.06.005
   Cruz Antonio Augusto Velasco e, 2007, Rev. Bras. Otorrinolaringol., V73, P684, DOI 10.1590/S0034-72992007000500015
   Davis SL, 2007, J CLIN MICROBIOL, V45, P1705, DOI 10.1128/JCM.02311-06
   Diekema DJ, 2001, CLIN INFECT DIS, V32, pS114, DOI 10.1086/320184
   Eady EA, 2003, CURR OPIN INFECT DIS, V16, P103, DOI 10.1097/00001432-200304000-00007
   El-Rashdi AS, 2006, ARCH DIS CHILD, V91, P351, DOI 10.1136/adc.2005.088831
   Eron Lawrence J., 2003, Journal of Antimicrobial Chemotherapy, V52, pi3
   Fortes CQ, 2008, BRAZ J INFECT DIS, V12, P541, DOI 10.1590/S1413-86702008000600020
   Gelatti LC, 2009, REV SOC BRAS MED TRO, V42, P458, DOI 10.1590/S0037-86822009000400019
   Givner LB, 2000, PEDIATRICS, V106, part. no., DOI 10.1542/peds.106.5.e61
   Goldstein Brahm, 2005, Pediatr Crit Care Med, V6, P2
   Hasanee K, 2004, CAN FAM PHYSICIAN, V50, P359
   Kaplan Sheldon L, 2006, Semin Pediatr Infect Dis, V17, P113, DOI 10.1053/j.spid.2006.06.004
   Lee MC, 2004, PEDIATR INFECT DIS J, V23, P123, DOI 10.1097/01.inf.0000109288.06912.21
   Lio PA, 2009, ARCH DIS CHILDHOOD-E, V94, P50, DOI 10.1136/adc.2009.159087
   Maltezou HC, 2006, INT J ANTIMICROB AG, V27, P87, DOI 10.1016/j.ijantimicag.2005.11.004
   Moran GJ, 2006, NEW ENGL J MED, V355, P666, DOI 10.1056/NEJMoa055356
   Nascimento-Carvalho CM, 2008, MICROB DRUG RESIST, V14, P129, DOI 10.1089/mdr.2008.0790
   Paganinia H, 2008, ARCH ARGENT PEDIATR, V106, P397, DOI 10.1590/S0325-00752008000500005
   Pallin DJ, 2008, ANN EMERG MED, V51, P291, DOI 10.1016/j.annemergmed.2007.12.004
   Purcell K, 2005, ARCH PEDIAT ADOL MED, V159, P980, DOI 10.1001/archpedi.159.10.980
   Ribeiro A, 2005, J CLIN MICROBIOL, V43, P1985, DOI 10.1128/JCM.43.4.1985-1988.2005
   Ruhe JJ, 2007, CLIN INFECT DIS, V44, P777, DOI 10.1086/511872
   Sadow KB, 1998, PEDIATRICS, V101, part. no., DOI 10.1542/peds.101.3.e4
   Sampaio C.M., 2001, ARQ BRAS OFTALMOL, V64, P203
   Stevens DL, 2005, CLIN INFECT DIS, V41, P1373, DOI 10.1086/497143
   Tanir G, 2006, JPN J INFECT DIS, V59, P258
   Teng CS, 2009, J MICROBIOL IMMUNOL, V42, P324
   World Health Organization, 2009, TRAIN COURS CHILD GR
   Ziebold C, 2001, PEDIATRICS, V108
NR 33
TC 5
Z9 5
U1 0
U2 2
PU NATL INST INFECTIOUS DISEASES
PI TOKYO
PA JPN J INFECT DIS ED OFF NATL INST INFECTIOUS DISEASES TOYAMA 1-23-1,
   SHINJUKU-KU, TOKYO, 162-8640, JAPAN
SN 1344-6304
EI 1884-2836
J9 JPN J INFECT DIS
JI Jpn. J. Infect. Dis.
PD JAN
PY 2012
VL 65
IS 1
BP 7
EP 12
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA 891EG
UT WOS:000300199400002
PM 22274151
DA 2020-12-17
ER

PT J
AU Key, NK
   Araujo-Neto, CA
   Cardoso, MR
   Nascimento-Carvalho, CM
AF Key, N. K.
   Araujo-Neto, C. A.
   Cardoso, M-Ra
   Nascimento-Carvalho, C. M.
TI Characteristics of radiographically diagnosed pneumonia in under-5
   children in Salvador, Brazil
SO INDIAN PEDIATRICS
LA English
DT Article
DE Acute respiratory infection; Brazil; Children; Pneumonia; Respiratory
   distress; Wheezing
ID COMMUNITY-ACQUIRED PNEUMONIA; SIMPLE CLINICAL SIGNS; CHEST RADIOGRAPHS;
   INFECTIONS; MANAGEMENT
AB To assess the association of demographic and clinical aspects with radiographically diagnosed pneumonia.
   By active surveillance, the admitted pneumonia cases by the pediatrician on duty were identified in a 2-year period. Demographic, clinical and radiographic data were registered into standardized forms.
   A public university pediatric hospital in Salvador, Northeast Brazil.
   Children < 5 years-old.
   Radiographically diagnosed pneumonia based on detection of pulmonary infiltrate/consolidation.
   301 cases had the chest X-ray evaluated by a pediatric radiologist blinded to clinical information, among whom pulmonary infiltrate and consolidation were described in 161 (54%) and 119 (40%), respectively. Chest X-ray was read normal for 140 cases. Overall, the median age was 17 months (mean 20 +/- 14, range 12 days-59 months). Pulmonary infiltrate was less frequently described among patients aged under 1 year (41.3% vs 59.9%, P=0.002, OR [95%CI] = 0.47 [0.29-0.76]) and hyperinflation was significantly more frequent in this age group (27.9% vs 4.1%, P < 0.001, OR [95%CI] = 9.14 [4.0-20.9]). By multiple logistic regression, fever on admission was independently associated with pulmonary infiltrate (OR [95%CI] = 1.68 [1.03-2.73]) or consolidation (1.79 [1.10-2.92]), wheezing was independently associated with absence of pulmonary infiltrate (0.53 [0.33-0.86]) or of consolidation (0.53 [0.33-0.87]). The positive likelihood ratio of fever on examination for pulmonary infiltrate and consolidation was 1.49 (95%CI: 1.11-1.98) and 1.49 (95%CI: 1.14-1.94), respectively.
   Presence of fever enhanced 2.5 times the chance of children hospitalized with lower respiratory tract disease to have radiographically diagnosed pneumonia.
C1 [Key, N. K.; Nascimento-Carvalho, C. M.] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
   [Araujo-Neto, C. A.] Univ Fed Bahia, Sch Med, Dept Image Diag, Salvador, BA, Brazil.
   Univ Sao Paulo, Dept Epidemiol, Fac Publ Hlth, Sao Paulo, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Rua Prof Aristides Novis 105-1201B, BR-40210630 Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
RI Cardoso, Maria Regina A/J-7280-2012
FU Brazilian Council for Science and Technology Development (CNPq)National
   Council for Scientific and Technological Development (CNPq)
FX Ng K Key was recipient of a fellowship from the Brazilian Council for
   Science and Technology Development (CNPq); Maria-Regina A Cardoso and
   Cristiana M Nascimento-Carvalho are investigators of CNPq. CNPq had no
   role in handling or completing the research. The authors had full
   control of all primary data.
CR CAMPBELL H, 1988, LANCET, V2, P742
   Castro AV, 2006, PEDIATR INFECT DIS J, V25, P757, DOI 10.1097/01.inf.0000227821.38732.1f
   Castro AV, 2005, INDIAN PEDIATR, V42, P773
   Cherian T, 2005, B WORLD HEALTH ORGAN, V83, P353
   CHERIAN T, 1988, LANCET, V2, P125
   Donnelly LF, 1999, AM J ROENTGENOL, V172, P505, DOI 10.2214/ajr.172.2.9930814
   El-Rashdi AS, 2006, ARCH DIS CHILD, V91, P351, DOI 10.1136/adc.2005.088831
   Factor SH, 2001, B WORLD HEALTH ORGAN, V79, P1096
   Graham SM, 2008, B WORLD HEALTH ORGAN, V86, P349, DOI 10.2471/BLT.07.048512
   Hazir T, 2006, BMJ-BRIT MED J, V333, P629, DOI 10.1136/bmj.38915.673322.80
   Lynch T, 2004, PEDIATRICS, V113, pE186, DOI 10.1542/peds.113.3.e186
   Mathews B, 2009, PEDIATRICS, V124, pE29, DOI 10.1542/peds.2008-2062
   SACHDEV HPS, 1995, INDIAN PEDIATR, V31, P1251
   SHANN F, 1984, B WORLD HEALTH ORGAN, V62, P749
   Smyth RL, 2006, LANCET, V368, P312, DOI 10.1016/S0140-6736(06)69077-6
   SPOONER V, 1989, J TROP PEDIATRICS, V35, P295, DOI 10.1093/tropej/35.6.295
   Stein RT, 2007, PEDIATR PULM, V42, P1095, DOI 10.1002/ppul.20652
   SWINGLER GH, 2007, CHEST RADIOGRAPH ACU, P3
   *WHO, 1997, WHONUT974
   World Health Organization, 2008, 5032 WC WHO
NR 20
TC 5
Z9 5
U1 0
U2 1
PU SPRINGER INDIA
PI NEW DELHI
PA 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001,
   INDIA
SN 0019-6061
J9 INDIAN PEDIATR
JI Indian Pediatrics
PD NOV
PY 2011
VL 48
IS 11
BP 873
EP 877
DI 10.1007/s13312-011-0142-6
PG 5
WC Pediatrics
SC Pediatrics
GA 852OY
UT WOS:000297368500008
PM 21555804
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, C
   Ferrero, F
AF Nascimento-Carvalho, Cristiana
   Ferrero, Fernando
TI Reply: The Difference between Invasive Disease and Etiology in Childhood
   Community-Acquired Pneumonia
SO PEDIATRIC PULMONOLOGY
LA English
DT Letter
C1 [Ferrero, Fernando] Hosp Ninos Elizalde, Buenos Aires, DF, Argentina.
   [Nascimento-Carvalho, Cristiana] Univ Fed Bahia, Dept Pediat, Sch Med, Salvador, BA, Brazil.
RP Ferrero, F (corresponding author), Hosp Ninos Elizalde, Maure 2536 3 A,C1428CUV, Buenos Aires, DF, Argentina.
EM fferrero@intramed.net
RI Ferrero, Fernando/AAE-1886-2020
OI Ferrero, Fernando/0000-0001-6335-0102
CR Chiou CCC, 2006, CURR OPIN CRIT CARE, V12, P470
   Farha Talal, 2005, Paediatr Respir Rev, V6, P76, DOI 10.1016/j.prrv.2005.03.001
   Ferrero F, 2010, PEDIATR PULM, V45, P1009, DOI 10.1002/ppul.21287
   Ranganathan SC, 2009, PEDIATR CLIN N AM, V56, P135, DOI 10.1016/j.pcl.2008.10.005
   SCHMIDT HJ, 2010, RESPIROLOGY, V15
   SINGHI S, 1994, ARCH DIS CHILD, V70, P413, DOI 10.1136/adc.70.5.413
NR 6
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8755-6863
EI 1099-0496
J9 PEDIATR PULM
JI Pediatr. Pulmonol.
PD AUG
PY 2011
VL 46
IS 8
BP 831
EP 831
DI 10.1002/ppul.21448
PG 1
WC Pediatrics; Respiratory System
SC Pediatrics; Respiratory System
GA 802WA
UT WOS:000293540500016
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, CM
   Cardoso, MRA
   Ruuskanen, O
   Lappalainen, M
AF Nascimento-Carvalho, Cristiana M.
   Cardoso, Maria-Regina A.
   Ruuskanen, Olli
   Lappalainen, Maija
TI Sole infection by human metapneumovirus among children with
   radiographically diagnosed community-acquired pneumonia in a tropical
   region
SO INFLUENZA AND OTHER RESPIRATORY VIRUSES
LA English
DT Article
DE Acute respiratory infection; lower tract respiratory infection; new
   respiratory virus; respiratory viral infection
ID VIRUSES; OLD
AB Background Limited information is available on the role of human metapneumovirus (HMPV) as the unique pathogen among children hospitalized for community-acquired pneumonia (CAP) in a tropical region.
   Objective We aimed to describe HMPV infection among children with CAP investigating bacterial and viral co-infections.
   Patients and methods A prospective study was carried out in Salvador, North-East Brazil. Overall, 268 children aged <5 years hospitalized for CAP were enrolled. Human metapneumovirus RNA was detected in nasopharyngeal aspirates (NPA) by reverse transcription polymerase chain reaction. Sixteen other bacterial and viral pathogens were investigated by an expanded panel of laboratory methods. Chest X-ray taken on admission was read by an independent paediatric radiologist unaware of clinical information or the established aetiology.
   Results Human metapneumovirus RNA was detected in NPAs of 11 (4.1%) children, of which 4 (36%) had sole HMPV infection. The disease was significantly shorter among patients with sole HMPV infection in comparison with patients with mixed infection (4 +/- 1 versus 7 +/- 2 days, P = 0.03). Three of those four patients had alveolar infiltrates.
   Conclusion Sole HMPV infection was detected in children with CAP in Salvador, North-East Brazil. HMPV may play a role in the childhood CAP burden.
C1 [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Paediat, BR-40210630 Salvador, BA, Brazil.
   [Cardoso, Maria-Regina A.] Univ Sao Paulo, Fac Publ Hlth, Sao Paulo, Brazil.
   [Ruuskanen, Olli] Univ Turku, Dept Paediat, Turku, Finland.
   [Lappalainen, Maija] Univ Cent Hosp Lab Div, Dept Virol, Helsinki, Finland.
RP Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia, Sch Med, Dept Paediat, Rua Prof Aristides Novis,105-1201B, BR-40210630 Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
RI Cardoso, Maria Regina A/J-7280-2012
OI Lappalainen, Maija/0000-0001-5400-1250
FU Fundacao de Amparo a Pesquisa no Estado da Bahia (FAPESB), Salvador,
   Brazil; Helsinki University Central Hospital, Helsinki, Finland;
   AbbottAbbott Laboratories; Roche Diagnostics
FX This study was supported by the Fundacao de Amparo a Pesquisa no Estado
   da Bahia (FAPESB), Salvador, Brazil and the Helsinki University Central
   Hospital Research and Development fund, Helsinki, Finland. C M
   Nascimento-Carvalho and M-R A Cardoso are investigators of Brazilian
   Council for Science and Technology Development (CNPq).; M Lappalainen
   has received reimbursement for attending a symposium organized by Abbott
   and Roche Diagnostics, and also received a fee for speaking from Abbott
   and Roche Diagnostics.
CR Albuquerque MCM, 2009, EMERG INFECT DIS, V15, P806, DOI 10.3201/eid1505.081603
   Cherian T, 2005, B WORLD HEALTH ORGAN, V83, P353
   Cilla G, 2008, J MED VIROL, V80, P1843, DOI 10.1002/jmv.21271
   Don M, 2008, SCAND J INFECT DIS, V40, P821, DOI 10.1080/00365540802227110
   El-Rashdi AS, 2006, ARCH DIS CHILD, V91, P351, DOI 10.1136/adc.2005.088831
   Lin Pen-Yi, 2005, Chang Gung Med J, V28, P683
   Nascimento-Carvalho CM, 2008, PEDIATR INFECT DIS J, V27, P939, DOI 10.1097/INF.0b013e3181723751
   Okada Takafumi, 2010, Kansenshogaku Zasshi, V84, P42
   Sloots TP, 2008, J CLIN VIROL, V42, P233, DOI 10.1016/j.jcv.2008.03.002
   van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098
   WHO UNICEF, 2008, INT MAN CHILDH ILLN
   Wolf DG, 2010, J PEDIATR-US, V156, P115, DOI 10.1016/j.jpeds.2009.07.014
   Zaki ME, 2009, MICROBIOL IMMUNOL, V53, P603, DOI 10.1111/j.1348-0421.2009.00162.x
NR 13
TC 21
Z9 21
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1750-2640
J9 INFLUENZA OTHER RESP
JI Influenza Other Respir. Viruses
PD JUL
PY 2011
VL 5
IS 4
BP 285
EP 287
DI 10.1111/j.1750-2659.2011.00206.x
PG 3
WC Infectious Diseases; Virology
SC Infectious Diseases; Virology
GA 789EU
UT WOS:000292497700010
PM 21651739
OA Green Published, Bronze
DA 2020-12-17
ER

PT J
AU Cardoso, MRA
   Nascimento-Carvalho, CM
   Ferrero, F
   Alves, FM
   Cousens, SN
AF Cardoso, Maria-Regina A.
   Nascimento-Carvalho, Cristiana M.
   Ferrero, Fernando
   Alves, Fatima M.
   Cousens, Simon N.
TI Adding fever to WHO criteria for diagnosing pneumonia enhances the
   ability to identify pneumonia cases among wheezing children
SO ARCHIVES OF DISEASE IN CHILDHOOD
LA English
DT Article
ID CLINICAL SIGNS; CHILDHOOD PNEUMONIA; CASE-MANAGEMENT;
   DEVELOPING-COUNTRIES; FACILITIES; PAKISTAN
AB Objective To examine the ability of the criteria proposed by the WHO to identify pneumonia among cases presenting with wheezing and the extent to which adding fever to the criteria alters their performance.
   Design Prospective classification of 390 children aged 2-59 months with lower respiratory tract disease into five diagnostic categories, including pneumonia. WHO criteria for the identification of pneumonia and a set of such criteria modified by adding fever were compared with radio-graphically diagnosed pneumonia as the gold standard.
   Results The sensitivity of the WHO criteria was 94% for children aged <24 months and 62% for those aged >= 24 months. The corresponding specificities were 20% and 16%. Adding fever to the WHO criteria improved specificity substantially (to 44% and 50%, respectively). The specificity of the WHO criteria was poor for children with wheezing (12%). Adding fever improved this substantially (to 42%). The addition of fever to the criteria apparently reduced their sensitivity only marginally (to 92% and 57%, respectively, in the two age groups).
   Conclusion The authors' results reaffirm that the current WHO criteria can detect pneumonia with high sensitivity, particularly among younger children. They present evidence that the ability of these criteria to distinguish between children with pneumonia and those with wheezing diseases might be greatly enhanced by the addition of fever.
C1 [Cardoso, Maria-Regina A.] Univ Sao Paulo, Dept Epidemiol, Fac Publ Hlth, BR-01246904 Sao Paulo, Brazil.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Dept Pediat, Sch Med, Salvador, BA, Brazil.
   [Ferrero, Fernando] Hosp Ninos Elizalde, Buenos Aires, DF, Argentina.
   [Alves, Fatima M.] Secretariat Hlth State Sao Paulo, Sao Paulo, Brazil.
   [Cousens, Simon N.] London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, London WC1, England.
RP Cardoso, MRA (corresponding author), Univ Sao Paulo, Dept Epidemiol, Fac Publ Hlth, Av Dr Arnaldo 715, BR-01246904 Sao Paulo, Brazil.
EM rcardoso@usp.br
RI Cardoso, Maria Regina A/J-7280-2012; Ferrero, Fernando/AAE-1886-2020
OI Ferrero, Fernando/0000-0001-6335-0102
FU International Development Research Centre (IDRC) - Canada
FX This research was funded by the International Development Research
   Centre (IDRC) - Canada.
CR Ayieko P, 2007, PEDIATR INFECT DIS J, V26, P432, DOI 10.1097/01.inf.0000260107.79355.7d
   Bryce J, 2005, LANCET, V365, P1147, DOI 10.1016/S0140-6736(05)71877-8
   Cardoso MRA, 2000, ACTA PAEDIATR, V89, P1484, DOI 10.1080/080352500456697
   Cashat-Cruz Miguel, 2005, Semin Pediatr Infect Dis, V16, P84, DOI 10.1053/j.spid.2005.12.005
   El-Radhi AS, 1999, ARCH DIS CHILD, V81, P231, DOI 10.1136/adc.81.3.231
   FALADE AG, 1995, B WORLD HEALTH ORGAN, V73, P299
   GADOMSKI AM, 1994, J CLIN EPIDEMIOL, V47, P1043, DOI 10.1016/0895-4356(94)90120-1
   Graham SM, 2008, B WORLD HEALTH ORGAN, V86, P349, DOI 10.2471/BLT.07.048512
   HARARI M, 1991, LANCET, V338, P928, DOI 10.1016/0140-6736(91)91785-S
   Hazir T, 2006, INT J TUBERC LUNG D, V10, P924
   Hazir T, 2004, ARCH DIS CHILD, V89, P1049, DOI 10.1136/adc.2003.035741
   Hazir T, 2006, BMJ-BRIT MED J, V333, P629, DOI 10.1136/bmj.38915.673322.80
   Mathews B, 2009, PEDIATRICS, V124, pE29, DOI 10.1542/peds.2008-2062
   MULHOLLAND EK, 1992, PEDIATR INFECT DIS J, V11, P77, DOI 10.1097/00006454-199202000-00004
   Nascimento-Carvalho Cristiana M C, 2002, Indian Pediatr, V39, P205
   Noorani QA, 2006, INT J TUBERC LUNG D, V10, P932
   Qazi SA, 1996, B WORLD HEALTH ORGAN, V74, P501
   REDD SC, 1994, B WORLD HEALTH ORGAN, V72, P113
   Sachdev H P, 1994, Indian Pediatr, V31, P1251
   Sachdev H P, 2001, Indian Pediatr, V38, P827
   Sazawal S, 2003, LANCET INFECT DIS, V3, P547, DOI 10.1016/S1473-3099(03)00737-0
   Shah S, 2010, PEDIATR INFECT DIS J, V29, P406, DOI 10.1097/INF.0b013e3181cb45a7
   SINGHI S, 1994, ANN TROP PAEDIATR, V14, P53, DOI 10.1080/02724936.1994.11747692
   Teng CL, 2008, J TROP PEDIATRICS, V54, P70, DOI 10.1093/tropej/fmm077
   Torzillo P J, 2001, Indian Pediatr, V38, P821
   *WHO, 2001, MOD TXB IMCI INT MAN
   *WHO, 1990, WHOARI905
NR 27
TC 32
Z9 33
U1 0
U2 3
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-9888
J9 ARCH DIS CHILD
JI Arch. Dis. Child.
PD JAN
PY 2011
VL 96
IS 1
BP 58
EP 61
DI 10.1136/adc.2010.189894
PG 4
WC Pediatrics
SC Pediatrics
GA 695RB
UT WOS:000285389200013
PM 20870628
OA Bronze
DA 2020-12-17
ER

PT J
AU Simbalista, R
   Araujo, M
   Nascimento-Carvalho, CM
AF Simbalista, Raquel
   Araujo, Marcelo
   Nascimento-Carvalho, Cristiana M.
TI Outcome of children hospitalized with community-acquired pneumonia
   treated with aqueous penicillin G
SO CLINICS
LA English
DT Article
DE Acute respiratory infection; Antibiotic; Beta-lactams; Lower respiratory
   tract infection; Treatment success
ID CHILDHOOD PNEUMONIA; ANTIMICROBIAL RESISTANCE; TREATMENT FAILURE;
   CASE-MANAGEMENT; MORTALITY; PNEUMOCOCCUS; AMOXICILLIN; DIAGNOSIS;
   THERAPY
AB OBJECTIVE: To describe the evolution and outcome of children hospitalized with community-acquired pneumonia receiving penicillin.
   METHODS: A search was carried out for all hospitalized community-acquired pneumonia cases in a 37-month period. Inclusion criteria comprised age >= 2 months, intravenous penicillin G use at 200,000 IU/kg/day for >= 48 h and chest x-ray results. Confounders leading to exclusion included underlying debilitating or chronic pulmonary illnesses, nosocomial pneumonia or transference to another hospital. Pneumonia was confirmed if a pulmonary infiltrate or pleural effusion was described by an independent radiologist blind to the clinical information. Data on admission and evolution were entered on a standardized form.
   RESULTS: Of 154 studied cases, 123 (80%) and 40 (26%) had pulmonary infiltrate or pleural effusion, respectively. Penicilli was substituted by other antibiotics in 28 (18%) patients, in whom the sole significant decrease was in the frequency of tachypnea from the first to the second day of treatment (86% vs. 50%, p = 0.008). Among patients treated exclusively with penicillin G, fever (46% vs. 26%, p = 0.002), tachypnea (74% vs. 59%, p = 0.003), chest indrawing (29% vs. 13%, p < 0.001) and nasal flaring (10% vs. 1.6%, p = 0.001) frequencies significantly decreased from admission to the first day of treatment. Patients treated with other antimicrobial agents stayed longer in the hospital than those treated solely with penicillin G (16 +/- 6 vs. 8 +/- 4 days, p < 0.001, mean difference (95% confidence interval) 8 (6-10)). None of the studied patients died.
   CONCLUSION: Penicillin G successfully treated 82% (126/154) of the study group and improvement was marked on the first day of treatment.
C1 [Simbalista, Raquel; Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
   [Araujo, Marcelo] Image Mem Unit, Salvador, BA, Brazil.
   [Araujo, Marcelo] Bahia Hosp, Salvador, BA, Brazil.
RP Simbalista, R (corresponding author), Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
CR Addo-Yobo E, 2004, LANCET, V364, P1141, DOI 10.1016/S0140-6736(04)17100-6
   Ayieko P, 2007, PEDIATR INFECT DIS J, V26, P432, DOI 10.1097/01.inf.0000260107.79355.7d
   Wolkers PCB, 2009, J PEDIAT-BRAZIL, V85, P421, DOI [10.2223/JPED.1931, 10.1590/S0021-75572009000500009]
   Cardoso MRA, 2008, ARCH DIS CHILD, V93, P221, DOI 10.1136/adc.2006.111625
   Cherian T, 2005, B WORLD HEALTH ORGAN, V83, P353
   Dowell SF, 2000, NEW ENGL J MED, V342, P1399, DOI 10.1056/NEJM200005113421904
   El-Rashdi AS, 2006, ARCH DIS CHILD, V91, P351, DOI 10.1136/adc.2005.088831
   Farha Talal, 2005, Paediatr Respir Rev, V6, P76, DOI 10.1016/j.prrv.2005.03.001
   Fitzpatrick M, 2002, THORAX, V57, P1, DOI 10.1136/thorax.57.1.1
   Giachetto G, 2004, PEDIATR INFECT DIS J, V23, P625, DOI 10.1097/01.inf.0000128783.11218.c9
   Hale KA, 2006, PAEDIATR RESPIR REV, V7, P145, DOI 10.1016/j.prrv.2006.03.011
   Jadavji T, 1997, CAN MED ASSOC J, V156, pS703
   Juven T, 2004, EUR J PEDIATR, V163, P140, DOI 10.1007/s00431-003-1397-2
   Korppi Matti, 2003, Paediatr Drugs, V5, P821, DOI 10.2165/00148581-200305120-00005
   Menendez R, 2007, CHEST, V132, P1348, DOI 10.1378/chest.06-1995
   Mulholland K, 2007, LANCET, V370, P285, DOI 10.1016/S0140-6736(07)61130-1
   Nascimento-Carvalho CMC, 2001, J TROP PEDIATRICS, V47, P253, DOI 10.1093/tropej/47.4.253
   Nascimento-Carvalho CM, 2009, J MED MICROBIOL, V58, P1390, DOI 10.1099/jmm.0.007765-0
   NASCIMENTOCARVA.CM, 2009, 6 WORLD C WORLD SOC
   NASCIMENTOCARVA.CM, 2008, J CLIN INVEST, V118, P1291, DOI DOI 10.1172/JCI33947
   Plouffe JF, 2004, INFECT DIS CLIN N AM, V18, P963, DOI 10.1016/j.idc.2004.07.010
   Sazawal S, 2003, LANCET INFECT DIS, V3, P547, DOI 10.1016/S1473-3099(03)00737-0
   Straus WL, 1998, LANCET, V352, P270, DOI 10.1016/S0140-6736(97)10294-X
   *WHO, 1990, ARI CHILDR CAS MAN S
   World Health Organization, 2008, 5032 WC WHO
   World Health Organization, 2008, TRAIN COURS CHILD GR
NR 26
TC 9
Z9 9
U1 0
U2 2
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
J9 CLINICS
JI Clinics
PY 2011
VL 66
IS 1
BP 95
EP 100
DI 10.1590/S1807-59322011000100017
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 739JH
UT WOS:000288712700017
PM 21437443
OA DOAJ Gold, Green Published
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, CM
   Cardoso, MRA
   Barral, A
   Araujo-Neto, CA
   Oliveira, JR
   Sobral, LS
   Saukkoriipi, A
   Paldanius, M
   Vainionpaa, R
   Leinonen, M
   Ruuskanen, O
AF Nascimento-Carvalho, Cristiana M.
   Cardoso, Maria-Regina A.
   Barral, Aldina
   Araujo-Neto, Cesar A.
   Oliveira, Juliana R.
   Sobral, Luciana S.
   Saukkoriipi, Annika
   Paldanius, Mika
   Vainionpaa, Raija
   Leinonen, Maija
   Ruuskanen, Olli
TI Seasonal patterns of viral and bacterial infections among children
   hospitalized with community-acquired pneumonia in a tropical region
SO SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID RESPIRATORY SYNCYTIAL VIRUS; DIAGNOSIS; MORTALITY; BRAZIL; ASSAYS
AB Community-acquired pneumonia (CAP) is a common cause of morbidity among children. Evidence on seasonality, especially on the frequency of viral and bacterial causative agents is scarce; such information may be useful in an era of changing climate conditions worldwide. To analyze the frequency of distinct infections, meteorological indicators and seasons in children hospitalized for CAP in Salvador, Brazil, nasopharyngeal aspirate and blood were collected from 184 patients aged < 5 y over a 21-month period. Fourteen microbes were investigated and 144 (78%) cases had the aetiology established. Significant differences were found in air temperature between spring and summer (p = 0.02) or winter (p < 0.001), summer and fall (p = 0.007) or winter (p < 0.001), fall and winter (p = 0.002), and on precipitation between spring and fall (p = 0.01). Correlations were found between: overall viral infections and relative humidity (p = 0.006; r = 0.6) or precipitation (p = 0.03; r = 0.5), parainfluenza and precipitation (p = 0.02; r = -0.5), respiratory syncytial virus (RSV) and air temperature (p = 0.048; r = -0.4) or precipitation (p = 0.045; r = 0.4), adenovirus and precipitation (p = 0.02; r = 0.5), pneumococcus and air temperature (p = 0.04; r = -0.4), and Chlamydia trachomatis and relative humidity (p = 0.02; r = -0.5). The frequency of parainfluenza infection was highest during spring (32.1%; p = 0.005) and that of RSV infection was highest in the fall (36.4%; p < 0.001). Correlations at regular strength were found between several microbes and meteorological indicators. Parainfluenza and RSV presented marked seasonal patterns.
C1 [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Paediat, BR-40210630 Salvador, BA, Brazil.
   [Cardoso, Maria-Regina A.] Univ Sao Paulo, Fac Publ Hlth, Dept Epidemiol, Sao Paulo, Brazil.
   [Barral, Aldina] Univ Fed Bahia, Sch Med, Dept Pathol, BR-40210630 Salvador, BA, Brazil.
   [Barral, Aldina] Fundacao Oswaldo Cruz, Ctr Pesquisa Goncalo Muniz, Salvador, BA, Brazil.
   [Araujo-Neto, Cesar A.] Univ Fed Bahia, Sch Med, Image Diag Dept, BR-40210630 Salvador, BA, Brazil.
   [Oliveira, Juliana R.; Sobral, Luciana S.] Univ Fed Bahia, Prof Hosannah de Oliveira Paediat Ctr, BR-40210630 Salvador, BA, Brazil.
   [Saukkoriipi, Annika; Paldanius, Mika; Leinonen, Maija] Natl Inst Hlth & Welf, Oulu, Finland.
   [Vainionpaa, Raija] Univ Turku, Dept Virol, Turku, Finland.
   [Ruuskanen, Olli] Univ Turku, Dept Paediat, Turku, Finland.
RP Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia, Sch Med, Dept Paediat, Rua Prof Aristides Novis 105-1201B, BR-40210630 Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
RI Barral, Aldina/B-4191-2009; Cardoso, Maria Regina A/J-7280-2012
OI Barral, Aldina/0000-0002-7177-464X; 
FU Fundacao de Amparo a Pesquisa no Estado da Bahia (FAPESB), Salvador,
   Brazil; Paediatric Research Foundation, Helsinki, Finland
FX C. M. Nascimento-Carvalho, M.-R. A. Cardoso and A. Barral are
   investigators of the Brazilian Council for Science and Technology
   Development (CNPq). The authors are thankful to the workers of the
   Institute of Water Monitoring in the State of Bahia, Brazil (INGA) as
   they provided access to the meteorological data. This study was
   supported by funding from the Fundacao de Amparo a Pesquisa no Estado da
   Bahia (FAPESB), Salvador, Brazil and the Paediatric Research Foundation,
   Helsinki, Finland.
CR Hyypia T, 1998, J CLIN MICROBIOL, V36, P2081
   *I WAT MON STAT BA, MET IND SALV
   KNOTT AM, 1994, PEDIATR INFECT DIS J, V13, P269, DOI 10.1097/00006454-199404000-00005
   Lin HC, 2009, CHRONOBIOL INT, V26, P1647, DOI 10.3109/07420520903520673
   Makela MJ, 1998, J CLIN MICROBIOL, V36, P539
   McIntosh K, 2002, NEW ENGL J MED, V346, P429, DOI 10.1056/NEJMra011994
   MCINTOSH K, 1991, REV INFECT DIS, V13, pS492
   Morre SA, 2002, J CLIN MICROBIOL, V40, P584, DOI 10.1128/JCM.40.2.584-587.2002
   Moura FEA, 2006, AM J TROP MED HYG, V74, P165, DOI 10.4269/ajtmh.2006.74.165
   Moura FEA, 2003, MEM I OSWALDO CRUZ, V98, P739, DOI 10.1590/S0074-02762003000600005
   Mulholland K, 2007, LANCET, V370, P285, DOI 10.1016/S0140-6736(07)61130-1
   NASCIMENTO JP, 1991, REV I MED TROP, V33, P287, DOI 10.1590/S0036-46651991000400008
   Nascimento-Carvalho CM, 2008, PEDIATR INFECT DIS J, V27, P939, DOI 10.1097/INF.0b013e3181723751
   NOHYNEK H, 1995, PEDIATR INFECT DIS J, V14, P478, DOI 10.1097/00006454-199506000-00003
   Panozzo CA, 2007, PEDIATR INFECT DIS J, V26, pS41, DOI 10.1097/INF.0b013e318157da82
   PICKERING LK, 2006, RED BOOK 2006 REPORT, P560
   Ramilo O, 2008, An Pediatr (Barc), V69, P1, DOI 10.1157/13124210
   Saukkoriipi A, 2002, MOL CELL PROBE, V16, P385, DOI 10.1006/mcpr.2002.0443
   Scott JAG, 2008, B WORLD HEALTH ORGAN, V86, P494, DOI 10.2471/BLT.08.052753
   Scott JAG, 2008, J CLIN INVEST, V118, P1291, DOI 10.1172/JCI33947
   Thomazelli LM, 2007, J PEDIAT-BRAZIL, V83, P422, DOI 10.1590/S0021-75572007000600005
   Waris ME, 1998, J CLIN MICROBIOL, V36, P3155, DOI 10.1128/JCM.36.11.3155-3159.1998
   White ANJ, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-196
NR 23
TC 35
Z9 41
U1 0
U2 11
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0036-5548
EI 1651-1980
J9 SCAND J INFECT DIS
JI Scand. J. Infect. Dis.
PD DEC
PY 2010
VL 42
IS 11-12
BP 839
EP 844
DI 10.3109/00365548.2010.498020
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA 679NO
UT WOS:000284168300007
PM 20608763
OA Green Published
DA 2020-12-17
ER

PT J
AU Ferrero, F
   Nascimento-Carvalho, CM
AF Ferrero, Fernando
   Nascimento-Carvalho, Cristiana M.
TI To Give or Not to Give Antibiotics to Children With Pneumonia
SO PEDIATRIC EMERGENCY CARE
LA English
DT Letter
ID CLINICAL-PREDICTION RULE; VALIDATION; BACTERIAL
C1 [Ferrero, Fernando] Hosp Ninos Pedro de Elizalde, Buenos Aires, DF, Argentina.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
RP Ferrero, F (corresponding author), Hosp Ninos Pedro de Elizalde, Buenos Aires, DF, Argentina.
EM fferrero@intramed.net
RI Ferrero, Fernando/AAE-1886-2020
OI Ferrero, Fernando/0000-0001-6335-0102
CR Bilkis MD, 2010, PEDIATR EMERG CARE, V26, P399, DOI 10.1097/PEC.0b013e3181e05779
   Lieberman JM, 2003, PEDIATR INFECT DIS J, V22, P1143, DOI 10.1097/01.inf.0000101851.57263.63
   Moreno L, 2006, PEDIATR PULM, V41, P331, DOI 10.1002/ppul.20364
   Peltola V, 2008, CLIN INFECT DIS, V46, P58, DOI 10.1086/524020
NR 4
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0749-5161
J9 PEDIATR EMERG CARE
JI Pediatr. Emerg. Care
PD NOV
PY 2010
VL 26
IS 11
BP 870
EP 870
DI 10.1097/PEC.0b013e3181f9dc57
PG 1
WC Emergency Medicine; Pediatrics
SC Emergency Medicine; Pediatrics
GA 675NW
UT WOS:000283838400019
PM 21057289
DA 2020-12-17
ER

PT J
AU Ferrero, F
   Nascimento-Carvalho, CM
   Cardoso, MR
   Camargos, P
   March, MFP
   Berezin, E
   Ruvinsky, R
   Sant'Anna, C
   Feris-Iglesias, J
   Maggi, R
   Benguigui, Y
AF Ferrero, F.
   Nascimento-Carvalho, C. M.
   Cardoso, M. -R.
   Camargos, P.
   March, M. -F. P.
   Berezin, E.
   Ruvinsky, R.
   Sant'Anna, C.
   Feris-Iglesias, J.
   Maggi, R.
   Benguigui, Y.
CA CARIBE Grp
TI Radiographic Findings Among Children Hospitalized With Severe
   Community-Acquired Pneumonia
SO PEDIATRIC PULMONOLOGY
LA English
DT Article
DE bacteremia; chest X-ray; pleural effusion; respiratory tract infection;
   Streptococcus pneumoniae
ID CHEST RADIOGRAPHS; STANDARDIZED INTERPRETATION
AB Background: Community-acquired pneumonia (CAP) is a leading cause of childhood death. There are few published reports of radiographic findings among children with severe CAP. Objective: To describe chest X-ray (CXR) findings and assess association between these radiographic findings and pneumococcal isolation in children with severe CAP. Methods: A prospective, multicenter, observational study was conducted in 12 centers in Argentina, Brazil, and the Dominican Republic. Children aged 3-59 months, hospitalized with severe pneumonia, were included. On admission, blood and pleural effusion cultures were performed. Streptococcus pneumoniae was identified according to standard procedures in the respective national reference laboratory. Chest X-rays were taken on admission and read before the culture results were reported. Results: Out of 2,536 enrolled patients, 283 (11.2%) had S. pneumoniae isolated, in 181 cases (7.1%) from blood. The follow radiographic patterns were observed: alveolar infiltrate (75.2%), pleural effusion (15.6%), and interstitial infiltrate (9.2%). Overall, pleural effusion was associated with pneumococcal isolation and pneumococcal bacteremia (P < 0.001). Infiltrates were unilateral (78.7%) or bilateral (21.3%), right-sided (76%) or left-sided (24%), in the lower lobe (53.6%) or the upper lobe (46.4%). Multivariate analysis including patients with affection of only one lobe showed that upper lobe affection and pleural effusion were associated with pneumococcal isolation (OR 1.8, 95% CI, 1.3-2.7; OR 11.0, 95% CI, 4.6-26.8, respectively) and with pneumococcal bacteremia (OR 1.7, 95% CI, 1.2-2.6; OR 3.1, 95% CI, 1.2-8.0, respectively). Conclusions: Three-quarters of the patients studied had alveolar infiltrates. Upper lobe compromising and pleural effusion were associated with pneumococcal invasive disease. Pediatr Pulmonol. 2010; 45:1009-1013. (C) 2010 Wiley-Liss, Inc.
C1 [Ferrero, F.] Hosp Ninos Pedro de Elizalde, Buenos Aires, DF, Argentina.
   [Nascimento-Carvalho, C. M.] Univ Fed Bahia, Dept Pediat, Sch Med, Salvador, BA, Brazil.
   [Cardoso, M. -R.] Univ Sao Paulo, Fac Publ Hlth, Sao Paulo, Brazil.
   [Camargos, P.] Univ Fed Minas Gerais, Dept Pediat, Sch Med, Belo Horizonte, MG, Brazil.
   [March, M. -F. P.; Sant'Anna, C.] Martagao Gesteira Pediat Inst, Rio De Janeiro, Brazil.
   [Berezin, E.] Santa Casa Sao Paulo Med Sch, Sao Paulo, Brazil.
   [Ruvinsky, R.] Hosp Gen Carlos Durand, Buenos Aires, DF, Argentina.
   [Feris-Iglesias, J.] Hosp Infantil Dr Robert Reid Cabral, Santo Domingo, Dominican Rep.
   [Maggi, R.] Inst Med Integral Prof Fernando Figueira, Pernambuco, Brazil.
   [Benguigui, Y.] Pan Amer Hlth Org, Child & Adolescent Hlth Unit, Washington, DC USA.
RP Ferrero, F (corresponding author), Amenabar 1935,C1428CUV, Buenos Aires, DF, Argentina.
EM fferrero@intramed.net
RI Anna, Clemax Sant/H-7923-2019; Ferrero, Fernando/AAE-1886-2020; Cardoso,
   Maria Regina A/J-7280-2012
OI Anna, Clemax Sant/0000-0001-8732-8065; Ferrero,
   Fernando/0000-0001-6335-0102; 
CR Bryce J, 2005, LANCET, V365, P1147, DOI 10.1016/S0140-6736(05)71877-8
   Cardoso MRA, 2008, ARCH DIS CHILD, V93, P221, DOI 10.1136/adc.2006.111625
   Cherian T, 2005, B WORLD HEALTH ORGAN, V83, P353
   Ferrero F, 2008, ARCH ARGENT PEDIATR, V106, P510, DOI 10.1590/S0325-00752008000600007
   Hansen J, 2006, PEDIATR INFECT DIS J, V25, P779, DOI 10.1097/01.inf.0000232706.35674.2f
   Hazir T, 2006, BMJ-BRIT MED J, V333, P629, DOI 10.1136/bmj.38915.673322.80
   Key NK, 2009, PEDIATR PULM, V44, P249, DOI 10.1002/ppul.20988
   KORPPI M, 1993, ACTA PAEDIATR, V82, P360, DOI 10.1111/j.1651-2227.1993.tb12697.x
   Michelow IC, 2004, PEDIATRICS, V113, P701, DOI 10.1542/peds.113.4.701
   Nascimento-Carvalho CMC, 2002, J TROP PEDIATRICS, V48, P253, DOI 10.1093/tropej/48.4.253
   Nascimento-Carvalho CMC, 2001, J TROP PEDIATRICS, V47, P253, DOI 10.1093/tropej/47.4.253
   Roxburgh CSD, 2008, ARCH DIS CHILD, V93, P316, DOI 10.1136/adc.2007.126540
   Sazawal S, 2003, LANCET INFECT DIS, V3, P547, DOI 10.1016/S1473-3099(03)00737-0
   Swingler GH, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001268.pub3
   Virkki R, 2005, PEDIATR PULM, V40, P223, DOI 10.1002/ppul.20258
   Virkki R, 2002, THORAX, V57, P438, DOI 10.1136/thorax.57.5.438
   *WHO, 1990, ARI CHILDR CAS MAN S
NR 17
TC 14
Z9 14
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8755-6863
EI 1099-0496
J9 PEDIATR PULM
JI Pediatr. Pulmonol.
PD OCT
PY 2010
VL 45
IS 10
BP 1009
EP 1013
DI 10.1002/ppul.21287
PG 5
WC Pediatrics; Respiratory System
SC Pediatrics; Respiratory System
GA 664WE
UT WOS:000282993700010
PM 20648670
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, CM
   Ruuskanen, O
AF Nascimento-Carvalho, Cristiana M.
   Ruuskanen, Olli
TI Severe Pneumonia Among Kenyan Infants and Children
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
ID COMMUNITY-ACQUIRED PNEUMONIA
C1 [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
   [Ruuskanen, Olli] Univ Turku, Dept Pediat, Turku, Finland.
RP Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
CR Berkley JA, 2010, JAMA-J AM MED ASSOC, V303, P2051, DOI 10.1001/jama.2010.675
   Chiang WC, 2007, RESPIROLOGY, V12, P254, DOI 10.1111/j.1440-1843.2006.01036.x
   Graham SM, 2008, B WORLD HEALTH ORGAN, V86, P349, DOI 10.2471/BLT.07.048512
   Nascimento-Carvalho CM, 2008, PEDIATR INFECT DIS J, V27, P939, DOI 10.1097/INF.0b013e3181723751
   Shah S, 2010, PEDIATR INFECT DIS J, V29, P406, DOI 10.1097/INF.0b013e3181cb45a7
NR 5
TC 0
Z9 0
U1 1
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD SEP 1
PY 2010
VL 304
IS 9
BP 963
EP 963
DI 10.1001/jama.2010.1242
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 645AD
UT WOS:000281422400017
PM 20810371
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, CM
   Cardoso, MRA
   Barral, A
   Araujo-Neto, CA
   Guerin, S
   Saukkoriipi, A
   Paldanius, M
   Vainionpaa, R
   Lebon, P
   Leinonen, M
   Ruuskanen, O
   Gendrel, D
AF Nascimento-Carvalho, Cristiana M.
   Cardoso, Maria-Regina A.
   Barral, Aldina
   Araujo-Neto, Cesar A.
   Guerin, Sylvie
   Saukkoriipi, Annika
   Paldanius, Mika
   Vainionpaa, Raija
   Lebon, Pierre
   Leinonen, Maija
   Ruuskanen, Olli
   Gendrel, Dominique
TI Procalcitonin is useful in identifying bacteraemia among children with
   pneumonia
SO SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID COMMUNITY-ACQUIRED PNEUMONIA; C-REACTIVE PROTEIN; RESPIRATORY
   VIRAL-INFECTIONS; DEVELOPING-COUNTRIES; SERUM PROCALCITONIN; BACTERIAL;
   ETIOLOGY; INTERLEUKIN-6; VIRUSES; COMMON
AB Empirical antibiotic use is prescribed in managing children with pneumonia worldwide. We assessed the usefulness of procalcitonin (PCT) and interferon-alpha (IFN-alpha) in differentiating viral from bacterial pneumonia. Among 159 hospitalized children, pneumonia was diagnosed based on clinical complaints plus pulmonary infiltrate. Aetiology was investigated for 9 viruses and 4 atypical and 3 typical bacteria. PCT and IFN-alpha were measured in the serum sample collected on admission. Eight patients had bacteraemic infections, 38 had non-bacteraemic typical infections, and 19 patients had atypical bacterial infections. Viral and unknown aetiology was established in 57 (36%) and 34 (21%) cases, respectively. Three patients with bacterial infection without collected blood culture were excluded. IFN-alpha (IU/ml) was detectable in 20 (13%) cases. The difference among median PCT values of the bacteraemic (4.22; 1.56-7.56), non-bacteraemic typical bacterial (1.47; 0.24-4.07), atypical bacterial (0.18; 0.06-1.03) and only viral (0.65; 0.11-2.22) subgroups was significant (p = 0.02). PCT was >= 2 ng/ml in 52 (33%) cases. The presence of IFN-alpha was associated with PCT <2 ng/ml (90% vs. 64%, p = 0.02). The negative predictive value (95% confidence interval) of PCT >= 2 ng/ml was 95% (89-100%), 89% (78-100%), 93% (85-100%) for differentiation of bacteraemic from viral, atypical bacterial and non-bacteraemic typical bacterial infection, respectively, and 58% (49-68%) for differentiation between bacterial and viral infection. PCT may be useful in identifying bacteraemia among children hospitalized with community-acquired pneumonia. IFN-alpha was uncommonly detected.
C1 [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Paediat, BR-40210630 Salvador, BA, Brazil.
   [Cardoso, Maria-Regina A.] Univ Sao Paulo, Fac Publ Hlth, Dept Epidemiol, Sao Paulo, Brazil.
   [Barral, Aldina] Univ Fed Bahia, Sch Med, Dept Pathol, BR-40210630 Salvador, BA, Brazil.
   [Barral, Aldina] Fundacao Oswaldo Cruz, Ctr Pesquisa Goncalo Muniz, Salvador, BA, Brazil.
   [Araujo-Neto, Cesar A.] Univ Fed Bahia, Sch Med, Image Diag Dept, BR-40210630 Salvador, BA, Brazil.
   [Guerin, Sylvie; Lebon, Pierre; Gendrel, Dominique] Paris Descartes Univ, St Vincent Cochin Hosp, Paris, France.
   [Saukkoriipi, Annika; Paldanius, Mika; Leinonen, Maija] Natl Inst Hlth & Welf, Oulu, Finland.
   [Vainionpaa, Raija] Univ Turku, Dept Paediat, Turku, Finland.
RP Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia, Sch Med, Dept Paediat, Rua Prof Aristides Novis,105-1201B, BR-40210630 Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
RI Cardoso, Maria Regina A/J-7280-2012; Barral, Aldina/B-4191-2009
OI Barral, Aldina/0000-0002-7177-464X
FU Fundacao de Amparo a Pesquisa no Estado da Bahia (FAPESB), Salvador,
   Brazil; Paediatric Research Foundation, Helsinki, Finland
FX This study was supported by funding from the Fundacao de Amparo a
   Pesquisa no Estado da Bahia (FAPESB), Salvador, Brazil and the
   Paediatric Research Foundation, Helsinki, Finland. C.M.N.-C., M.-R.A.C.
   and A.B. are investigators of the Brazilian Council for Science and
   Technology Development (CNPq).
CR ASSICOT M, 1993, LANCET, V341, P515, DOI 10.1016/0140-6736(93)90277-N
   Christ-Crain M, 2006, AM J RESP CRIT CARE, V174, P84, DOI 10.1164/rccm.200512-1922OC
   Cilla G, 2008, J MED VIROL, V80, P1843, DOI 10.1002/jmv.21271
   Gendrel D, 1999, PEDIATR INFECT DIS J, V18, P875, DOI 10.1097/00006454-199910000-00008
   HALE KA, 2006, PEDIAT RESP REV, V7, P45
   Hyypia T, 1998, J CLIN MICROBIOL, V36, P2081
   Juven T, 2000, PEDIATR INFECT DIS J, V19, P293, DOI 10.1097/00006454-200004000-00006
   Korppi M, 2008, EUR J CLIN MICROBIOL, V27, P167, DOI 10.1007/s10096-007-0436-8
   Korppi M, 2006, RESPIROLOGY, V11, P80, DOI 10.1111/j.1440-1843.2006.00788.x
   Korppi M, 2008, ACTA PAEDIATR, V97, P943, DOI 10.1111/j.1651-2227.2008.00789.x
   Makela MJ, 1998, J CLIN MICROBIOL, V36, P539
   Maniaci V, 2008, PEDIATRICS, V122, P701, DOI 10.1542/peds.2007-3503
   Moulin F, 2001, ARCH DIS CHILD, V84, P332, DOI 10.1136/adc.84.4.332
   Muller B, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-10
   Nascimento-Carvalho C M, 2001, Braz J Infect Dis, V5, P87
   Nascimento-Carvalho CM, 2008, PEDIATR INFECT DIS J, V27, P939, DOI 10.1097/INF.0b013e3181723751
   Niederman MS, 2008, CLIN INFECT DIS, V47, pS127, DOI 10.1086/591393
   Peltola V, 2008, CLIN INFECT DIS, V46, P58, DOI 10.1086/524020
   Prat C, 2003, PEDIATR INFECT DIS J, V22, P963, DOI 10.1097/01.inf.0000095197.72976.4f
   Price GE, 2000, J VIROL, V74, P3996, DOI 10.1128/JVI.74.9.3996-4003.2000
   Rudan I, 2008, B WORLD HEALTH ORGAN, V86, P408, DOI 10.2471/BLT.07.048769
   Saukkoriipi A, 2002, MOL CELL PROBE, V16, P385, DOI 10.1006/mcpr.2002.0443
   SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017
   Toikka P, 2000, PEDIATR INFECT DIS J, V19, P598, DOI 10.1097/00006454-200007000-00003
   WHO UNICEF, 2008, INT MAN CHILDH ILLN
NR 25
TC 28
Z9 32
U1 0
U2 3
PU TAYLOR & FRANCIS AS
PI OSLO
PA KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY
SN 0036-5548
J9 SCAND J INFECT DIS
JI Scand. J. Infect. Dis.
PD SEP
PY 2010
VL 42
IS 9
BP 644
EP 649
DI 10.3109/00365541003796775
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA 661HG
UT WOS:000282716000001
PM 20438288
DA 2020-12-17
ER

PT J
AU Fontoura, MSH
   Araujo-Neto, CA
   Andrade, SCS
   Brim, RV
   Matutino, AR
   Silva, CC
   Santana, MC
   Nobre-Bastos, M
   Oliveira, F
   Barreto, BB
   Santos, PM
   Noblat, L
   Cardoso, MRA
   Nascimento-Carvalho, CM
AF Fontoura, Maria-Socorro H.
   Araujo-Neto, Cesar A.
   Andrade, Sandra C. S.
   Brim, Rosa V.
   Matutino, Adriana R.
   Silva, Carolina C.
   Santana, Milena C.
   Nobre-Bastos, Monalisa
   Oliveira, Felipe
   Barreto, Bruna B.
   Santos, Pablo M.
   Noblat, Lucia
   Cardoso, Maria-Regina A.
   Nascimento-Carvalho, Cristiana M.
CA PNEUMOPAC-Efficacy Study Grp
TI Clinical failure among children with nonsevere community-acquired
   pneumonia treated with amoxicillin
SO EXPERT OPINION ON PHARMACOTHERAPY
LA English
DT Review
DE acute respiratory infection; amoxicillin; lower respiratory tract
   disease; lung disease; outcome
ID ANTIMICROBIAL RESISTANCE; COTRIMOXAZOLE; MANAGEMENT; THERAPY
AB Objective: To estimate the clinical failure and adverse events in children with nonsevere pneumonia receiving amoxicillin, identifying risk factors. Research design/methods: 192 patients aged 2 - 59 months were prospectively followed up. Pneumonia diagnosis was based on respiratory complaints and radiographic pulmonary infiltrate or pleural effusion. Amoxicillin (50 mg/kg/day) was given. Demographic data and clinical findings on admission, daily evolution up to the 5th day of treatment and 2 - 4 weeks after enrollment were collected. Main outcome measures: Clinical failure included persistence of fever, difficulty breathing or tachypnea beyond the first 48 h of treatment or of cough beyond the first 96 h of treatment or sign of severe/very severe disease up to the 5th day of treatment. Results: Amoxicillin failed in 6 (3.1%) cases. By excluding one child diagnosed with cystic fibrosis after continued follow-up, the final clinical failure rate was 2.6%. The total adverse effect frequency was 14 (7.3%), but amoxicillin was discontinued only in 1 (0.5%) case. No relapse was identified at the 2 - 4-week interval evaluation. By multivariate analysis, age (OR = 1.1; 95% CI 1.01 - 1.19) was an independent risk factor for clinical failure which occurred in older children (47 +/- 9 vs 31 +/- 16 months; p = 0.01). Conclusions: Clinical failures were few, especially among those aged < 2 years. Amoxicillin discontinuation due to adverse reaction was rare.
C1 [Fontoura, Maria-Socorro H.; Matutino, Adriana R.; Silva, Carolina C.; Santana, Milena C.; Nobre-Bastos, Monalisa; Barreto, Bruna B.; Nascimento-Carvalho, Cristiana M.; PNEUMOPAC-Efficacy Study Grp] Univ Fed Bahia, Sch Med, Dept Pediat, BR-40210630 Salvador, BA, Brazil.
   [Araujo-Neto, Cesar A.; Brim, Rosa V.] Univ Fed Bahia, Sch Med, Dept Image Diag, BR-40210630 Salvador, BA, Brazil.
   [Andrade, Sandra C. S.] Fed Univ Bahia Hosp, Image Diag Unit, Salvador, BA, Brazil.
   [Oliveira, Felipe] Bahiana Fdn Sci Dev, Bahiana Sch Med, Salvador, BA, Brazil.
   [Santos, Pablo M.; Noblat, Lucia] Fed Univ Bahia Hosp, Pharm Unit, Salvador, BA, Brazil.
   [Cardoso, Maria-Regina A.] Univ Sao Paulo, Fac Publ Hlth, Dept Epidemiol, Sao Paulo, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia, Sch Med, Dept Pediat, Rua Prof Aristides Novis 105-1201B, BR-40210630 Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
RI Santos, Pablo/W-7141-2019; Santos, Pablo Moura/P-5966-2016; Cardoso,
   Maria Regina A/J-7280-2012
OI Matutino Kahn, Adriana/0000-0002-5306-0571
FU Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB); M-RA Cardoso;
   Brazilian Council for Science and Technology Development (CNPq)National
   Council for Scientific and Technological Development (CNPq)
FX This research was supported by the Fundacao de Amparo a Pesquisa do
   Estado da Bahia (FAPESB). M-RA Cardoso and CM Nascimento-Carvalho are
   investigators of the Brazilian Council for Science and Technology
   Development (CNPq). The authors state no conflict of interest and have
   received no payment in preparation of this manuscript.
CR Awasthi S, 2004, BMJ-BRIT MED J, V328, P791
   Awasthi S, 2008, J TROP PEDIATRICS, V54, P382, DOI 10.1093/tropej/fmn050
   Awasthi S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001991
   Ayieko P, 2007, PEDIATR INFECT DIS J, V26, P432, DOI 10.1097/01.inf.0000260107.79355.7d
   Wolkers PCB, 2009, J PEDIAT-BRAZIL, V85, P421, DOI [10.2223/JPED.1931, 10.1590/S0021-75572009000500009]
   Benguigui Yehuda, 2006, Semin Pediatr Infect Dis, V17, P80, DOI 10.1053/j.spid.2006.04.006
   Cherian T, 2005, B WORLD HEALTH ORGAN, V83, P353
   Council for International Organisations of Medical Sciences, 2001, CURR CHALL PHARM PRA
   Dimopoulos G, 2008, DRUGS, V68, P1841, DOI 10.2165/00003495-200868130-00004
   El-Rashdi AS, 2006, ARCH DIS CHILD, V91, P351, DOI 10.1136/adc.2005.088831
   Grant GB, 2009, LANCET INFECT DIS, V9, P185, DOI 10.1016/S1473-3099(09)70044-1
   Haider BA, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005976.pub2
   Hazir T, 2002, LANCET, V360, P835
   Hazir T, 2007, ARCH DIS CHILD, V92, P291, DOI 10.1136/adc.2005.092494
   Jacobs MR, 2008, EXPERT REV ANTI-INFE, V6, P619, DOI 10.1586/14787210.6.5.619
   Korppi Matti, 2003, Paediatr Drugs, V5, P821, DOI 10.2165/00148581-200305120-00005
   McCracken GH, 2000, PEDIATR INFECT DIS J, V19, P373, DOI 10.1097/00006454-200004000-00032
   McIntosh K, 2002, NEW ENGL J MED, V346, P429, DOI 10.1056/NEJMra011994
   Nascimento-Carvalho C M, 2001, Braz J Infect Dis, V5, P87
   Nascimento-Carvalho CM, 2004, REV PANAM SALUD PUBL, V15, P380, DOI 10.1590/S1020-49892004000600003
   Nascimento-Carvalho CMC, 2001, J TROP PEDIATRICS, V47, P253, DOI 10.1093/tropej/47.4.253
   Nascimento-Carvalho CM, 2008, PEDIATR INFECT DIS J, V27, P939, DOI 10.1097/INF.0b013e3181723751
   Nascimento-Carvalho CM, 2010, EXPERT OPIN PHARMACO, V11, P225, DOI 10.1517/14656560903433714
   Pichichero Michael E, 2009, Paediatr Drugs, V11, P243, DOI 10.2165/00148581-200911040-00003
   Shann F, 1995, CLIN INFECT DIS, V21, pS218, DOI 10.1093/clind/21.Supplement_3.S218
   Straus WL, 1998, LANCET, V352, P270, DOI 10.1016/S0140-6736(97)10294-X
   Virkki R, 2005, PEDIATR PULM, V40, P223, DOI 10.1002/ppul.20258
   World Health Organization, 2008, 5032 WC WHO
NR 28
TC 4
Z9 4
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1465-6566
EI 1744-7666
J9 EXPERT OPIN PHARMACO
JI Expert Opin. Pharmacother.
PD JUN
PY 2010
VL 11
IS 9
BP 1451
EP 1458
DI 10.1517/14656561003777034
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 613BL
UT WOS:000278950900002
PM 20408745
DA 2020-12-17
ER

PT J
AU Mello, CD
   Andrade, BB
   Lopes, MA
   Pedral-Sampaio, DB
   Sadigursky, M
   Barral, A
   Nascimento-Carvalho, CM
AF Mello, Caroline D.
   Andrade, Bruno B.
   Lopes, Maria-Angela
   Pedral-Sampaio, Diana B.
   Sadigursky, Moyses
   Barral, Aldina
   Nascimento-Carvalho, Cristiana M.
TI An Infant with Down Syndrome and Fever of Unknown Origin
SO PEDIATRIC ANNALS
LA English
DT Article
C1 [Mello, Caroline D.; Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
   [Andrade, Bruno B.] Fundacao Oswaldo Cruz, Ctr Pesquisa Goncalo, Salvador, BA, Brazil.
   [Sadigursky, Moyses; Barral, Aldina] Univ Fed Bahia, Sch Med, Dept Pathol, BR-41170290 Salvador, BA, Brazil.
   [Pedral-Sampaio, Diana B.] Fed Univ Bahia Univ Hosp, Infect Dis Unit, Bahia Blanca, Buenos Aires, Argentina.
   [Barral, Aldina] Fundacao Oswaldo Cruz, Ctr Pesquisa Goncalo Moniz, Rio De Janeiro, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Rua Prof Aristides Novis,105-1201B, BR-40210630 Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
RI Mello-Amoedo, Caroline/N-5049-2014; Barral, Aldina/B-4191-2009; Andrade,
   Bruno/J-9111-2012; Andrade, Bruno/AAI-2248-2020
OI Mello-Amoedo, Caroline/0000-0002-2003-8116; Barral,
   Aldina/0000-0002-7177-464X; Andrade, Bruno/0000-0001-6833-3811; 
CR Akpede GO, 2001, PEDIATR DRUGS, V3, P247, DOI 10.2165/00128072-200103040-00002
   ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2
   de Noronha ALL, 2008, PATHOL RES PRACT, V204, P155, DOI 10.1016/j.prp.2007.10.008
   Douglas SD, 2005, J PEDIATR-US, V147, P723, DOI 10.1016/j.jpeds.2005.09.002
   Garrison MM, 2005, J PEDIATR-US, V147, P748, DOI 10.1016/j.jpeds.2005.06.032
   Hattori M, 2000, NATURE, V405, P311
   Hing YC, 2005, J PEDIAT, V147, P744
   Murphy M, 1995, Prog Clin Biol Res, V393, P147
   MUSIANI P, 1990, AM J MED GENET, P219
   Ulloa R, 1998, PEDIATR INFECT DIS J, V17, P758, DOI 10.1097/00006454-199808000-00022
   Yang QH, 2002, LANCET, V359, P1019, DOI 10.1016/S0140-6736(02)08092-3
NR 11
TC 1
Z9 1
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 0090-4481
EI 1938-2359
J9 PEDIATR ANN
JI Pediatr. Ann.
PD APR
PY 2010
VL 39
IS 4
BP 192
EP 197
DI 10.3928/00904481-20100318-03
PG 6
WC Pediatrics
SC Pediatrics
GA 580UZ
UT WOS:000276477300004
PM 20411895
OA Green Published
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, CM
AF Nascimento-Carvalho, Cristiana M.
TI Pharmacotherapy of childhood pneumonia
SO EXPERT OPINION ON PHARMACOTHERAPY
LA English
DT Review
ID COMMUNITY-ACQUIRED PNEUMONIA; CASE-MANAGEMENT; CHILDREN; ETIOLOGY;
   RESISTANCE; PENICILLIN; MORTALITY; EPIDEMIOLOGY; ANTIBIOTICS; DIAGNOSIS
AB Importance of the field: Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality among children under Syears. Although viral infections have been frequently recognized, death has been attributable to bacterial infections (especially due to Streptococcus pneumoniae).
   Areas covered in this review: In the past twenty years, childhood mortality due to CAP has been declining because of accessible health care and prompt antibiotic use. The basic options of antibiotics to treat children with CAP are presented.
   What the reader will gain: In daily practice, antibiotic prescription to treat childhood CAP is based on age and severity assessment. For those children aged less than 2 months, hospitalization and parenteral administration of ampicillin plus aminoglycoside or ampicillin plus third-generation cephalosporin is mandatory. For those patients aged 2 months and older with non-severe or severe CAP, the first option is amoxicillin or aqueous penicillin G, respectively; for very severe presentation, oxacillin and third-generation cephalosporin are recommended. If atypical bacteria infection is suspected, macrolide must be given in any age or severity group.
   Take home message: Few antibiotics are included in the guidelines to treat childhood CAP. The choice of which antibiotic should be given is based on clinical evaluation.
C1 Univ Fed Bahia, Sch Med, Dept Pediat, BR-40210630 Salvador, BA, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia, Sch Med, Dept Pediat, Rua Prof Aristides Novis 105-1201B, BR-40210630 Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
CR Aspa J, 2008, EXPERT OPIN PHARMACO, V9, P229, DOI 10.1517/14656566.9.2.229 
   Atkinson M, 2007, THORAX, V62, P1102, DOI 10.1136/thx.2006.074906
   Ayieko P, 2007, PEDIATR INFECT DIS J, V26, P432, DOI 10.1097/01.inf.0000260107.79355.7d
   Bryce J, 2005, LANCET, V365, P1147, DOI 10.1016/S0140-6736(05)71877-8
   Cardoso MRA, 2008, ARCH DIS CHILD, V93, P221, DOI 10.1136/adc.2006.111625
   Chetty Krishne, 2007, Paediatr Drugs, V9, P401, DOI 10.2165/00148581-200709060-00007
   *CSLI, 2008, PERF STAND ANT SUSC
   DAGAN R, 1994, DRUGS, V47, P43, DOI 10.2165/00003495-199400473-00008
   Delport SD, 2002, SAMJ S AFR MED J, V92, P907
   Fitzpatrick M, 2002, THORAX, V57, P1, DOI 10.1136/thorax.57.1.1
   Garau J, 2005, EUR J CLIN MICROBIOL, V24, P83, DOI 10.1007/s10096-005-1287-9
   Garcia-Rey C, 2002, J CLIN MICROBIOL, V40, P159, DOI 10.1128/JCM.40.1.159-164.2002
   Gessner BD, 2005, EPIDEMIOL INFECT, V133, P877, DOI 10.1017/S0950268805004449
   Grant GB, 2009, LANCET INFECT DIS, V9, P185, DOI 10.1016/S1473-3099(09)70044-1
   GRANT JP, 1990, STATE WORLDS CHILDRE
   Haider BA, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005976.pub2
   Hale KA, 2006, PAEDIATR RESPIR REV, V7, P145, DOI 10.1016/j.prrv.2006.03.011
   Hazir T, 2002, LANCET, V360, P835
   Jacobs MR, 2008, EXPERT REV ANTI-INFE, V6, P619, DOI 10.1586/14787210.6.5.619
   Jadavji T, 1997, CAN MED ASSOC J, V156, pS703
   KABRA SK, 2006, COCHRANE DB SYST REV, V3
   Kastner U, 2001, INFECTION, V29, P251, DOI 10.1007/s15010-001-1072-3
   Korppi M, 2002, APMIS, V110, P515, DOI 10.1034/j.1600-0463.2002.11007801.x
   Korppi Matti, 2003, Paediatr Drugs, V5, P821, DOI 10.2165/00148581-200305120-00005
   Marsh DR, 2008, B WORLD HEALTH ORGAN, V86, P381, DOI 10.2471/BLT.07.048462
   McIntosh K, 2002, NEW ENGL J MED, V346, P429, DOI 10.1056/NEJMra011994
   Mulholland K, 2007, LANCET, V370, P285, DOI 10.1016/S0140-6736(07)61130-1
   Nascimento-Carvalho C M, 2001, Braz J Infect Dis, V5, P87
   Nascimento-Carvalho CM, 2004, REV PANAM SALUD PUBL, V15, P380, DOI 10.1590/S1020-49892004000600003
   Nascimento-Carvalho Cristiana M.C., 2002, Braz J Infect Dis, V6, P22, DOI 10.1590/S1413-86702002000100004
   NASCIMENTOCARVA.CM, 2008, J CLIN INVEST, V118, P1291, DOI DOI 10.1172/JCI33947
   Ostapchuk M, 2004, AM FAM PHYSICIAN, V70, P899
   Peltola V, 2008, CLIN INFECT DIS, V46, P58, DOI 10.1086/524020
   Pickering LK, 2006, REPORT COMMITTEE INF
   Principi N, 2003, EXPERT OPIN PHARMACO, V4, P761, DOI 10.1517/eoph.4.5.761.22214
   Reese RE, 2000, HDB ANTIBIOTICS
   Rudan I, 2008, B WORLD HEALTH ORGAN, V86, P408, DOI 10.2471/BLT.07.048769
   Sazawal S, 2003, LANCET INFECT DIS, V3, P547, DOI 10.1016/S1473-3099(03)00737-0
   Scott JAG, 2008, B WORLD HEALTH ORGAN, V86, P494, DOI 10.2471/BLT.08.052753
   SHANN F, 1989, PEDIATR INFECT DIS J, V8, P852, DOI 10.1097/00006454-198912000-00005
   SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017
   Virkki R, 2002, THORAX, V57, P438, DOI 10.1136/thorax.57.5.438
   Wardlaw T, 2006, LANCET, V368, P1048, DOI 10.1016/S0140-6736(06)69334-3
   *WHO, 1985, WHORSD8515
   World Health Organization, 2008, 5032 WC WHO
   Zar HJ, 2005, SAMJ S AFR MED J, V95, P977
NR 46
TC 5
Z9 5
U1 0
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1465-6566
EI 1744-7666
J9 EXPERT OPIN PHARMACO
JI Expert Opin. Pharmacother.
PD FEB
PY 2010
VL 11
IS 2
BP 225
EP 231
DI 10.1517/14656560903433714
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 548TB
UT WOS:000273988100007
PM 20088744
DA 2020-12-17
ER

PT J
AU Costa, DT
   Serra, MIF
   Nascimento-Carvalho, CM
AF Costa, Davi T.
   Serra, Maria-Ivete F.
   Nascimento-Carvalho, Cristiana M.
TI An 11-month-old Girl with Saliva Impaction and Vomiting
SO PEDIATRIC ANNALS
LA English
DT Editorial Material
ID CONGENITAL ESOPHAGEAL STENOSIS; CHILDREN
C1 [Costa, Davi T.; Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Dept Pediat, Sch Med, Salvador, BA, Brazil.
   [Nascimento-Carvalho, Cristiana M.] Brazilian Council Sci & Technol Dev CNPq, Salvador, BA, Brazil.
   [Serra, Maria-Ivete F.] Childrens Hosp, Endoscopy Serv, Salvador, BA, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Rua Prof Aristides Novis 105-1201B, BR-40210630 Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
OI Tanajura Costa, Davi/0000-0002-4583-2391
CR Broto J, 1989, Cir Pediatr, V2, P129
   Diab N, 1999, EUR J PEDIATR SURG, V9, P177, DOI 10.1055/s-2008-1072237
   DOMINGUEZ R, 1985, CLIN RADIOL, V36, P263, DOI 10.1016/S0009-9260(85)80056-8
   Huang YC, 2004, PEDIATR SURG INT, V20, P207, DOI 10.1007/s00383-004-1153-3
   Katzka DA, 2000, AM J GASTROENTEROL, V95, P32
   Kawahara H, 2001, SURGERY, V129, P29, DOI 10.1067/msy.2001.109064
   MURPHY SG, 1995, J PEDIATR SURG, V30, P1238, DOI 10.1016/0022-3468(95)90032-2
   Myers N A, 1995, Semin Pediatr Surg, V4, P166
   Ouanes I, 2006, ARCH PEDIATRIE, V13, P1043, DOI 10.1016/j.arcped.2006.03.144
   Ramesh JC, 2001, PEDIATR SURG INT, V17, P188, DOI 10.1007/s003830000458
   RODE H, 1992, J PEDIATR SURG, V27, P462, DOI 10.1016/0022-3468(92)90337-7
   Setty SP, 2004, EUR J PEDIATR SURG, V14, P283, DOI 10.1055/s-2004-817943
   Takamizawa S, 2002, J PEDIATR SURG, V37, P197, DOI 10.1053/jpsu.2002.30254
NR 13
TC 0
Z9 0
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 0090-4481
EI 1938-2359
J9 PEDIATR ANN
JI Pediatr. Ann.
PD NOV
PY 2009
VL 38
IS 11
BP 603
EP +
DI 10.3928/00904481-20091016-01
PG 3
WC Pediatrics
SC Pediatrics
GA 518JE
UT WOS:000271686600003
PM 19968202
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, CM
   Cardoso, MR
   Brandileone, MC
   Ferrero, F
   Camargos, P
   Berezin, E
   Ruvinsky, R
   Sant'Anna, C
   March, MF
   Feris-Iglesias, J
   Maggi, R
   Benguigui, Y
AF Nascimento-Carvalho, Cristiana M.
   Cardoso, Maria-Regina
   Brandileone, Maria-Cristina
   Ferrero, Fernando
   Camargos, Paulo
   Berezin, Eitan
   Ruvinsky, Raul
   Sant'Anna, Clemax
   March, Maria-Fatima
   Feris-Iglesias, Jesus
   Maggi, Rubem
   Benguigui, Yehuda
CA CARIBE Grp
TI Penicillin/ampicillin efficacy among children with severe pneumonia due
   to penicillin-resistant pneumococcus (MIC=4 mu g ml(-1))
SO JOURNAL OF MEDICAL MICROBIOLOGY
LA English
DT Article
ID COMMUNITY-ACQUIRED PNEUMONIA; MANAGEMENT
C1 [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Paediat, Salvador, BA, Brazil.
   [Cardoso, Maria-Regina] Univ Sao Paulo, Fac Publ Hlth, Sao Paulo, Brazil.
   [Brandileone, Maria-Cristina] Adolfo Lutz Inst, Bacteriol Branch, Sao Paulo, Brazil.
   [Ferrero, Fernando] Hosp Ninos Elizalde, Buenos Aires, DF, Argentina.
   [Camargos, Paulo] Univ Fed Minas Gerais, Sch Med, Dept Pediat, Belo Horizonte, MG, Brazil.
   [Berezin, Eitan] Santa Casa Sao Paulo Med Sch, Sao Paulo, Brazil.
   [Ruvinsky, Raul] Hosp Municipal Durand, Buenos Aires, DF, Argentina.
   [Sant'Anna, Clemax; March, Maria-Fatima] Martagao Gesteira Paediat Inst, Rio De Janeiro, Brazil.
   [Feris-Iglesias, Jesus] Hosp Infantil Dr Robert Reid Cabral, Santo Domingo, Dominican Rep.
   [Maggi, Rubem] Inst Materno Infantil Pernambuco, Recife, PE, Brazil.
   [Benguigui, Yehuda] Pan Amer Hlth Org, Child & Adolescent Hlth Unit, Washington, DC USA.
RP Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia, Sch Med, Dept Paediat, Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
RI Anna, Clemax Sant/H-7923-2019; Cardoso, Maria Regina A/J-7280-2012;
   Ferrero, Fernando/AAE-1886-2020
OI Anna, Clemax Sant/0000-0001-8732-8065; Ferrero,
   Fernando/0000-0001-6335-0102
CR Aguado-Garcia JM, 2004, ENFERM INFEC MICR CL, V22, P230, DOI 10.1157/13059054
   [Anonymous], 2008, M100S15 CLSI
   Ayieko P, 2007, PEDIATR INFECT DIS J, V26, P432, DOI 10.1097/01.inf.0000260107.79355.7d
   Cardoso MRA, 2008, ARCH DIS CHILD, V93, P221, DOI 10.1136/adc.2006.111625
   Clinical and Laboratory Standards Institute (CLSI), 2007, M100S15 CLSI
   Dagan Ron, 2003, International Journal of Infectious Diseases, V7, pS21, DOI 10.1016/S1201-9712(03)90067-1
   Facklam R, 1991, MANUAL CLIN MICROBIO, P238
   Heffelfinger JD, 2000, ARCH INTERN MED, V160, P1399, DOI 10.1001/archinte.160.10.1399
   Jacobs Michael R., 2003, International Journal of Infectious Diseases, V7, pS13, DOI 10.1016/S1201-9712(03)90066-X
   Rothermel CD, 2004, CLIN INFECT DIS, V38, pS346, DOI 10.1086/382691
   Sinaniotis CA, 2005, CURR OPIN PULM MED, V11, P218, DOI 10.1097/01.mcp.0000159831.82529.85
   *WHO, 1990, ARI CHILDR CAS MAN S
NR 12
TC 8
Z9 8
U1 0
U2 1
PU SOC GENERAL MICROBIOLOGY
PI READING
PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG,
   BERKS, ENGLAND
SN 0022-2615
J9 J MED MICROBIOL
JI J. Med. Microbiol.
PD OCT
PY 2009
VL 58
IS 10
BP 1390
EP 1392
DI 10.1099/jmm.0.007765-0
PG 3
WC Microbiology
SC Microbiology
GA 503GJ
UT WOS:000270521300021
PM 19541781
OA Bronze
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, CM
AF Nascimento-Carvalho, Cristiana Maria
TI Pneumococcal conjugate vaccination and otitis media: differences among
   high-risk and low-risk populations
SO EXPERT REVIEW OF VACCINES
LA English
DT Article
DE burden; children; otitis media; prevention; Streptococcus pneumoniae;
   vaccine
ID STREPTOCOCCUS-PNEUMONIAE; CHILDREN; PROSPECTS
AB The impact of the heptavalent pneumococcal conjugate vaccine (PCV7) on the natural history of otitis media (OM) has been studied recently. in a high-risk population, PCV7 significantly reduced the risk of recurrent, bilateral or multiple tympanic membrane perforation, as well as the risk of chronic suppurative OM at 9 months of age. PCV7 did not reduce the time to the development of OM nor the burden of OM. Major challenges are the polymicrobial etiology of OM (Streptococcus pneumoniae and Haemophilus influenzae) in high-risk populations and the serotype replacement among pneumococcal strains. A vaccine including nontypable H. influenzae and 11 pneumococcal serotypes has been identified as a more efficacious option for preventing OM. In the near future, the development and evaluation of a vaccine containing pneumococcal protein, such as pneumococcal surface protein A, which is a structurally variable and serologically cross-reactive surface protein important to the pneumococcal virulence, will be a potential tool against OM.
C1 Univ Fed Bahia, Dept Pediat, Sch Med, BR-40210406 Salvador, BA, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia, Dept Pediat, Sch Med, Rua Prof Aristides Novis 105-1201B, BR-40210406 Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
CR Cripps AW, 2006, EXPERT REV VACCINES, V5, P517, DOI 10.1586/14760584.5.4.517
   Curns AT, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.3.e41
   DURANDO R, VACCINE, DOI DOI 10.1016/J.VACCINE.2009.01.052
   Fletcher MA, 2007, VACCINE, V25, P2507, DOI 10.1016/j.vaccine.2006.09.027
   Haggard M, 2008, VACCINE, V26, pG20, DOI 10.1016/j.vaccine.2008.11.009
   LEACH AJ, 2006, STREPTOCOCCI NEW INS, P89
   Leach AJ, 2007, PEDIATR INFECT DIS J, V26, pS4, DOI 10.1097/INF.0b013e318154b238
   Leach AJ, 2008, BMC PEDIATR, V8, DOI 10.1186/1471-2431-8-23
   Mackenzie GA, 2009, BMC PEDIATR, V9, DOI 10.1186/1471-2431-9-14
   Melin MM, 2008, CLIN VACCINE IMMUNOL, V15, P1555, DOI 10.1128/CVI.00177-08
   Morris Peter S, 2005, BMC Pediatr, V5, P27, DOI 10.1186/1471-2431-5-27
   O'Brien KL, 2003, PEDIATR INFECT DIS J, V22, P133, DOI 10.1097/00006454-200302000-00009
   Pichichero ME, 2007, JAMA-J AM MED ASSOC, V298, P1772, DOI 10.1001/jama.298.15.1772
   Poehling KA, 2007, PEDIATRICS, V119, P707, DOI 10.1542/peds.2006-2138
   Prymula R, 2006, LANCET, V367, P740, DOI 10.1016/S0140-6736(06)68304-9
   Rovers MM, 2008, VACCINE, V26, pG2, DOI 10.1016/j.vaccine.2008.11.005
   Tarlow M, 1998, Ear Nose Throat J, V77, P3
NR 17
TC 2
Z9 2
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1476-0584
EI 1744-8395
J9 EXPERT REV VACCINES
JI Expert Rev. Vaccines
PD JUN
PY 2009
VL 8
IS 6
BP 695
EP 698
DI 10.1586/ERV.09.42
PG 4
WC Immunology
SC Immunology
GA 457TV
UT WOS:000266957500011
PM 19485750
DA 2020-12-17
ER

PT J
AU Moreira, LLL
   Netto, EM
   Nascimento-Carvalho, CM
AF Moreira, L. L. L.
   Netto, E. M.
   Nascimento-Carvalho, C. M.
TI Use of corticosteroid is a risk factor for nosocomial infection in
   paediatric patients
SO JOURNAL OF HOSPITAL INFECTION
LA English
DT Letter
C1 [Moreira, L. L. L.; Nascimento-Carvalho, C. M.] Prof Hosannah Oliveira Paediat Ctr, Infect Control Serv, Salvador, BA, Brazil.
   [Netto, E. M.] Univ Fed Bahia, Univ Hosp, Infect Dis Unit, Sch Med, Salvador, BA, Brazil.
   [Nascimento-Carvalho, C. M.] Univ Fed Bahia, Sch Med, Dept Paediat, Salvador, BA, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Rua Prof Aristides Novis 105-1201B, BR-40210630 Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
RI Netto, Eduardo/D-1432-2013
OI Netto, Eduardo/0000-0003-1691-6761
CR HORAN TC, 2004, HOSP EPIDEMIOLOGY IN, P1659
   Moreira LLL, 2009, VACCINE, V27, P416, DOI 10.1016/j.vaccine.2008.10.074
   Muhlemann K, 2004, INFECT CONT HOSP EP, V25, P765, DOI 10.1086/502474
   Pittet D, 2008, J HOSP INFECT, V68, P285, DOI 10.1016/j.jhin.2007.12.013
   Posfay-Barbe KM, 2008, LANCET INFECT DIS, V8, P19, DOI 10.1016/S1473-3099(07)70310-9
   Tabone MD, 2000, PATHOL BIOL, V48, P893
   *WHO, 1997, WHONUT974
NR 7
TC 2
Z9 2
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0195-6701
EI 1532-2939
J9 J HOSP INFECT
JI J. Hosp. Infect.
PD MAR
PY 2009
VL 71
IS 3
BP 287
EP 288
DI 10.1016/j.jhin.2008.11.001
PG 2
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 415UW
UT WOS:000263962200017
PM 19070937
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, CM
   Cardoso, MRA
   Paldanius, M
   Barral, A
   Araujo-Neto, CA
   Saukkoriipi, A
   Vainionpaa, R
   Leinonen, M
   Ruuskanen, O
AF Nascimento-Carvalho, Cristiana M.
   Cardoso, Maria-Regina A.
   Paldanius, Mika
   Barral, Aldina
   Araujo-Neto, Cesar A.
   Saukkoriipi, Annika
   Vainionpaa, Raija
   Leinonen, Maija
   Ruuskanen, Olli
TI Simkania negevensis infection among Brazilian children hospitalized with
   community-acquired pneumonia
SO JOURNAL OF INFECTION
LA English
DT Letter
C1 [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Dept Paediat, Sch Med, BR-40110100 Salvador, BA, Brazil.
   [Cardoso, Maria-Regina A.] Univ Sao Paulo, Fac Publ Hlth, Dept Epidemiol, BR-01246904 Sao Paulo, Brazil.
   [Paldanius, Mika; Saukkoriipi, Annika; Leinonen, Maija] Natl Publ Hlth Inst, Oulu 90220, Finland.
   [Barral, Aldina] Univ Fed Bahia, Dept Pathol, Sch Med, BR-40110100 Salvador, BA, Brazil.
   [Barral, Aldina] Fundacao Oswaldo Cruz, Ctr Pesquisa Goncalo Muniz, BR-40110100 Salvador, BA, Brazil.
   [Araujo-Neto, Cesar A.] Univ Fed Bahia, Dept Image Diag, Sch Med, BR-40110100 Salvador, BA, Brazil.
   [Vainionpaa, Raija] Univ Turku, Dept Virol, FIN-20520 Turku, Finland.
   [Ruuskanen, Olli] Univ Turku, Dept Pediat, FIN-20520 Turku, Finland.
RP Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia, Dept Paediat, Sch Med, Rua Prof Aristides Novis 105-1201B,40210-630, BR-40110100 Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
RI Cardoso, Maria Regina A/J-7280-2012; Barral, Aldina/B-4191-2009
OI Barral, Aldina/0000-0002-7177-464X
CR Fasoli L, 2008, SCAND J INFECT DIS, V40, P269, DOI 10.1080/00365540701642146
   Friedman MG, 2003, MICROBES INFECT, V5, P1013, DOI 10.1016/S1286-4579(03)00188-6
   Greenberg D, 2003, SCAND J INFECT DIS, V35, P506, DOI 10.1080/00365540310014648
   Heiskanen-Kosma T, 2008, SCAND J INFECT DIS, V40, P127, DOI 10.1080/00365540701558680
   Kahane S, 2007, J INFECTION, V54, P75, DOI 10.1016/j.jinf.2006.01.011
   Kumar S, 2005, PEDIATR INFECT DIS J, V24, P989, DOI 10.1097/01.inf.0000183755.24578.0b
   Nascimento-Carvalho CM, 2008, PEDIATR INFECT DIS J, V27, P939, DOI 10.1097/INF.0b013e3181723751
   Yamaguchi T, 2005, FEMS IMMUNOL MED MIC, V43, P21, DOI 10.1016/j.femsim.2004.06.023
NR 8
TC 18
Z9 19
U1 0
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0163-4453
J9 J INFECTION
JI J. Infect.
PD MAR
PY 2009
VL 58
IS 3
BP 250
EP 253
DI 10.1016/j.jinf.2009.01.008
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA 429UJ
UT WOS:000264945300013
PM 19232738
OA Green Published
DA 2020-12-17
ER

PT J
AU Key, NK
   Araujo-Neto, CA
   Nascimento-Carvalho, CM
AF Key, Ng Kin
   Araujo-Neto, Cesar Augusto
   Nascimento-Carvalho, Cristiana Maria
TI Severity of Childhood Community-Acquired Pneumonia and Chest
   Radiographic Findings
SO PEDIATRIC PULMONOLOGY
LA English
DT Article
DE pulmonary infiltrate; pneumonia location; severity predictor
ID CHILDREN; DIAGNOSIS
AB To assess if chest radiographic findings present on admission are associated with severity of childhood community-acquired pneumonia (CAP), a total of 161 children hospitalized with pulmonary infiltrate were enrolled in the study; 48 (30%) patients were excluded because of presence of bilateral chest radiographic alterations (33; 20%) and presence of underlying diseases (15; 9%). According to WHO and BTS criteria, severe CAP was present in 57 (50%) and in 96 (85%) cases, respectively; 29 (26%) were aged less than 1 year. The median age (months) was 22 (mean 24 +/- 14, range 2-58). Overall, radiographic finding was right-sided in 77 (68%) cases and the upper lobe was compromised in 36 (32%) cases. By analyzing data stratified to age, the frequency of upper lobe involvement was significantly higher among severe cases (WHO criteria) only for those patients aged >= 1 year (13/35 [37%] vs. 7/45 [16%], P = 0.03, OR [95% CI] 3.2 [1.1-9.2]). The specificity and positive predictive value of upper lobe involvement for severity among the latter group of patients were 84% (95% CI 70-93%) and 65% (95% CI 41-84%), respectively No association was found by using the BTS criteria. The admission chest radiography was useful to predict severity of children aged >= 1 year hospitalized with CAP Pediatr Pulmonol. 2009; 44:249-252. (C) 2009 Wiley-Liss, Inc.
C1 [Key, Ng Kin; Nascimento-Carvalho, Cristiana Maria] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
   [Araujo-Neto, Cesar Augusto] Univ Fed Bahia, Sch Med, Dept Image Diag, Salvador, BA, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Aristides Novis, 105-1201 B Salvador, BR-40210630 Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
FU Brazilian Council for Science and Technology Development (CNPq)National
   Council for Scientific and Technological Development (CNPq)
FX Ng Kin Key is recipient of a fellowship from the Brazilian Council for
   Science and Technology Development (CNPq); Cristiana Maria
   Nascimento-Carvalho is an investigator of CNPq.
CR *BRIT THOR SOC STA, 2002, THORAX, V57, pI1, DOI DOI 10.1136/THX.57.SUPPL_1.I1
   Cherian T, 2005, B WORLD HEALTH ORGAN, V83, P353
   Clark JE, 2007, ARCH DIS CHILD, V92, P394, DOI 10.1136/adc.2006.097402
   Donnelly LF, 1999, AM J ROENTGENOL, V172, P505, DOI 10.2214/ajr.172.2.9930814
   El-Rashdi AS, 2006, ARCH DIS CHILD, V91, P351, DOI 10.1136/adc.2005.088831
   Grafakou O, 2004, PEDIATR PULM, V38, P465, DOI 10.1002/ppul.20112
   GUYTON AC, 2005, TXB MED PHYSL, P476
   Jadavji T, 1997, CAN MED ASSOC J, V156, pS703
   Kumar P, 2004, J INFECTION, V48, P134, DOI 10.1016/j.jinf.2003.10.013
   Mulholland K, 2007, VACCINE, V25, P2394, DOI 10.1016/j.vaccine.2006.09.007
   Scott JAG, 2008, J CLIN INVEST, V118, P1291, DOI 10.1172/JCI33947
   SHANN F, 1989, PEDIATR INFECT DIS J, V8, P852, DOI 10.1097/00006454-198912000-00005
   *WHO, 1990, ARI CHILDR CAS MAN S
   *WHO, 1997, WHONUT974
NR 14
TC 14
Z9 15
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8755-6863
EI 1099-0496
J9 PEDIATR PULM
JI Pediatr. Pulmonol.
PD MAR
PY 2009
VL 44
IS 3
BP 249
EP 252
DI 10.1002/ppul.20988
PG 4
WC Pediatrics; Respiratory System
SC Pediatrics; Respiratory System
GA 417RU
UT WOS:000264095600007
PM 19205052
DA 2020-12-17
ER

PT J
AU Moreira, LLL
   Netto, EM
   Nascimento-Carvalho, CM
AF Moreira, Licia L. L.
   Netto, Eduardo M.
   Nascimento-Carvalho, Cristiana M.
TI Risk factors for nosocomial rotavirus infection in a paediatric
   hospital: The potential role for rotavirus vaccine use
SO VACCINE
LA English
DT Article
DE Rotavirus infection; Nosocomial gastroenteritis; Nosocomial rotavirus
   infection
ID PREVENTION; DISEASE; EPIDEMIOLOGY; SURVEILLANCE; DIARRHEA; CHILDREN;
   PROGRAM; BURDEN
AB To analyze the incidence and risk factors (RF) of nosocomial infection (NI) in a paediatric teaching hospital, a retrospective cohort study was conducted in Salvador, Brazil. The Centres for Disease Control and Prevention definitions were used. The detection of the rotavirus antigen in stool was performed using a rapid latex agglutination test. The study group comprised 2978 admissions that accounted for 32,924 patient-days. The incidence of NI was 8.3/1000 patient-days and 9.2/100 admissions. Of the 274 NI episodes, the most common illness and causative agent were gastroenteritis (125; 45.6%) and rotavirus (59; 21.5%), respectively. The RF for rotavirus NI was young age (10 8 months vs. 27 33 months; mean difference 17 months, 95% CI 15-20 months, p<0.001). The temporal distribution of community-acquired and NI rotavirus showed similar trends. The universal use of rotavirus vaccine is a potential tool to control NI among children. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Moreira, Licia L. L.; Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Infect Control Serv Prof Hosannah de Oliveira Pae, Salvador, BA, Brazil.
   [Netto, Eduardo M.] Univ Fed Bahia, Univ Hosp, Infect Dis Unit, Salvador, BA, Brazil.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Paediat, Salvador, BA, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Rua Prof Aristides Novis 105-1201B, BR-40210630 Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
RI Netto, Eduardo/D-1432-2013
OI Netto, Eduardo/0000-0003-1691-6761
FU Brazilian Council for Science and Technology Development (CNPq)National
   Council for Scientific and Technological Development (CNPq)
FX The authors thank Mrs. Elizabeth de Araujo Mendes for her assistance in
   entering the data. C.M. N.-C. is an investigator of the Brazilian
   Council for Science and Technology Development (CNPq).
CR Aho LS, 2000, PATHOL BIOL, V48, P885
   Banyai K, 2006, EPIDEMIOL INFECT, V134, P908, DOI 10.1017/S0950268806006091
   Barnes GL, 2003, J PEDIATR-US, V142, P722, DOI 10.1067/mpd.2003.240
   Carvalho AMC, 2001, J HOSP INFECT, V47, P71, DOI 10.1053/jhin.2000.0824
   Cavalcante SS, 2006, PEDIATR INFECT DIS J, V25, P438, DOI 10.1097/01.inf.0000217377.54597.92
   Chandran A, 2006, J PEDIATR-US, V149, P441, DOI 10.1016/j.jpeds.2006.04.054
   DENNEHY PH, 1989, PEDIATR INFECT DIS J, V8, P290
   Fischer TK, 2004, VACCINE, V22, pS49, DOI 10.1016/j.vaccine.2004.08.017
   Frank PI, 2004, FAM PRACT, V21, P33, DOI 10.1093/fampra/cmh108
   Girouard S, 2001, AM J INFECT CONTROL, V29, P158, DOI 10.1067/mic.2001.115405
   Gleizes O, 2006, PEDIATR INFECT DIS J, V25, pS12, DOI 10.1097/01.inf.0000197563.03895.91
   HORAN TC, 2004, HOSP EPIDEMIOLOGY IN, P1659
   Kordidarian R, 2007, J HEALTH POPUL NUTR, V25, P231
   Lopes JMM, 2002, AM J INFECT CONTROL, V30, P1, DOI 10.1067/mic.2002.117039
   Manangan LP, 1999, AM J INFECT CONTROL, V27, P270, DOI 10.1053/ic.1999.v27.a98398
   Mesa F, 1996, Enferm Infecc Microbiol Clin, V14, P106
   Raymond J, 2000, INFECT CONT HOSP EP, V21, P260, DOI 10.1086/501755
   Rodrigues A, 2007, PEDIATR INFECT DIS J, V26, P233, DOI 10.1097/01.inf.0000254389.65667.8b
   Rouget F, 2000, ARCH PEDIATRIE, V7, P948, DOI 10.1016/S0929-693X(00)90008-3
   Wadhwa V, 2005, J HOSP INFECT, V61, P358, DOI 10.1016/j.jhin.2005.06.025
   *WHO, 2006, WHONUT974
NR 21
TC 6
Z9 6
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 14
PY 2009
VL 27
IS 3
BP 416
EP 420
DI 10.1016/j.vaccine.2008.10.074
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 399DJ
UT WOS:000262780300013
PM 19014989
DA 2020-12-17
ER

PT J
AU Moreira, LL
   Netto, EM
   Nascimento-Carvalho, CM
AF Moreira, Licia L.
   Netto, Eduardo M.
   Nascimento-Carvalho, Cristiana M.
TI Nosocomial Gastroenteritis in Children With and Without Rotavirus
   Infection
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Letter
ID DISEASE
C1 [Moreira, Licia L.] Univ Fed Bahia, Infect Control Serv, Prof Hosannah de Oliveira Pediat Ctr, Salvador, BA, Brazil.
   [Netto, Eduardo M.] Univ Fed Bahia, Infect Dis Unit, Univ Hosp, Salvador, BA, Brazil.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
RP Moreira, LL (corresponding author), Univ Fed Bahia, Infect Control Serv, Prof Hosannah de Oliveira Pediat Ctr, Salvador, BA, Brazil.
RI Netto, Eduardo/D-1432-2013
OI Netto, Eduardo/0000-0003-1691-6761
CR Gleizes O, 2006, PEDIATR INFECT DIS J, V25, pS12, DOI 10.1097/01.inf.0000197563.03895.91
   Parashar UD, 2006, EMERG INFECT DIS, V12, P304
   Rodrigues A, 2007, PEDIATR INFECT DIS J, V26, P233, DOI 10.1097/01.inf.0000254389.65667.8b
   Staat MA, 2002, PEDIATR INFECT DIS J, V21, P221, DOI 10.1097/00006454-200203000-00012
NR 4
TC 3
Z9 3
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD JAN
PY 2009
VL 28
IS 1
BP 72
EP 72
DI 10.1097/INF.0b013e31818ec288
PG 1
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 391QG
UT WOS:000262247200022
PM 19034059
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, CM
   Ribeiro, CT
   Cardoso, MRA
   Barral, A
   Araujo-Neto, CA
   Oliveira, JR
   Sobral, LS
   Viriato, D
   Souza, AL
   Saukkoriipi, A
   Paldanius, M
   Vainionpaa, R
   Leinonen, M
   Ruuskanen, O
AF Nascimento-Carvalho, Cristiana M.
   Ribeiro, Catarina T.
   Cardoso, Maria Regina A.
   Barral, Aldina
   Araujo-Neto, Cesar A.
   Oliveira, Juliana R.
   Sobral, Luciana S.
   Viriato, Daniel
   Souza, Andre L.
   Saukkoriipi, Annika
   Paldanius, Mika
   Vainionpaa, Raija
   Leinonen, Maija
   Ruuskanen, Olli
TI The role of respiratory viral infections among children hospitalized for
   community-acquired pneumonia in a developing country
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE etiology; respiratory syncytial virus; rhinovirus; Streptococcus
   pneumoniae
ID ETIOLOGY; AGE
AB We report an investigation for 16 bacteria and viruses among 184 children hospitalized with pneumonia in Salvador, Brazil. Etiology was established in 144 (78%) cases. Viral, bacterial, and mixed infections were found in 110 (60%), 77 (42%), and 52 (28%) patients, respectively. Rhinovirus (21%) and Streptococcus pneumoniae (21%) were the most common pathogens. Our results demonstrate the importance of viral and pneumococcal infections among those patients.
C1 [Nascimento-Carvalho, Cristiana M.; Ribeiro, Catarina T.; Viriato, Daniel; Souza, Andre L.] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
   [Cardoso, Maria Regina A.] Univ Sao Paulo, Dept Epidemiol, Fac Publ Hlth, Sao Paulo, Brazil.
   [Barral, Aldina] Univ Fed Bahia, Sch Med, Dept Pathol, Salvador, BA, Brazil.
   [Barral, Aldina] Fundacao Oswaldo Cruz, Ctr Pesquisa Goncalo Muniz, Salvador, BA, Brazil.
   [Araujo-Neto, Cesar A.] Univ Fed Bahia, Sch Med, Dept Image Diag, BR-41170290 Salvador, BA, Brazil.
   [Oliveira, Juliana R.; Sobral, Luciana S.] Univ Fed Bahia, Prof Hosannah Oliveira Pediat Ctr, BR-41170290 Salvador, BA, Brazil.
   [Saukkoriipi, Annika; Paldanius, Mika; Leinonen, Maija] Natl Publ Hlth Inst, Oulu, Finland.
   [Vainionpaa, Raija] Univ Turku, Dept Virol, Turku, Finland.
   [Ruuskanen, Olli] Univ Turku, Dept Pediat, Turku, Finland.
RP Nascimento-Carvalho, CM (corresponding author), Rua Prof Aristides Novis 105-1201B, BR-40210630 Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
RI Barral, Aldina/B-4191-2009; Cardoso, Maria Regina A/J-7280-2012
OI Barral, Aldina/0000-0002-7177-464X; 
FU Fundacao de Amparo a Pesquisa no Estado da Bahia (FAPESB), Salvador,
   Brazil; Pediatric Research Foundation, Helsinki, Finland
FX Supported by funding from Fundacao de Amparo a Pesquisa no Estado da
   Bahia (FAPESB), Salvador, Brazil and Pediatric Research Foundation,
   Helsinki, Finland.
CR Arnold JC, 2008, PEDIATRICS, V121, pE631, DOI 10.1542/peds.2006-3073
   Black SB, 2002, PEDIATR INFECT DIS J, V21, P810, DOI 10.1097/00006454-200209000-00005
   Counihan ME, 2001, PEDIATR INFECT DIS J, V20, P646, DOI 10.1097/00006454-200107000-00003
   EDMUNDSON WC, 1989, SOC SCI MED, V29, P975, DOI 10.1016/0277-9536(89)90053-1
   Gendrel D, 1997, EUR J CLIN MICROBIOL, V16, P388, DOI 10.1007/BF01726370
   Juven T, 2000, PEDIATR INFECT DIS J, V19, P293, DOI 10.1097/00006454-200004000-00006
   Laundy M, 2003, PEDIATR INFECT DIS J, V22, pS223, DOI 10.1097/01.inf.0000092192.59459.8b
   Papadopoulos NG, 2000, J INFECT DIS, V181, P1875, DOI 10.1086/315513
   Saukkoriipi A, 2002, MOL CELL PROBE, V16, P385, DOI 10.1006/mcpr.2002.0443
   Tsolia MN, 2004, CLIN INFECT DIS, V39, P681, DOI 10.1086/422996
   Wardlaw T, 2006, LANCET, V368, P1048, DOI 10.1016/S0140-6736(06)69334-3
NR 11
TC 73
Z9 73
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD OCT
PY 2008
VL 27
IS 10
BP 939
EP 941
DI 10.1097/INF.0b013e3181723751
PG 3
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 356FZ
UT WOS:000259765400023
PM 18756190
OA Green Published
DA 2020-12-17
ER

PT J
AU Moreno-Carvalho, OA
   Cardoso, MRA
   Nascimento-Carvalho, CM
AF Moreno-Carvalho, Otavio A.
   Cardoso, Maria-Regina A.
   Nascimento-Carvalho, Cristiana M.
CA Newborn CSF Study Grp
TI Neutrophils and red blood cells in the cerebrospinal fluid of newborns
SO ACTA PAEDIATRICA
LA English
DT Article
ID REFERENCE-VALUES
C1 [Moreno-Carvalho, Otavio A.] Jose Silveira Fdn, Cerebrospinal Fluid Lab, Salvador, BA, Brazil.
   [Cardoso, Maria-Regina A.] Univ Sao Paulo, Fac Publ Hlth, Sao Paulo, Brazil.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Rua Prof Aristides Novis N 105-1201B, BR-40210630 Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
RI Cardoso, Maria Regina A/J-7280-2012
CR Ahmed A, 1996, PEDIATR INFECT DIS J, V15, P298, DOI 10.1097/00006454-199604000-00004
   BONADIO WA, 1992, PEDIATR INFECT DIS J, V11, P589, DOI 10.1097/00006454-199207000-00015
   Garges HP, 2006, PEDIATRICS, V117, P1094, DOI 10.1542/peds.2005-1132
   HAYWARD RA, 1988, ARCH INTERN MED, V148, P1623, DOI 10.1001/archinte.148.7.1623
   Ishimine P, 2006, PEDIATR CLIN N AM, V53, P167, DOI 10.1016/j.pcl.2005.09.012
   Mazor SS, 2003, PEDIATRICS, V111, P525
   Nascimento-Carvalho CMC, 1998, ARQ NEURO-PSIQUIAT, V56, P375, DOI 10.1590/S0004-282X1998000300005
   RASCOL MM, 1980, SEM HOP PARIS, V56, P449
   REIS JB, 1980, ARQ NEURO-PSIQUIAT, V38, P231
   Shah KH, 2003, ACAD EMERG MED, V10, P151, DOI 10.1111/j.1553-2712.2003.tb00033.x
   Wong M, 2000, ARCH PEDIAT ADOL MED, V154, P827, DOI 10.1001/archpedi.154.8.827
NR 11
TC 0
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0803-5253
J9 ACTA PAEDIATR
JI Acta Paediatr.
PD JUN
PY 2008
VL 97
IS 6
BP 816
EP 818
DI 10.1111/j.1651-2227.2008.00769.x
PG 3
WC Pediatrics
SC Pediatrics
GA 296FJ
UT WOS:000255528600029
PM 18397355
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, CM
   Lyra, TG
   Alves, NN
   Caldas, RM
   Barberino, MG
AF Nascimento-Carvalho, Cristiana M.
   Lyra, Ticiana G.
   Alves, Noraney N.
   Caldas, Renilza M.
   Barberino, Maria Goreth
TI Resistance to methicillin and other antimicrobials among
   community-acquired and nosocomial Staphylococcus aureus strains in a
   pediatric teaching hospital in Salvador, Northeast Brazil
SO MICROBIAL DRUG RESISTANCE
LA English
DT Article
ID INFECTIONS; CHILDREN; CARRIAGE; CASSETTE
AB To report the frequency of methicillin-resistant Staphylococcus aureus (MRSA) infection and to compare the antimicrobial resistance patterns between community-acquired (CA) and nosocomial (NI) strains stratified for resistance to methicillin, this retrospective study on patients under 20 years of age was conducted from April 1995 to December 2005 in a pediatric teaching hospital in Salvador, Brazil. Of 308 S. aureus strains isolated, 185 (60.1%) were reviewed, out of which 125 (67.6%) and 55 (29.7%) had CA or NI infection, respectively, and 5 were defined as colonization. Out of the nine patients with MRSA initially diagnosed as CA, three were excluded from the analysis because of report of hospitalization during the previous year. Resistance to methicillin was more frequent among NI (30.9% vs. 4.9%, p < 0.001). Resistance to other antimicrobials was more common among NI-MRSA compared with CA-MRSA. Although at a low rate, CA-MRSA has occurred among children, in this region.
C1 [Nascimento-Carvalho, Cristiana M.; Lyra, Ticiana G.] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
   [Alves, Noraney N.; Caldas, Renilza M.; Barberino, Maria Goreth] Univ Fed Bahia, Univ Hosp, Bacteriol Labs, Salvador, BA, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Rua Prof Aristides Novis 105-1201B, BR-40210630 Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
CR Brites Carlos, 2006, Braz J Infect Dis, V10, P235, DOI 10.1590/S1413-86702006000400003
   Cavalcanti Silvana M.M., 2005, Braz J Infect Dis, V9, P56, DOI 10.1590/S1413-86702005000100010
   Chen CJ, 2007, DIAGN MICR INFEC DIS, V59, P287, DOI 10.1016/j.diagmicrobio.2007.05.015
   *CLIN LAB STAND I, 2007, ML00S17 CLSI
   Daum RS, 2002, J INFECT DIS, V186, P1344, DOI 10.1086/344326
   GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3
   Guilarde AO, 2006, J HOSP INFECT, V63, P330, DOI 10.1016/j.jhin.2006.02.011
   Lamaro-Cardosa J, 2007, DIAGN MICR INFEC DIS, V57, P467, DOI 10.1016/j.diagmicrobio.2006.10.008
   Maltezou HC, 2006, INT J ANTIMICROB AG, V27, P87, DOI 10.1016/j.ijantimicag.2005.11.004
   Marcinak JF, 2003, CURR OPIN INFECT DIS, V16, P265, DOI 10.1097/00001432-200306000-00014
   Mishaan AMA, 2005, PEDIATR INFECT DIS J, V24, P201, DOI 10.1097/01.inf.0000151107.29132.70
   Oliveira DC, 2006, ANTIMICROB AGENTS CH, V50, P3457, DOI 10.1128/AAC.00629-06
   Ribeiro A, 2007, DIAGN MICR INFEC DIS, V59, P339, DOI 10.1016/j.diagmicrobio.2007.05.007
   Wertheim HFL, 2005, LANCET INFECT DIS, V5, P751, DOI 10.1016/S1473-3099(05)70295-4
NR 14
TC 9
Z9 10
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1076-6294
J9 MICROB DRUG RESIST
JI Microb. Drug Resist.
PD JUN
PY 2008
VL 14
IS 2
BP 129
EP 131
DI 10.1089/mdr.2008.0790
PG 3
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA 322ZS
UT WOS:000257414400006
PM 18479198
DA 2020-12-17
ER

PT J
AU Cardoso, MRA
   Nascimento-Carvalho, CM
   Ferrero, F
   Berezin, EN
   Ruvinsky, R
   Camargos, PAM
   Sant'Anna, CC
   Brandileone, MCC
   March, MDP
   Feris-Iglesias, J
   Maggi, RS
   Benguigui, Y
AF Cardoso, Maria Regina A.
   Nascimento-Carvalho, Cristiana M.
   Ferrero, Fernando
   Berezin, Eltan N.
   Ruvinsky, Raul
   Camargos, Paulo A. M.
   Sant'Anna, Clemax C.
   Brandileone, Maria Cristina C.
   March, Maria de Fatima P.
   Feris-Iglesias, Jesus
   Maggi, Ruben S.
   Benguigui, Yehuda
CA CARIBE Grp
TI Penicillin-resistant pneumococcus and risk of treatment failure in
   pneumonia
SO ARCHIVES OF DISEASE IN CHILDHOOD
LA English
DT Article
ID STREPTOCOCCUS-PNEUMONIAE; CLINICAL CHARACTERISTICS; MORTALITY; CHILDREN;
   INFECTIONS; BACTEREMIA; THERAPY
AB Objective: To determine whether the presence of in vitro penicillin-resistant Streptococcus pneumoniae increases the risk of clinical failure in children hospitalised with severe pneumonia and treated with penicillin/ampicillin.
   Design: Multicentre, prospective, observational study.
   Setting: 12 tertiary-care centres in three countries in Latin America.
   Patients: 240 children aged 3-59 months, hospitalised with severe pneumonia and known in vitro susceptibility of S pneumoniae.
   Intervention: Patients were treated with intravenous penicillin/ampicillin after collection of blood and, when possible, pleural fluid for culture. The minimal inhibitory concentration (MIC) test was used to determine penicillin susceptibility of the pneumococcal strains isolated. Children were continuously monitored until discharge.
   Main outcome measures: The primary outcome was treatment failure (using clinical criteria).
   Results: Overall treatment failure was 21%. After allowing for different potential confounders, there was no evidence of association between treatment failure and in vitro resistance of S pneumoniae to penicillin according to the Clinical Laboratory Standards Institute (CLSI)/National Committee for Clinical Laboratory Standards (NCCLS) interpretative standards (adjRR = 1.03; 95%Cl: 0.49-1.90 for resistant S pneumoniae).
   Conclusions: Intravenous penicillin/ampicillin remains the drug of choice for treating penicillin-resistant pneumococcal pneumonia in areas where the MIC does not exceed 2 mu g/ml.
C1 [Cardoso, Maria Regina A.] Univ Sao Paulo, Fac Saude Publ, Sao Paulo, Brazil.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Fac Med Bahia, BR-41170290 Salvador, BA, Brazil.
   [Ferrero, Fernando] Hosp Ninos Elizalde, Buenos Aires, DF, Argentina.
   [Berezin, Eltan N.] Fac Ciencias Med Santa Casa, Sao Paulo, Brazil.
   [Ruvinsky, Raul] Hosp Municipal Durand, Buenos Aires, DF, Argentina.
   [Camargos, Paulo A. M.] Univ Fed Minas Gerais, Fac Med, Belo Horizonte, MG, Brazil.
   [Sant'Anna, Clemax C.; March, Maria de Fatima P.] Inst Puericulture & Pediat Martagao Gasteira, Rio De Janeiro, Brazil.
   [Brandileone, Maria Cristina C.] Adolfo Lutz Inst, Div Bacteriol, Sao Paulo, Brazil.
   [Feris-Iglesias, Jesus] Hosp Infantil Dr Robert Reid Cabral, Santo Domingo, Dominican Rep.
   [Maggi, Ruben S.] Inst Materno Infantil Pernambuco, Recife, PE, Brazil.
   [Benguigui, Yehuda] Pan Amer Hlth Org, Child & Adolescent Hlth Unit, Washington, DC USA.
RP Cardoso, MRA (corresponding author), Ave Dr Amaldo 715, BR-01246904 Sao Paulo, Brazil.
EM rcardoso@usp.br
RI Cardoso, Maria Regina A/J-7280-2012; Anna, Clemax Sant/H-7923-2019;
   Ferrero, Fernando/AAE-1886-2020
OI Anna, Clemax Sant/0000-0001-8732-8065; Ferrero,
   Fernando/0000-0001-6335-0102
CR AUSTRIAN R, 1964, ANN INTERN MED, V60, P759, DOI 10.7326/0003-4819-60-5-759
   Bishai W, 2002, J ANTIMICROB CHEMOTH, V49, P433, DOI 10.1093/jac/49.3.433
   Bishai William R, 2005, Treat Respir Med, V4 Suppl 1, P19
   Bogaert D, 2004, VACCINE, V22, P2209, DOI 10.1016/j.vaccine.2003.11.038
   Brandileone MCC, 2006, J MED MICROBIOL, V55, P567, DOI 10.1099/jmm.0.46387-0
   Choi EH, 1998, CLIN INFECT DIS, V26, P1346, DOI 10.1086/516340
   CLSI, 2005, PERF STAND ANT SUSC
   Cunha BA, 2004, INFECTION, V32, P98, DOI 10.1007/s15010-004-3065-5
   Dagan R, 2001, J ANTIMICROB CHEMOTH, V47, P129, DOI 10.1093/jac/47.2.129
   Deeks SL, 1999, PEDIATRICS, V103, P409, DOI 10.1542/peds.103.2.409
   DiFabio JL, 1997, MICROB DRUG RESIST, V3, P131, DOI 10.1089/mdr.1997.3.131
   Dowell SF, 2000, NEW ENGL J MED, V342, P1399, DOI 10.1056/NEJM200005113421904
   El-Rashdi AS, 2006, ARCH DIS CHILD, V91, P351, DOI 10.1136/adc.2005.088831
   FACKLAM RR, 1991, MANUAL CLIN MICROBIO
   File TM, 2002, CLIN INFECT DIS, V34, pS17, DOI 10.1086/324526
   FRIEDLAND IR, 1992, AM J DIS CHILD, V146, P920, DOI 10.1001/archpedi.1992.02160200042023
   FRIEDLAND IR, 1995, PEDIATR INFECT DIS J, V14, P885, DOI 10.1097/00006454-199510000-00013
   FRIEDLAND IR, 1992, LANCET, V339, P405, DOI 10.1016/0140-6736(92)90087-J
   Garau J, 2001, RESP MED, V95, pS7, DOI 10.1053/rmed.2001.1087
   Giachetto G, 2004, PEDIATR INFECT DIS J, V23, P625, DOI 10.1097/01.inf.0000128783.11218.c9
   HANSMAN D, 1967, LANCET, V2, P264
   Kaplan Sheldon L, 2004, Paediatr Respir Rev, V5 Suppl A, pS153, DOI 10.1016/S1526-0542(04)90030-9
   Michelow IC, 2004, PEDIATRICS, V113, P701, DOI 10.1542/peds.113.4.701
   PALLARES R, 1995, NEW ENGL J MED, V333, P474, DOI 10.1056/NEJM199508243330802
   Sazawal S, 2003, LANCET INFECT DIS, V3, P547, DOI 10.1016/S1473-3099(03)00737-0
   Tan TQ, 2002, PEDIATRICS, V110
   Turett GS, 1999, CLIN INFECT DIS, V29, P321, DOI 10.1086/520209
   Wexler ID, 2006, PEDIATR PULM, V41, P726, DOI 10.1002/ppul.20383
   *WHO, 1990, ARI CHILDR CAS MAN S
   WHO, 1991, TECHN BAS WHO REC MA
   Williams BG, 2002, LANCET INFECT DIS, V2, P25, DOI 10.1016/S1473-3099(01)00170-0
   World Health Organization, 2005, WORLD HLTH REP 2005
   Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690
NR 33
TC 41
Z9 42
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-9888
EI 1468-2044
J9 ARCH DIS CHILD
JI Arch. Dis. Child.
PD MAR
PY 2008
VL 93
IS 3
BP 221
EP 225
DI 10.1136/adc.2006.111625
PG 5
WC Pediatrics
SC Pediatrics
GA 268PM
UT WOS:000253591700013
PM 17848490
DA 2020-12-17
ER

PT J
AU Cardozo, DM
   Nascimento-Carvalho, CM
   Andrade, ALSS
   Silvany-Neto, AM
   Daltro, CHC
   Brandao, MAS
   Brandao, AP
   Brandileone, MCC
AF Cardozo, Dea M.
   Nascimento-Carvalho, Cristiana M.
   Andrade, Ana-Lucia S. S.
   Silvany-Neto, Annibal M.
   Daltro, Carla H. C.
   Brandao, Maria-angelica S.
   Brandao, Angela P.
   Brandileone, Maria-Cristina C.
TI Prevalence and risk factors for nasopharyngeal carriage of Streptococcus
   pneumoniae among adolescents
SO JOURNAL OF MEDICAL MICROBIOLOGY
LA English
DT Article
ID COLONIZATION; CHILDREN; RESISTANCE; EXPOSURE; SEROTYPE; SMOKING; DISEASE
AB Data on the prevalence of pneumooccal nasopharyngeal carriage and its risk factors among adolescents are scarce. The aim of this study was to provide such information. A cross-sectional, population-based prospective study was conducted. Participants were 10 13 adolescents (age range 10-19 years) randomly recruited in 22 public schools. Those schools were randomly chosen among 307 public schools from 11 Sanitary Districts of Salvador, Brazil. Nasopharyngeal samples were assessed by standard procedures to recover and identify Streptococcus pneumoniae. Data on potential risk factors were gathered by confidential interview based on a standardized questionnaire. Pneumococci were recovered from 8.2% [83/1013, 95% confidence interval (CI) 6.6-10.0]. By stepwise logistic regression, pneumococcal colonization was independently associated with younger age [odds ratio (OR) 0.85, 95% Cl 0.77-0.94, P=0.001], being male (OR 1.78, 95% CI 1.11-2.85, P=0.02), exposure to passive smoke in the household (OR 1.76, 95% CI 1.10-2.79, P=0.02), having an upper respiratory infection during recruitment (OR 2.67, 95% CI 1.67-4.28, P<0.001) and having a history involving an episode of acute asthma during the last year (OR 2.89, 95% CI 1.18-7.08, P=0.03). The estimated probability of pneumococcal colonization decreased with age (chi(2) for trend=8.52, P=0.003). These findings provide tools for increasing the use of prevention strategies for pneumococcal diseases, such as pneumococcal vaccination among asthmatic patients and public health measures to stop smoking.
C1 [Cardozo, Dea M.; Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Paediat, BR-40110100 Salvador, BA, Brazil.
   [Andrade, Ana-Lucia S. S.] Univ Fed Goias, Inst Trop Pathol & Publ Hlth, Goiania, Go, Brazil.
   [Silvany-Neto, Annibal M.] Univ Fed Bahia, Sch Med, Dept Prevent Med, Salvador, BA, Brazil.
   [Daltro, Carla H. C.] Bahiana Sch Med & Publ Hlth, Salvador, BA, Brazil.
   [Brandao, Maria-angelica S.] Cent Lab Bahia, Salvador, BA, Brazil.
   [Brandao, Angela P.; Brandileone, Maria-Cristina C.] Adolfo Lutz Inst, Bacterial Branch, Sao Paulo, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia, Sch Med, Dept Paediat, Avenida Reitor Miguel Calmon,S-N, BR-40110100 Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
RI Andrade, Ana Lucia/L-5751-2013; Brandao, Angela Pires/AAG-2758-2020
CR [Anonymous], 2000, MMWR Recomm Rep, V49, P1
   [Anonymous], 1997, MMWR Recomm Rep, V46, P1
   AUSTRIAN R, 1986, J ANTIMICROB CHEMOTH, V18, P35, DOI 10.1093/jac/18.Supplement_A.35
   Avadhanula V, 2006, J VIROL, V80, P1629, DOI 10.1128/JVI.80.4.1629-1636.2006
   BENGUIGUI Y, 1992, MANUAL MED ADOLESCEN, P225
   Black S, 2006, VACCINE, V24, pS79, DOI 10.1016/j.vaccine.2005.01.132
   Bogaert D, 2004, LANCET INFECT DIS, V4, P144, DOI 10.1016/S1473-3099(04)00938-7
   Bogaert D, 2004, LANCET, V363, P1871, DOI 10.1016/S0140-6736(04)16357-5
   Brueggemann AB, 2003, J INFECT DIS, V187, P1424, DOI 10.1086/374624
   Cardozo Déa M., 2006, Braz J Infect Dis, V10, P293, DOI 10.1590/S1413-86702006000400015
   Cardozo DM, 2006, MICROB DRUG RESIST, V12, P29, DOI 10.1089/mdr.2006.12.29
   Ciftci E, 2000, PEDIATR INT, V42, P552, DOI 10.1046/j.1442-200x.2000.01269.x
   Coen PG, 2006, INT J EPIDEMIOL, V35, P330, DOI 10.1093/ije/dyi295
   Dagan R, 1998, J CLIN MICROBIOL, V36, P669, DOI 10.1128/JCM.36.3.669-673.1998
   Falagas ME, 2007, RESP MED, V101, P1845, DOI 10.1016/j.rmed.2007.04.011
   Greenberg D, 2006, CLIN INFECT DIS, V42, P897, DOI 10.1086/500935
   Heiskanen-Kosma T, 1998, PEDIATR INFECT DIS J, V17, P986, DOI 10.1097/00006454-199811000-00004
   Hennessy TW, 2002, CLIN INFECT DIS, V34, P1543, DOI 10.1086/340534
   Hussain M, 2005, EPIDEMIOL INFECT, V133, P891, DOI 10.1017/S0950268805004012
   Inostroza J, 1998, CLIN DIAGN LAB IMMUN, V5, P176, DOI 10.1128/CDLI.5.2.176-180.1998
   Muhlemann K, 2003, J INFECT DIS, V187, P589, DOI 10.1086/367994
   Nuorti JP, 2000, NEW ENGL J MED, V342, P681, DOI 10.1056/NEJM200003093421002
   O'Brien KL, 2003, VACCINE, V21, P1815, DOI 10.1016/S0264-410X(02)00807-1
   O'Brien KL, 2003, PEDIATR INFECT DIS J, V22, P133, DOI 10.1097/00006454-200302000-00009
   *PAHO, 1998, PLAN ACT HLTH DEV AD
   Santelli John S, 2003, J Adolesc Health, V33, P396
   Talbot TR, 2005, NEW ENGL J MED, V352, P2082, DOI 10.1056/NEJMoa044113
   *WHO, 1994, MAN NAT SURV ANT RES
NR 28
TC 45
Z9 49
U1 0
U2 8
PU MICROBIOLOGY SOC
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER ST, LONDON WC1N 2JU, ERKS, ENGLAND
SN 0022-2615
EI 1473-5644
J9 J MED MICROBIOL
JI J. Med. Microbiol.
PD FEB
PY 2008
VL 57
IS 2
BP 185
EP 189
DI 10.1099/jmm.0.47470-0
PG 5
WC Microbiology
SC Microbiology
GA 263LT
UT WOS:000253219300008
PM 18201984
OA Bronze
DA 2020-12-17
ER

PT J
AU Lott-Duarte, AH
   Dourado, L
   Tostes, M
   Nascimento-Carvalho, CM
AF Lott-Duarte, Andre Henrique
   Dourado, Luciano
   Tostes, Meire
   Nascimento-Carvalho, Cristiana M.
TI Extensive spondylodiscitis with epidural abscess causing fever and lower
   limbs pain in a child with sickle cell disease
SO JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
LA English
DT Article
DE spondylodiscitis; epidural abscess; sickle cell disease
ID OSTEOMYELITIS
AB Spondylodiscitis is an unusual diagnosis among children and consequent abscess formation is even rarer. A 6-year-old girl with fever, hip pain, and refusal to walk was evaluated. The neurologic examination was normal. Recurrent joint pain with cold weather, iron for anemia without improvement, and decreased intervertebral spaces raised the use of ceftriaxone, oxacillin, and external immobilization. Hemoglobin sickle cell disease, spondylodiscitis with paravertebral collections, and epidural abscess were documented. She was fully recovered. The treatment was conservative because there was no neurologic deficit. We add to the literature I case of spondylodiscitis with epidural abscess that was successfully treated with antibiotics alone.
C1 [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Rua Prof Aristides Novis 105-1201B, Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
CR Almeida A, 2005, BRIT J HAEMATOL, V129, P482, DOI 10.1111/j.1365-2141.2005.05476.x
   Auletta JJ, 2001, CLIN INFECT DIS, V32, P9, DOI 10.1086/317527
   Bair-Merritt MH, 2000, PEDIATRICS, V106, part. no., DOI 10.1542/peds.106.3.e39
   Burnett MW, 1998, PEDIATRICS, V101, P296, DOI 10.1542/peds.101.2.296
   Devrim I, 2005, TURKISH J PEDIATR, V47, P369
   Fernandez M, 2000, PEDIATRICS, V105, P1299, DOI 10.1542/peds.105.6.1299
   Garcia-Alix Perez A, 2005, An Pediatr (Barc), V63, P1
   Hadjipavlou AG, 2000, SPINE, V25, P1668, DOI 10.1097/00007632-200007010-00010
   Kayser R, 2005, SPINE, V30, P318, DOI 10.1097/01.brs.0000152097.57891.98
   Lohr M, 2005, ACTA NEUROCHIR, V147, P159, DOI 10.1007/s00701-004-0414-1
   RUBIN G, 1993, PEDIATR INFECT DIS J, V12, P1007, DOI 10.1097/00006454-199312000-00009
   Zarrouk V, 2007, RHEUMATOLOGY, V46, P292, DOI 10.1093/rheumatology/kel228
NR 12
TC 4
Z9 4
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1077-4114
EI 1536-3678
J9 J PEDIAT HEMATOL ONC
JI J. Pediatr. Hematol. Oncol.
PD JAN
PY 2008
VL 30
IS 1
BP 70
EP 72
DI 10.1097/MPH.0b013e318159a5a6
PG 3
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA 252ZO
UT WOS:000252486900016
PM 18176186
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, CM
AF Nascimento-Carvalho, Cristiana Maria
TI Markers to be added to the case management of childhood pneumonia in
   developing countries
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Letter
C1 Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia, Sch Med, Dept Pediat, Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
CR Ayieko P, 2007, PEDIATR INFECT DIS J, V26, P432, DOI 10.1097/01.inf.0000260107.79355.7d
   Castro AV, 2006, PEDIATR INFECT DIS J, V25, P757, DOI 10.1097/01.inf.0000227821.38732.1f
   Castro AV, 2005, INDIAN PEDIATR, V42, P773
   Sachdev H P, 2001, Indian Pediatr, V38, P827
NR 4
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD OCT
PY 2007
VL 26
IS 10
BP 969
EP 969
DI 10.1097/INF.0b013e31814689d7
PG 1
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 221GM
UT WOS:000250215400024
PM 17901813
DA 2020-12-17
ER

PT J
AU Miranda, VMM
   Nascimento-Carvalho, CM
AF Miranda, V. M. M.
   Nascimento-Carvalho, C. M.
TI Assessing vaccination rates at an emergency room
SO AMERICAN JOURNAL OF INFECTION CONTROL
LA English
DT Letter
C1 Univ Fed Bahia, Dept Pediat, Sch Med, Salvador, BA, Brazil.
RP Miranda, VMM (corresponding author), Univ Fed Bahia, Dept Pediat, Sch Med, Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
CR BART KJ, 1991, JAMA-J AM MED ASSOC, V266, P1547
   BERNIER RH, 1993, JAMA-J AM MED ASSOC, V269, P1817, DOI 10.1001/jama.1993.03500140069038
   Hinman AR, 2000, AM J PREV MED, V18, P92
   Sabnis SS, 1998, PEDIATRICS, V101, part. no., DOI 10.1542/peds.101.5.e5
   TAYLOR JH, 1902, NEGRO MUSIC J, V1, P10
   Tugumisirize F, 2002, East Afr Med J, V79, P347
NR 6
TC 1
Z9 1
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-6553
EI 1527-3296
J9 AM J INFECT CONTROL
JI Am. J. Infect. Control
PD MAY
PY 2007
VL 35
IS 4
BP 286
EP 287
DI 10.1016/j.ajic.2006.10.008
PG 2
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 168BY
UT WOS:000246498500015
PM 17483004
DA 2020-12-17
ER

PT J
AU Cardozo, DM
   Nascimento-Carvalho, CM
   Andrade, ALSS
   Souza, FR
   Silva, NMS
AF Cardozo, D. M.
   Nascimento-Carvalho, C. M.
   Andrade, A. L. S. S.
   Souza, F. R.
   Silva, N. M. S.
TI The burden of acute nasopharyngitis among adolescents
SO ARCHIVES OF DISEASE IN CHILDHOOD
LA English
DT Letter
ID DISEASES; CHILDREN; HEALTH
C1 Fed Univ Goias, Inst Trop Pathol & Publ Hlth, Goiania, Go, Brazil.
   Univ Fed Bahia, Sch Biochem, Salvador, BA, Brazil.
   Univ Fed Bahia, Sch Med, Dept Paediat, Salvador, BA, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Rua Prof Aristides Novis 105-1201B, BR-40210630 Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
CR Aymard M, 2003, PEDIATR INFECT DIS J, V22, pS211, DOI 10.1097/01.inf.0000092189.42748.cc
   Fagan JK, 2001, ANN ALLERG ASTHMA IM, V86, P177, DOI 10.1016/S1081-1206(10)62688-9
   Janson C, 2004, INT J TUBERC LUNG D, V8, P510
   Santelli JS, 1995, J ADOLESCENT HEALTH, V17, P270, DOI 10.1016/1054-139X(95)00181-Q
NR 4
TC 1
Z9 1
U1 0
U2 0
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-9888
J9 ARCH DIS CHILD
JI Arch. Dis. Child.
PD DEC
PY 2006
VL 91
IS 12
BP 1045
EP 1045
DI 10.1136/adc.2006.105718
PG 1
WC Pediatrics
SC Pediatrics
GA 108BO
UT WOS:000242215400038
PM 17119096
OA Green Published
DA 2020-12-17
ER

PT J
AU Castro, AV
   Nascimento-Carvalho, CM
   Ney-Oliveira, F
   Araujo-Neto, CA
   Andrade, SC
   Loureiro, L
   Luz, P
AF Castro, Andrea V.
   Nascimento-Carvalho, Cristiana M.
   Ney-Oliveira, Fabrizio
   Araujo-Neto, Cesar A.
   Andrade, Sandra C.
   Loureiro, Luciana
   Luz, Pierangeli
TI Pulmonary infiltrate among children with cough and tachypnea
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Letter
ID PNEUMONIA; DIAGNOSIS
C1 Univ Fed Bahia, Sch Med, Jorge Valente Hosp, Bahia Blanca, Argentina.
   Univ Fed Bahia, Sch Med, Dept Pediat, Bahia Blanca, Argentina.
   Univ Fed Bahia, Sch Med, Dept Image & Radiol Diagnosis, Bahia Blanca, Argentina.
RP Castro, AV (corresponding author), Univ Fed Bahia, Sch Med, Jorge Valente Hosp, Emergency Room, Bahia Blanca, Argentina.
CR Altman D.G., 1991, PRACTICAL STAT MED R
   Castro AV, 2005, INDIAN PEDIATR, V42, P773
   DAI YH, 1995, PEDIATR INFECT DIS J, V14, P48, DOI 10.1097/00006454-199501000-00010
   Jadavji T, 1997, CAN MED ASSOC J, V156, pS703
   *PNEUM VACC TRIAL, 2001, VB0135 WHO PNEUM VAC
   SWINGLER GH, 2004, BMC MED IMAGING, V1, P1
   *WHO, 1985, WORK GROUP M GEN WHO
   WHO WHO Global Strategy for Containment of Antimicrobial Resistance, 2001, WHOCDSCSRDRS20012
NR 8
TC 5
Z9 5
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD AUG
PY 2006
VL 25
IS 8
BP 757
EP 757
DI 10.1097/01.inf.0000227821.38732.1f
PG 1
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 072TX
UT WOS:000239697000022
PM 16874185
DA 2020-12-17
ER

PT J
AU Cardozo, DM
   Nascimento-Carvalho, CM
   Brandao, MA
   Azevedo, GMS
   De Souza, FR
   Silva, NMS
   Brandao, AP
   De Andrade, ALSS
   Brandileone, MCC
AF Cardozo, DM
   Nascimento-Carvalho, CM
   Brandao, MA
   Azevedo, GMS
   De Souza, FR
   Silva, NMS
   Brandao, AP
   De Andrade, ALSS
   Brandileone, MCC
TI Antimicrobial resistance and serotypes of nasopharyngeal strains of
   Streptococcus pneumoniae in Brazilian adolescents
SO MICROBIAL DRUG RESISTANCE
LA English
DT Article
ID CHILDREN; CARRIAGE; PNEUMOCOCCI; MENINGITIS; INFECTIONS; PREVALENCE
AB The aim of this study was to describe the frequency of antimicrobial-resistance and serotypes of nasopharyngeal pneumococcal isolates from adolescents. Clinical data and nasopharyngeal specimens for culture were collected from 1,013 adolescents as a part of a population-based study. A total of 83 isolates of Streptococcus pneumoniae were identified (8.2%). Seventy-four of the 83 isolates were serotyped. The median age of the 83 adolescents colonized by pneumococci was 14 years (mean 14 +/- 2.2 yrs); 55.4% were males. Intermediate resistance to penicillin was detected in 7.2% (6/83). No strain showed high resistance to penicillin. All isolates were susceptible to clindamycin, chloramphenicol, rifampin, and vancomycin; 37.3%, 18.1%, and 4.8% were resistant to trimethoprim-sulfamethoxazole, tetracycline, and erythromycin, respectively. The most frequent serotypes (5-10% of strains each) were 6B, 6A, 23F, and 18C among 28 serotypes/serogroups identified; 18.9% of the strains were nontypeable (NT). Intermediate resistance to penicillin was detected in serotypes 6B, 14, and NT. The rate of resistance to penicillin of nasopharyngeal isolates is low considering data from other studies about invasive strains recovered from children in Brazil. Serotype patterns are similar, except for type 14, which was unusually infrequent.
C1 Univ Fed Bahia, Fac Med, Dept Pediat, BR-40210 Salvador, BA, Brazil.
   Cent Lab Bahia, LACEN, BR-40210 Salvador, BA, Brazil.
   Univ Fed Bahia, Fac Biochem, BR-40210 Salvador, BA, Brazil.
   Adolfo Lutz Inst, Bacteriol Div, Sao Paulo, Brazil.
   Natl Fdn Hlth, Sao Paulo, Brazil.
   Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   Univ Fed Goias, Inst Trop Pathol & Publ Hlth, Goiania, Go, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Rua Prof Aristides Novis,105,Apto 1201B, BR-40210630 Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
RI Brandao, Angela Pires/AAG-2758-2020; Andrade, Ana Lucia/L-5751-2013
CR AUSTRIAN R, 1986, J ANTIMICROB CHEMOTH, V18, P35, DOI 10.1093/jac/18.Supplement_A.35
   Austrian R, 2000, VACCINE, V19, pS71, DOI 10.1016/S0264-410X(00)00282-6
   Brandileone MCD, 1997, MICROB DRUG RESIST, V3, P141
   Brazilian Institute of Geography and Statistics (IBGE), CENS 2000
   Clinical and Laboratory Standards Institute, 2005, M100S15 CLSINCCLS
   Dagan R, 2000, VACCINE, V19, pS9, DOI 10.1016/S0264-410X(00)00272-3
   Douglas RM, 1999, CLIN INFECT DIS, V28, P192, DOI 10.1086/515112
   DUCHIN JS, 1995, PEDIATR INFECT DIS J, V14, P745, DOI 10.1097/00006454-199509000-00004
   GRAY BM, 1980, J INFECT DIS, V142, P923, DOI 10.1093/infdis/142.6.923
   Hennessy TW, 2002, CLIN INFECT DIS, V34, P1543, DOI 10.1086/340534
   Klugman KP, 1995, MICROB DRUG RESIST, V1, P5, DOI 10.1089/mdr.1995.1.5
   Ko AI, 2000, CLIN INFECT DIS, V30, P78, DOI 10.1086/313619
   Muhlemann K, 2003, J INFECT DIS, V187, P589, DOI 10.1086/367994
   Nascimento-Carvalho Cristiana M., 2003, J. Pediatr. (Rio J.), V79, P209, DOI 10.1590/S0021-75572003000300005
   O'Brien KL, 2003, PEDIATR INFECT DIS J, V22, P133, DOI 10.1097/00006454-200302000-00009
   *PAHO, 1998, DOC PLAN ACT HLTH DE
   Peltola H, 2001, CLIN INFECT DIS, V32, P64, DOI 10.1086/317534
   Rapola S, 1997, J CLIN MICROBIOL, V35, P1077, DOI 10.1128/JCM.35.5.1077-1079.1997
   ROBINSBROWNE RM, 1984, J HYG-CAMBRIDGE, V93, P9, DOI 10.1017/S0022172400060873
   Ruzany M H, 1999, J Pediatr (Rio J), V75, P327
   SCHREIBER JR, 1995, PEDIATR CLIN N AM, V42, P519
   Tomasz A, 1998, MICROB DRUG RESIST, V4, P195, DOI 10.1089/mdr.1998.4.195
   *WHO, 1994, MAN NAT SURV ANT RES
NR 23
TC 2
Z9 2
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1076-6294
EI 1931-8448
J9 MICROB DRUG RESIST
JI Microb. Drug Resist.
PD SPR
PY 2006
VL 12
IS 1
BP 29
EP 32
DI 10.1089/mdr.2006.12.29
PG 4
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA 031EG
UT WOS:000236686300006
PM 16584305
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, CM
   Moreno-Carvalho, OA
AF Nascimento-Carvalho, CM
   Moreno-Carvalho, OA
TI Changing the diagnostic framework of meningococcal disease
SO LANCET
LA English
DT Editorial Material
ID CARE; CHILDREN
C1 Univ Fed Bahia, Fac Med, Dept Paediat, Salvador, BA, Brazil.
   Jose Silveira Fdn, Salvador, BA, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia, Fac Med, Dept Paediat, Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
CR APICELLA MA, 2000, MANDELL DOUGLAS BENN, P2228
   Booy R, 2001, ARCH DIS CHILD, V85, P386, DOI 10.1136/adc.85.5.386
   BROWNER WS, 1988, DESIGNING CLIN RES, P87
   Granier S, 1998, BRIT J GEN PRACT, V48, P1167
   Ninis N, 2005, BRIT MED J, V330, P1475, DOI 10.1136/bmj.330.7506.1475
   Riordan FAI, 1996, BRIT MED J, V313, P1255, DOI 10.1136/bmj.313.7067.1255
   Rosenstein NE, 2001, NEW ENGL J MED, V344, P1378, DOI 10.1056/NEJM200105033441807
   Thompson MJ, 2006, LANCET, V367, P397, DOI 10.1016/S0140-6736(06)67932-4
   VICTORA CG, 1992, SOC SCI MED, V34, P899, DOI 10.1016/0277-9536(92)90258-R
NR 9
TC 3
Z9 3
U1 0
U2 1
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD FEB 4
PY 2006
VL 367
IS 9508
BP 371
EP 372
DI 10.1016/S0140-6736(06)67934-8
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 009UR
UT WOS:000235139400004
PM 16458743
DA 2020-12-17
ER

PT J
AU Costa, FF
   Castro, G
   Andrade, J
   Jesus, AD
   de Almeida, RP
   Nascimento-Carvalho, CM
AF Costa, FF
   Castro, G
   Andrade, J
   Jesus, AD
   de Almeida, RP
   Nascimento-Carvalho, CM
TI Resistant Mycobacterium bovis disseminated infection
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Letter
ID TUBERCULOSIS
C1 Univ Fed Bahia, Fac Med, Dept Pediat, Salvador, BA, Brazil.
   Univ Fed Bahia, Hosannah Oliveira Pediat Ctr, Salvador, BA, Brazil.
   Univ Fed Bahia, Dept Med, Salvador, BA, Brazil.
   Univ Fed Bahia, Dept Pathol, Salvador, BA, Brazil.
RP Costa, FF (corresponding author), Univ Fed Bahia, Fac Med, Dept Pediat, Salvador, BA, Brazil.
CR Koscielniak E, 2003, PEDIATR INFECT DIS J, V22, P378
   Murray DL, 2004, PEDIATR INFECT DIS J, V23, P1072, DOI 10.1097/01.inf.0000146645.33050.3d
   Remus N, 2001, PEDIATR RES, V50, P8, DOI 10.1203/00006450-200107000-00005
   TELENTI A, 1993, LANCET, V341, P647, DOI 10.1016/0140-6736(93)90417-F
   Yellin L, 2004, PEDIATR INFECT DIS J, V23, P590, DOI 10.1097/00006454-200406000-00027
NR 5
TC 5
Z9 5
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD FEB
PY 2006
VL 25
IS 2
BP 190
EP 190
DI 10.1097/01.inf.0000200103.69932.4c
PG 1
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 015QY
UT WOS:000235567100025
PM 16462308
DA 2020-12-17
ER

PT J
AU Moreno-Carvalho, O
   Nascimento-Carvalho, C
   Cardoso, M
   Moreira, L
   Araujo, K
   Pelegrini, R
   Ribeiro, F
   Leite, M
   Chaves, N
AF Moreno-Carvalho, O
   Nascimento-Carvalho, C
   Cardoso, M
   Moreira, L
   Araujo, K
   Pelegrini, R
   Ribeiro, F
   Leite, M
   Chaves, N
TI Full-term gestation and premature neonates: Cerebrospinal fluid (CSF)
   reference values
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Meeting Abstract
CT 18th World Congress of Neurology
CY NOV 05-11, 2005
CL Sydney, AUSTRALIA
C1 Fed Univ Bahia, Fac Med, Dept Pediat, Salvador, BA, Brazil.
   CSF Lab, JSF, Salvador, BA, Brazil.
   Univ Sao Paulo, Fac Publ Hlth, Sao Paulo, Brazil.
   JSF, Santo Amaro Hosp, Salvador, BA, Brazil.
   Alianca Hosp, Salvador, BA, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD NOV 15
PY 2005
VL 238
SU 1
BP S478
EP S479
PG 2
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 009CF
UT WOS:000235088004233
DA 2020-12-17
ER

PT J
AU Castro, AV
   Nascimento-Carvalho, CM
   Ney-Oliveira, F
   Araujo-Neto, CA
   Andrade, SCS
   Loureiro, LLS
   Luz, PO
AF Castro, AV
   Nascimento-Carvalho, CM
   Ney-Oliveira, F
   Araujo-Neto, CA
   Andrade, SCS
   Loureiro, LLS
   Luz, PO
TI Additional markers to refine the world health organization algorithm for
   diagnosis of pneumonia
SO INDIAN PEDIATRICS
LA English
DT Article
DE asthma; bronchodilator; children; pneumonia; tachypnea
ID CHILDREN; ASTHMA
AB Introduction: WHO guidelines for primary care of children with tachypnea indicate that all should receive antibiotics for presumed pneumonia. These guidelines have led to excessive antibiotic use. Objective: To examine the value of history of previous respiratory distress, chest indrawing and fever, and response to bronchodilator(BD) to refine these guidelines. Design: Prospective study. Setting: Urban tertiary care hospital. Subjects: Children, between the ages of 6 and 59 months, presenting with cough and tachypnea. Methods: 182 children were enrolled. Each child had a chest X-ray that was read by two blinded, independent radiologists. Discordance between the two radiologists led to excluding 17 patients. The remaining 165 children were examined for fever and/or chest indrawing, and if they had a history of previous respiratory distress, challenge with a BD. The association of persistent tachypnea after BD and presence of pulmonary infiltrates was recorded. Results: The median age was 22 months (mean 25.1 +/- 14.5mo) and 75.8% were aged >= 1 year. There were 58.8% males. Previous respiratory distress occurred in 65.0% and 79.2% of children aged < 1 year and 1 year, respectively. Pneumonia was radiologically diagnosed in 261165 (15.8%). 2140 (5%) of children without a history of previous respiratory distress had pneumonia diagnosed. Of 125 children with history of previous respiratory distress, pneumonia was identified in 24 (19.2%). Persistence of tachypnea after BD was associated with pulmonary infiltrate in 14124 (58.3%), whereas, lackypnea persisted in 321101 (31.7%) children without pulmonary infiltrates (P = 0.02). The negative predictive value of resolution of tachypnea was 87.3% (95% CI 77.5-93.4). BD non-response was most useful in children without fever and/or with chest indrawing to indicate pneumonia as the cause of the tachypnea. Conclusion: This study indicates that by adding the simple procedures of a history of previous respiratory distress, recording of fever and chest indrawing, and observing the response to bronchodilators, pneumonia can be reliably identified in children presenting with tachypnea and cough. It is probable that this approach to management of children with cough and tachypnea could reduce unnecessary use of antibiotics.
C1 Univ Fed Bahia, Fac Med, Dept Pediat, BR-40210 Salvador, BA, Brazil.
   Univ Fed Bahia, Dept Radiodiag, BR-40210 Salvador, BA, Brazil.
   Jorge Valente Hosp, Emergency Dept, Salvador, BA, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia, Fac Med, Dept Pediat, Rua Prof Aristides Novis,105 apartment 120-B Fede, BR-40210 Salvador, BA, Brazil.
EM nascitnentocarvalho@hotmail.com
CR BENGUIGUI Y, 1998, INFECCOES RESPIRATOR
   BENGUIGUI Y, 1997, INFECCOES RESPIRATO
   DAI YH, 1995, PEDIATR INFECT DIS J, V14, P48, DOI 10.1097/00006454-199501000-00010
   Donnelly LF, 1999, AM J ROENTGENOL, V172, P505, DOI 10.2214/ajr.172.2.9930814
   Low DE, 2004, CLIN PEDIATR, V43, P135, DOI 10.1177/000992280404300203
   Nascimento-Carvalho CM, 2002, PEDIATR PULM, V33, P244, DOI 10.1002/ppul.10078
   NASCIMENTOCARVA.CM, 2003, RECENT ADV PEDIAT, V13, P159
   Okoromah Christy N, 2002, Niger Postgrad Med J, V9, P221
   Organization W. H., 2001, STAND INT CHEST RAD
   Sachdev H P, 2001, Indian Pediatr, V38, P827
   SACHDEV HPS, 1995, INDIAN PEDIATR, V31, P1251
   Sole D, 2001, J INVEST ALLERG CLIN, V11, P123
   TAYLOR JA, 1995, ARCH PEDIAT ADOL MED, V149, P283, DOI 10.1001/archpedi.1995.02170150063011
   Torzillo P J, 2001, Indian Pediatr, V38, P821
   *WHO, 1985, WHORSD8515REV1
   *WHO, 1991, WHOARI91120
   WHO WHO Global Strategy for Containment of Antimicrobial Resistance, 2001, WHOCDSCSRDRS20012
   Yeatts K, 2003, ARCH PEDIAT ADOL MED, V157, P540, DOI 10.1001/archpedi.157.6.540
NR 18
TC 15
Z9 16
U1 0
U2 0
PU SPRINGER INDIA
PI NEW DELHI
PA 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001,
   INDIA
SN 0019-6061
EI 0974-7559
J9 INDIAN PEDIATR
JI Indian Pediatrics
PD AUG
PY 2005
VL 42
IS 8
BP 773
EP 781
PG 9
WC Pediatrics
SC Pediatrics
GA 003VY
UT WOS:000234711100003
PM 16141478
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, CMC
   Gesteira, MDF
   Azul-Neto, LS
   Andrade, MQ
AF Nascimento-Carvalho, CMC
   Gesteira, MDF
   Azul-Neto, LS
   Andrade, MQ
TI Prolonged treatment with albendazole for massive Trichuriasis infection
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Letter
C1 Univ Fed Bahia, Fac Med, Dept Pediat, Salvador, BA, Brazil.
   Univ Fed Bahia, Pediat Ctr, Salvador, BA, Brazil.
RP Nascimento-Carvalho, CMC (corresponding author), Univ Fed Bahia, Fac Med, Dept Pediat, Salvador, BA, Brazil.
CR Chandrasekhar M R, 2003, Indian J Pathol Microbiol, V46, P492
   HALL A, 1994, T ROY SOC TROP MED H, V88, P110, DOI 10.1016/0035-9203(94)90525-8
   MAHMOUD AAF, 2000, PRINCIPLES PRACTICE, P2939
   Norhayati M., 1997, Southeast Asian Journal of Tropical Medicine and Public Health, V28, P563
   PICKERING LK, 2003, RED BOOK 2003 REPORT, P638
   RAMALINGAM S, 1983, AM J TROP MED HYG, V32, P984, DOI 10.4269/ajtmh.1983.32.984
   Sirivichayakul C, 2003, ANN TROP MED PARASIT, V97, P847, DOI 10.1179/000349803225002480
NR 7
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD NOV
PY 2004
VL 23
IS 11
BP 1070
EP 1070
DI 10.1097/01.inf.0000143657.25336.8b
PG 1
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 872HD
UT WOS:000225197400024
PM 15545874
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, CM
   Moreno-Carvalho, OA
AF Nascimento-Carvalho, CM
   Moreno-Carvalho, OA
TI Etiology of bacterial meningitis among children aged 2-59 months in
   Salvador, Northeast Brazil, before and after routine use of Haemophilus
   influenzae type B vaccine
SO ARQUIVOS DE NEURO-PSIQUIATRIA
LA English
DT Article
DE meningitis; childhood; Haemophilus influenzae type B; immunization;
   cerebrospinal fluid; bacterial meningitis of unknown etiology
AB Objective: To describe the frequency of etiologic agents of bacterial meningitis (BM) among children aged 2-59 months in a sample of patients in Salvador, Northeast Brazil, with emphasis on the frequency of BM of unknown etiology (BMUE), just before, during and after the implementation of routine immunization of infants with Haemophilus influenzae type b (Hib) vaccination. Method: Demographic, clinical and cerebrospinal fluid (CSF) information was collected from the chart of every patient, aged 2-59 months, whose CSF exam was performed at the CSF Lab - Jose Silveira Foundation, between January 1989 and December 2001. Every CSF exam was completely performed according to standard methods. The etiologic diagnosis was based on either culture and/or latex-agglutination test. When the agent was only seen on Gram stained smear, the diagnosis was descriptive. BMUE was defined as: glucose less than or equal to40mg/dl, protein greater than or equal to 100 mg/dl, white blood cell count greater than or equal to 20 cells/mm(3), percentage of neutrophils greater than or equal to 80%. Results: Of 1519 patients, 894 (58.9%) had normal exams and BM was diagnosed in 95 (6.2%). Etiologic agents were: Hib (44.2%), meningococcus (13.7%), Gram-negative bacilli (11.6%), Mycobacterium tuberculosis (6.3%), pneumococcus (4.2%), other agents (4.2%); BMUE was diagnosed in 15.8% of cases with BM. By analysing the frequency of BMUE and Hib among all exams performed yearly, the peaks were recorded in 1989 (5.3%) and 1990 (16.9%), respectively, decreasing to 0.7% and 0% in 2001. Conclusion: It is possible that the implementation of the conjugate Hib vaccine during the 1990's has been decreasing not only the occurrence of Hib meningitis but also of BMUE.
C1 Univ Fed Bahia, Fac Med, Dept Pediat, BR-41170290 Salvador, BA, Brazil.
   Jose Silveira Fdn, CSF Lab, Salvador, BA, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Rua Prof Aristides Novis 105-1201B, BR-40210630 Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
CR DAVEY PG, 1982, J HYG-CAMBRIDGE, V88, P383, DOI 10.1017/S002217240007025X
   Landaverde M, 1999, Rev Panam Salud Publica, V5, P200, DOI 10.1590/S1020-49891999000300022
   PETER G, 1991, PEDIATRICS, V88, P169
   Prober CG, 2000, NELSON TXB PEDIAT, P751
   Schuchat A, 1997, NEW ENGL J MED, V337, P970, DOI 10.1056/NEJM199710023371404
   TUNKEL AR, 2000, MANDELL DOUGLAS BENN, P975
   1998, MMWR MORB MORTAL WKL, V47, P993
NR 7
TC 7
Z9 8
U1 0
U2 0
PU ASSOC ARQUIVOS DE NEURO- PSIQUIATRIA
PI SAO PAULO SP
PA PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL
SN 0004-282X
J9 ARQ NEURO-PSIQUIAT
JI Arq. Neuro-Psiquiatr.
PD JUN
PY 2004
VL 62
IS 2A
BP 250
EP 252
DI 10.1590/S0004-282X2004000200011
PG 3
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 824TK
UT WOS:000221709400011
PM 15235726
OA DOAJ Gold
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, CM
   Souza-Marques, HH
AF Nascimento-Carvalho, CM
   Souza-Marques, HH
TI Recommendation of the Brazilian Society of Pediatrics for antibiotic
   therapy in children and adolescents with community-acquired pneumonia
SO REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC
   HEALTH
LA Portuguese
DT Article
ID RESPIRATORY-TRACT INFECTION; RESISTANT STREPTOCOCCUS-PNEUMONIAE; SIMPLE
   CLINICAL SIGNS; CHILDHOOD PNEUMONIA; ANTIMICROBIAL THERAPY;
   PENICILLIN-RESISTANT; INVASIVE INFECTIONS; BLOOD CULTURES; RISK-FACTORS;
   ETIOLOGY
AB Objective. To standardize the use of antibiotics to treat community-acquired pneumonia in children and adolescents in Brazil.
   Methods. The following data sources were utilized: the Medline and LILACS (Literatura Latino-Americana e do Caribe em Ciencias da Saude) bibliographic databases; World Health Organization and Pan American Health Organization documents published between 1980 and 2002; Internet materials in Portuguese, Spanish, or English located using the search terms "pneumonia, child, adolescent, etiology, treatment"; and interviews with renowned experts in the field.
   Results. Hospitalization is always required for children younger than 2 months of age. That age group should be treated with ampicillin and aminoglycosides or third-generation cephalosporins. Children older than 2 months must be hospitalized if there is severe pneumonia. Tachypnea should be used as the criterion to distinguish between acute respiratory infection and pneumonia. Pneumonia is considered to be very severe when there are seizures, sleepiness, stridor at rest, severe malnutrition, no ingestion of fluids, or signs of respiratory failure such as central cyanosis. Children who are 2 months of age or older may receive outpatient treatment with amoxicillin or penicillin G procaine. In the case of inpatient treatment, crystalline penicillin or ampicillin may be used for severe cases, and oxacillin and chloramphenicol or ceftriaxone for very severe cases. A macrolide, preferably erythromycin, should be employed when the etiologic agent is suspected to be Chlamydia trachomatis, C. pneumoniae, Mycoplasma pneumoniae, or Bordetella pertussis.
   Conclusions. The diagnosis of pneumonia and the need for hospitalization can be based on clinical assessment. The main antibiotics to be used are amoxicillin, penicillin, erythromycin, ampicillin, oxacillin, chloramphenicol, ceftriaxone, and aminoglycosides, depending on the age of the patient and the severity of the disease.
C1 Univ Fed Bahia, Fac Med, Dept Pediat, Salvador, BA, Brazil.
   Univ Sao Paulo, Fac Med, Dept Pediat, Sao Paulo, Brazil.
   Hosp Clin Sao Paulo, Inst Crianca, Sao Paulo, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Rua Prof Aristides Novis 105,Apartamento 1201B, BR-40210730 Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com; heloisahsm@icr.hcnet.usp.br
CR AGRE F, 1985, AM J DIS CHILD, V139, P809, DOI 10.1001/archpedi.1985.02140100071033
   AMARAL JJF, 2000, MANEJO INFECCOES RES
   [Anonymous], 1996, MMWR Recomm Rep, V45, P1
   BARROS FC, 1986, PEDIATRICS, V78, P656
   BECKER AR, 1986, EVOLUCAO MORTALIDA C
   BENGUIGUI Y, 1997, INFECCOES RESP AGUDA
   BENGUIGUI Y, 1997, CONTROLE INFECCOES R
   BERMAN S, 1985, REV INFECT DIS, V7, P674
   Brandileone MCD, 1997, MICROB DRUG RESIST, V3, P141
   *BRAS MIN SAUD, 1994, ASS CONTR INF RESP A
   *BRAS MIN SAUD, 1998, DATASUS SIST INF MOR
   *BRAS MIN SAUD, 1984, ASS INT SAUD CRIANC
   *BRAS MIN SAUD CEN, 1979, COEF MORT INF PNEUM
   *BRAS MIN SAUD DAT, 1999, SIST INF HOSP SUS MO
   *BRAS MIN SAUD FUN, 1989, EST MORT
   *BRAS MIN SAUD ORG, 1993, PROGR SAUD MAT INF P
   Bryan CS, 1999, CHEST, V116, P1153, DOI 10.1378/chest.116.5.1153
   CAMPBELL H, 1988, LANCET, V2, P742
   CHAMBERLAIN N, 2002, CLIN SYNDROMES PNEUM
   CHERIAN T, 1988, LANCET, V2, P125
   Choi EH, 1998, CLIN INFECT DIS, V26, P1346, DOI 10.1086/516340
   CHRETIEN J, 1984, NEW ENGL J MED, V310, P982, DOI 10.1056/NEJM198404123101509
   CLAESSON BA, 1989, PEDIATR INFECT DIS J, V8, P856, DOI 10.1097/00006454-198912000-00006
   CONNOCHIE KM, 1986, AM J DIS CHILD, V140, P806
   DENNY FW, 1986, AM J TROP MED HYG, V35, P1
   Di Fabio JL, 2001, PEDIATR INFECT DIS J, V20, P959, DOI 10.1097/00006454-200110000-00009
   FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P42, DOI 10.1097/00006454-199101000-00009
   FORMAN MR, 1984, INT J EPIDEMIOL, V13, P447, DOI 10.1093/ije/13.4.447
   FRIEDLAND IR, 1995, PEDIATR INFECT DIS J, V14, P885, DOI 10.1097/00006454-199510000-00013
   FRIEDLAND IR, 1994, NEW ENGL J MED, V331, P377, DOI 10.1056/NEJM199408113310607
   Heffelfinger JD, 2002, PEDIATR INFECT DIS J, V21, P108, DOI 10.1097/00006454-200202000-00005
   Heiskanen-Kosma T, 1998, PEDIATR INFECT DIS J, V17, P986, DOI 10.1097/00006454-199811000-00004
   Hickey RW, 1996, ANN EMERG MED, V27, P721, DOI 10.1016/S0196-0644(96)70189-0
   Juven T, 2000, PEDIATR INFECT DIS J, V19, P293, DOI 10.1097/00006454-200004000-00006
   KLEIN JO, 1998, TXB PEDIAT INFECT DI, P273
   KORPPI M, 1993, ACTA PAEDIATR, V82, P360, DOI 10.1111/j.1651-2227.1993.tb12697.x
   Leowski J, 1986, World Health Stat Q, V39, P138
   LEVENTHAL JM, 1982, CLIN PEDIATR, V21, P730, DOI 10.1177/000992288202101205
   Margolis P, 1998, JAMA-J AM MED ASSOC, V279, P308, DOI 10.1001/jama.279.4.308
   MCCARTHY PL, 1981, CLIN PEDIATR, V20, P686, DOI 10.1177/000992288102001101
   McCracken GH, 2000, PEDIATR INFECT DIS J, V19, P373, DOI 10.1097/00006454-200004000-00032
   McIntosh K, 2002, NEW ENGL J MED, V346, P429, DOI 10.1056/NEJMra011994
   Mulholland K, 1999, LANCET, V354, P590, DOI 10.1016/S0140-6736(98)10238-6
   Nascimento-Carvalho C M, 2001, Braz J Infect Dis, V5, P13, DOI 10.1590/S1413-86702001000100003
   Nascimento-Carvalho C M, 2001, Braz J Infect Dis, V5, P87
   Nascimento-Carvalho CMC, 2002, J TROP PEDIATRICS, V48, P253, DOI 10.1093/tropej/48.4.253
   Nascimento-Carvalho CMC, 2002, J TROP PEDIATRICS, V48, P58, DOI 10.1093/tropej/48.1.58
   Nascimento-Carvalho CMC, 2001, J TROP PEDIATRICS, V47, P253, DOI 10.1093/tropej/47.4.253
   Nascimento-Carvalho Cristiana M.C., 2002, Braz J Infect Dis, V6, P22, DOI 10.1590/S1413-86702002000100004
   Nascimento-Carvalho Cristiana M C, 2002, Indian Pediatr, V39, P205
   National Committee for Clinical Laboratory Standards, 2000, METH DIL ANT SUSC TE
   NIOBEY FML, 1992, REV SAUDE PUBL, V26, P229, DOI 10.1590/S0034-89101992000400004
   NOHYNEK H, 1991, AM J DIS CHILD, V145, P618, DOI 10.1001/archpedi.1991.02160060036016
   *ORG PAN AM SAUD, 2000, MELH SAUD CRIANC AID
   *ORG PAN AM SAUD, 1996, 29 IRA
   *ORG PAN SAL, 2000, NIN SAN MET 2002 INF
   *ORG PAN SAL, 1992, INF RESP AG AM
   PAISLEY JW, 1984, PEDIATR INFECT DIS J, V3, P14, DOI 10.1097/00006454-198401000-00005
   Paiva MAS, 1998, J PNEUMOL, V24, P101
   PALLARES R, 1995, NEW ENGL J MED, V333, P474, DOI 10.1056/NEJM199508243330802
   *PAN AM HLTH ORG W, 1995, 1 ARI PAHO
   Pickering L. K., 2003, RED BOOK REPORT COMM
   RAMSEY BW, 1986, PEDIATRICS, V78, P1
   Reese RE, 2000, HDB ANTIBIOTICS
   ROZOV T, 1989, PNEUMONIAS AGUDAS EM, P6
   RUUSKANEN O, 1992, EUR J CLIN MICROBIOL, V11, P217, DOI 10.1007/BF02098083
   Sachdev H P, 2001, Indian Pediatr, V38, P827
   SANTOS AS, 2002, 20 SEM EST PESQ 6 8, P11
   SHANN F, 1989, PEDIATR INFECT DIS J, V8, P852, DOI 10.1097/00006454-198912000-00005
   SHANN F, 1984, B WORLD HEALTH ORGAN, V62, P749
   SPOONER V, 1989, J TROP PEDIATRICS, V35, P295, DOI 10.1093/tropej/35.6.295
   TURNER RB, 1987, J PEDIATR-US, V111, P194
   Welliver RC, 1998, TXB PEDIAT INFECT DI, P249
   *WHO, 1985, CAS MAN AC RESP INF
   World Health Organization, 1990, PROGR CONTR AC RESP
NR 75
TC 24
Z9 28
U1 0
U2 1
PU PAN AMER HEALTH ORGANIZATION
PI WASHINGTON
PA 525 23RD ST NW, WASHINGTON, DC 20037 USA
SN 1020-4989
J9 REV PANAM SALUD PUBL
JI Rev. Panam. Salud Publica
PD JUN
PY 2004
VL 15
IS 6
BP 380
EP 387
DI 10.1590/S1020-49892004000600003
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 899XD
UT WOS:000227178200003
PM 15272984
OA Bronze
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, CM
   Moreno-Carvalho, OA
AF Nascimento-Carvalho, CM
   Moreno-Carvalho, OA
TI Clinical and cerebrospinal fluid findings in patients less than 20 years
   old with a presumptive diagnosis of neuroschistosomiasis
SO JOURNAL OF TROPICAL PEDIATRICS
LA English
DT Article
ID TRANSVERSE MYELITIS; SPINAL-CORD; SCHISTOSOMIASIS
AB CNS manifestations are rarely attributable to Schistosoma mansoni infection although systemic distribution of S mansoni eggs is well recorded. We describe 73 patients aged less than 20 years who presented S: mansoni eggs in the stool or rectal biopsy and IFA and/or HAI positive CSF tests to S. mansoni, and who had neurological signs and symptoms. Paraparesis (54.8 per cent), urinary retention (53.4 per cent), and paraplegia (20.5 per cent) were the most commonly observed CNS manifestations. In the CSF, pleocytosis (range 7-560 WBC/mm(3)) associated with eosinophilia (85.7 per cent vs. 50.0 per cent, p=0.02) and elevated protein concentration (96.8 per cent vs. 40.0 per cent; p=0.00003) were observed. We conclude that in areas of the world where infection by S. mansoni is common, neuroschistosomiasis should be an important diagnostic consideration in children with neurological signs and symptoms.
C1 Univ Fed Bahia, Fac Med, Dept Pediat, BR-41170290 Salvador, BA, Brazil.
   Jose Silveira Fdn, CSF Lab, Salvador, BA, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Rua Prof Aristides Novis 105-1201B, BR-40210630 Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
CR Andrade A N, 1989, Arq Neuropsiquiatr, V47, P100
   BOYCE TG, 1990, PEDIATR INFECT DIS J, V9, P279, DOI 10.1097/00006454-199004000-00011
   BUDZILOVICH GN, 1964, ARCH PATHOL, V77, P383
   CORREA RLB, 1983, REV BRAS NEUROL, V19, P101
   KING CH, 2000, NELSON TXB PEDIAT, P1073
   Livramento J A, 1985, Arq Neuropsiquiatr, V43, P372
   Mahmond AAF, 2000, MANDELL DOUGLAS BENN, P2950
   NAZER H, 1993, ANN TROP PAEDIATR, V13, P353, DOI 10.1080/02724936.1993.11747670
   Peregrino A J, 1988, Arq Neuropsiquiatr, V46, P49
   Peregrino AJP, 2002, ARQ NEURO-PSIQUIAT, V60, P603, DOI 10.1590/S0004-282X2002000400016
   Pittella JEH, 1997, BRAIN PATHOL, V7, P649, DOI 10.1111/j.1750-3639.1997.tb01080.x
   Santos E C, 2001, Arq Neuropsiquiatr, V59, P772
   WARREN KS, 1967, AM J PATHOL, V51, P735
   1984, MMWR, V33, P445
NR 14
TC 10
Z9 13
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0142-6338
J9 J TROP PEDIATRICS
JI J. Trop. Pediatr.
PD APR
PY 2004
VL 50
IS 2
BP 98
EP 100
DI 10.1093/tropej/50.2.98
PG 3
WC Pediatrics; Tropical Medicine
SC Pediatrics; Tropical Medicine
GA 810QX
UT WOS:000220719900008
PM 15088799
DA 2020-12-17
ER

PT J
AU Nuevo, H
   Nascimento-Carvalho, CMC
   Athayde-Oliveira, CP
   Lyra, I
   Moreira, LMO
AF Nuevo, H
   Nascimento-Carvalho, CMC
   Athayde-Oliveira, CP
   Lyra, I
   Moreira, LMO
TI Thrombocytopenic purpura after hepatitis B vaccine: Case report and
   review of the literature
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Letter
DE thrombocytopenia; immunization; vaccine safety; hepatitis B vaccine
C1 Univ Fed Bahia, Dept Pediat, Fac Med, Salvador, BA, Brazil.
RP Nuevo, H (corresponding author), Univ Fed Bahia, Dept Pediat, Fac Med, Salvador, BA, Brazil.
CR *ADV COMM IMM PRAC, 1991, MMWR-MORBID MORTAL W, V40, pRR13
   Cines DB, 2002, NEW ENGL J MED, V346, P995, DOI 10.1056/NEJMra010501
   Conesa V, 2001, Haematologica, V86, pE09
   Ferreira GC, 2002, PEDIAT ATUAL, V15, P16
   Jadavji T, 2003, PEDIATR INFECT DIS J, V22, P119
   Kao JH, 2002, LANCET INFECT DIS, V2, P395, DOI 10.1016/S1473-3099(02)00315-8
   Lliminana C, 1999, MED CLIN-BARCELONA, V113, P39
   Maezono R, 2000, J Pediatr (Rio J), V76, P395
   Medeiros D, 2000, CURR OPIN PEDIATR, V12, P4, DOI 10.1097/00008480-200002000-00002
   MEYBOOM RHB, 1995, LANCET, V345, P1638, DOI 10.1016/S0140-6736(95)90143-4
   Miller E, 2001, ARCH DIS CHILD, V84, P227, DOI 10.1136/adc.84.3.227
   Neau D, 1998, SCAND J INFECT DIS, V30, P115, DOI 10.1080/003655498750003465
   Nugent DJ, 2002, BLOOD REV, V16, P27, DOI 10.1054/blre.2001.0177
   POULLIN P, 1994, LANCET, V344, P1293, DOI 10.1016/S0140-6736(94)90777-3
   Ronchi F, 1998, ARCH DIS CHILD, V78, P273, DOI 10.1136/adc.78.3.273
NR 15
TC 9
Z9 9
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD FEB
PY 2004
VL 23
IS 2
BP 183
EP 184
DI 10.1097/01.inf.0000109846.59440.a1
PG 2
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 777GY
UT WOS:000189169000022
PM 14872193
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, CM
   Moreno-Carvalho, OA
AF Nascimento-Carvalho, CM
   Moreno-Carvalho, OA
TI Frequency of lymphocytic meningitis associated with mumps before and
   after a mass campaign for mumps vaccination in children from Salvador,
   northeast Brazil
SO ARQUIVOS DE NEURO-PSIQUIATRIA
LA English
DT Article
DE meningitis; mumps; immunization; cerebrospinal fluid; lymphocytic
   meningtis
AB Objective: To describe the frequency of lymphocytic meningitis(LM) concomitant with mumps, before and after the mumps mass immunization campaign in 1997. Method: Demographic, clinical and cerebrospinal fluid(CSF) information was collected from the chart of all patients aged from 2 to 59 months, whose CSF exam was performed at the CSF Lab/FJS, between 1989 and 2001. LM was defined as pleocytosis composed by lymphomononuclear cells and negative exams for bacterial or mycologic infection. Results: Of 1,519 patients, 894(58.9%) had normal exams. LM was present in 301(19.8%) patients, out of which 22(7.3%) had concomitant mumps. The frequency of LM ranged from 15.8% in 1989 to 19.7% in 2001 and of LM with concomitant Mumps ranged from 10.5% in 1989 to 4.7% in 1995, when the last cases were registered. Conclusion: It is probable that the mumps vaccine campaign has influenced the absence of LM with concomitant Mumps, from 1996 to 2001.
C1 Univ Fed Bahia, Fac Med, Dept Pediat, Salvador, BA, Brazil.
   CSF Lab, Jose Silveira Fdn, Salvador, BA, Brazil.
RP Nascimento-Carvalho, CM (corresponding author), Rua Prof Aristides Novis 105-1201B, BR-40210630 Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
CR *CDC, 1989, MMWR-MORBID MORTAL W, V38, P388
   *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P1
   *CDP, 1995, MMWR-MORBID MORTAL W, V44, P1
   CHERRY JD, 1998, TXB PEDIAT INFECT DI, P450
   de la Loma A, 2002, MED CLIN-BARCELONA, V118, P694, DOI 10.1016/S0025-7753(02)72499-8
   Dourado I, 2000, AM J EPIDEMIOL, V151, P524, DOI 10.1093/oxfordjournals.aje.a010239
   KELSEY JL, 1996, METHODS OBSERVATIONA, P74
   MALDONADO Y, 2000, NELSON TXB PEDIAT, P954
   PROBER CG, 2000, NELSON TXB PEDIAT, P757
   Prober CG, 2000, NELSON TXB PEDIAT, P751
   TUNKEL AR, 2000, MANDELL DOUGLAS BENN, P975
NR 11
TC 5
Z9 5
U1 0
U2 0
PU ASSOC ARQUIVOS NEURO- PSIQUIATRIA
PI SAO PAULO SP
PA PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL
SN 0004-282X
EI 1678-4227
J9 ARQ NEURO-PSIQUIAT
JI Arq. Neuro-Psiquiatr.
PD SEP
PY 2003
VL 61
IS 3B
BP 728
EP 730
DI 10.1590/S0004-282X2003000500005
PG 3
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 734DR
UT WOS:000186040400005
PM 14595473
OA DOAJ Gold
DA 2020-12-17
ER

PT J
AU Moreno-Carvalho, OA
   Nascimento-Carvalho, CM
   Bacelar, ALD
   Andrade, AD
   Costa, G
   Fontes, JB
   Assis, T
AF Moreno-Carvalho, OA
   Nascimento-Carvalho, CM
   Bacelar, ALD
   Andrade, AD
   Costa, G
   Fontes, JB
   Assis, T
TI Clinical and cerebrospinal fluid (CSF) profile and CSF criteria for the
   diagnosis of spinal cord schistosomiasis
SO ARQUIVOS DE NEURO-PSIQUIATRIA
LA English
DT Article
DE neuroschistosomiasis; cerebrospinal fluid; CSF diagnosis; myelitis;
   myeloradiculitis; Schistosoma mansoni
ID MANSONI; INVOLVEMENT; PARAPLEGIA; INFECTION
AB Objectives: To describe the clinical and CSF findings among patients with presumptive neuroschistosomiasis (NS) and to suggest a classification for the CSF diagnosis of presumptive NS. Method: The charts of all patients whose CSF exam was performed at the CSF Lab, Jose Silveira Foundation, Salvador, Brazil, from 1988 to 2002 were reviewed. Those with clinically suspected NS whose indirect fluorescent antibody test (IFA) and or hemagglutination-inhibiting antibodies test (HAI) were positive to S. mansoni were identified. Results: Of 377 patients, 67.9% were males; the median age was 36 years (mean 37 +/- 16 yrs, range 3-92 yrs). The most frequent complaints were paraparesis (59.9%), urinary retention (36.2%), lower limb pain (22.8%). WBC of CSF (count/mm(3)) was > 4 in 66.0% (mean 83 +/- 124, median 40, range 4.3-1,100), protein (mg/dl) was > 40 in 84.6% (mean 185 +/- 519, median 81, range 41-6,800) and eosinophils were present in 46.9%. IFA and HAI were positive in 75.3%. WBC > 4 and presence of eosinophils were associated with IFA and HAI positive (67.3% versus 51.4%, p 0.014; 49.1% versus 23.0%, p 0.0001, respectively) and protein > 40 was not (85.4% versus 77.0%, p 0.09). Presence of WBC > 4, protein > 40 and eosinophils was associated with IFA and HAI positive (71.6% versus 38.2%, p 0.0003) but presence of eosinophils and any other combination of WBC and protein were not. Conclusion: NS should be considered as a possible diagnosis in patients who had had contact with schistosome-infected water and present with spinal cord compromising. Presence of IFA and HAI positive to S. mansoni, WBC > 4, protein > 40 and presence of eosinophils in the CSF may be considered as a criterium of highly probable presumptive diagnosis.
C1 Jose Silveira Fdn, CSF Lab, Salvador, BA, Brazil.
   Univ Fed Bahia, Fac Med, Dept Pediat, BR-41170290 Salvador, BA, Brazil.
   Univ Fed Bahia, Fac Med, Dept Neuropsychiat, BR-41170290 Salvador, BA, Brazil.
   Neurol & Neurosurg Fdn Bahia, Salvador, BA, Brazil.
EM nascimentocarvalho@hotmail.com
RI de Assis, Telma Maria Rocha/AAW-6736-2020
OI de Assis, Telma Maria Rocha/0000-0002-9943-3396
CR Andrade A N, 1986, Arq Neuropsiquiatr, V44, P275
   Andrade AD, 1996, ARQ NEURO-PSIQUIAT, V54, P232
   ANDRADE NA, 1989, ARQ NEURO-PSIQUIAT, V47, P100
   BIRD AV, 1964, NEUROLOGY, V14, P647, DOI 10.1212/WNL.14.7.647
   Brito J C, 1992, Arq Neuropsiquiatr, V50, P207
   BROWNER WS, 1988, DESIGNING CLIN RES, P87
   BUDZILOVICH GN, 1964, ARCH PATHOL, V77, P383
   *CEGET CNRS OMS, 1987, ATL REP MOND SCHIST
   CORREA RLB, 1983, REV BRAS NEUROL, V19, P101
   DEMUYLDER E, 1945, CR SOC BIOL, V139, P334
   FISHMAN RA, 1992, CEREBROSPINAL FLUID, V2
   GALVAO ACR, 1985, ARQ BRAS NEUROCIRURG, V4, P133
   Junker J, 2001, CLIN NEUROL NEUROSUR, V103, P39, DOI 10.1016/S0303-8467(00)00124-4
   Lambertucci J.R., 1987, Revista da Sociedade Brasileira de Medicina Tropical, V20, P47, DOI 10.1590/S0037-86821987000100010
   Liu LX, 1996, NEW ENGL J MED, V334, P382, DOI 10.1056/NEJM199602083340608
   Livramento J A, 1985, Arq Neuropsiquiatr, V43, P372
   Nobre V, 2001, MEM I OSWALDO CRUZ, V96, P137, DOI 10.1590/S0074-02762001000900020
   Peregrino A J, 1988, Arq Neuropsiquiatr, V46, P49
   Peregrino AJP, 2002, ARQ NEURO-PSIQUIAT, V60, P603, DOI 10.1590/S0004-282X2002000400016
   Peregrino AJP, 2002, ARQ NEURO-PSIQUIAT, V60, P597, DOI 10.1590/S0004-282X2002000400015
   PEREGRINO AJP, 1998, NEUROINFECCAO, V98, P45
   PRATA A, 1980, REV I MED TROP SA S4, V22, P182
   ROSENBAUM RM, 1972, AM J TROP MED HYG, V21, P182, DOI 10.4269/ajtmh.1972.21.182
   ROSS GL, 1952, NEW ENGL J MED, V246, P823, DOI 10.1056/NEJM195205222462105
   Santos E C, 2001, Arq Neuropsiquiatr, V59, P772
   SCRIMGEOUR EM, 1981, BMJ-BRIT MED J, V283, P975, DOI 10.1136/bmj.283.6297.975
   SCRIMGEOUR EM, 1985, BRAIN, V108, P1023, DOI 10.1093/brain/108.4.1023
   Spina-Franca A, 1980, Arq Neuropsiquiatr, V38, P360
   1984, JAMA, V252, P1116
NR 29
TC 19
Z9 21
U1 0
U2 0
PU ASSOC ARQUIVOS NEURO- PSIQUIATRIA
PI SAO PAULO SP
PA PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL
SN 0004-282X
EI 1678-4227
J9 ARQ NEURO-PSIQUIAT
JI Arq. Neuro-Psiquiatr.
PD JUN
PY 2003
VL 61
IS 2B
BP 353
EP 358
DI 10.1590/S0004-282X2003000300006
PG 6
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 699FZ
UT WOS:000184047200006
PM 12894266
OA DOAJ Gold, Green Published
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, CMC
   Alves, NN
   Athayde, LA
   Caldas, RM
   Barberino, MGMA
   Duarte, J
   Brandao, MAS
   Brandileone, MCC
   Guerra, MLLS
   Di Fabio, JL
AF Nascimento-Carvalho, CMC
   Alves, NN
   Athayde, LA
   Caldas, RM
   Barberino, MGMA
   Duarte, J
   Brandao, MAS
   Brandileone, MCC
   Guerra, MLLS
   Di Fabio, JL
TI Is there any association of a specific chest X-ray pattern and
   bacteremia in children with pneumonia?
SO JOURNAL OF TROPICAL PEDIATRICS
LA English
DT Letter
ID COMMUNITY-ACQUIRED PNEUMONIA; ETIOLOGY; INFECTIONS
C1 Univ Fed Bahia, Fac Med, Dept Pediat, BR-40210730 Salvador, BA, Brazil.
   Univ Fed Bahia, Prof Hosannah de Oliveira Pediat Ctr, BR-40210730 Salvador, BA, Brazil.
   Alianca Hosp, Cent Lab Bahia, Salvador, BA, Brazil.
   Adolfo Lutz Inst, Bacteriol Div, Sao Paulo, Brazil.
   Pan Amer Hlth Org, Washington, DC USA.
RP Nascimento-Carvalho, CMC (corresponding author), Univ Fed Bahia, Fac Med, Dept Pediat, Rua Prof Aristide Novis 105-1201B, BR-40210730 Salvador, BA, Brazil.
CR Bryan CS, 1999, CHEST, V116, P1153, DOI 10.1378/chest.116.5.1153
   CHRETIEN J, 1984, NEW ENGL J MED, V310, P982, DOI 10.1056/NEJM198404123101509
   Garenne Michel, 1992, World Health Statistics Quarterly, V45, P180
   Juven T, 2000, PEDIATR INFECT DIS J, V19, P293, DOI 10.1097/00006454-200004000-00006
   KORPPI M, 1993, ACTA PAEDIATR, V82, P360, DOI 10.1111/j.1651-2227.1993.tb12697.x
   MCCARTHY PL, 1981, CLIN PEDIATR, V20, P686, DOI 10.1177/000992288102001101
   McCracken GH, 2000, PEDIATR INFECT DIS J, V19, P373, DOI 10.1097/00006454-200004000-00032
   SWISCHUK LE, 1986, PEDIATR RADIOL, V16, P278, DOI 10.1007/BF02386862
NR 8
TC 4
Z9 5
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0142-6338
J9 J TROP PEDIATRICS
JI J. Trop. Pediatr.
PD AUG
PY 2002
VL 48
IS 4
BP 253
EP 254
DI 10.1093/tropej/48.4.253
PG 3
WC Pediatrics; Tropical Medicine
SC Pediatrics; Tropical Medicine
GA 572TG
UT WOS:000176790600017
PM 12200992
OA Bronze
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, CM
   Rocha, H
   Benguigui, Y
AF Nascimento-Carvalho, CM
   Rocha, H
   Benguigui, Y
TI Effects of socioeconomic status on presentation with acute lower
   respiratory tract disease in children in Salvador, northeast Brazil
SO PEDIATRIC PULMONOLOGY
LA English
DT Article
DE pneumonia; asthma; children; hospitalization; mortality; outpatients;
   rhinitis; socioeconomic status; lower respiratory tract disease;
   second-hand smoke; epidemiology
ID COMMUNITY-ACQUIRED PNEUMONIA; CHILDHOOD PNEUMONIA; RISK-FACTORS;
   ETIOLOGY; INFECTIONS; PREVALENCE; GERMANY; ASTHMA
AB Two different socioeconomic groups of children with pneumonia were studied, and their clinical and demographic aspects were evaluated. The diagnosis of pneumonia was based on findings of cough and tachypnea, or on crackles on auscultation or on radiologically confirmed infiltrate. This was a prospective cross-sectional study conducted at the Professor Hosannah de Oliveira Pediatric Center, which cares for children of lower socioeconomic status (PHOPC), and at one private hospital which cares for children from middle to high socioeconomic status (Alianga Hospital, AH). Demographics and clinical differences were assessed by the Pearson chi-square test or Fisher's exact test as appropriate; means of continuous variables were compared by Mann-Whitney U-test.
   In a 26-month period, 3,431 cases were recruited. The 2,476 cases identified at the PHOPC were younger than the 955 identified at AH (2.2 +/- 2.3 vs. 4.5 +/- 3.1 years, P < 0.0001) and had higher scores for severity (3.5 +/-1.5 vs. 2.7 +/-1.7, P < 0.0001), duration of hospitalization (days) (10.9 +/- 12.1 vs. 6.2 +/- 7, P < 0.0001), frequency of tobacco smoker in the household (48% vs. 31%, P < 0.0001), cardiopathy (15.3% vs. 5.9%, P = 0.003), fever (44.4% vs. 36.3%, P=.0001), tachypnea (67.6% vs. 32.3%, P < 0.0001), crackles (69.5% vs. 64.9%, P = 0.02), somnolence (19.9% vs. 10.4%, P<0.0001), malnutrition (13.7% vs. 5%, P<0.0001), hospitalization rate (27.4% vs. 22.5%, P=0.003), and death (0.9% vs. 0.1%, P=0.009). However, other features were more frequent among AH cases: parent's university level of education (38.2% vs. 1.0%, P< 0.0001), underlying chronic illness (40.6% vs. 28.5%, P< 0.0001), asthma (62.7% vs. 50.8%, P= 0.01), rhinitis (9.2% vs. 0.4%, P< 0.0001), previous use of antibiotics (34.3% vs. 27.1%, P=0.001), and wheezing (53.1%vs. 42.2%, P<0.0001).
   Children of lower socioeconomic status have more serious lower respiratory tract disease, whereas children with pneumonia of middle to high socioeconomic status have more allergic diseases (rhinitis, asthma) and wheezing. (C) 2002 Wiley-Liss. Inc.
C1 Univ Fed Bahia, Prof Hosannah De Oliveira Pediat Ctr, Fac Med, Dept Pediat, BR-40210730 Salvador, BA, Brazil.
   Alianca Hosp, Salvador, BA, Brazil.
   Univ Fed Bahia, Fac Med, Dept Internal Med, Salvador, BA, Brazil.
   Pan Amer Hlth Org, Washington, DC USA.
RP Nascimento-Carvalho, CM (corresponding author), Univ Fed Bahia, Prof Hosannah De Oliveira Pediat Ctr, Fac Med, Dept Pediat, Rua Prof Aristides Novis 105-1201B, BR-40210730 Salvador, BA, Brazil.
CR AZEVEDO ES, 1982, HUM BIOL, V54, P329
   BENGUIGUI Y, 1997, CONTROLE INFECCOES R
   BERMAN S, 1985, REV INFECT DIS, V7, P674
   Chang MY, 2000, PEDIATR PULM, V29, P257, DOI 10.1002/(SICI)1099-0496(200004)29:4<257::AID-PPUL4>3.3.CO;2-M
   CHRETIEN J, 1984, NEW ENGL J MED, V310, P982, DOI 10.1056/NEJM198404123101509
   Garenne Michel, 1992, World Health Statistics Quarterly, V45, P180
   Greenwood B, 1999, PHILOS T R SOC B, V354, P777, DOI 10.1098/rstb.1999.0430
   Heiskanen-Kosma T, 1998, PEDIATR INFECT DIS J, V17, P986, DOI 10.1097/00006454-199811000-00004
   ISAACS D, 1989, PEDIATR INFECT DIS J, V8, P143
   JOKINEN C, 1993, AM J EPIDEMIOL, V137, P977, DOI 10.1093/oxfordjournals.aje.a116770
   Juven T, 2000, PEDIATR INFECT DIS J, V19, P293, DOI 10.1097/00006454-200004000-00006
   KLEIN JO, 1998, TXB PEDIAT INFECT DI, P273
   Lemanske RF, 2001, NEW ENGL J MED, V344, P1643
   Melander E, 1998, EUR J CLIN MICROBIOL, V17, P834, DOI 10.1007/s100960050202
   MURPHY TF, 1981, AM J EPIDEMIOL, V113, P12, DOI 10.1093/oxfordjournals.aje.a113061
   NIOBEY FML, 1992, REV SAUDE PUBL, V26, P229, DOI 10.1590/S0034-89101992000400004
   PECHERE JC, 1995, COMMUNITY ACQUIRED P
   SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017
   STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259
   VASCONCELOS FAG, 1993, AVALIACAO NUTRICIONA
   VICTORA CG, 1992, SOC SCI MED, V34, P899, DOI 10.1016/0277-9536(92)90258-R
   VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358, DOI 10.1164/ajrccm.149.2.8306030
   VONMUTIUS E, 1992, BMJ-BRIT MED J, V305, P1395, DOI 10.1136/bmj.305.6866.1395
   *WHO, 1985, WHORSD8515
   Wubbel L, 1999, PEDIATR INFECT DIS J, V18, P98, DOI 10.1097/00006454-199902000-00004
NR 25
TC 16
Z9 20
U1 0
U2 1
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 8755-6863
J9 PEDIATR PULM
JI Pediatr. Pulmonol.
PD APR
PY 2002
VL 33
IS 4
BP 244
EP 248
DI 10.1002/ppul.10078
PG 5
WC Pediatrics; Respiratory System
SC Pediatrics; Respiratory System
GA 536QT
UT WOS:000174713900002
PM 11921452
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, CMC
   Gomes, MDBS
   Magalhaes, MP
   Oliveira, JR
   Vilas-Boas, AL
   Ferracuti, R
   Alves, NN
   Athayde, LA
   Caldas, RM
   Barberino, MGMA
   Duarte, J
   Brandao, MAS
   Brandileone, MCC
   Guerra, MLLS
   Rocha, H
   Benguigui, Y
   Di Fabio, JL
AF Nascimento-Carvalho, CMC
   Gomes, MDBS
   Magalhaes, MP
   Oliveira, JR
   Vilas-Boas, AL
   Ferracuti, R
   Alves, NN
   Athayde, LA
   Caldas, RM
   Barberino, MGMA
   Duarte, J
   Brandao, MAS
   Brandileone, MCC
   Guerra, MLLS
   Rocha, H
   Benguigui, Y
   Di Fabio, JL
TI Blood cultures from Brazilian pediatric outpatients with
   community-acquired pneumonia (CAP)
SO JOURNAL OF TROPICAL PEDIATRICS
LA English
DT Letter
ID CHILDREN; ETIOLOGY; INFECTIONS; BACTERIAL; DIAGNOSIS
C1 Univ Fed Bahia, Alianca Hosp, Pediat Ctr Professor Hosannah de Oliveira, Fac Med,Dept Pediat, Salvador, BA, Brazil.
   Univ Fed Bahia, Alianca Hosp, Pediat Ctr Professor Hosannah de Oliveira, Fac Med,Dept Internal Med, Salvador, BA, Brazil.
   Cent Lab Bahia, Salvador, BA, Brazil.
   Adolfo Lutz Inst, Bacteriol Div, Sao Paulo, Brazil.
   Pan Amer Hlth Org, Washington, DC USA.
RP Nascimento-Carvalho, CMC (corresponding author), Univ Fed Bahia, Alianca Hosp, Pediat Ctr Professor Hosannah de Oliveira, Fac Med,Dept Pediat, Salvador, BA, Brazil.
CR Bryan CS, 1999, CHEST, V116, P1153, DOI 10.1378/chest.116.5.1153
   CHRETIEN J, 1984, NEW ENGL J MED, V310, P982, DOI 10.1056/NEJM198404123101509
   CLAESSON BA, 1989, PEDIATR INFECT DIS J, V8, P856, DOI 10.1097/00006454-198912000-00006
   Garenne Michel, 1992, World Health Statistics Quarterly, V45, P180
   Juven T, 2000, PEDIATR INFECT DIS J, V19, P293, DOI 10.1097/00006454-200004000-00006
   LORCH DG, 1987, AM REV RESPIR DIS, V136, P565, DOI 10.1164/ajrccm/136.3.565
   NOHYNEK H, 1991, AM J DIS CHILD, V145, P618, DOI 10.1001/archpedi.1991.02160060036016
   RAMSEY BW, 1986, PEDIATRICS, V78, P1
   *WHO, 1983, TRIARIMTP831 WHO
   *WHO, 1985, WHORSD8515
   Wubbel L, 1999, PEDIATR INFECT DIS J, V18, P98, DOI 10.1097/00006454-199902000-00004
NR 11
TC 2
Z9 3
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0142-6338
J9 J TROP PEDIATRICS
JI J. Trop. Pediatr.
PD FEB
PY 2002
VL 48
IS 1
BP 58
EP 60
DI 10.1093/tropej/48.1.58
PG 3
WC Pediatrics; Tropical Medicine
SC Pediatrics; Tropical Medicine
GA 527MD
UT WOS:000174189100013
PM 11871370
OA Bronze
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, CMC
   Lopes, AA
   Gomes, MDBS
   Magalhaes, MP
   Oliveira, JR
   Vilas-Boas, AL
   Rocha, H
   Benguigui, Y
AF Nascimento-Carvalho, CMC
   Lopes, AA
   Gomes, MDBS
   Magalhaes, MP
   Oliveira, JR
   Vilas-Boas, AL
   Rocha, H
   Benguigui, Y
TI The burden of pneumonia among children
SO JOURNAL OF TROPICAL PEDIATRICS
LA English
DT Letter
ID ACUTE RESPIRATORY-INFECTIONS
C1 Univ Fed Bahia, Fac Med, Dept Pediat, BR-40210730 Salvador, BA, Brazil.
   Univ Fed Bahia, Fac Med, Clin Epidemiol Unit, BR-40210730 Salvador, BA, Brazil.
   Univ Fed Bahia, Fac Med, Dept Internal Med, BR-40210730 Salvador, BA, Brazil.
   Univ Fed Bahia, Fac Med, Prof Hosannah de Oliveira Pediat Ctr, BR-40210730 Salvador, BA, Brazil.
   Alianca Hosp, Salvador, BA, Brazil.
   Pan Amer Hlth Org, Washington, DC USA.
RP Nascimento-Carvalho, CMC (corresponding author), Univ Fed Bahia, Fac Med, Dept Pediat, Rua Prof Aristides Novis 105-1201B, BR-40210730 Salvador, BA, Brazil.
CR BENGUIGUI Y, 1997, INFECCOES RESP AGUDA, P2
   BERMAN S, 1985, REV INFECT DIS, V7, P674
   DENNY FW, 1986, AM J TROP MED HYG, V35, P1
   *WHO, 1985, WHORSD8515
NR 4
TC 4
Z9 4
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0142-6338
J9 J TROP PEDIATRICS
JI J. Trop. Pediatr.
PD AUG
PY 2001
VL 47
IS 4
BP 253
EP 254
DI 10.1093/tropej/47.4.253
PG 2
WC Pediatrics; Tropical Medicine
SC Pediatrics; Tropical Medicine
GA 469DP
UT WOS:000170798700016
PM 11523771
OA Bronze
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, CMC
   Brandileone, MCC
   Guerra, MLLS
   Di Fabio, JL
AF Nascimento-Carvalho, CMC
   Brandileone, MCC
   Guerra, MLLS
   Di Fabio, JL
TI Do viridans streptococci cause pneumonia in children?
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Letter
DE viridans streptococci; pneumonia; children
ID INFECTIONS
C1 Univ Fed Bahia, Fac Med, Dept Pediat, Prof Hosannah de Oliveira Pediat Ctr, BR-40210730 Salvador, BA, Brazil.
   Adolfo Lutz Inst, Bacteriol Div, Sao Paulo, Brazil.
   Pan Amer Hlth Org, Washington, DC USA.
RP Nascimento-Carvalho, CMC (corresponding author), Univ Fed Bahia, Fac Med, Dept Pediat, Prof Hosannah de Oliveira Pediat Ctr, Rua Prof Aristides Novis,No 105-1201B, BR-40210730 Salvador, BA, Brazil.
CR BOURGAULT AM, 1979, J INFECT DIS, V140, P316, DOI 10.1093/infdis/140.3.316
   GAUDREAU C, 1981, CAN MED ASSOC J, V125, P1246
   Johnson CC, 1995, PRINCIPLES PRACTICE, P1845
   LORCH DG, 1987, AM REV RESPIR DIS, V136, P565, DOI 10.1164/ajrccm/136.3.565
   MAHOMED AG, 1992, S AFR MED J, V82, P432
   MARRIE TJ, 1993, CLIN INVEST MED, V16, P38
   PRATTER MR, 1980, JAMA-J AM MED ASSOC, V243, P2515, DOI 10.1001/jama.243.24.2515
   QUINN JP, 1988, J INFECT DIS, V157, P764, DOI 10.1093/infdis/157.4.764
   ROSE HD, 1981, JAMA-J AM MED ASSOC, V245, P32, DOI 10.1001/jama.1981.03310260016015
   SARKAR TK, 1989, CHEST, V96, P831, DOI 10.1378/chest.96.4.831
NR 10
TC 2
Z9 2
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD JUL
PY 2001
VL 20
IS 7
BP 726
EP 728
DI 10.1097/00006454-200107000-00024
PG 3
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 452JV
UT WOS:000169855300024
PM 11465856
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, CMC
AF Nascimento-Carvalho, CMC
TI Invasive antibiotic-resistant Streptococcus pneumoniae infection in
   children: Concerning clinical outcome
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Letter
DE Streptococcus pneumoniae; odds ratio; antibiotic; resistance
C1 Univ Fed Bahia, Dept Pediat, Salvador, BA, Brazil.
RP Nascimento-Carvalho, CMC (corresponding author), Univ Fed Bahia, Dept Pediat, Salvador, BA, Brazil.
CR ALTMAN DG, 1992, ANN INTERN MED S2, V116, pA28
   Baquero F, 1997, J ANTIMICROB CHEMOTH, V39, P1, DOI 10.1093/jac/39.suppl_1.1
   HANSMAN D, 1967, LANCET, V2, P264
   HENNEKENS CH, 1987, EPIDEMIOLOGY MED, P54
   JACOBS MR, 1978, NEW ENGL J MED, V299, P735, DOI 10.1056/NEJM197810052991402
   LECLERCQ R, 1988, NEW ENGL J MED, V319, P157, DOI 10.1056/NEJM198807213190307
   Ramos JT, 1998, PEDIATR INFECT DIS J, V17, P252, DOI 10.1097/00006454-199803000-00018
NR 7
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD OCT
PY 1998
VL 17
IS 10
BP 936
EP 937
DI 10.1097/00006454-199810000-00027
PG 2
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 131CE
UT WOS:000076557500026
PM 9802649
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, CMC
   Moreno-Carvalho, OA
AF Nascimento-Carvalho, CMC
   Moreno-Carvalho, OA
TI Normal cerebrospinal fluid values in full-term gestation and premature
   neonates
SO ARQUIVOS DE NEURO-PSIQUIATRIA
LA English
DT Article
DE cerebrospinal fluid; neonate; cisternal puncture; normal values
ID MENINGITIS; INFANTS
AB Results of cerebrospinal fluid (CSF) examinations from 77 high-risk neonates were reviewed. The mean CSF white cells (WBC) count was 4.5 cell/mm(3), being two standard deviations above the mean 11.7 cells/mm(3) in the full-term gestation neonate group; in the premature neonate one, the mean CSF WBC count was 5.1 cells/mm(3), being two standard deviations above the mean 16.7 cell/mm(3). PMNs (polymorphonuclear leukocytes) were present in less than 40% of those children, being the mean PMN percentage 4.2% and 0.6%, the mean ANC (absolute neutrophil count) was 0.3/mm(3) and 0.06/mm(3), in full-term gestation neonate group and premature neonate one, respectively. The mean CSF protein concentration is significantly greater in those premature neonates (101.2 mg/dl) compared with that in term neonates (77.6 mg/dl). The average glucose was just the same in both groups (67 mg/dl). All of these values were from patients who underwent nontraumatic cisternal puncture, with no red blood cells (RBC/mm(3)=0). Traumatic puncture, even up to 500 RBC/mm(3), interfered on CSF parameters.
C1 Univ Fed Bahia, Hosp Univ Professor Edgard Santos, Serv Pediat, BR-41170290 Salvador, BA, Brazil.
   Fdn Jose Silveira, Lab Liquorol, Salvador, BA, Brazil.
CR BONADIO W A, 1989, Pediatric Emergency Care, V5, P94, DOI 10.1097/00006565-198906000-00005
   BONADIO WA, 1992, PEDIATR INFECT DIS J, V11, P589, DOI 10.1097/00006454-199207000-00015
   BONADIO WA, 1992, PEDIATR INFECT DIS J, V11, P423, DOI 10.1097/00006454-199206000-00001
   de Albuquerque Diniz E M, 1982, Bol Med Hosp Infant Mex, V39, P473
   Diniz E M, 1982, Bol Med Hosp Infant Mex, V39, P409
   DINIZ EMA, 1982, B MED HOSP INFANT M, V39, P253
   Fishman R., 1992, CEREBROSPINAL FLUID, P253
   FISHMAN RA, 1992, CEREBROSPINAL FLUID, P69
   HASUE M, 1983, SPINE, V8, P50, DOI 10.1097/00007632-198301000-00010
   LUZ BR, 1972, THESIS U SAO PAULO S
   NAIDOO B T, 1968, South African Medical Journal, V42, P933
   Otila E., 1948, ACTA PAEDIAT UPPS S8, V35, P3
   PORTNOY JM, 1985, PEDIATRICS, V75, P484
   Roberts MH, 1925, J AMER MED ASSOC, V85, P500, DOI 10.1001/jama.1925.02670070020006
   ROSSITTI S L, 1991, Arquivos de Neuro-Psiquiatria, V49, P307
   RSSITTI SL, 1990, ARQ NUROPSIQUIATR, V48, P469
   SAMSON K, 1931, ERG INN MED KINDERHK, V41, P665
   SARFF LD, 1976, J PEDIATR-US, V88, P473, DOI 10.1016/S0022-3476(76)80271-5
   SCHMIDLEY JW, 1981, ANN NEUROL, V9, P81, DOI 10.1002/ana.410090116
   VAZ FACV, 1977, ARQ NEURO-PSIQUIAT, V35, P183, DOI 10.1590/S0004-282X1977000300001
   VISSER VE, 1980, J PEDIATR-US, V96, P1063, DOI 10.1016/S0022-3476(80)80643-3
   WIDELL S, 1958, Acta Paediatr Suppl, V47, P1
   WYERS H J, 1954, Maandschr Kindergeneeskd, V22, P253
NR 23
TC 9
Z9 10
U1 0
U2 1
PU ASSOC ARQUIVOS DE NEURO- PSIQUIATRIA
PI SAO PAULO SP
PA PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL
SN 0004-282X
J9 ARQ NEURO-PSIQUIAT
JI Arq. Neuro-Psiquiatr.
PD SEP
PY 1998
VL 56
IS 3A
BP 375
EP 380
DI 10.1590/S0004-282X1998000300005
PG 6
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 108KR
UT WOS:000075266000005
PM 9754417
OA Other Gold
DA 2020-12-17
ER

PT J
AU Nascimento-Carvalho, CMC
   Moreno-Carvalho, OA
AF Nascimento-Carvalho, CMC
   Moreno-Carvalho, OA
TI Etiology of bacterial meningitis among some children in Salvador - Bahia
SO ARQUIVOS DE NEURO-PSIQUIATRIA
LA Portuguese
DT Article
DE bacterial meningitis; etiology; epidemiology; children
ID INFLUENZAE TYPE-B; UNITED-STATES; SURVEILLANCE; DISEASE; VACCINE;
   EPIDEMIOLOGY; THERAPY; REGION
AB Bacterial meningitis remains a very important disease world-wide, mainly during childhood. In order to describe the etiology of bacterial meningitis among some children in Salvador, Bahia - Brazil, we retrospectively reviewed 7000 cerebrospinal fluid exams, performed within the period of September 1988 up to August 1995, at the CSF Laboratory, Jose Silveira Foundation; 892(12.7%) exams met the inclusion criteria: patients less than 16 years of age and clinical meningitis diagnosis. Among 139 cases of bacterial meningitis, H. influenzae type b (Hib) was the most frequent cause (26.0%), all of the cases in children under 5 years. We have been questioning whether the declining Hib disease trend since 1992 has been associated with the use of Hib conjugate vaccines among those children.
C1 Univ Fed Bahia, Hosp Univ Professor Edgard Santos, Serv Pediat, BR-41170290 Salvador, BA, Brazil.
   Fdn Jose Silveira, Lab Liquorol, Salvador, BA, Brazil.
CR ADAMS WG, 1993, JAMA-J AM MED ASSOC, V269, P221, DOI 10.1001/jama.269.2.221
   Adegbola RA, 1996, ANN TROP PAEDIATR, V16, P103, DOI 10.1080/02724936.1996.11747812
   BARAFF LJ, 1993, PEDIATR INFECT DIS J, V12, P389, DOI 10.1097/00006454-199305000-00008
   Barone AA, 1996, NEUROINFECTIONS 1996, P141
   BELL WE, 1992, PEDIATR CLIN N AM, V39, P651
   BONADIO WA, 1990, AM J CLIN PATHOL, V94, P426
   BROADHURST LE, 1993, JAMA-J AM MED ASSOC, V269, P227, DOI 10.1001/jama.269.2.227
   BRYAN JP, 1990, REV INFECT DIS, V12, P128
   *CDCP, 1990, MMWR-MORBID MORTAL W, V39, P698
   *CDCP, 1990, MMWR-MORBID MORTAL W, V39, P925
   Centers for Disease Control and Prevention (CDC), 1996, MMWR-MORBID MORTAL W, V45, P901
   DAUND AS, 1995, J TROP PEDIATRICS, V41, P308
   FARHAT CK, 1993, INFECT PEDIAT, P100
   FISHMAN RA, 1992, CEREBROSPINAL FLUID, P256
   FORTNUM HM, 1993, ARCH DIS CHILD, V68, P763, DOI 10.1136/adc.68.6.763
   HARRISON SA, 1988, PEDIATR INFECT DIS J, V7, P143, DOI 10.1097/00006454-198802000-00020
   Hoen B, 1994, Rev Prat, V44, P2148
   Ishikawa T, 1996, PEDIATR NEUROL, V14, P244, DOI 10.1016/0887-8994(96)00024-0
   KAPLAN SL, 1986, PEDIATR INFECT DIS J, V5, P626, DOI 10.1097/00006454-198611000-00005
   LUTSAR I, 1995, PEDIATR INFECT DIS J, V14, P624, DOI 10.1097/00006454-199507000-00014
   MURPHY TV, 1993, JAMA-J AM MED ASSOC, V269, P246, DOI 10.1001/jama.269.2.246
   NASCIMENTO CMP, 1994, THESIS U FEDERAL BAH
   PELTOLA H, 1992, LANCET, V340, P592, DOI 10.1016/0140-6736(92)92117-X
   SCHLECH WF, 1985, JAMA-J AM MED ASSOC, V253, P1749, DOI 10.1001/jama.253.12.1749
   SHAPIRO ED, 1993, JAMA-J AM MED ASSOC, V269, P264, DOI 10.1001/jama.269.2.264
   URWIN G, 1994, BRIT MED J, V309, P1412, DOI 10.1136/bmj.309.6966.1412
   WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316
NR 27
TC 2
Z9 2
U1 0
U2 1
PU ASSOC ARQUIVOS DE NEURO- PSIQUIATRIA
PI SAO PAULO SP
PA PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL
SN 0004-282X
J9 ARQ NEURO-PSIQUIAT
JI Arq. Neuro-Psiquiatr.
PD MAR
PY 1998
VL 56
IS 1
BP 83
EP 87
DI 10.1590/S0004-282X1998000100013
PG 5
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA ZC303
UT WOS:000072563500013
PM 9686125
OA Other Gold
DA 2020-12-17
ER

PT J
AU MORENOCARVALHO, OA
   NASCIMENTOCARVALHO, CMC
   GALVAOCASTRO, B
AF MORENOCARVALHO, OA
   NASCIMENTOCARVALHO, CMC
   GALVAOCASTRO, B
TI HTLV-I-ASSOCIATED TROPICAL SPASTIC PARAPARESIS - CEREBRAL SPINAL-FLUID
   EVOLUTIVE ASPECTS IN 128 CASES
SO ARQUIVOS DE NEURO-PSIQUIATRIA
LA English
DT Article
DE TROPICAL SPASTIC PARAPARESIS; CEREBROSPINAL FLUID; HTLV-I
ID MYELOPATHY
AB In order to evaluate if there is variation on the intensity of cerebral spinal fluid (CSF) response during HTLV-I associated tropical spastic paraparesis (TSP) evolution we retrospectively reviewed 128 cases. The results indicate that although CSF inflammatory alterations can persist over a 10-year period, they tend to become slight or even absent after the second year of TSP evolution.
C1 FDN JOSE SILVEIRA,LCR,BR-40140000 SALVADOR,BA,BRAZIL.
   UNIV FED BAHIA,BR-40210 SALVADOR,BA,BRAZIL.
CR AKIZUKI S, 1987, LANCET, V1, P156
   Araujo A. Q.-C., 1993, Acta Neurologica Scandinavica, V88, P59
   BERQUO ES, 1980, BIOESTATSTICA, P205
   CARTIERROVIROSA L, 1989, LANCET, V1, P556
   GARRUTO R, 1989, RETROVIRUS HUMANOS H
   GESSAIN A, 1985, LANCET, V2, P407
   JANSSEN RS, 1991, NEUROLOGY, V41, P1355, DOI 10.1212/WNL.41.9.1355
   Melo A, 1993, Arq Neuropsiquiatr, V51, P329
   MONTGOMERY RD, 1964, BRAIN, V87, P425, DOI 10.1093/brain/87.3.425
   Moreno-Carvalho O A, 1992, Arq Neuropsiquiatr, V50, P183
   ROMAN GC, 1988, ANN NEUROL, V23, pS113, DOI 10.1002/ana.410230728
   ROMAN GC, 1987, NEUROLOGY, V37, P1323, DOI 10.1212/WNL.37.8.1323
   ROMAN GC, 1989, HDB CLIN NEUROLOGY, V56, P525
   Spina-Franca A, 1990, Arq Neuropsiquiatr, V48, P441
   VERNANT JC, 1988, ANN NEUROL, V23, pS133, DOI 10.1002/ana.410230731
NR 15
TC 10
Z9 11
U1 0
U2 0
PU ASSOC ARQUIVOS DE NEURO- PSIQUIATRIA
PI SAO PAULO SP
PA C/O DR OSWALDO LANGE, CAIXA POSTAL 8877, 01065-970 SAO PAULO SP, BRAZIL
SN 0004-282X
J9 ARQ NEURO-PSIQUIAT
JI Arq. Neuro-Psiquiatr.
PD SEP
PY 1995
VL 53
IS 3B
BP 604
EP 607
DI 10.1590/S0004-282X1995000400009
PG 4
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA TB699
UT WOS:A1995TB69900009
PM 8585817
OA Green Published, Other Gold
DA 2020-12-17
ER

EF